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Abstract
Most biological processes are intrinsically coordinated through complex networks of
protein-protein interactions. The diversity and the scale of these networks of inter-
actions offer a highly selective and tunable way of modulating protein function. The
importance of protein-protein interactions is further highlighted by the fact that many
genetic disease-associated mutations are known to be enriched at protein interacting
interfaces and, consequently, directly affecting their ability to interact with their part-
ners. My PhD has focused on the systematic analysis of protein-protein interactions as
means to provide a deeper molecular understanding of the mechanisms by which they
are driven.
I have conducted a large scale analysis of all protein-protein interactions available on the
Protein Data Bank and I have shown that, contrary to what was originally thought and
corroborating more recent studies, interacting interface regions are not flat and feature-
less. In fact, a detailed examination of the geometrical and physicochemical properties
revealed that the majority of interactions made use of small concavities at the inter-
face, presenting opportunities for single residue sites to be used for fragment targeting,
and the development of competitive interface small molecules. In addition, I applied
sophisticated data analysis and machine learning techniques to develop novel methods
to explore the different mechanisms by which mutations affect protein dynamics, sta-
bility and binding affinity to other proteins. These methods have been broadly applied
to a variety of different studies, from drug resistance in Mycobacterium Tuberculosis to
analysing genetic variants in proteins of SARs-CoV-2.
Finally, I investigated the properties of small molecules capable of inhibiting protein-
protein complexes. Overall, these were larger than orally available small molecules,
R05, and the most potent ones were shown to be enriched with ring substructures,
including biphenyls. I explored structure and chemical properties of compounds with
inhibitory activity against 23 distinct protein-protein interactions, and used them to
propose a novel method to assist in rapid screening and ranking of inhibitors for any
protein-protein interaction.
The outcomes of my research provide powerful and valuable biological insights into the
nature of protein-protein interactions, improving our understanding of how these can
be better targeted for drug discovery and in the context of disease, particularly through
mutation characterisation and modulation.
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Proteins are involved in most fundamental biological processes, including cell prolifer-
ation [1], signalling [2], host-pathogen interactions [3] and protein transport [4], which
are all intrinsically coordinated through complex networks of protein-protein interactions
(PPIs).
Each protein will often interact through specific regions with several different protein
partners (Figure 1.1). While the size of the human proteome is estimated to be ≈20,000,
the number of interactions, also known as the interactome, has been estimated to be over
650,000 [5], offering a highly selective and tunable way to modulate protein activities
and pathways.
1.1.2 PPI Interfaces
The physical association of two or more protein surfaces forms a protein-protein inter-
face, which includes the area of surfaces between protomers that are buried from solvent
(the interface core), and the regions of each protomer surrounding the core that par-
ticipate in non-bonding interactions with partner proteins (the interface periphery or
rim region). Interfacial residues are more conserved than the rest of the protein surface,
and, more specifically, residues located in interface core regions (those buried from bulk
solvent) tend to be more conserved than those in the periphery surrounding the core [7].
This differential rate of conservation of surface residues has been used to predict likely
protein interaction interfaces [8]. Furthermore, PPI interfaces have been described as
exhibiting electrostatic charge complementarity [9], and also being 80-90% dehydrated
with water molecules participating in interactions mostly with residues at the interface
periphery, as opposed to near 100% dehydration in the hydrophobic cores of globular
protein monomers [7].
Originally, interface regions were considered to be large (400 Å2 to 4000 Å2), hydropho-
bic, flat and featureless [10], leading to their classification as poor targets for the devel-
opment of small molecule modulators. This idea, however, has been challenged through
LITERATURE REVIEW 3
Figure 1.1: Interactome of Homo Sapiens DNA repair protein RAD51 homolog 1.
A single protein can interact with many other protein partners to coordinate different
functions in different signalling pathways. Only first-neighbour interacting partners of
RAD51 (highlighted in red in center) are shown. Node borders and edges in the network
are coloured by whether or not the protein or interaction respectively have experimental
or computationally modelled structural data. Protein structures, when available, are
shown as a cartoon representation within the node. The mix of interactions with and
without structures is a product of the lack of comprehensive structural coverage for
PPI networks. Generated using Interactome3D [6].
their structural and thermodynamic characterisation [11], and has also allowed the classi-
fication of these regions into three broad classes of interactions: (A) interaction between
globular proteins, relatively rigid, interacting with little or no change to their structure;
(B) at least one of the preformed proteins undergoes a significant change in structure
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upon binding (induced fit); and (C) concerted folding upon binding, a disordered region
of a protein folds upon interaction with another partner (Figure 1.2). The interfaces
of interactions falling into the first two classes have been shown to comprise binding
regions located in more than one discontinuous segment of the protein sequence, while
those of the last class are normally made through binding regions located on a single
sequence stretch. In addition, the structural characterisation of PPI interactions allowed
for further categorisation of pairwise interactions according to the nature of interacting
partners and interface residues as summarised in Figure 1.3.
Figure 1.2: Types of PPIs according to structural and thermodynamic characterisa-
tion. The first group (A) represents association between preformed structures, relatively
rigid, that suffer none or little conformational changes upon complexation (rBTI-trypsin
complex, PDB IDs: 2A7H, 3RDY and 3RDZ). The second group (B) depicts interac-
tions in which at least one of the partners undergoes under conformational changes
(highlighted in yellow) (CDK2 cyclin A in complex with a substrate peptide, PDB IDs:
1VIN, 2R3I and 2CCH). Finally, the third type (C) occurs when a disordered region
folds upon interaction with another protein (Phosphatase 1 alpha (PP1) in complex
with Spinophilin, PDB IDs: 2FFT and 3EGG).
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Figure 1.3: Interface types according to structural characterisation of pairwise PPIs.
Isologous homopairs (PDB ID: 3FPC) represent associations of two proteins with the
same sequence (or highly identical sequences - 95% identity), using nearly identical
residues on each side of the interface. Non-isologous homopairs (PDB ID: 1CZY) com-
prise interactions between two proteins with high sequence similarity, but using different
interface residues. Association of two distinct globular proteins were classified as het-
eropairs (PDB ID: 1OQD). Interfaces the interacting pair comprised a globular protein
and a peptide (sequence length <41) were further split into Enzyme:peptides (PDB ID:
8PCH) and Protein:peptides interactions (PDB ID: 1P4U).
The ability to identify residues that form the interface of PPIs is critical for understand-
ing the structural and physicochemical determinants of protein recognition and binding
affinity. It also has wide applications in modeling and validating protein interactions
predicted by high-throughput methods, in engineering proteins, and in prioritising drug
targets [12–14].
Protein complex interfaces can be defined using two different in-silico methods. The
first simply defines residues as being at the interacting interface by the physical dis-
tance between these and any other residue from the partner protein, using a threshold
value which can vary according to the study, but it is commonly set to 5 Å[15–17]. Al-
ternatively, one can use the assumption that interface regions are buried from solvent,
allowing for them to be identified by comparing the difference in solvent accessible sur-
face area (SASA) at the residue level between the individual protomers and within the
complex (Equation 1.1) [18]. Residues that show a decrease superior to a predefined
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threshold, commonly set between 4-5% [19, 20], in their SASA upon complexation are
then considered to be part of the interface.
SASAAB = SASAA + SASAB − SASAAB (1.1)
A and B are protein chains in a pairwise interaction.
At the molecular level, PPIs are mainly established through electrostatic contacts by the
atoms on the side chains of the amino acid residues comprising each protein interface
[21]. Figure 1.4 shows in detail two monomers (single chain proteins) and the interatomic
interactions among the residues located on their region of binding. Over 75% of contacts
are formed based on side-chain structures of the residues at the interface.
1.1.3 Thermodynamics and Kinetics of Protein-Protein Binding
The strength of PPIs is mainly dictated by the repertoire of molecular interactions es-
tablished and lost in complex formation [23]. In the study of the kinetics of molecular
complexes, the binding affinity between two molecules, M1 and M2, can be experimen-
tally quantified by the dissociation constant (KD), which measures the propensity of






where [M1], [M2] and [M1M2] represent the equilibrium concentrations of the two
molecules (M1 and M2) and the complex (M1M2), respectively.
Molecular affinities can also be experimentally determined by Isothermal Titration Calorime-
try (ITC), from Surface Plasmon Resonance (SPR) kinetic equilibrium constants, or by
analysing interference patterns of white light reflected from the surface of a biosensor
tip, namely Bio-Layer Interferometry (BLI). These can be quantitatively calculated us-
ing KD by the Gibbs Free Energy of binding (∆G
Binding) under standard conditions
(1.0 mol initial concentration of bound and unbound complex and its components, 1
LITERATURE REVIEW 7
Figure 1.4: PPI complex of Bcl2 and Bak proteins. Both proteins (Bcl-xL and Bak
BH3 complex, PDB: 5FMJ) are depicted using cartoon representation with Bcl2 and
Bak coloured in grey and orange, respectively. Different types of interatomic interac-
tions are illustrated by different colours. Ionic interactions are shown in yellow, red
for hydrogen bonds and blue for halogen bonding interactions. The thickness of each
dash is proportional to the distance of the between interacting atoms. Other types of
interactions were hidden for visual purposes. Interactions calculated using Arpeggio
[22]
atmosphere of pressure, and at a temperature of 298.15 Kelvin). The mathematical
equation that defines ∆GBinding is defined is represented in Equation 1.3.
∆GBinding = −R× T × lnKD (1.3)
R is the ideal gas constant ≈ 1.9872cal ×K−1mol−1, T is the temperature in Kelvin,
and KD is the equilibrium dissociation constant, which measures the potential of a
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complex of two proteins to dissociate into its separate components (Equation 1.2) as a
spontaneous reaction.
In addition, the formation of molecular interactions can also be interpreted in terms
of entropy (S), which relates to the degrees of freedom for the rearrangements of ele-
ments, being a log measure of the possible configurations of the system; and enthalpy
(H), representing the sum of the internal energy of the system and is related to the
establishment of van der Waals’, hydrogen and charge interactions [24]. These two con-
cepts can be modelled as a thermodynamic state function that quantitatively measures
the likelihood of association between two molecules spontaneously occurring at constant
pressure and temperature, also known as Gibbs Free Energy of folding(∆G) (Equation
1.4). In this sense, associations resulting in negative ∆G values are spontaneous and
the more negative the more likely to happen.
∆G = ∆H − T × ∆S (1.4)
∆H represents the change in enthalpy on binding in Jmol−1, ∆S depicts the change in
entropy on binding in JK−1mol−1 and T is the temperature in Kelvin.
1.1.4 Hotspots
An important observation with respect to the energetics and kinetics of PPI binding was
that key interface residues, namely ”hotspots”, contribute to a large proportion of the
overall binding energy. Experimentally, the identification of hotspots is measured via
a process known as Alanine Scanning [25], all wild-type interface residues are mutated
to alanine (Ala), one at the time, followed by measurements of changes in Binding Free
Energy (∆GBinding) [26] (Figure 1.5). Because Alanine has a small side chain, substi-
tutions to this amino-acid are likely to affect interatomic interactions and consequently
impact on the energetic contribution of a particular residue.
Hotspots residues are often large, amphipathic residues, such as Tyrosine (Tyr), Trypto-
phan (Trp) and Arginine (Arg), that form central connections in structurally conserved,
densely-packed residue interaction networks at the PPI interface [28, 29]. However,
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Figure 1.5: Summary of Alanine Scanning results for the PPI complex of Subtilisin
Carlsberg and Eglin C proteins. Most substitutions to Ala decrease binding affinity with
negative changes in Gibbs Free Energy of Binding (∆GBinding). Positions mutations
have mild effects have been hidden in the x-axis for visualisation purposes. Generated
using mCSM-PPI2 [27].
no single attribute (shape, charge or hydrophobicity, for instance) has been found to
unequivocally define a hotspot [30, 31].
The computational and experimental exploration of interface areas has refined the tradi-
tional definition of hotspots, with PPI interface landscapes containing important ”com-
plemented pockets” and ”anchor” residues (Figure 1.6). Complemented pockets are
defined as small pockets on PPI surface with sufficient volume to occupy a single residue
of a partner protein [32]. Anchor residues are residues burying the largest proportional
of their surface area upon binding, and are hypothesised to be critical in rapid ”lock
and key” complex formation, followed by induced fitting of the rest of the interface [33].
These residues often play a very important role in both specificity and binding affinity.
1.1.5 Disease Mutations on PPIs
Studies have shown that disease-associated non-synonymous single nucleotide variants
(nsSNVs) are enriched in both protein cores and protein interaction interfaces [34–36].
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Figure 1.6: Complemented pocket at the interacting interface of the complex of blood
Coagulation Factor VIIa (grey) and mutant BPTI-5L15 (yellow) (PDB: 1FAK). Pro-
truding Arg15 (green) from BPTI-5L15 occupies the complemented pocket (magenta)
at the interface region of the blood coagulation factor VIIa.
Interestingly, a study with 100.000 disease-associated variants, has suggested that while
the majority of these mutations can alter PPIs, affecting binding affinity or resulting
in novel interactions, they maintained protomer stability [37]. Furthermore, neutral
nsSNVs were observed to be more likely localised at peripheral/rim regions. Not sur-
prisingly, hotspot residues, which provide the largest energetic contribution towards
binding, were enriched amongst disease-associated nsSNVs [38].
The importance of understanding the relationship between disease mutations and PPIs
accompanied by advances in next-generation sequencing techniques has prompted the
development of comprehensive databases of experimentally measured binding energy
changes, most of which derived from alanine scanning mutagenesis, and thermodynamics
properties of PPIs. These large compilations of data represent valuable sources for
mining information that can be used to help assess individual energetic contribution
of residues at PPI interfaces, and more importantly help elucidate the mechanisms by
which missense variants affect PPIs leading to diseases. Table 1.1 summarises a selection
of databases compiling information on the effects of mutations on PPIs.
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Name Description Reference
SKEMPI2 It comprises a total of 6,187 unique entries (single
and multiple mutations), of which more than half
corresponded to mutations to alanine
[39]
SKEMPI Database of experimental measurements of changes
in ∆GBinding upon single variants
[40]
PROXiMATE Database of effects of missense mutations in het-
erodimeric PPIs with structural and functional in-
formation
[41]
ABbind Database of antibody-antigen, antibody-effector and
antibody-like protein complexes, including non-
alanine mutations
[42]
dbMPIKT Database of experimental kinetic and thermodynam-
ics data on of mutant protein interactions
[43]
ASEdb Manually curated database of experimentally derived
hotspots (from alanine scanning mutagenesis stud-
ies)
[44]
PCRPi Database of computationally predicted hotspots [45]
ProTherm Database of experimentally determined thermody-
namic parameters of protein stability changes upon
mutations
[46]
ThermoMutDB Manually curated database of thermodynamic and
kinetic parameters for wild-type and mutant proteins
[47]
Table 1.1: Summary of comprehensive databases compiling experimental data on the
effects of missense mutations on PPIs
1.1.6 Predicting the Effects of Mutations on PPIs
Given the importance of understanding the role of mutations on PPIs and the time-
consuming task of assessing these effects with wet-lab experiments, a number of com-
putational tools that try to predict the effects of mutations in-silico have also been
proposed. The development and evaluation of these approaches has been greatly facil-
itated by the rising of large collections of data, such as the ones described previously.
These computational approaches can be categorised into 4 broad classes: molecular
dynamics simulations, energy-based, machine learning-based and other methods.
Molecular Dynamics (MD) has been used to simulate alanine substitutions and esti-
mate the corresponding changes in ∆GBinding [48]. This approach has been used to
suggest that energetically important residues are highly immobile and tend to cluster
in functionally important regions involved in protein-protein recognition [49]. However,
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the enormous computational cost of MD simulations led the authors to suggest that it
should not be used as a sole method for hotspots identification.
Energy-based methods rely upon a free energy scoring function to estimate the energetic
contribution to binding for every interface residue [50, 51]. In addition, a study using
rigid-body docking with electrostatics and desolvation scorings have also been used to
generate energy scoring functions, which calculate the tendency of a given residue to be
located at the interface and infer potential hotspots [52].
Machine learning-based (ML) approaches leverage the wealth of information on ther-
modynamic and kinetic characteristics of PPIs accumulated over the years, and try to
identify complex relationships that can then be used to characterise hotspots and predict
the effects of mutations. These are known for using a broad range of distinct features,
including physicochemical properties and shape specificity [53], solvent accessibility and
statistical potentials [54], distance patterns among residues from graph-based represen-
tation of residue environment [55], and atom contacts, atom contact areas from the
target residue and its neighbouring residues [56].
Lastly, a variety of other methods have also been proposed. These range from more basic
approaches, which only consider simple geometric characteristics of interface residues to
investigate changes in burial level of atoms from interface before and after binding [57],
to investigation of spatially conserved physico-chemical interactions (hydrogen bonds,
hydrophobic and aromatic interactions) within PPI families [58], and knowledge-based
(KB) methods [59]. Finally, a more recent computational framework, AESOP (Analysis
of Electrostatic Structures of Proteins) [60], has also been proposed in order to allow in-
silico alanine scanning and facilitate the investigation of electrostatics in PPI. AESOP
evaluates the contribution of single amino acids based on electrostatic potential functions
generated from family-based comparisons.
In terms of performance, the outcome for these methods are highly dependent on the
data in which they were trained, performing poorly on independent test sets. In addition,
studies have shown that in most cases these present a certain bias towards destabilising
mutations, given the inherent bias within the databases used for building such methods
[61]. Finally, many diseases, like cancer, might occur due the presence of multiple
mutations [62, 63], and the majority of approaches available for in-silico predictions are
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limited to analysis of single point mutations. A selection of methods to assess the impact
of mutations on PPIs is summarised in Table 1.2 and 1.3.
Name Mutation
type
Data set Approach Correlation Reference
mCSM Single ProTherm ML 0.67 [64]
DUET Single ProTherm ML 0.71 [65]
SDM Single ProTherm KB 0.61 [59, 66]
SAAFEC-
SEQ
Single ProTherm KB+MD 0.61 [67]
SAAFEC Single ProTherm KB+MD 0.65 [68]
ENCoM Single NA NMA NA [69]










Data set Approach Correlation Reference
mCSM Single SKEMPI ML 0.80 [64]
iSEE Single SKEMPI ML 0.80 [72]
AESOP Single NA Scoring function NA [60]
BeAtMuSiC Single SKEMPI Statistical
potentials
0.40 [73]




Scoring function 0.75 [50]
MMPBSA Single and
Multiple
NA MD NA [75]
BindProfX Single and
Multiple
SKEMPI Scoring function 0.73/0.69 [76]
MutaBind2 Single and
Multiple
SKEMPI Scoring function 0.76/0.74 [77]
FoldX Single and
Multiple
SKEMPI Energy function 0.81/0.37 [71]
ZEMu Single and
Multiple
SKEMPI MD 0.53/0.65 [78]
Table 1.3: Computational approaches to assess the effects of mutations on
∆∆GBinding
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1.1.7 PPIs as Drug Targets
The enormous diversity of PPIs within the cells offers potential for the development
of chemical and biological modulators that target specific pathways, through either the
inhibition or stabilisation of specific interactions [79]. Although PPIs were initially
considered ’undruggable’ targets, a number of PPI inhibitors are now approved or in
clinical trials [80], especially through targeting hotspots at the interacting interface [11].
These take advantage of the selectivity that can be difficult to achieve through inhibitors
of members of enzyme superfamilies.
Application of new drug development approaches (fragment-based screening, targeting
hotspots and increased structural data availability) has greatly facilitated PPI modulator
development efforts. Furthermore, efforts to enrich screening libraries that can serve as
probes for guiding rational design of new and more potent PPI modulators have been
proposed, mainly via statistical analyses of physicochemical properties of compounds
with activity over PPIs [81, 82], and the development of publicly available databases of
PPI small molecules modulators [83]. However, PPIs are still considered very challenging
drug development targets, and advances in new methods and computational tools can
help guide and improve PPI modulator development.
In order to overcome the complexity of using PPIs as drug targets, the concept of com-
plemented anchoring pockets at interface regions has been exploited for research into
PPI drug discovery [84–86]. Furthermore, a study has suggested that such anchoring
pockets may only exist transiently in the unbound protein, which make them difficult
to be captured in virtual or experimental chemical screening [87]. In this regard, com-
putationally expensive MD methods are required to sample transient states at atomic
resolution, which is time consuming and not feasible for large scale analysis [88].
1.2 Aims
The overall goal of this project is to conduct a systematic analysis of the physicochem-
ical and geometrical nature of PPI interfaces, including through the development of
new computational methods, in order to gain a better understanding of how PPIs are
disrupted in disease and can be modulated.
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In Chapter 2, I explored the structural landscapes of PPI interfaces based on the PDB.
I calculated geometrical and physicochemical properties of PPI interfaces using in-silico
tools and compared the distributions of these features across different classes of inter-
faces, and discussed implications for druggability.
In Chapter 3, I developed two methods, DynaMut and DynaMut2, to help understand
the effects of missense mutations on protein stability and flexibility. By incorporating
the dynamics component, using Normal Mode Analysis (NMA), these methods have
shown more balanced predictions for stabilising and destabilising mutations. Further-
more, both methods include analyses and visualisation of protein dynamics by sampling
conformations via NMA using protein 3D structure.
In Chapter 4, I explored the effects of single-point mutations on PPI binding affinity,
working from experiences using in-house framework of graph-based signatures. Here I
demonstrated how my method, mCSM-PPI2, was able to outperform more than 23 other
methods and was also shown to be valuable in identifying hotspots at PPI interfaces.
In Chapter 5, I expanded the in-house framework of graph-based signatures to rapid
identification and ranking of small-molecules likely to inhibit PPI complexes. In agree-
ment with previous studies and building on more recent data, I showed that more potent
PPI inhibitors are larger and enriched with complex ring substructures. The outcome
of this chapter will be an important tool for guiding more efficient screening of new PPI
inhibitors.
In Chapter 6, I investigated the effects of single-point mutations on phosphorylation-
mediated interactions. Here I explored structural- and sequence-based properties of
protein kinases to help identify gain of function mutations likely to lead their constitutive
activation, as well as prioritise variants for further investigation.
In Chapter 7, leveraging knowledge from Chapters 3 and 4, I developed a predictive
method to assess the impact of multiple-point mutations on PPI binding affinity. I
calculated physicochemical and geometrical properties for multiple residue environments
and combined them with evolutionary scores, dynamics features from NMA and non-
covalent contacts, as evidence to train and validate a machine learning method, mmCSM-
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Abstract  
Proteins are capable of highly specific interactions and are responsible for a wide range of 
functions, making them attractive in the pursuit of new therapeutic options. Previous studies 
focusing on overall geometry of protein-protein interfaces, however, concluded that PPI 
interfaces were generally flat. More recently this idea has been challenged by their structural 
and thermodynamic characterisation, suggesting the existence of concave binding sites that 
are closer in character to traditional small-molecule binding sites, rather than exhibiting 
complete flatness. Here we present a large-scale analysis of binding geometry and 
physicochemical properties of all protein-protein interfaces available in the Protein Data Bank. 
Our analysis provides a comprehensive overview of the protein-protein interface landscape, 
including evidence that even for overall larger, more flat interfaces that utilise discontinuous 
interacting regions, small and potentially druggable pockets are utilised at binding sites. 
 
Significance Statement 
PPIs are promising but underutilised drug targets, partially due to the misconception that they 
are flat and featureless. This has been put into question with accumulation of structurally 
resolved complexes, thermodynamic characterisation and success of PPI modulators that 
have reached the market in recent years. The analysis presented here provides a detailed and 
more comprehensive understanding of the landscape of therapeutically relevant PPI 
interfaces, suggesting opportunities for more rational approaches to drug design. We show 
that while interfaces forming continuous segments make greater use of concavity, leading to 
being more tractable from a traditional druggability perspective, discontinuous interfaces are 










Proteins are involved in most fundamental biological processes, including cell proliferation1, 
signalling2, host-pathogen interactions3 and transport4, via tightly coordinated and complex 
networks of interactions. Each protein will often interact through specific regions on their 
surface with several different protein partners. Given protein size and diversity, in humans, the 
proteome is estimated to be ~20,000, while the interactome over 650,0005, with protein-protein 
interactions (PPIs) long been considered to offer a highly selective and tunable way to 
modulate protein activities and pathways.  
 
Originally, interacting interface regions were considered to be large, hydrophobic, flat and 
featureless6, leading to their characterisation as poor targets for the development of small 
molecule modulators. However, recent structural and thermodynamic characterisation7 has 
allowed the classification of PPIs based on the nature of interacting partners, and further 
suggested that binding pockets at the interface may play important roles in molecular 
recognition and binding. However, due to the lack of understanding and complexity of PPI 
interface regions, this remains a challenging area. 
 
While large compilations of PPI networks are important to elucidate which proteins interact 
with each other, they lack in-depth information of how those interactions occur. Despite a 
relatively small proportion of the interactome being covered by structural data, advances in 
experimental structure resolution and application of structural bioinformatics8-10 add promising 
contributions to a more complete and broad structural characterisation of PPI interactions. 
 
Here we report the results of a large-scale analysis for the structural landscapes of PPI 
interfaces based on 3D structures available in the Protein Data Bank (PDB)11. We investigate 
a range of geometric and physicochemical properties of over 55,000 PPI interfaces, including 
planarity, shape complementary, secondary structure content, solvent accessibility, use of 
concavity and identification of hotspots, across different classes of interfaces, and discussed 




Protein-Protein Interface Properties: Analysis of the interface segmentation distribution of 
PPI interfaces within the PDB revealed that having up to 5 interface segments were the most 
prevalent, accounting for 70% of interfaces (Figure S1 and Table S1), with interactions 
involving peptides being predominantly single segmented. This allowed us to categorise the 
interfaces as either single (continuous) or multi-segmented (discontinuous). Figure S2 shows 
the distribution of planarity for interfaces of different segmentations and types. Single 
segmented interfaces were significantly more planar than multi segmented ones (Table S2) 
and, while there was no significant difference in segmentation between peptide-type 
interfaces, Non-identical pairs were significantly more planar than identical pairs with 
symmetric and non-symmetric interfaces. The former was the most planar among all interface 
types (Table S3).  
 
Single and multi segmented interfaces were also largely composed of residues in loops and 
ɑ-helices in their core and periphery regions (Figure S3, Figure S4, Table S4 and Table S5). 
Loop residues dominated on average at smaller sides of single segmented interfaces, and on 
both sides of multi segmented interfaces, while 𝛽-sheet residues were significantly less 
prevalent in all interfaces. However, ɑ-helix dominated in the interface cores of multi 
segmented interfaces and the larger sides of single segmented interfaces, but not in the 
smaller sides of single segmented interfaces. Loops were significantly more present in the 
interface peripheries of all segmentations of interfaces than ɑ-helix, which in turn were 
significantly more present than 𝛽-sheet residues. With respect to secondary structure use by 
interface types, loops were more prevalent at identical non-symmetrical than ɑ-helix, whereas 
there were no significant differences in ɑ-helix and loop usage in identical symmetric 
interfaces. Peptides were significantly more looped than other interfaces, however, while the 
enzyme’s interface regions of Enzyme-Peptide interfaces tended to be formed of loops, the 
protein interface regions of Protein-peptide interfaces were significantly more helical than 
unstructured. In the interface core, however, for peptides of Protein-peptide interfaces, ɑ-helix 
made up a greater proportion of interface cores than ɑ-helix overall, and helices were 
significantly more present in identical symmetric core residues than loops, as opposed to the 
opposite in the all interfaces. Loops were significantly more present in the interface peripheries 
of all interface types, followed by ɑ-helix and  𝛽-sheets. 
 
With respect to Normalised Interface Packing (NIP), single segmented interfaces were 
significantly more well-packed than multi segmented interfaces (Figure S5 and Table S6). 
Peptidic interfaces were most well packed, followed by identical pairs with non-symmetric 
interfaces and Non-identical pairs, which did not differ significantly in packing, and Identical 
pairs with symmetric interfaces (Table S7). Similar to NIP, Normalised Shape correlation (NSc) 
was significantly higher in single segmented interfaces than in multi segmented interfaces 
(Figure S6 and Table S8). Peptidic interfaces were the most complementary, however, 
Enzyme-peptide interfaces had significantly higher NSc values than Protein-peptide ones. 
Identical pairs with symmetric interfaces were the least complementary and Non-identical 
pairs and Identical pairs with non-symmetric interfaces were not significantly different from 
each other (Table S9).  
 
The average buried surface area (BSA) was significantly higher for multi segmented interfaces 
than single segmented interfaces, by over 1,000 Å2 (Figure S7). Single segmented interfaces 
used significantly greater proportions of interface core residues on their larger sides than either 
side of multi segmented interfaces (Tables S10 and Table S11). However, they utilised a 
significantly smaller proportion of interface core residues per interface on the smaller side of 
the interface than multi segmented interfaces, which differ significantly between smaller and 
larger side (Figure S8, Figure S9, Table S12 and Table S13). 
 
Looking at the intermolecular interactions per 100 Å2 BSA revealed interesting differences 
between the classes of interfaces. Figures S10-S11 and Tables S14-S45 show distributions 
of use of non-covalent contacts for PPI interfaces in the dataset, by interface segmentation 
and interface type, respectively. Single segmented interfaces were significantly enriched in 
VdW, hydrogen/polar, atom-ring interactions compared to interfaces with multiple segments, 
which showed to have significantly more ionic, hydrophobic, carbonyl, amide-ring and amide-
amide interactions. With respect to types of interfaces, individual interaction types showed 
different variations. For some interface types, numbers of interactions per 100 Å2 BSA 
matched those elucidated from analysing interactions by interface segmentation alone, such 
as peptidic interfaces making greater use of VDW clash, proximal, hydrogen/polar bonding, 
weak hydrogen/polar bonding, hydrophobic, carbonyl, atom ring interactions. However, in 
other cases, variations between use of interactions were more interface type-dependent than 
segmentation-dependent. For example, there has been significantly more use of amide-amide 
interactions by Identical pairs with non-symmetric interfaces than any other interface type, 
while other interface types were not significantly different between interface types, with the 
exception of Protein-peptide interfaces, which made use of significantly fewer ionic 
interactions. Identical pairs with symmetric interfaces consistently made significantly lower or 
similar use of non-covalent interactions, with the exceptions of amide-amide, Carbon-PI and 
ionic interactions, compared to all other interface types. 
 
Concavity Across Interfaces: Concave geometry of protein surfaces is implicated in the 
formation of surface regions suitable for the binding of small, potentially drug-like, molecules. 
The majority of observations indicated that both single and multi segmented interfaces made 
use of concavities over the whole interface surface, however, single segmented interfaces 
were bound significantly deeper on average, binding at a “groove” magnitude of concavity 
(Figure 1, Figure S12, Tables S46 and S47). By comparison, small-molecule natural product 
ligands occupy concavities of less than 5 Å with 60-95% of their atoms12 (measured per-atom, 
rather than summarised by deepest value per-residue).  
 
The importance of concavity on average and at the deepest level varied as the protein 
molecule size and interface size of the protomer increased (Figure S13) (R=0.32, p-value 
<0.05). Both single and multi segmented interfaces exhibited outliers with very large chain 
lengths. Single segmented interfaces also utilised significantly fewer interacting residues than 
multi segmented interfaces (Figure 2A and Tables S48), while each globular interface type 
was significantly different in number of interacting residues from one another (Table S49). No 
significant difference in the chain length for the two types of peptidic interfaces was observed, 
neither between identical pairs with symmetric and non-symmetric interfaces (Figure 2B, 
TableS S50 and S51). Notably, identical pairs with symmetric interfaces used significantly 
more residues than all the other types of interfaces. 
 
Inspecting averaged concavity, showed that smaller protomers with smaller interfaces were 
more likely to utilise concavity on average (Figure S13, Tables S46 and S47). As protomer 
length increased, interfaces became overall flatter regardless of the number of interacting 
residues. With respect to deepest concavity utilised at interfaces, deep concavities (< 4 Å) 
were utilised by at least part of the interface for a majority of observations. However, interface 
deepest concavity tended to take less concave values for longer protomers with fewer 
interacting residues (Figure S13). Some exceptions to this trend were where longer protomers 
used deep concavities at their deepest, although the interacting region of these two large 
chains resembles more a peptidic interface.  
 
Exploring use of Concavity: Looking more closely, we analysed how concavity at interfaces 
was used by individual residues. Residue utilisation of concavity, how well the residues of one 
side of each interface make use of the (sub-)pockets available to them on the partner protein, 
varied with the nearby formation of concavity on the binding partner protein (Figures S14 and 
S15). Here, single and multi segmented interfaces made use of concavity in both the core and 
periphery. For multi segment/globular interface categories, residues in the interface core were 
observed in bimodal distributions; a mode where the residue is bound deeply and using local 
concavity, and a mode where the residue is bound with varying degrees of local concavity on 
the partner chain. Multi segment interfaces utilising discontinuous binding regions were not 
only larger than single segmented interfaces, but also less well packed and less 
complementary in shape compared to single segment interfaces. These observations suggest 
that single interacting segments make tight, selective interactions with their globular partner 
proteins, compared to looser interfaces in larger multi segmented complexes. Deepest 
average use of concavity was by peptide interface core residues, and peptide interface 
periphery residues occupied deeper concavities than Identical pairs with symmetric and non-
symmetric interface core residues, which did not differ significantly.  
 
The large proportion of interfaces that at their deepest occupied deep concavities (Figures 
S14 and S15) raised the hypothesis that both surfaces of PPI interfaces provide “anchoring” 
points for one another. Analysis of interfaces revealed that an “interlocking” phenomenon, 
where deep concavity utilised in the 0.5 Å to 2 Å range was complemented by reciprocal 
concavity use on the other side of the interface, existed in a greater proportion for multi 
segmented, globular interfaces, than for single segmented, peptidic interfaces (Figures 3 and 
S16). Helix residues bound significantly deeper than loop and sheet residues in single 
segmented interfaces given the same solvent accessibility, for multi segmented interfaces 
helices and sheets bound significantly deeper than loops, however, they were not significantly 
different from each other (Figure S17, Figure S18, Tables S52 and S53). 
 
Concavity use by residues in different interfaces and solvent accessibility environments were 
also different by residue amino acid. Overall, bulkier residues used the most concavity than 
any residue environment in the interface core and periphery for single and multi segmented 
interfaces (Figure S19 and Table S54), and across the different interface types (Figure S20 
and Table S55). Interestingly, minimum concavity values were consistently low across all 
interface types and solvent accessibilities, suggesting individual residue uses of concavity by 
each amino acid, in all residue environments.  
 
Energetic Hot Spots: Hotspot density in different interface segmentations and types was 
calculated using mCSM-PPI to identify the number of hotspots per 100 Å2 BSA (Figure S21). 
Single segment interfaces used significantly more hotspots per 100 Å2 BSA than multi 
segmented interfaces. Interfaces involving peptides had the highest densities of hotspots and 
were significantly different between the two classes (Enzyme-peptide and Protein-peptide 
interactions) (Tables S56 and S57). For interactions involving globular proteins, Identical pairs 
with symmetric interactions used significantly more hotspots per 100 Å2 BSA than the other 
two classes and identical pairs with non-symmetric interfaces utilised significantly fewer 
hotspots per 100 Å2 BSA than any other interface type. Figures S22 and S23 illustrate the 
relationship between residue use of concavity, solvent accessibility, and energetic importance 
for each type of interface in the dataset. Overall, for residues originating from the more deeply 
bound sides of interfaces, there was no significant correlation between residue occupation of 
concavity and energetic importance (Pearson correlation coefficient R = -0.05). When 
separated by solvent accessibility, the correlations were R = 0.23 for interface core residues 
and R=0.02 for peripheral residues. Correlations of hotspots with use of concavity ranged from 
-0.04 to 0.25 for all interface types and environments (Figure S23). 
 
Clustering of Orthosteric Sub-Pockets on PPI Interfaces: The anchor hypothesis of 
interaction proposes that initial, fast recognition between protomers is mediated by residues, 
usually from the smaller interacting partner, that bury a large portion (> 100 Å2) of surface area 
and adopt the same rotameric states when bound and unbound. We explored this concept 
using concavity as a metric for determining anchoring residues, in addition to solvent 
accessibility, which we define here as “enclosed” residues. Looking at the numbers of 
enclosed residues present in PPI interfaces (Figure S24) showed that around 80% of PPI 
interfaces had at least one enclosed residue. Enzyme-peptide interfaces exhibited the largest 
proportion of interfaces with at least one enclosed residue (93%), followed by Protein-Peptides 
(90%), Identical pairs with symmetric interface (88%), Identical pairs with non-symmetric 
interface (76 %), and non-Identical pairs (75%). 
 
To explore how residues utilising concavity may be exploited for drug discovery, enclosed 
residues at PPI interfaces were clustered in 3D. These enclosed residue clusters represent 
pockets, or adjacent sub-pockets, that are demonstrably utilised by proteins at interfaces and 
thus have potential for orthosteric challenge with small-molecules. This revealed that 9,253 
interfaces possessed enclosed residue clusters (16% of the dataset) (Figure 4). Protein-
Peptide interfaces had the smallest proportion of interfaces with enclosed residue clusters 
(11%), followed by Identical pairs with non-symmetric interfaces (12%), non-identical pairs 
(12%), Enzyme-Peptides (13%), and identical pairs with symmetric interfaces with the highest 
proportion (26%). 
 
The existence of small, buried protein-occupied pockets in larger, multi segment interfaces, 
consisting of clusters of multiple small-volume pockets may present opportunities for single 
residue sites to be competed for with fragments, which could be elaborated into interface 
competitive small molecules for transient interfaces where interface on/off kinetics could allow 
competitive inhibition. Geometric clustering of deeply bound and solvent inaccessible residues 
at interfaces revealed cases in the dataset that presented these dense clusters of enclosed 
residues, which were potentially occupying druggable pockets. However, the presence of such 
clusters is not an essential requisite for druggability, as evidenced by only one drugged PPI 




In this study we explored the nature of PPI binding interfaces with respect to binding-mode 
geometry, interatomic interactions, and structural and energetic importance of interface 
residues. While often considered flat and featureless, we showed that while the majority of 
interfaces extracted from the PDB were indeed flat on average, many interfaces did utilise 
concavity at their deepest point, suggesting that an element of concavity is important for many 
protein-protein interactions. Peptidic interfaces and those utilising continuous binding regions 
at the interface made greater use of concavity on average, suggesting that these binding sites 
may be better defined with respect to potential exploitation in drug discovery. Depth may 
provide a way of improving encapsulation of a residue in smaller interfaces, as evidenced by 
the greater proportion of peptide interface core residues in Protein-Peptide interfaces using 
deeper binding modes, and making proportionally higher use of the local binding site space 
(complemented pockets) available in comparison to other residue environments. Our findings 
support the anchor hypothesis of many interfaces having deeply bound, solvent inaccessible 
and energetically important residues, which can be an important venue in drug discovery. We 
show that many interfaces provide concavity on both sides of the interface to support 
interactions. 
 
We hypothesise that differences in interatomic contact usage by smaller, continuous 
interfaces compared to larger multi segmented interfaces may reflect differences in the nature 
of their recognition. As single segments tended to bind using more grooves than multi 
segmented PPIs, the significantly greater use of more specifically directional interactions, such 
as hydrogen bonding, by single segment interfaces may indicate an evolved imperative for the 
use of directional interactions to lock a segment into a deep binding site without requiring 
rearrangement of the globular binding partner. Conversely, for larger and multi segment 
interfaces, ionic interactions that may be involved in longer range electrostatic steering may 
contribute more to recognition where overall concavity is not present, and residues occupying 
concavities are less prevalent. 
 
By analysing a large-scale dataset of structurally characterised PPIs from the PDB, we found 
that interfaces forming a continuous binding segment make greater overall use of protrusion 
into partner protein concavities on average than do globular discontinuous interactions. 
Deeply bound residues existed in a large proportion of all interactions and there was a 
relationship between depth and solvent accessibility depending on the continuity of the 
interface. Over 80% of interfaces utilised at least one deeply bound, solvent inaccessible 
residue, and over 16% of interfaces made use of multiple, small-volume sub-pockets of the 
kind bound by previously developed orthosteric PPI inhibitors.  
 
We propose that while continuous binding sites that make use of concave binding modes 
overall may be more immediately tractable from a druggability perspective, there may be 
benefit in targeting globular protein interfaces with discrete, complemented sub-pockets, into 
which residue-sized small-molecule fragments could protrude. Through analysing the 
chemistry of interfaces as an aggregate property, summarising pairwise atomic interactions, 
we uncovered different chemical preferences between continuous and discontinuous binding 
sites, suggesting that single continuous segments require more specific directional 
interactions, whereas discontinuous interfaces burying larger surface areas rely more on 
aromatic sealing of the interface, and on electrostatic interactions. These discontinuous 
interfaces may be more amenable to target by allosteric or interface approaches. Our results 
move towards a better understanding of the features used at therapeutically relevant PPI 
interfaces, which can then be used on a more rational approach to drug design. 
 
Materials and Methods 
 
Data: Pairwise structures of interacting proteins were extracted from the PDB (accessed on 
14 April 2021). Interactions with missing atoms at the interface, interfaces that overlapped with 
other interfaces (overlapping interfaces, where more than two protomers were bound together 
using the same residues, interfered with interpretation of concavity), interfaces where the 
product of the number of residues contributed by each protein partner was less than 25 and 
interfaces where less than 100 Å2 was buried between the two proteins, were removed from 
the dataset. The latter two filters were used to remove interfaces where the chains did not 
make substantial contact14. To simplify large scale analysis, only the first model of NMR 
derived structures was considered. 
 
A non-redundant set of PPI interfaces was generated by clustering interfaces first on whether 
the interacting pair of proteins was identical using CD-HIT at 95% identity cutoff15 and 
subsequently by clustering interactions involving identical protein chains based on the 
interface sequence. Here, we used the SequenceMatcher module, available in the difflib 
Python package, to compare short peptide sequences, with a similarity cutoff of 75%. 
Representative interface pairs for each cluster were chosen based on a structure quality 
score14. 
 
The final dataset of interfaces was partitioned by categorising interactions between globular 
proteins and protein-peptide interactions. The dataset consisted of 55,189 interfaces, of which 
15,920 were Identical pairs with symmetric interface, 8,580 were Identical pairs with non-
symmetric interface, 28,165 were Non-identical pairs, 1,702 were Protein-peptide interfaces, 
and 822 were Enzyme-peptide interfaces. Interactions between peptides and enzymes were 
separated from interactions with non-enzymatic proteins by identifying enzyme chains using 
the SIFTS cross-database mappings of the PDB to EC enzyme classification database16, to 
differentiate enzyme-substrate and enzyme-inhibitor interactions that may involve active site 
cavities from non-catalytic site protein-peptide interfaces. 
 
Interface Properties: Pairwise PPI interfaces consist of two interacting protein surfaces. 
Some properties of these interfaces, such as buried surface area, are property of the whole 
interface. However, other properties including binding depth belong to one side of the 
interactions. For the latter we conducted the analysis from the perspective of the smaller side 
of the interface (the side contributing the fewest residues; for example, the peptide in a protein-
peptide interface), unless otherwise stated. Properties analysed included shape 
complementary, interface packing and planarity for whole interfaces. The shape correlation 
(Sc) measure uses interface region surface normal vectors to determine how well fit is the 
interface between two proteins17. However, in this work we used a more recent implementation 
which uses Delauney triangulation to calculate a Normalised Sc (NSc) and Interface Packing 
(NIP)18. Planarity of the interface was measure by using RMSD of interface residues Cɑ atoms 
from a least-squares fitted plane through the interface. The resulting planarity value, measured 
in angstroms (Å), is lower for more planar interfaces, and higher otherwise. 
 
As for properties of protein residues, here we calculated type of secondary structure (ɑ-helix, 
𝛃-sheets and loop) using DSSP via Biopython19, solvent accessibility was generated via 
NACCESS20, non-covalent interactions were calculated using Arpeggio21 and concavity was 
measured using the inaccessible probe radius (Rinaccess) value, in angstroms, calculated using 
Ghecom12. Concavity per residue was measured by using the deepest-bound atom’s concavity 
value, while whole interface concavity was calculated via arithmetic mean of these deepest 
per-residue values across all interface residues. 
  
Residues within 5 Å of any of the binding partner’s protein atoms were considered to be part 
of the interface, and were further categorised as being core or periphery based on their solvent 
accessibility14, 22. Relative Solvent Accessibility (RSA) gives a measurement of burial from 
solvent that is comparable between residues of different volumes, and is used to determine 
which residues are buried in protein or interface cores. The categories used for residue solvent 
exposure are outlined in Table S58. 
 
Energetically Important Interface Residues: The Ghecom measurement of concavity 
together with solvent accessibility was used to elucidate potential anchor residues from 
interface structure. Any residue that was solvent inaccessible with a residue minimum 
concavity threshold of 4 Å or less were classified as enclosed residues. The DBSCAN density-
based clustering algorithm23 was used to geometrically cluster enclosed residues at interfaces 
to search for possible orthosteric pockets, defined by clusters of anchors. 
 
In addition, ΔΔGBinding values from mCSM-PPI24 were used to perform computational alanine 
scanning of each interface, in order to determine the energetic importance of each binding 
residue. The threshold of |ΔΔGBinding| > 1 kcal/mol was then used to determine whether a 
residue was a hotspot or non-hotspot25. 
 
Statistical analysis: The one-way analysis of variance (ANOVA), as implemented in the stats 
module of SciPy26, was used to compare distributions between different groups. Where 
ANOVA indicated significant differences between groups, we used Tukey’s Honestly 
Significant Difference (Tukey’s HSD) to categorise observations into their similar or different 
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Figure 1 - Point and 2D density distributions of occupation of concavity at PPI interfaces, on 
average and at deepest point. Each point represents the smaller side of one interface from the non-
redundant set of non-overlapping PPI interfaces. Concavity is as measured by Ghecom, representing 
the smallest spherical probe size that was able to enter a space around the partner protein’s surface 
(where smaller values represent deeper binding). Interfaces are coloured by segmentation, and PPI 
interfaces from 2P2I dataset for which small-molecule inhibitors have been developed are overlaid as 
black points and are labelled. 
 
 
Figure 2 - 2D density distributions showing interface classifications by chain length and size of 
interacting surfaces. Density distributions are shown at a single density level for interfaces by A) 




Figure 3 - Point and 2D density distributions of deepest concavity occupation on the larger and 
smaller sides of PPI interfaces. Concavity is as measured by Ghecom, representing the smallest 
spherical probe size that was able to enter a space sound the partner protein’s surface (where smaller 




Figure 4 - Elucidating potential orthosteric binding pockets utilised by PPI protein partners, by 
clustering deeply bound, solvent inaccessible interface residues. The distribution of protein 
partner chain length as compared to binding site size is shown as gray points overlaid with coloured 
circles representing interfaces for which clusters of enclosed residues were found. Interfaces from the 
2P2I set for which small-molecule inhibitors have been designed are overlaid as circles and labelled. 
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Figure S1 - Histogram distribution of interface binding continuity for PPI interfaces. Binding 
continuity is shown for the smaller side (fewest interacting residues) of each pairwise PPI interface in 







Figure S2 - Histogram distributions of interface planarity for single and multi segmented 
interfaces. Histograms are stacked and filled based on the type of interface. A) displays the distribution 
of interface planarity for single segmented interfaces and B) for discontinuous interfaces. Solid line 





Figure S3 -  Boxplot distributions of interface proportions of secondary structure types, by 
interface segmentation. Gray boxes indicate proportions of interfaces with a given secondary 
structure type. Coloured boxes represent proportions of interfaces with a given secondary structure by 
interface solvent exposure type. 
 
 
Figure S4 - Boxplot distributions of interface proportions of secondary structure types, by 
interface segmentation and interface type. Gray boxes indicate proportions of interfaces with a given 
secondary structure type. Coloured boxes represent proportions of interfaces with a given secondary 
structure by interface solvent exposure type. 
 
 
Figure S5 - Histogram distributions of interface normalised interface packing (NIP) for single 
and multi segmented interfaces. Histograms are stacked and filled based on the type of interface. A) 
displays the distribution of interface packing for single segmented interfaces and B) for discontinuous 
interfaces. Solid line indicates distribution mean and dashed line shows the geometrical mean. 
 
 
Figure S6 - Histogram distributions of interface normalised shape correlation (NSc) for single 
and multi segmented interfaces. Histograms are stacked and filled based on the type of interface. A) 
displays the distribution of interface shape complementarity for single segmented interfaces and B) for 




Figure S7 - Histogram of buried surface area distributions for single and multi segmented 
interfaces. Histograms are stacked and filled by type of interface. A) displays the distribution of 
interface shape complementarity for single segmented interfaces and B) for discontinuous interfaces. 
Solid line indicates distribution mean and dashed line shows the geometrical mean. 
 
 
Figure S8 - Boxplot distributions of interface proportions of residues that were core or 
periphery, by interface segmentation. Outliers are shown as translucent gray circles. “Smaller side” 
refers to the side of the pairwise interface with fewer interacting residues than the “Larger side”. 
 
 
Figure S9 - Boxplot distributions of interface proportions of residues that were core or 
periphery, by interface segmentation and interface type. Outliers are shown as translucent gray 
circles. “Smaller side” refers to the side of the pairwise interface with fewer interacting residues than 
the “Larger side”. 
 
Figure S10 - Boxplot distributions of Arpeggio structural interactomics analysis of non-covalent 
interactions per 100Å2 of PPI interfaces, comparing interfaces by segmentation. Outliers are 
shown as gray circles. 
 
 
Figure S11 - Boxplot distributions of Arpeggio structural interactomics analysis of non-covalent 
interactions per 100Å2 of PPI interfaces, comparing interfaces by interface type. Outliers are 




Figure S12 - Point and 2D density distributions of occupation of concavity at PPI interfaces, on 
average and at deepest. Each point represents the smaller side of one interface from the non-
redundant set of non-overlapping PPI interfaces. Concavity is measured by Ghecom, representing the 
smallest spherical probe size that was able to enter a space around the partner protein’s surface 9where 
smaller values represent deeper binding). Interfaces are coloured by interface type, and PPI interfaces 
from the 2P2I dataset for which small-molecule inhibitors have been developed are overlaid as black 
points and are labelled. 
 
 
Figure S13 - Summary plots showing exploitation of concavity by PPI interfaces as the size of 
interacting protomers and their interacting surface varied. Each coloured block represents the 
arithmetic mean of A the average (red) or B the deepest (blue) concavity exploited by interfaces within 
the plot space covered by the block. 
 
 
Figure S14 - Distribution of binding mode and extent of local concavity of residue in different 
interface segmentations. The use of concavity interface residues from the shorter chain of interactions 
of each class is shown on the abscissa. The depth of concavity formation by the deepest surface atom 
of the partner protein withing 5Å of the abscissa residue is shown on the ordinate. Each open circle 
represents a residue, and the 2D density distribution is shown where red, orange, yellow and blue 
represent areas of higher through lower point density, respectively. 
 
 
Figure S15 - Distribution of binding mode and extent of local concavity for residues in different 
interface classes. The use of concavity interface residues from the shorter chain of interactions of 
each class is shown on the abscissa. The extent of concavity formation by the deepest surface atom of 
the partner protein within 5Å of the abscissa residue is shown on the ordinate. Each open circle 
represents a residue, and the 2D density distribution is shown where red, orange, yellow and blue 
represent areas of higher through lower point density, respectively. 
 
 
Figure S16 - Point and 2D density distributions of deepest concavity occupation on the larger 
and smaller sides of PPI interfaces. Concavity is measured by Ghecom, representing the smallest 
spherical probe size that was able to enter a space around the partner protein’s surface (where smaller 
values represent deeper binding). Density distributions are coloured according to interface type. 
 
 
Figure S17 - Boxplot distributions of interface residue use of concavity by secondary structure, 
solvent exposure and interface segmentation. Concavity is measured by Ghecom, representing the 
smallest spherical probe size that was able to enter a space around the partner protein’s surface (where 
smaller values represent deeper binding). 
 
 
Figure S18 - Boxplot distributions of interface residue use of concavity by secondary structure, 
solvent exposure and interface type. Concavity is measured by Ghecom, representing the smallest 
spherical probe size that was able to enter a space around the partner protein’s surface (where smaller 
values represent deeper binding). 
 
 
Figure S19 - Boxplot distributions of PPI residue use of concavity by amino acid. Residue 
distributions are coloured according to a modified version of the Lest colour scheme (Lesk, 2005) (small 
non-polar = orange, hydrophobic = green, polar = magenta, negatively charger = red, positively charged 
= blue). Concavity is measured by Ghecom, representing the smallest spherical probe size that was 
able to enter a space around the partner protein’s surface (where smaller values represent deeper 
binding). Plots are divided by interface segmentation and solvent accessibility. 
 
 
Figure S20 - Boxplot distributions of PPI residue use of concavity by amino acid. Residue 
distributions are coloured according to a modified version of the Lest colour scheme1 (small non-polar 
= orange, hydrophobic = green, polar = magenta, negatively charger = red, positively charged = blue). 
Concavity is measured by Ghecom, representing the smallest spherical probe size that was able to 
enter a space around the partner protein’s surface (where smaller values represent deeper binding). 
Plots are divided by interface type and solvent accessibility. 
 
 
Figure S21 - Boxplot distributions of hotspots per 100Å2 buried surface area. Distributions of 
mCSM-PPI predicted hotspots (ΔΔGBinding > 1 kcal/mol) for PPI interfaces by A) interface segmentation 
and B) interface type. 
 
 
Figure S22 - Relationships between residue energetic hotspot predictions and use of concavity 
for interfaces by interface segmentation. Residue use of concavity as measured by Ghecom is 
shown on the abscissa, and mCSM-PPI alanine scanning ΔΔGBinding predictions are shown on the 
ordinate. All residues originate from the deepest bound binding partner. The horizontal red lines show 
the threshold for mCSM-PPI predictions which consider a residue as a hotspot. Plots are divided by 
interface type. Linear model fitting is shown by gray lines. R values for Pearson correlation coefficient 
estimates are shown. 
 
 
Figure S23 - Relationships between residue energetic hotspot predictions and use of concavity 
for different interfaces types. Residue use of concavity as measured by Ghecom is shown on the 
abscissa, and mCSM-PPI alanine scanning ΔΔGBinding predictions are shown on the ordinate. All 
residues originate from the deepest bound binding partner. The horizontal red lines show the threshold 
for mmCSM-PPI predictions to consider a residue as a hotspot. Plots are divided by interface classes. 




Figure S24 - Histogram distributions of numbers of deeply bound, solvent inaccessible residues 
in PPI interfaces. Distributions of the number of enclosed residues for the non-redundant set of PPI 
interfaces. Enclosed residues were solvent buried (interface core) residues with a concavity value of ≤ 
4Å. The distribution for all interfaces is shown in gray, and the distributions for interface types in colours 




Table S1 - Summary statistics and ANOVA analysis of PPI interface numbers of 
interface segmentation by interface type. ANOVA p-value < 0.05 
Interface type ANOVA Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 1.01 0.13 822 1 1 3 1 
Protein-peptide a 1.03 0.24 1702 1 1 4 1 
Non-identical b 3.41 2.99 28165 1 3 32 1 
Identical-symmetric c 4.99 2.92 15920 1 4 33 4 
Identical-nonsymmetric d 4.3 3.95 8580 1 3 47 2 
 
Table S2 - Summary statistics and ANOVA analysis of PPI interface planarity (Å) by 
interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 4.54 1.82 10694 0.40 4.20 19.86 0.40 
Multi b 6.28 2.80 44415 0.51 5.53 20.03 0.51 
 
Table S3 - Summary statistics and ANOVA analysis of PPI interface planarity (Å) by 
interface type. ANOVA p-value < 0.05. 
Interface type ANOVA Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 4.18 0.99 822 1.91 4.07 8.17 1.91 
Protein-peptide a 4.40 1.21 1702 0.70 4.32 9.51 0.69 
Non-identical b 5.74 2.65 28165 1.02 5.06 20.03 1.01 
Identical-symmetric c 6.52 2.72 15920 0.67 5.86 19.97 0.67 
Identical-nonsymmetric d 6.00 3.03 8580 0.40 5.12 19.97 0.40 
 
Table S4 - Summary statistics and ANOVA analysis of proportions of secondary 
structure types in PPI interfaces in interface cores by interface type. Anova p-value < 
0.05. 
Segmentation SST Side 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single Helices Smaller a 0.34 0.38 10694 0.00 0.20 1.00 0.00 
Single Sheets Smaller b 0.08 0.17 10694 0.00 0.00 1.00 0.00 
Single Loops Smaller c 0.58 0.35 10694 0.00 0.60 1.00 1.00 
Multi Helices Smaller a 0.35 0.28 44415 0.00 0.32 1.00 0.00 
Multi Sheets Smaller d 0.16 0.20 10694 0.00 0.09 1.00 0.00 
Multi Loops Smaller e 0.49 0.23 10694 0.00 0.47 1.00 0.50 
Single Helices Larger f 0.41 0.34 10694 0.00 0.38 1.00 0.00 
Single Sheets Larger g 0.18 0.23 10694 0.00 0.07 1.00 0.00 
Single Loops Larger f 0.41 0.27 10694 0.00 0.38 1.00 0.00 
Multi Helices Larger a 0.35 0.27 44415 0.00 0.33 1.00 0.00 
Multi Sheets Larger d 0.18 0.20 44415 0.00 0.11 1.00 0.00 
Multi Loops Larger g 0.47 0.22 44415 0.00 0.46 1.00 0.50 
 
Table S5 - Summary statistics and ANOVA analysis of proportions of secondary 
structure types in PPI interfaces in interface periphery by interface type. Anova p-value 
< 0.05. 
Segmentation SST Side 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single Helices Smaller a 0.33 0.42 10694 0.00 0.00 1.00 0.00 
Single Sheets Smaller b 0.02 0.13 10694 0.00 0.00 1.00 0.00 
Single Loops Smaller a 0.34 0.42 10694 0.00 0.00 1.00 0.00 
Multi Helices Smaller c 0.36 0.32 44415 0.00 0.33 1.00 0.00 
Multi Sheets Smaller d 0.16 0.23 10694 0.00 0.00 1.00 0.00 
Multi Loops Smaller e 0.46 0.29 10694 0.00 0.46 1.00 0.50 
Single Helices Larger f 0.42 0.38 10694 0.00 0.40 1.00 0.00 
Single Sheets Larger dg 0.16 0.26 10694 0.00 0.00 1.00 0.00 
Single Loops Larger h 0.39 0.34 10694 0.00 0.33 1.00 0.00 
Multi Helices Larger i 0.37 0.32 44415 0.00 0.33 1.00 0.00 
Multi Sheets Larger g 0.17 0.24 44415 0.00 0.00 1.00 0.00 
Multi Loops Larger j 0.45 0.29 44415 0.00 0.43 1.00 0.00 
 
Table S6 - Summary statistics and ANOVA analysis of PPI interface NIP by interface 
segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.00078 0.00057 10694 0.00002 0.000628 0.00918 0.000265 
Multi b 0.0004 0.00041 44415 0 0.000256 0.01391 0.000081 
 
Table S7 - Summary statistics and ANOVA analysis of PPI interface NIP by interface 
type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.0008 0.00036 822 0.00018 0.000735 0.00237 0.000336 
Protein-peptide a 0.00078 0.00055 1702 0.00018 0.00064 0.00918 0.000242 
Non-identical b 0.00053 0.00048 28165 0 0.000373 0.00403 0.000009 
Identical-symmetric c 0.0003 0.00037 15920 0 0.000172 0.00443 0.000099 
Identical-nonsymmetric b 0.00052 0.00049 8580 0 0.00037 0.01391 0.000156 
 
Table S8 - Summary statistics and ANOVA analysis of PPI interface NSc by interface 
segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.00093 0.00063 10694 0 0.0007755 0.0071 0.000526 
Multi b 0.00051 0.00048 44415 0 0.000376 0.00864 0.000154 
 
Table S9 - Summary statistics and ANOVA analysis of PPI interface NSc by interface 
type. ANOVA p-value < 0.05. 
Interface type ANOVA Mean SD N Min Med Max Mode 
Group 
Enzyme-peptide a 0.00124 0.00056 822 0.00027 0.0011165 0.00396 0.000551 
Protein-peptide b 0.00104 0.00054 1702 0.00033 0.000902 0.00467 0.000558 
Non-identical c 0.00065 0.00055 28165 0 0.000504 0.00864 0.000154 
Identical-symmetric d 0.00038 0.00039 15920 0 0.000243 0.00701 0.000159 
Identical-nonsymmetric c 0.00065 0.00055 8580 0 0.000509 0.00572 0.000143 
 
Table S10 - Summary statistics and ANOVA analysis of PPI interface BSA by interface 
segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1173.17 957.48 10694 195.54 904.76 13496.83 386.22 
Multi b 2259.09 2259.79 44415 152.55 1621.27 27463.39 316.977 
 
Table S11 - Summary statistics and ANOVA analysis of PPI interface BSA by interface 
type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 828.08 294.95 822 315.57 772.13 2073.21 315.574 
Protein-peptide a 1005.93 455.06 1702 268.02 913.98 2403.32 268.024 
Non-identical b 1819.32 2053.82 28165 152.55 1253.41 22558.12 316.97 
Identical-symmetric c 2707.22 2030.73 15920 155.22 2230.63 26718.4 816.413 
Identical-nonsymmetric d 1900.42 2429.5 8580 199.08 1192.15 27463.39 318.71 
 
Table S12 - Summary statistics and ANOVA analysis of PPI interface proportion of core 
residues by interface segmentation. ANOVA p-value < 0.05. Larger side refers to the side 





Group Mean SD N Min Med Max Mode 
Single Larger a 0.23 0.16 10694 0 0.19 0.94 0 
Single Smaller b 0.1 0.14 10694 0 0.04 1 0 
Multi Larger c 0.2 0.14 44415 0 0.21 0.62 0 
Multi Smaller d 0.19 0.15 44415 0 0.19 0.77 0 
 
Table S13 - Summary statistics and ANOVA analysis of PPI interface proportion of core 
residues by interface type. ANOVA p-value < 0.05. Larger side refers to the side of the 
pairwise interface with fewer interacting residues than the smaller side. 
Interface type Interface side 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide Larger a 0.29 0.14 822 0.00 0.29 0.74 0.33 
Enzyme-peptide Smaller b 0.09 0.14 822 0.00 0.00 0.67 0.00 
Protein-peptide Larger a 0.30 0.18 1702 0.00 0.29 0.94 0.00 
Protein-peptide Smaller c 0.15 0.19 1702 0.00 0.10 1.00 0.00 
Non-identical Larger d 0.19 0.14 28124 0.00 0.18 0.64 0.00 
Non-identical Smaller c 0.15 0.14 28124 0.00 0.13 0.82 0.00 
Identical-symmetric Larger e 0.25 0.14 15912 0.00 0.27 0.62 0.00 
Identical-symmetric Smaller e 0.26 0.14 15912 0.00 0.27 0.62 0.00 
Identical-nonsymmetric Larger f 0.17 0.13 8549 0.00 0.17 0.62 0.00 
Identical-nonsymmetric Smaller c 0.15 0.14 8549 0.00 0.14 0.61 0.00 
 
Table S14 - Summary statistics and ANOVA analysis of VdW Clash interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.53 0.43 10694 -0.62 1.52 2.97 1.00 
Multi b 1.52 0.40 44415 -1.17 1.48 3.52 1.00 
 
Table S15 - Summary statistics and ANOVA analysis of VdW Clash interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 1.57 0.32 822 0.71 1.57 2.51 0.70 
Protein-peptide b 1.47 0.30 1702 0.20 1.46 2.73 0.19 
Non-identical a 1.56 0.42 28165 -1.13 1.53 3.52 1.00 
Identical-symmetric c 1.42 0.37 15920 -1.17 1.39 2.97 1.00 
Identical-nonsymmetric a 1.58 0.43 8580 -1.16 1.57 2.96 1.00 
 
Table S16 - Summary statistics and ANOVA analysis of VdW interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.27 0.43 10694 -0.82 1.26 2.76 1.00 
Multi b 1.26 0.39 44415 -1.31 1.22 3.03 0.00 
 
Table S17 - Summary statistics and ANOVA analysis of VdW interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 1.29 0.33 822 0.41 1.29 2.29 0.40 
Protein-peptide b 1.18 0.30 1702 0.15 1.16 2.41 0.14 
Non-identical a 1.30 0.41 28165 -1.31 1.28 3.03 0.00 
Identical-symmetric b 1.16 0.37 15920 -1.07 1.13 2.76 0.00 
Identical-nonsymmetric c 1.32 0.42 8580 -1.24 1.30 2.61 0.00 
 
Table S18 - Summary statistics and ANOVA analysis of Proximal interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 2.99 0.43 10694 1.00 2.99 4.38 1.00 
Multi a 2.99 0.38 44415 1.00 2.96 4.55 1.00 
 
Table S19 - Summary statistics and ANOVA analysis of Proximal interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 3.06 0.31 822 2.22 3.07 3.99 2.21 
Protein-peptide b 2.96 0.29 1702 2.12 2.95 4.12 2.11 
Non-identical c 3.02 0.39 28165 1.00 3.01 4.52 1.00 
Identical-symmetric d 2.90 0.37 15920 1.00 2.88 4.55 1.00 
Identical-nonsymmetric a 3.05 0.42 8580 1.00 3.04 4.33 1.00 
 
Table S20 - Summary statistics and ANOVA analysis of Hydrogen bonds at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.45 0.42 10694 -0.14 1.45 2.83 0.00 
Multi b 1.44 0.38 44415 0.00 1.41 2.96 0.00 
 
Table S21 - Summary statistics and ANOVA analysis of Hydrogen bonds at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a,b 1.49 0.32 822 0.62 1.51 2.42 0.62 
Protein-peptide c 1.39 0.29 1702 0.20 1.38 2.56 0.19 
Non-identical b 1.47 0.40 28165 0.00 1.46 2.96 0.00 
Identical-symmetric d 1.36 0.36 15920 -0.14 1.33 2.96 0.00 
Identical-nonsymmetric a 1.50 0.42 8580 0.00 1.50 2.77 0.00 
 
Table S22 - Summary statistics and ANOVA analysis of Weak Hydrogen bonds at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.30 0.42 10694 -0.88 1.30 2.69 0.00 
Multi a 1.29 0.38 44415 -1.02 1.27 2.84 0.00 
 
Table S23 - Summary statistics and ANOVA analysis of Weak Hydrogen bonds at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 1.37 0.31 822 0.41 1.37 2.28 0.40 
Protein-peptide b 1.27 0.29 1702 0.26 1.27 2.38 0.25 
Non-identical c 1.31 0.39 28165 -1.02 1.30 2.82 0.00 
Identical-symmetric d 1.22 0.36 15920 -0.34 1.20 2.84 0.00 
Identical-nonsymmetric a 1.35 0.42 8580 -0.93 1.35 2.64 0.00 
 
Table S24 - Summary statistics and ANOVA analysis of Ionic interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.40 0.50 10694 -1.84 0.43 2.09 0.00 
Multi b 0.44 0.45 44415 -1.77 0.44 2.31 0.00 
 
Table S25 - Summary statistics and ANOVA analysis of Ionic interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.53 0.43 822 -0.99 0.57 1.62 0.00 
Protein-peptide b 0.45 0.35 1702 -1.14 0.50 1.73 0.00 
Non-identical c 0.41 0.45 28165 -1.84 0.41 1.99 0.00 
Identical-symmetric b 0.43 0.44 15920 -1.77 0.44 2.31 0.00 
Identical-nonsymmetric a 0.50 0.51 8580 -1.54 0.52 2.01 0.00 
 
Table S26 - Summary statistics and ANOVA analysis of Hydrophobic interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.71 0.49 10694 -0.25 1.75 3.20 0.00 
Multi b 1.73 0.45 44415 -1.05 1.74 3.42 0.00 
 
Table S27 - Summary statistics and ANOVA analysis of Hydrophobic interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 1.87 0.32 822 0.78 1.88 2.81 0.78 
Protein-peptide b 1.76 0.29 1702 0.69 1.77 2.88 0.68 
Non-identical c 1.72 0.48 28165 -1.05 1.75 3.27 0.00 
Identical-symmetric d 1.70 0.40 15920 -0.40 1.69 3.42 0.00 
Identical-nonsymmetric b 1.79 0.51 8580 -0.69 1.82 3.16 0.00 
 
Table S28 - Summary statistics and ANOVA analysis of Carbonyl interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.44 0.54 10694 -1.65 0.48 2.07 0.00 
Multi b 0.48 0.45 44415 -1.66 0.46 2.53 0.00 
 
Table S29 - Summary statistics and ANOVA analysis of Carbonyl interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.53 0.34 822 -0.63 0.54 1.36 -0.63 
Protein-peptide b 0.47 0.38 1702 -1.21 0.47 1.58 0.00 
Non-identical a 0.52 0.48 28165 -1.57 0.52 2.53 0.00 
Identical-symmetric c 0.35 0.44 15920 -1.66 0.35 2.10 0.00 
Identical-nonsymmetric a 0.54 0.48 8580 -1.50 0.54 2.20 0.00 
 
Table S30 - Summary statistics and ANOVA analysis of Polar interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.63 0.42 10694 0.00 1.62 3.03 0.00 
Multi b 1.61 0.39 44415 0.00 1.58 3.17 0.00 
 
Table S31 - Summary statistics and ANOVA analysis of Polar interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide ac 1.66 0.33 822 0.75 1.68 2.62 0.74 
Protein-peptide b 1.55 0.30 1702 0.39 1.54 2.77 0.39 
Non-identical c 1.64 0.41 28165 0.00 1.63 3.17 0.00 
Identical-symmetric b 1.54 0.37 15920 0.00 1.51 3.07 0.00 
Identical-nonsymmetric a 1.67 0.43 8580 0.00 1.67 2.98 0.00 
 
Table S32 - Summary statistics and ANOVA analysis of Weak Polar interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 1.40 0.43 10694 -0.04 1.39 2.90 0.00 
Multi b 1.39 0.39 44415 0.00 1.35 3.23 0.00 
 
Table S33 - Summary statistics and ANOVA analysis of Weak Polar interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide ac 1.43 0.32 822 0.61 1.45 2.40 0.61 
Protein-peptide b 1.34 0.29 1702 -0.04 1.34 2.53 -0.04 
Non-identical c 1.43 0.41 28165 0.00 1.42 3.23 0.00 
Identical-symmetric d 1.29 0.37 15920 0.00 1.27 2.90 0.00 
Identical-nonsymmetric e 1.44 0.42 8580 0.00 1.44 2.74 0.00 
 
Table S34 - Summary statistics and ANOVA analysis of atom-ring Carbon-𝜋 interactions 
at PPI interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.50 0.42 10694 -0.65 0.52 2.43 0.00 
Multi b 0.55 0.42 44415 -0.90 0.57 2.54 0.00 
 
Table S35 - Summary statistics and ANOVA analysis of atom-ring Carbon-𝜋 interactions 
at PPI interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.69 0.38 822 -0.19 0.77 1.99 0.00 
Protein-peptide a 0.73 0.37 1702 -0.17 0.80 1.86 0.00 
Non-identical b 0.51 0.42 28165 -0.77 0.52 2.34 0.00 
Identical-symmetric c 0.59 0.40 15920 -0.90 0.63 2.30 0.00 
Identical-nonsymmetric b 0.50 0.44 8580 -0.79 0.49 2.54 0.00 
 
Table S36 - Summary statistics and ANOVA analysis of atom-ring Cation-𝜋 interactions 
at PPI interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.03 0.18 10694 -1.00 0.00 1.45 0.00 
Multi b 0.00 0.23 44415 -1.33 0.00 1.43 0.00 
 
Table S37 - Summary statistics and ANOVA analysis of atom-ring Cation-𝜋 interactions 
at PPI interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.06 0.17 822 -0.30 0.00 0.98 0.00 
Protein-peptide a 0.07 0.21 1702 -0.33 0.00 1.31 0.00 
Non-identical b 0.01 0.21 28165 -1.28 0.00 1.43 0.00 
Identical-symmetric c 0.00 0.22 15920 -1.15 0.00 1.43 0.00 
Identical-nonsymmetric b 0.01 0.23 8580 -1.33 0.00 1.45 0.00 
 
Table S38 - Summary statistics and ANOVA analysis of atom-ring Donor-𝜋 interactions 
at PPI interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.09 0.25 10694 -1.12 0.00 1.62 0.00 
Multi b 0.07 0.29 44415 -1.26 0.00 1.72 0.00 
 
Table S39 - Summary statistics and ANOVA analysis of atom-ring Donor-𝜋 interactions 
at PPI interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.18 0.25 822 -0.20 0.00 1.60 0.00 
Protein-peptide a 0.17 0.26 1702 -0.32 0.02 1.35 0.00 
Non-identical b 0.07 0.28 28165 -1.26 0.00 1.72 0.00 
Identical-symmetric c 0.06 0.29 15920 -1.12 0.00 1.60 0.00 
Identical-nonsymmetric b 0.07 0.29 8580 -1.01 0.00 1.66 0.00 
 
Table S40 - Summary statistics and ANOVA analysis of Ring-Ring interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.27 0.49 10694 -1.83 0.27 1.91 0.00 
Multi b 0.26 0.48 44415 -1.87 0.24 2.22 0.00 
 
Table S41 - Summary statistics and ANOVA analysis of Ring-Ring interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.40 0.47 822 -0.75 0.43 1.52 0.00 
Protein-peptide b 0.33 0.39 1702 -0.99 0.42 1.46 0.00 
Non-identical c 0.28 0.47 28165 -1.57 0.27 1.91 0.00 
Identical-symmetric d 0.19 0.48 15920 -1.87 0.17 2.22 0.00 
Identical-nonsymmetric b 0.31 0.52 8580 -1.68 0.28 1.99 0.00 
 
Table S42 - Summary statistics and ANOVA analysis of Amide-Amide interactions at 
PPI interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.12 0.51 10694 -1.71 0.13 1.73 0.00 
Multi b 0.15 0.43 44415 -1.71 0.12 1.91 0.00 
 
Table S43 - Summary statistics and ANOVA analysis of Amide-Amide interactions at 
PPI interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.15 0.41 822 -1.05 0.20 1.29 0.00 
Protein-peptide b 0.00 0.41 1702 -1.26 0.00 1.27 0.00 
Non-identical c 0.20 0.45 28165 -1.53 0.19 1.91 0.00 
Identical-symmetric b 0.03 0.42 15920 -1.71 0.02 1.83 0.00 
Identical-nonsymmetric d 0.23 0.47 8580 -1.73 0.19 1.85 0.00 
 
Table S44 - Summary statistics and ANOVA analysis of Amide-Ring interactions at PPI 
interfaces by interface segmentation. ANOVA p-value < 0.05. 
Segmentation 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single a 0.74 0.52 10694 -1.12 0.79 2.28 0.00 
Multi b 0.75 0.47 44415 -1.04 0.75 2.60 0.00 
 
Table S45 - Summary statistics and ANOVA analysis of Amide-Ring interactions at PPI 
interfaces by interface type. ANOVA p-value < 0.05. 
Interface type 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.91 0.43 822 -0.15 0.95 1.89 0.00 
Protein-peptide b 0.84 0.40 1702 -0.18 0.88 1.86 0.00 
Non-identical c 0.77 0.48 28165 -0.92 0.79 2.29 0.00 
Identical-symmetric d 0.67 0.46 15920 -1.12 0.68 2.60 0.00 
Identical-nonsymmetric e 0.79 0.51 8580 -1.04 0.81 2.40 0.00 
 
Table S46 - Summary statistics and ANOVA analysis of PPI interface use of concavity 
at their deepest and average depth by interface segmentation. ANOVA p-value < 0.05. 
Segmentation Concavity 
ANOVA 
Group Mean SD N Min Med Max Mode 
Single average a 4.37 1.34 10694 1.04 4.30 9.65 5.13 
Single deepest b 0.81 0.84 10694 0.35 0.71 8.81 0.58 
Multi average c 4.40 0.71 44415 1.77 4.27 9.13 4.10 
Multi deepest d 1.03 0.54 44415 0.29 0.66 8.77 0.62 
 
Table S47 - Summary statistics and ANOVA analysis of PPI interface use of concavity 
at their deepest and average depth by interface type. ANOVA p-value < 0.05. 
Interface type Concavity 
ANOVA 
Group Mean SD N Min Med Max Mode 
Enzyme-peptide average a 3.11 1.21 822 1.04 2.98 9.65 1.04 
Enzyme-peptide deepest b 0.75 0.78 822 0.45 0.61 7.76 0.58 
Protein-peptide average c 3.45 1.45 1702 1.07 3.24 9.09 2.86 
Protein-peptide deepest d 0.85 0.85 1702 0.44 0.61 6.78 0.56 
Non-identical average e 4.54 0.91 28124 1.60 4.39 9.13 4.10 
Non-identical deepest f 0.93 0.69 28124 0.29 0.69 8.81 0.62 
Identical-symmetric average g 4.22 0.55 15912 2.86 4.13 8.07 4.32 
Identical-symmetric deepest b 0.70 0.30 15912 0.34 0.63 7.35 0.60 
Identical-nonsymmetric average h 4.58 0.74 8549 2.11 4.44 8.43 5.13 
Identical-nonsymmetric deepest d 0.87 0.63 8549 0.36 0.69 7.77 0.63 
 
Table S48 - Summary statistics and ANOVA analysis of interface length by interface 
segmentation. ANOVA p-value < 0.05. 
Segmentation ANOVA Group Mean SD N Min Med Max Mode 
Single a 10.99 0.65 10694 2 8 238 5 
Multi b 27.21 26.84 44415 3 20 516 5 
 
Table S49 - Summary statistics and ANOVA analysis of interface length by interface 
segmentation. ANOVA p-value < 0.05. 
Interface type ANOVA Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 5.32 2.05 822 2 5 10 4 
Protein-peptide a 6.72 2.02 1702 2 7 10 9 
Non-identical b 20.69 23.34 28165 3 14 249 5 
Identical-symmetric c 33.41 24.23 15920 5 28 343 19 
Identical-nonsymmetric d 23.04 30.71 8580 3 14 516 5 
 
Table S50 - Summary statistics and ANOVA analysis of chain length by interface 
segmentation. ANOVA p-value < 0.05. 
Segmentation ANOVA Group Mean SD N Min Med Max Mode 
Single a 107.54 164.42 10694 2 47 2136 9 
Multi b 284.27 236.85 44415 5 222 3795 213 
 
Table S51 - Summary statistics and ANOVA analysis of chain length by interface 
segmentation. ANOVA p-value < 0.05. 
Interface type ANOVA Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 5.76 2.32 822 2 6 10 4 
Protein-peptide a 7.63 2.07 1702 2 8 10 9 
Non-identical b 246.89 263.23 28165 11 178 3795 11 
Identical-symmetric c 277.15 173.05 15920 32 250 2750 141 
Identical-nonsymmetric c 281.32 230.72 8580 11 229 3303 121 
 
Table S52 - Summary statistics and ANOVA analysis of interface residue use of 
concavity, by interface segmentation, secondary structure (SST), and solvent 
accessibility. ANOVA p-value < 0.05. 
Segmentation Exposure SST 
ANOVA 
group Mean SD N Min Med Max Mode 
Single core helices ag 1.23 0.67 30698 0.45 0.98 5.55 0.75 
Single core sheets b 1.29 1.07 13539 0.44 0.91 8.42 0.65 
Single core loops c 2.10 1.68 14655 0.47 1.30 8.86 0.83 
Single periphery helices d 1.80 0.81 97394 0.41 1.64 6.62 1.43 
Single periphery sheets e 2.38 1.62 26462 0.43 1.81 8.25 0.78 
Single periphery loops f 3.30 1.67 107417 0.42 3.22 9.88 1.33 
Multi core helices a 1.24 0.65 272412 0.38 1.01 6.01 0.74 
Multi core sheets g 1.25 0.76 158120 0.32 0.97 7.61 0.68 
Multi core loops h 1.61 0.96 211237 0.40 1.26 8.73 0.87 
Multi periphery helices I 1.75 0.88 601464 0.39 1.53 7.34 0.88 
Multi periphery sheets d 1.80 1.09 254394 0.37 1.42 8.18 0.72 
Multi periphery loops j 2.57 1.35 898933 0.36 2.34 9.47 1.03 
 
Table S53 - Summary statistics and ANOVA analysis of interface residue use of 
concavity, by interface type, secondary structure (SST), and solvent accessibility. 
ANOVA p-value < 0.05. 
Interface type Exposure SST 
ANOV
A 
group Mean SD N Min Med Max Mode 
Enzyme-peptide core helices a 0.79 0.35 1003 0.45 0.71 4.86 0.66 
Enzyme-peptide core sheets b,g,p,r 1.23 1.11 1294 0.51 0.89 7.36 0.65 
Enzyme-peptide core loops c,n,o,s 1.86 1.90 1683 0.51 0.94 8.79 0.82 
Enzyme-peptide periphery helices d 1.40 0.88 1849 0.49 1.06 5.30 0.73 
Enzyme-peptide periphery sheets e 2.41 1.91 2287 0.51 1.49 7.37 0.80 
Enzyme-peptide periphery loops f 3.49 2.22 7790 0.52 3.09 9.88 0.97 
Protein-peptide core helices a 0.87 0.41 4554 0.48 0.77 5.20 0.71 
Protein-peptide core sheets g 1.11 1.04 3383 0.44 0.83 7.67 0.74 
Protein-peptide core loops h 3.05 2.27 3014 0.49 2.19 8.86 0.78 
Protein-peptide periphery helices I 1.54 0.83 7565 0.49 1.32 6.02 0.82 
Protein-peptide periphery sheets j 2.18 1.75 4091 0.50 1.31 7.51 0.74 
Protein-peptide periphery loops k 3.75 1.92 14942 0.49 3.96 9.28 1.02 
Non-identical core helices b 1.24 0.66 117380 0.38 1.00 6.01 0.76 
Non-identical core sheets b 1.22 0.78 74336 0.32 0.93 8.42 0.68 
Non-identical core loops l 1.66 1.03 98715 0.40 1.28 8.73 0.87 
Non-identical periphery helices m 1.79 0.90 307932 0.41 1.57 6.98 0.98 
Non-identical periphery sheets n 1.82 1.15 126756 0.42 1.41 8.25 0.71 
Non-identical periphery loops o 2.72 1.42 496872 0.39 2.52 9.47 1.08 
Identical-symmetric core helices p 1.24 0.63 146895 0.42 1.02 5.45 0.78 
Identical-symmetric core sheets b 1.30 0.78 69368 0.34 1.00 6.65 0.69 
Identical-symmetric core loops I 1.57 0.93 92179 0.42 1.23 8.72 0.86 
Identical-symmetric periphery helices q 1.72 0.84 271587 0.39 1.52 6.56 0.92 
Identical-symmetric periphery sheets c 1.87 1.13 102161 0.47 1.47 7.05 0.72 
Identical-symmetric periphery loops e 2.48 1.32 331673 0.36 2.23 9.05 1.03 
Identical-nonsymmetric core helices r 1.30 0.69 33278 0.44 1.06 5.55 0.73 
Identical-nonsymmetric core sheets b 1.28 0.80 23278 0.47 0.98 6.52 0.66 
Identical-nonsymmetric core loops l 1.64 0.97 30301 0.44 1.29 7.52 0.84 
Identical-nonsymmetric periphery helices c 1.77 0.86 109925 0.45 1.56 7.34 1.38 
Identical-nonsymmetric periphery sheets s 1.88 1.14 45561 0.37 1.49 7.57 0.68 
Identical-nonsymmetric periphery loops t 2.60 1.35 155073 0.39 2.39 9.29 1.08 
 
Table S54 - Summary statistics and ANOVA analysis of interface residue use of 





group Mean SD N Min Med Max Mode 
Single GLY core klmn 2.26 1.47 3631 0.62 1.83 8.42 0.93 
Single ALA core q 1.89 1.21 5415 0.55 1.57 8.79 0.96 
Single SER core rs 1.68 1.29 3174 0.50 1.17 7.78 0.84 
Single PRO core op 2.07 1.55 1521 0.52 1.35 8.86 0.87 
Single VAL core tu 1.50 1.11 5308 0.46 1.11 7.48 0.79 
Single THR core uv 1.42 1.06 2719 0.52 1.01 7.40 0.71 
Single CYS core tu 1.50 1.04 1050 0.55 1.13 7.03 0.88 
Single ILE core uv 1.38 1.00 5058 0.44 1.04 7.47 0.84 
Single LEU core uv 1.38 1.06 8873 0.47 1.01 8.49 0.80 
Single ASN core xy 1.23 0.86 2165 0.52 0.92 7.18 0.71 
Single ASP core wxy 1.24 0.91 1561 0.47 0.92 7.04 0.72 
Single GLN core xyz 1.21 0.96 1480 0.52 0.85 6.91 0.66 
Single LYS core pq 1.93 1.87 735 0.50 0.95 7.63 0.70 
Single GLU core xyzA 1.19 0.94 1685 0.48 0.85 7.59 0.68 
Single MET core vw 1.35 1.06 1959 0.51 0.98 7.58 0.70 
Single HIS core B 1.06 0.85 1256 0.48 0.78 6.83 0.61 
Single PHE core xyz 1.21 0.97 4040 0.48 0.87 7.21 0.73 
Single ARG core vwx 1.29 1.21 1510 0.48 0.83 7.52 0.74 
Single TYR core B 1.01 0.87 3915 0.45 0.76 7.82 0.64 
Single TRP core B 1.04 0.86 1837 0.45 0.78 7.03 0.67 
Multi GLY core mn 2.22 1.14 46276 0.55 1.95 8.73 1.15 
Multi ALA core r 1.71 0.87 55637 0.50 1.46 7.40 0.97 
Multi SER core t 1.52 0.80 39923 0.40 1.25 6.84 0.89 
Multi PRO core s 1.63 0.87 26302 0.49 1.34 6.65 0.90 
Multi VAL core vw 1.33 0.74 55805 0.44 1.07 7.07 0.80 
Multi THR core v 1.35 0.75 35527 0.42 1.09 7.18 0.78 
Multi CYS core u 1.43 0.77 9881 0.51 1.15 7.11 0.93 
Multi ILE core xy 1.22 0.67 50814 0.32 0.98 6.74 0.79 
Multi LEU core xyz 1.19 0.66 85502 0.34 0.96 8.21 0.73 
Multi ASN core wx 1.26 0.71 20223 0.43 1.01 7.32 0.74 
Multi ASP core wx 1.27 0.69 20158 0.42 1.04 8.72 0.78 
Multi GLN core yzA 1.16 0.62 18732 0.41 0.93 7.22 0.77 
Multi LYS core xyzA 1.17 0.70 10210 0.46 0.91 6.87 0.70 
Multi GLU core xyzA 1.18 0.64 20668 0.36 0.95 6.73 0.70 
Multi MET core xy 1.23 0.69 22999 0.42 0.99 7.00 0.73 
Multi HIS core zA 1.12 0.61 14682 0.45 0.90 6.60 0.71 
Multi PHE core yzA 1.15 0.63 41058 0.37 0.94 6.43 0.76 
Multi ARG core AB 1.08 0.60 21951 0.35 0.86 6.63 0.67 
Multi TYR core B 1.06 0.62 32928 0.42 0.84 6.30 0.68 
Multi TRP core B 1.06 0.60 12493 0.44 0.82 5.60 0.69 
Single GLY periphery a 3.95 1.68 10820 0.68 3.92 9.88 4.73 
Single ALA periphery c 3.35 1.62 12685 0.55 2.97 8.93 2.31 
Single SER periphery d 3.12 1.59 13044 0.58 2.79 8.39 1.33 
Single PRO periphery c 3.39 1.54 10122 0.53 3.36 8.68 1.51 
Single VAL periphery g 2.61 1.50 12089 0.54 2.11 8.73 1.66 
Single THR periphery f 2.71 1.53 12299 0.45 2.26 8.80 1.88 
Single CYS periphery e 2.84 1.62 1692 0.57 2.36 7.95 1.79 
Single ILE periphery jk 2.31 1.40 11545 0.54 1.80 8.16 1.52 
Single LEU periphery no 2.19 1.33 21408 0.47 1.71 8.72 1.35 
Single ASN periphery h 2.52 1.42 10873 0.42 2.11 7.85 1.85 
Single ASP periphery gh 2.56 1.44 13299 0.53 2.17 8.12 1.35 
Single GLN periphery jkl 2.29 1.34 11699 0.51 1.88 8.55 1.34 
Single LYS periphery i 2.37 1.43 16946 0.41 1.92 8.67 1.08 
Single GLU periphery ij 2.34 1.36 18572 0.48 1.91 8.24 1.50 
Single MET periphery jklm 2.28 1.45 5919 0.50 1.74 8.03 1.42 
Single HIS periphery mno 2.20 1.40 5819 0.50 1.72 7.67 1.35 
Single PHE periphery lmn 2.23 1.47 9321 0.43 1.68 9.78 1.06 
Single ARG periphery klm 2.27 1.45 17946 0.46 1.79 9.05 0.73 
Single TYR periphery p 1.96 1.40 10926 0.46 1.39 8.15 0.83 
Single TRP periphery q 1.84 1.35 4249 0.49 1.28 7.52 0.64 
Multi GLY periphery b 3.44 1.40 96823 0.64 3.43 9.47 3.43 
Multi ALA periphery e 2.78 1.27 91491 0.55 2.60 9.05 1.83 
Multi SER periphery g 2.61 1.29 106607 0.53 2.38 9.25 1.53 
Multi PRO periphery g 2.60 1.24 89625 0.47 2.43 8.10 1.56 
Multi VAL periphery o 2.18 1.18 80025 0.46 1.86 8.77 1.04 
Multi THR periphery lmn 2.25 1.19 96688 0.47 1.98 9.29 1.02 
Multi CYS periphery jkl 2.29 1.27 12347 0.57 1.95 9.05 1.04 
Multi ILE periphery p 1.95 1.10 68657 0.45 1.62 8.48 0.99 
Multi LEU periphery q 1.91 1.07 125722 0.42 1.58 9.41 0.98 
Multi ASN periphery o 2.15 1.16 89736 0.47 1.84 8.31 1.28 
Multi ASP periphery no 2.20 1.18 116906 0.46 1.90 8.73 1.12 
Multi GLN periphery p 1.96 1.09 91517 0.40 1.66 8.71 0.80 
Multi LYS periphery p 1.99 1.14 128948 0.46 1.67 8.71 0.76 
Multi GLU periphery p 2.05 1.13 146375 0.36 1.76 8.74 0.86 
Multi MET periphery p 2.04 1.24 37029 0.43 1.67 8.34 0.91 
Multi HIS periphery q 1.90 1.11 51098 0.45 1.54 9.06 1.12 
Multi PHE periphery q 1.82 1.08 63823 0.46 1.47 8.58 0.96 
Multi ARG periphery q 1.76 1.04 156945 0.42 1.44 8.59 0.79 
Multi TYR periphery s 1.66 1.04 78700 0.37 1.30 8.20 0.81 
Multi TRP periphery s 1.62 1.00 25729 0.39 1.27 7.59 0.70 
 
Table S55 - Summary statistics and ANOVA analysis of interface residue use of 





group Mean SD N Min Med Max Mode 
Enzyme peptide GLY core nop 1.80 1.51 423 0.63 1.28 8.27 0.89 
Enzyme peptide ALA core opq 1.66 1.75 343 0.57 0.99 8.79 0.97 
Enzyme peptide SER core qrs 1.34 1.35 280 0.55 0.84 7.36 0.80 
Enzyme peptide PRO core ij 2.51 2.22 134 0.58 1.02 7.85 0.66 
Enzyme peptide VAL core pqr 1.43 1.50 239 0.51 0.86 6.74 0.68 
Enzyme peptide THR core rst 1.18 1.10 141 0.59 0.85 6.50 0.71 
Enzyme peptide CYS core qrst 1.25 1.19 108 0.58 0.89 6.90 0.69 
Enzyme peptide ILE core qrst 1.28 1.30 227 0.57 0.85 7.47 0.82 
Enzyme peptide LEU core qrs 1.33 1.35 322 0.52 0.85 6.89 0.84 
Enzyme peptide ASN core rst 1.15 1.13 127 0.55 0.77 6.68 0.66 
Enzyme peptide ASP core rst 1.12 1.20 161 0.52 0.81 7.04 0.68 
Enzyme peptide GLN core qrst 1.29 1.53 112 0.56 0.76 6.91 0.65 
Enzyme peptide LYS core hij 2.60 2.41 65 0.58 0.81 7.14 0.59 
Enzyme peptide GLU core t 0.92 0.95 108 0.52 0.73 7.59 0.64 
Enzyme peptide MET core nopq 1.74 1.86 107 0.56 0.89 7.35 0.78 
Enzyme peptide HIS core t 0.81 0.59 264 0.48 0.69 5.42 0.61 
Enzyme peptide PHE core rst 1.16 1.23 307 0.51 0.78 7.16 0.67 
Enzyme peptide ARG core jklmnop 1.96 2.11 107 0.53 0.89 7.52 0.62 
Enzyme peptide TYR core st 1.09 1.15 246 0.51 0.76 6.37 0.62 
Enzyme peptide TRP core t 0.87 0.65 159 0.45 0.72 6.06 0.65 
Protein peptide GLY core jkl 2.09 1.87 555 0.65 1.20 8.23 0.93 
Protein peptide ALA core jk 2.12 2.06 579 0.57 1.10 8.16 0.83 
Protein peptide SER core nopq 1.72 1.82 659 0.58 0.92 7.67 0.80 
Protein peptide PRO core fgh 2.91 2.08 240 0.52 2.82 8.86 0.66 
Protein peptide VAL core mnop 1.83 1.86 700 0.51 0.96 7.48 0.70 
Protein peptide THR core qrst 1.28 1.35 630 0.52 0.73 7.40 0.67 
Protein peptide CYS core opq 1.68 1.68 150 0.59 1.04 7.03 1.07 
Protein peptide ILE core nopq 1.73 1.71 612 0.44 0.92 7.21 0.71 
Protein peptide LEU core jklmn 1.99 1.93 1134 0.53 0.89 8.49 0.73 
Protein peptide ASN core rst 1.12 0.98 698 0.56 0.84 7.18 0.73 
Protein peptide ASP core rst 1.15 1.08 376 0.48 0.83 6.68 0.82 
Protein peptide GLN core rst 1.19 1.23 330 0.56 0.73 6.50 0.71 
Protein peptide LYS core cd 3.59 2.53 154 0.56 3.90 7.63 6.25 
Protein peptide GLU core rst 1.13 1.24 458 0.54 0.72 6.70 0.68 
Protein peptide MET core jklmno 1.96 1.97 206 0.55 0.89 7.58 0.82 
Protein peptide HIS core st 1.09 1.03 321 0.52 0.79 6.83 0.75 
Protein peptide PHE core pq 1.49 1.57 595 0.49 0.85 7.21 0.65 
Protein peptide ARG core qr 1.42 1.48 389 0.52 0.81 7.08 0.86 
Protein peptide TYR core t 0.97 1.01 1508 0.51 0.73 7.82 0.68 
Protein peptide TRP core t 1.03 0.97 657 0.51 0.80 7.03 0.80 
Non-identical GLY core j 2.28 1.22 19594 0.59 1.96 8.73 1.15 
Non-identical ALA core nop 1.75 0.94 23061 0.53 1.47 8.38 0.90 
Non-identical SER core pq 1.53 0.84 18854 0.40 1.24 7.78 0.97 
Non-identical PRO core opq 1.67 0.91 12201 0.49 1.34 6.65 0.87 
Non-identical VAL core qr 1.34 0.78 24497 0.46 1.07 7.36 0.82 
Non-identical THR core qr 1.37 0.78 15145 0.48 1.09 7.36 0.79 
Non-identical CYS core pq 1.48 0.82 5007 0.53 1.18 7.11 0.88 
Non-identical ILE core rst 1.23 0.71 22447 0.32 0.98 6.32 0.79 
Non-identical LEU core rst 1.23 0.74 38787 0.43 0.96 8.21 0.71 
Non-identical ASN core qrst 1.25 0.75 9335 0.48 0.97 7.32 0.74 
Non-identical ASP core qrs 1.29 0.73 9140 0.47 1.04 6.55 0.78 
Non-identical GLN core rst 1.15 0.63 8826 0.41 0.91 5.72 0.77 
Non-identical LYS core qrst 1.24 0.81 4847 0.46 0.92 6.87 0.71 
Non-identical GLU core rst 1.21 0.68 9135 0.36 0.96 7.45 0.69 
Non-identical MET core rst 1.23 0.72 10406 0.42 0.98 6.95 0.73 
Non-identical HIS core st 1.10 0.63 6296 0.45 0.86 6.76 0.66 
Non-identical PHE core rst 1.17 0.66 19772 0.40 0.94 6.83 0.71 
Non-identical ARG core rst 1.10 0.67 10243 0.35 0.85 6.63 0.67 
Non-identical TYR core t 1.03 0.65 16407 0.42 0.80 6.32 0.68 
Non-identical TRP core rst 1.12 0.65 6431 0.45 0.85 5.90 0.67 
Identical symmetric GLY core j 2.16 1.08 22232 0.55 1.93 6.65 0.98 
Identical symmetric ALA core opq 1.69 0.83 29322 0.54 1.46 6.36 0.94 
Identical symmetric SER core pq 1.50 0.79 17652 0.53 1.25 6.03 0.78 
Identical symmetric PRO core opq 1.60 0.86 11538 0.49 1.33 5.55 1.08 
Identical symmetric VAL core qrs 1.32 0.71 28250 0.45 1.07 6.97 0.80 
Identical symmetric THR core qrs 1.34 0.74 17211 0.42 1.09 6.10 0.87 
Identical symmetric CYS core qr 1.39 0.72 4468 0.51 1.15 5.55 0.82 
Identical symmetric ILE core rst 1.23 0.66 25860 0.46 0.99 6.59 0.80 
Identical symmetric LEU core rst 1.17 0.61 44069 0.34 0.97 5.63 0.74 
Identical symmetric ASN core qrst 1.26 0.68 9124 0.43 1.04 5.61 0.73 
Identical symmetric ASP core qrst 1.25 0.66 8834 0.42 1.03 8.72 0.79 
Identical symmetric GLN core rst 1.14 0.59 8175 0.45 0.93 5.12 0.70 
Identical symmetric LYS core rst 1.11 0.63 4173 0.49 0.89 5.59 0.70 
Identical symmetric GLU core rst 1.14 0.58 9663 0.47 0.93 5.58 0.69 
Identical symmetric MET core rst 1.24 0.68 11220 0.44 1.00 7.00 0.76 
Identical symmetric HIS core rst 1.13 0.61 7260 0.50 0.94 6.60 0.71 
Identical symmetric PHE core rst 1.14 0.62 19627 0.37 0.93 6.11 0.76 
Identical symmetric ARG core st 1.05 0.55 9601 0.49 0.86 4.85 0.67 
Identical symmetric TYR core st 1.09 0.61 14506 0.45 0.88 5.12 0.70 
Identical symmetric TRP core t 1.01 0.58 5657 0.44 0.80 5.21 0.67 
Identical non-
symmetric GLY core j 2.27 1.13 7103 0.61 2.00 7.52 1.15 
Identical non-
symmetric ALA core nop 1.79 0.90 7747 0.50 1.55 6.83 1.01 
Identical non-
symmetric SER core opq 1.62 0.86 5652 0.46 1.34 6.48 1.01 
Identical non-
symmetric PRO core opq 1.62 0.88 3710 0.52 1.33 6.18 0.75 
Identical non-
symmetric VAL core qr 1.40 0.81 7427 0.44 1.11 6.05 0.77 
Identical non-
symmetric THR core qr 1.37 0.76 5119 0.51 1.09 7.18 0.82 
Identical non-
symmetric CYS core qr 1.42 0.78 1198 0.55 1.12 5.50 0.73 
Identical non-
symmetric ILE core qrst 1.25 0.70 6726 0.50 1.01 6.74 0.74 
Identical non-
symmetric LEU core rst 1.20 0.64 10063 0.46 0.97 6.81 0.84 
Identical non-
symmetric ASN core qrs 1.31 0.68 3104 0.52 1.10 5.96 0.92 
Identical non-
symmetric ASP core qrs 1.30 0.68 3208 0.45 1.08 6.02 0.85 
Identical non-
symmetric GLN core qrst 1.25 0.70 2769 0.47 1.01 7.22 0.75 
Identical non-
symmetric LYS core rst 1.13 0.65 1706 0.50 0.91 5.44 0.70 
Identical non-
symmetric GLU core qrst 1.24 0.71 2989 0.46 0.99 6.43 0.70 
Identical non-
symmetric MET core rst 1.23 0.65 3019 0.50 1.04 5.56 0.73 
Identical non-
symmetric HIS core rst 1.14 0.63 1797 0.47 0.91 5.19 0.62 
Identical non-
symmetric PHE core rst 1.17 0.67 4797 0.49 0.94 6.42 0.75 
Identical non-
symmetric ARG core rst 1.11 0.63 3121 0.44 0.87 6.08 0.66 
Identical non-
symmetric TYR core st 1.07 0.60 4176 0.44 0.85 5.24 0.66 
Identical non-
symmetric TRP core t 0.98 0.58 1426 0.49 0.79 5.94 0.69 
Enzyme peptide GLY periphery c 3.75 2.22 875 0.68 3.22 9.88 1.12 
Enzyme peptide ALA periphery a 4.60 2.44 676 0.68 5.31 8.93 0.93 
Enzyme peptide SER periphery d 3.44 2.14 733 0.58 2.85 8.39 0.92 
Enzyme peptide PRO periphery b 4.10 1.94 621 0.58 4.21 7.97 3.53 
Enzyme peptide VAL periphery de 3.28 2.22 568 0.65 2.58 8.01 0.92 
Enzyme peptide THR periphery ef 3.05 2.09 569 0.59 2.34 8.80 0.78 
Enzyme peptide CYS periphery def 3.20 2.22 175 0.65 2.55 7.77 0.73 
Enzyme peptide ILE periphery fgh 2.79 2.03 482 0.61 1.78 8.00 0.89 
Enzyme peptide LEU periphery fg 2.97 2.22 678 0.49 1.90 8.72 0.79 
Enzyme peptide ASN periphery j 2.33 1.70 514 0.55 1.68 7.85 0.86 
Enzyme peptide ASP periphery h 2.69 2.01 898 0.56 1.87 7.74 0.87 
Enzyme peptide GLN periphery hij 2.56 1.88 524 0.53 1.72 7.79 0.76 
Enzyme peptide LYS periphery h 2.74 2.06 682 0.55 1.83 8.67 0.87 
Enzyme peptide GLU periphery fgh 2.86 1.97 718 0.55 2.27 7.63 0.78 
Enzyme peptide MET periphery ij 2.48 1.91 272 0.61 1.60 7.76 0.65 
Enzyme peptide HIS periphery jklmn 2.00 1.78 453 0.50 1.10 7.08 0.65 
Enzyme peptide PHE periphery hi 2.63 2.07 580 0.53 1.45 9.78 0.84 
Enzyme peptide ARG periphery hij 2.56 2.02 948 0.52 1.66 9.05 0.97 
Enzyme peptide TYR periphery jklm 2.02 1.83 683 0.49 1.13 7.78 0.66 
Enzyme peptide TRP periphery jklmn 2.00 1.74 277 0.50 1.11 7.17 0.60 
Protein peptide GLY periphery b 4.04 2.04 1484 0.75 4.04 9.28 2.30 
Protein peptide ALA periphery b 4.06 2.00 1439 0.55 4.01 8.45 3.94 
Protein peptide SER periphery d 3.39 1.95 1541 0.63 3.01 7.93 1.58 
Protein peptide PRO periphery bc 3.95 1.75 1291 0.61 4.26 8.35 4.58 
Protein peptide VAL periphery f 3.02 1.95 1387 0.59 2.40 7.88 0.90 
Protein peptide THR periphery fgh 2.86 1.84 1766 0.57 2.18 7.78 0.94 
Protein peptide CYS periphery bc 3.96 2.08 140 0.61 4.38 7.72 1.00 
Protein peptide ILE periphery gh 2.77 1.86 1038 0.55 1.93 7.24 0.74 
Protein peptide LEU periphery ef 3.03 1.88 1603 0.51 2.84 8.11 0.98 
Protein peptide ASN periphery hi 2.61 1.73 1339 0.56 1.95 7.65 0.70 
Protein peptide ASP periphery fgh 2.87 1.80 1428 0.55 2.43 7.86 1.22 
Protein peptide GLN periphery ij 2.41 1.63 1138 0.56 1.91 7.28 0.87 
Protein peptide LYS periphery hi 2.60 1.75 1902 0.52 2.08 7.41 0.78 
Protein peptide GLU periphery h 2.69 1.85 1776 0.57 1.99 8.24 0.84 
Protein peptide MET periphery gh 2.76 1.99 485 0.53 1.89 7.48 0.97 
Protein peptide HIS periphery j 2.36 1.63 680 0.57 1.82 7.49 0.88 
Protein peptide PHE periphery gh 2.76 1.92 1006 0.53 2.28 8.06 0.61 
Protein peptide ARG periphery h 2.68 1.94 2130 0.51 1.89 7.70 0.73 
Protein peptide TYR periphery mnop 1.86 1.58 2047 0.49 1.16 7.24 0.83 
Protein peptide TRP periphery opq 1.65 1.51 978 0.49 0.79 6.52 0.64 
Non-identical GLY periphery cd 3.58 1.45 48538 0.64 3.55 9.47 3.43 
Non-identical ALA periphery fg 2.92 1.35 46185 0.55 2.72 8.84 2.38 
Non-identical SER periphery h 2.75 1.36 58114 0.53 2.52 9.25 1.53 
Non-identical PRO periphery gh 2.79 1.32 46430 0.50 2.62 8.68 1.51 
Non-identical VAL periphery j 2.31 1.27 42914 0.53 1.96 8.77 1.06 
Non-identical THR periphery j 2.38 1.26 51515 0.45 2.10 8.25 1.16 
Non-identical CYS periphery ij 2.47 1.39 7102 0.57 2.12 9.05 1.21 
Non-identical ILE periphery jk 2.09 1.21 38951 0.45 1.74 8.48 0.98 
Non-identical LEU periphery jkl 2.04 1.16 70542 0.42 1.68 9.41 1.09 
Non-identical ASN periphery j 2.25 1.23 46999 0.42 1.92 8.31 1.01 
Non-identical ASP periphery j 2.31 1.25 59342 0.51 2.02 8.61 0.94 
Non-identical GLN periphery jkl 2.04 1.17 48949 0.46 1.73 8.71 0.77 
Non-identical LYS periphery jk 2.10 1.24 69125 0.41 1.75 8.31 0.76 
Non-identical GLU periphery j 2.16 1.20 75013 0.45 1.84 8.49 1.19 
Non-identical MET periphery jk 2.11 1.27 20728 0.48 1.72 8.34 1.09 
Non-identical HIS periphery jklmn 1.97 1.18 24802 0.46 1.59 7.94 1.12 
Non-identical PHE periphery klmnop 1.96 1.19 35589 0.46 1.56 8.58 0.96 
Non-identical ARG periphery lmnop 1.91 1.15 79750 0.42 1.55 8.49 0.98 
Non-identical TYR periphery nop 1.74 1.12 45797 0.39 1.33 8.18 0.79 
Non-identical TRP periphery nop 1.75 1.09 15175 0.49 1.40 7.59 0.70 
Identical symmetric GLY periphery d 3.35 1.39 39409 0.66 3.33 8.66 4.29 
Identical symmetric ALA periphery h 2.70 1.23 38679 0.58 2.51 9.05 1.83 
Identical symmetric SER periphery ij 2.50 1.25 40503 0.55 2.26 8.21 1.40 
Identical symmetric PRO periphery ij 2.51 1.20 36922 0.47 2.33 8.68 1.42 
Identical symmetric VAL periphery jkl 2.08 1.11 32036 0.51 1.79 7.55 0.99 
Identical symmetric THR periphery j 2.15 1.14 37075 0.52 1.86 8.76 1.15 
Identical symmetric CYS periphery j 2.17 1.16 4857 0.59 1.86 7.24 1.18 
Identical symmetric ILE periphery mnop 1.85 1.03 25907 0.47 1.54 7.02 0.99 
Identical symmetric LEU periphery nop 1.81 0.98 51008 0.46 1.52 8.73 0.99 
Identical symmetric ASN periphery jkl 2.08 1.11 34752 0.52 1.78 7.34 1.02 
Identical symmetric ASP periphery jk 2.12 1.12 47534 0.46 1.83 8.58 1.12 
Identical symmetric GLN periphery klmnop 1.91 1.04 35606 0.40 1.63 8.62 0.82 
Identical symmetric LYS periphery klmnop 1.94 1.09 51493 0.49 1.64 8.21 0.90 
Identical symmetric GLU periphery jklmn 1.98 1.06 61640 0.36 1.71 8.74 0.86 
Identical symmetric MET periphery jkl 2.04 1.27 14669 0.43 1.65 7.76 0.91 
Identical symmetric HIS periphery mnop 1.86 1.09 23441 0.49 1.52 7.70 0.85 
Identical symmetric PHE periphery nop 1.74 1.02 25200 0.48 1.42 7.49 0.82 
Identical symmetric ARG periphery opq 1.69 0.97 65706 0.47 1.38 7.61 0.76 
Identical symmetric TYR periphery opq 1.63 0.99 29253 0.39 1.29 8.09 0.78 
Identical symmetric TRP periphery pq 1.51 0.95 9731 0.47 1.16 6.84 0.78 
Identical non-
symmetric GLY periphery cd 3.53 1.38 17337 0.69 3.53 8.36 4.58 
Identical non-
symmetric ALA periphery fgh 2.84 1.28 17197 0.61 2.66 9.05 2.23 
Identical non-
symmetric SER periphery h 2.66 1.27 18760 0.57 2.46 8.13 1.55 
Identical non-
symmetric PRO periphery hi 2.60 1.22 14483 0.54 2.44 8.56 1.56 
Identical non-
symmetric VAL periphery j 2.22 1.18 15209 0.46 1.90 8.08 0.94 
Identical non-
symmetric THR periphery j 2.31 1.20 18062 0.52 2.06 9.29 1.05 
Identical non-
symmetric CYS periphery j 2.22 1.16 1765 0.57 1.96 7.47 1.08 
Identical non-
symmetric ILE periphery klmnop 1.95 1.07 13824 0.52 1.65 7.40 1.30 
Identical non-
symmetric LEU periphery lmnop 1.89 1.07 23299 0.49 1.56 8.05 0.88 
Identical non-
symmetric ASN periphery j 2.23 1.17 17005 0.51 1.94 8.11 1.47 
Identical non-
symmetric ASP periphery j 2.21 1.17 21003 0.46 1.92 8.73 1.17 
Identical non-
symmetric GLN periphery jklm 2.00 1.08 16999 0.46 1.71 7.88 1.02 
Identical non-
symmetric LYS periphery jklmn 1.97 1.10 22692 0.46 1.67 8.71 0.82 
Identical non-
symmetric GLU periphery jkl 2.06 1.12 25800 0.46 1.77 8.67 0.95 
Identical non-
symmetric MET periphery jklmn 1.99 1.17 6794 0.50 1.63 8.30 0.89 
Identical non-
symmetric HIS periphery klmnop 1.94 1.14 7541 0.45 1.59 9.06 0.79 
Identical non-
symmetric PHE periphery nop 1.80 1.05 10769 0.43 1.45 8.57 0.75 
Identical non-
symmetric ARG periphery nop 1.75 1.02 26357 0.47 1.45 8.59 0.81 
Identical non-
symmetric TYR periphery opq 1.68 1.04 11846 0.37 1.32 8.20 0.74 
Identical non-
symmetric TRP periphery pq 1.57 0.96 3817 0.39 1.24 6.69 0.70 
 
Table S56 - Summary statistics and ANOVA analysis of hotspots per 100 Å2 BSA by 
interface segmentation. ANOVA p-value < 0.05. 
Segmentation ANOVA Group Mean SD N Min Med Max Mode 
Single a 0.87 0.36 10694 0 0.87 3.74 0 
Multi b 0.80 0.32 44415 0 0.81 3.33 0 
 
Table S57 - Summary statistics and ANOVA analysis of hotspots per 100 Å2 BSA by 
interface type. ANOVA p-value < 0.05. 
Interface type ANOVA Group Mean SD N Min Med Max Mode 
Enzyme-peptide a 0.97 0.35 822 0.17 0.95 2.25 0.17 
Protein-peptide b 1.04 0.33 1702 0.13 1.07 2.34 0.13 
Non-identical c 0.77 0.33 28165 0 0.77 3.49 0.00 
Identical-symmetric d 0.90 0.30 15920 0 0.92 3.74 0.00 
Identical-nonsymmetric e 0.73 0.32 8580 0 0.73 3.46 0.00 
 
Table S58 - Residue exposure based on distance from interacting chain (s) and change 
in residue side-chain relative solvent accessibility (RSA) on complexation. A residue is 
considered to be at the interface if at least one of its atoms is within 5 Å of any of the binding 
partner’s protein atoms. 
Residue % RSA (Single 
chain) 
Residue % RSA (Whole 
complex) 
Is interface? Exposure category 
≤ 7 Any Any Protein Core 
> 7 Any False Surface exposed 
> 7 ≤ 7 True Interface Core 
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ABSTRACT
Proteins are highly dynamic molecules, whose func-
tion is intrinsically linked to their molecular mo-
tions. Despite the pivotal role of protein dynamics,
their computational simulation cost has led to most
structure-based approaches for assessing the im-
pact of mutations on protein structure and function
relying upon static structures. Here we present Dy-
naMut, a web server implementing two distinct, well
established normal mode approaches, which can be
used to analyze and visualize protein dynamics by
sampling conformations and assess the impact of
mutations on protein dynamics and stability result-
ing from vibrational entropy changes. DynaMut in-
tegrates our graph-based signatures along with nor-
mal mode dynamics to generate a consensus predic-
tion of the impact of a mutation on protein stability.
We demonstrate our approach outperforms alterna-
tive approaches to predict the effects of mutations
on protein stability and flexibility (P-value < 0.001),
achieving a correlation of up to 0.70 on blind tests.
DynaMut also provides a comprehensive suite for
protein motion and flexibility analysis and visualiza-
tion via a freely available, user friendly web server at
http://biosig.unimelb.edu.au/dynamut/.
INTRODUCTION
Proteins are dynamic macromolecules, whose function is in-
tricately linked to their biological motions (1,2). We have
shown previously that drug resistant and genetic disease
mutations can both act through changes in protein confor-
mational equilibria and dynamics (3–7). In order to fully
understand the molecular consequences of a mutation it
is, therefore, important to consider changes in protein dy-
namics. Despite their pivotal role, the computational cost
of dynamics simulation has led to most structure-based ap-
proaches for assessing mutations effects on protein struc-
ture and function relying upon static structures.
Normal Mode Analysis (NMA) is a computational ap-
proach that approximates the dynamics of a system around
a conformation through harmonic motion. This has been
used to generate possible movements and therefore pro-
vide valuable insights into protein motions, and their ac-
cessible conformational repertoires. Previous studies have
shown that NMA can be a powerful tool to analyze pro-
tein structure–function relationship (8) and to predict the
effects of single-point mutations on protein stability (9).
Many NMA methods have been proposed (10–14) to ad-
dress the lack of easy to use interfaces that limited their use
to those with specialist knowledge. However, these are lim-
ited to the analysis of protein structures and do not provide
approaches to evaluate the effect of mutations within their
pipelines.
To fill this gap, we introduce DynaMut, a web server that
introduces the dynamics component to mutation analysis.
This is achieved by implementing and integrating well es-
tablished normal mode approaches with our graph-based
signatures in a consensus predictor for protein stability
changes upon mutation, which we show optimizes overall
prediction performance.
DynaMut implements NMA through two different ap-
proaches, Bio3D (8) and ENCoM (9), providing rapid and
simplified access to powerful and insightful analysis of pro-
tein motions. In addition, DynaMut also enables rapid
analysis of the impact of mutations on a protein’s dynam-
ics and stability resulting from vibrational entropy changes.
Integration of these two different approaches with other
well-established methods and characteristics of the wild-
type residue environment into a consensus prediction en-
ables DynaMut to provide an accurate assessment of the
impact of a mutation on protein stability, and provide a
comprehensive suite for protein motion and flexibility anal-
ysis and visualization via an easy-to-use web interface (http:
//biosig.unimelb.edu.au/dynamut/).
*To whom correspondence should be addressed. Tel: +61 90354794; Email: david.ascher@unimelb.edu.au
Correspondence may also be addressed to Douglas E. V. Pires. Email: douglas.pires@minas.fiocruz.br
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MATERIALS AND METHODS
Data sets
In this work, we used the previously established S2648
dataset (15–18), derived from the ProTherm database (19).
This dataset is comprised of 2648 different point-mutations
across 131 globular proteins with experimentally deter-
mined structures whose impact on protein stability has been
experimentally measured (602 stabilizing and 2046 desta-
bilizing). The DynaMut training set comprises 2297 muta-
tions randomly selected from the original dataset. A blind
test set composed of 351 non-redundant mutations derived
from the S2648 set was also compiled. This blind test set
has been widely used in the literature (15–18), enabling di-
rect comparative performance of methods that quantify the
impact of mutations on the folding free energy.
Previous studies have reported performance comparisons
of difference methods on predicting changes in folding free
energy (G) using these datasets (20–22). Given the un-
balanced nature of the original dataset, here we have con-
sidered the hypothetical reverse mutations (22) in order to
build a more robust, balanced and self-consistent predic-
tive method. The change in folding free energy is a thermo-
dynamic state function, and it has been proposed that the
change in folding free energy of a mutation from a wild-type
protein to its mutant (GWT→MT) should be equivalent to
the negative change in folding free energy of the hypotheti-
cal reverse mutation––from the mutant to the wild-type pro-
tein (–GMT→WT) (16,22–24). Including the hypothetical
reverse mutations, our predictive model was trained using
4594 mutations and our blind test was comprised of 702
single-point mutations.
Normal mode analysis
NMA allows the study of harmonic motions in a system,
providing insights into its dynamics and accessible confor-
mations. It has been widely used for studies of protein dy-
namics as an alternative to more computationally inten-
sive molecular dynamics approaches (25–28). While molec-
ular dynamics approaches provide motion trajectories for a
given molecule over time, conformational fluctuations can
be evaluated by NMA via superposition of normal modes
(Eigenvectors) and their associated frequencies (Eigenval-
ues) (29). NMA can also use simplified representations of
the protein structure, such as modeling the amino acids us-
ing their C atoms, reducing computational cost. NMA has
been successfully applied to the study of the effects of muta-
tions on protein dynamics, with ENCoM (9) including the
nature of the amino acids in the protein as an extra layer
of information to compute the effects of single-point muta-
tions on the vibrational entropy (S) and protein stability.
Other structure-based approaches
Structure-based approaches to predict the impact of muta-
tions on stability utilize protein structural information from
the 3D space of a natively folded protein. Even though these
structure-based methods are essentially based on the same
structural data, they are built using broadly different, so-
phisticated, approaches, such as statistical potential func-
tion energy calculations, used in SDM (16) and structural
pattern mining approaches such as mCSM-Stability (18).
The consensus method DUET highlighted that these ap-
proaches were complimentary, and that their integration
provided more accurate and reliable predictions (17). This
has been used to provide invaluable insights into disease and
drug resistance mutations, and help guide protein engineer-
ing efforts (30–39).
DynaMut––consensus predictions
Within DynaMut we have implemented a consensus es-
timate of changes upon mutation on protein folding free
energy, which combines the effects of mutations on pro-
tein stability and dynamics calculated by Bio3D, ENCoM
and DUET to generate an optimized and more robust pre-
dictor. Moreover, DynaMut includes a set of complemen-
tary information regarding the environment characteris-
tics of the wild-type residue (e.g., relative solvent accessi-
bility, residue depth and secondary structure) and graph-
based signatures representing the wild-type structure. The
graph-based signatures concept, used in the development
of mCSM-Stability and to generate the consensus DUET
predictions, has been widely applied to the study of pro-
tein structure, including protein–ligand interactions (40),
and how mutations alter protein interactions with other
molecules (23,24,41–43). These were supplied as evidence
for training the consensus predictor using Random Forest
(44). Figure 1 shows the workflow used to train the con-
sensus predictions. The DynaMut consensus prediction was
trained under 10-fold cross validation, and validated us-
ing the non-redundant blind test set (Supplementary Ma-
terials). The machine learning algorithm, evaluation proce-
dures, performance metrics and details on the methods used
on the consensus prediction are described in Supplementary
Materials.
WEB SERVER
We have implemented DynaMut as a user-friendly,
freely available web server (http://biosig.unimelb.edu.au/
dynamut/). The server front end was built using Bootstrap
framework version 3.3.7, while the back-end was built in
Python via the Flask framework (Version 0.12.2). It is
hosted on a Linux server running Apache.
Input
DynaMut can be used in two different ways, to either (1) an-
alyze protein dynamics or (2) to analyze the effect of point
mutations on protein dynamics and stability. For protein
dynamics analysis (Supplementary Figure S1), the server
requires the user to input a protein structure by either up-
loading a file in PDB format or by providing the four-letter
accession code for any entry on the PDB database. In addi-
tion, users have the option to choose a specific force field,
which is used to describe the molecular interactions within
the structure for normal mode analysis. The force field op-
tions available are summarized in Supplementary Table S1
of Supplementary Materials.
Alternatively, for assessing the effects of mutations on
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Figure 1. Methodology workflow. The DynaMut methodology can be di-
vided into four steps. In step 1, data was collected from the previously
established S2648 subset of mutations with experimental evidence from
ProTherm. In step 2, DynaMut combines the effects of mutations on pro-
tein stability and dynamics calculated by Bio3D, ENCoM and DUET. In
addition, DynaMut also includes a set of complementary information re-
garding the environment characteristics of the wild-type residue (e.g. rel-
ative solvent accessibility, residue depth and secondary structure) and the
graph-based signatures generated by mCSM. All these features are used as
evidence for training supervised learning algorithms in step 3. After eval-
uating the performance of the predictive model, the consensus prediction
was integrated into the DynaMut web server.
are available (Supplementary Figure S2). The ‘Single mu-
tation’ option requires the user to provide a PDB file or
PDB accession code, the point mutation specified as a string
containing the wild-type residue one-letter code, its corre-
sponding residue number and the mutant residue one-letter
code. The ‘Mutation list’ option allows users to upload a list
of mutations in a file for batch processing. For both input
options the user is also asked to specify the chain identifier
in which the wild-type residue is located.
In order to assist users to submit their jobs for analysis
and predictions, sample submission entries are available in
both submission pages and a help page is available via the
top navigation bar.
Output
For the analysis of protein dynamics, the results are dis-
played in four tabs. In the first tab (Supplementary Figure
S3), porcupine plots show the trajectory of movement ac-
cording to the first non-trivial mode of the molecule. The
second tab (Supplementary Figure S4) allows users to vi-
sualize the non-trivial modes generated, including an ani-
mated plot that describes the motion of the molecule. Visual
representations of deformation energy and atomic fluctua-
tion are displayed on the third tab (Supplementary Figure
S5). Finally, the last tab shows the cross-correlation between
residue movements as both a correlation matrix and the 3D
structure of the submitted protein (Supplementary Figure
S6).
The mutational analysis results are also split into tabs
to enable users to easily navigate the different analyses
available for evaluating the effects of mutations on pro-
tein stability and dynamics. For the ‘Single mutation’ op-
tion, the server outputs the predicted change in stability
(in kcal/mol), along with the variation in entropy energy
between wild-type and mutant structures (in kcal/mol/K)
in the first tab (Supplementary Figure S7). For compari-
son purposes, in a separate panel the changes in stability
calculated by structure-based methods are shown (16–18).
DynaMut enables visualization of the non-covalent molec-
ular interactions calculated by Arpeggio (45) (Supplemen-
tary Table S2, Supplementary Figure S8) and deformation
energies and atomic fluctuations of wild-type and mutant
residues (Supplementary Table S3, Supplementary Figure
S9) in their respective 3D structures. For the ‘Mutation list’
option, the server output is summarized as a downloadable
table, and users have the option to analyze each mutation
separately, similar to the analysis of a single mutation (Sup-
plementary Figure S10).
DynaMut also generates and makes available for down-
load pymol sessions for flexibility analysis and for inter-
residue interactions for both wild-type and mutant struc-
tures to facilitate easy visualisation and figure preparation.
VALIDATION
The performance of DynaMut was compared to well-
established methods that also provide measurements of ef-
fects of single-point mutations on protein stability. All mu-
tations from the data set described previously were submit-
ted to each tool and the Pearson’s Correlation Coefficient
and Root Mean Squared Error were used to assess the com-
parison among all methods. Moreover, outliers were consid-
ered based on the absolute difference between predicted and
actual values of G.
Since this definition can vary across the methods and for
comparison purposes we defined G ≥ 0 as stabilizing
and G < 0 as destabilizing. In the case that a method
does not follow such definition, its results were adapted.
Performance on cross validation
Across the full training set (forward and reverse mutations),
DynaMut achieved a Pearson’s correlation of r = 0.67, and
RMSE = 1.31 kcal/mol (r = 0.79 and  = 0.01 on 90%
of the data) under 10-fold cross validation. This correlation
was significantly higher than the individual methods used
in the consensus prediction (P-value < 0.0001). Supplemen-
tary Table S1 on Supplementary Materials summarizes the
performance for all the methods during training of Dyna-
Mut. Figure 2A shows the regression analysis for perfor-
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Figure 2. Regression analysis of the performance of DynaMut over training and blind test. Left panel shows the correlation during training and Right
panel depicts the correlation between the actual values of G and the predictions of DynaMut. Pearson’s correlation coefficient (r) and RMSE are shown.
Crosses in pink show the 10% outliers. The performance results are shown on the top left of each panel. The results colored in pink are related to the entire
dataset and the results colored in black were obtained after removing 10% of the outliers.
Table 1. Performance of DynaMut on Blind test for the 351 mutations with experimental 3D structure (forward), the 351 hypothetical reverse mutations
(reverse) and the overall results for all the 702 mutations (Overall). The performance of well-established methods are also shown for comparison purposes
Method Forward Reverse Overall
Pearson (r) RMSE Pearson (r) RMSE Pearson (r) RMSE
DynaMut 0.69 1.39 0.58 1.51 0.70 1.45
I-Mutant 2 (46) 0.73 1.01 0.21a 2.55 0.49a 1.97
Maestro (47) 0.20a 2.13 0.60 2.12 0.49a 2.13
DUET (17) 0.75 1.05 0.27a 2.39 0.56a 1.85
SDM2 (16) 0.52a 1.80 0.42a 2.16 0.50a 1.99
mCSM (18) 0.76 1.09 0.23a 2.50 0.54a 1.93
ENCoM (9) 0.44a 1.79 −0.50a 2.31 0.35a 1.79
FoldX (48) 0.35a 2.33 −0.29a 2.23 −0.55a 2.32
aP-value < 0.001 compared to DynaMut using z-test.
Blind test
The non-redundant blind test was used to evaluate the gen-
eralization of the consensus predictions. Across the com-
plete blind test set of 702 mutations containing both for-
ward and hypothetical reverse mutations, DynaMut ob-
tained a Pearson’s correlation coefficient of 0.70 (RMSE =
1.45; Figure 2B). After removing 10% outliers, DynaMut
achieves a correlation of up to r = 0.79 (RMSE = 1.10; Fig-
ure 2B). This was significantly higher (P-value < 0.001) than
comparable methods (Table 1).
Looking specifically at those data points with experi-
mental data, the original core 351 non-redundant muta-
tions, DynaMut achieved a Pearson’s correlation of r = 0.69
(RMSE = 1.39), significantly higher than the performance
of either ENCoM, FoldX, SDM or Maestro, but lower than
I-Mutant2, DUET and mCSM (P-value < 0.001; Table
1). Considering the hypothetical reverse mutations alone,
DynaMut significantly outperformed all other algorithms
tested, achieving a Pearson’s correlation of 0.58 (RMSE =
1.51; Table 1).
Previous studies have highlighted that many machine
learning based structural approaches are unbalanced, and
can less accurately identify stabilizing mutations (16). We
therefore considered method performance across stabiliz-
ing and destabilizing mutations separately (Supplemen-
tary Table S2). Considering the destabilizing mutations
alone, DynaMut has a comparable correlation coefficient
but higher RMSE (1.42) than mCSM (1.02), DUET (1.04)
and iMutant2 (1.07), and outperformed the other methods
tested. Across the stabilizing mutations, however, DynaMut
achieved a correlation of r = 0.51 (RMSE = 1.48), signifi-
cantly higher than all comparative methods (P < 0.01; Sup-
plementary Table S3). This highlights that DynaMut pro-
vides the most accurate and balanced approach for the pre-
diction of both destabilizing and stabilizing mutations.
CONCLUSION
Here, we present DynaMut, an integrated computational
method that provides users with easy access to powerful
and insightful analysis of protein motions and their changes
upon mutation. By consolidating these insights with our
graph-based signatures, DynaMut is able to accurately as-
sess the effects of missense mutations on protein stability.
This consensus approach allows for the more accurate and
reliable prediction of both stabilizing and destabilizing mu-
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applications, ranging from protein functional analysis, op-
timization of stability and understanding the role of muta-
tions in diseases. The method is freely available as a user
friendly and easy to use web server at http://biosig.unimelb.
edu.au/dynamut/.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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Bio3D is a R package that contains utilities that helps one to process, organize and 
explore protein structure and sequence data. Among other features available, Bio3D 
provides the ability to read, write and process biomolecular structure, sequence and 
dynamics trajectory data; perform ensemble normal mode analysis on large structure sets 
to explore evolutionary dynamics and structure sets to explore evolutionary dynamics and 
structure dependent protein flexibility; and also various utility functions are provided to 
enable the statistical and graphical power of the R environment when working with 





ENCoM is an Elastic Network Contact Model that employs a potential energy function 
and includes a pairwise atom-type non-bonded interaction term to add an extra layer of 
information regarding the effect of the specific nature of amino acids on dynamics within 
the context of NMA (2). ENCoM tries to approximate ΔΔG through the calculations of the 
vibrational entropy (ΔS) (3) of wild-type and mutant structures. The ΔS between two 
conformations (A, B) in terms of their respective sets of eigenvalues is given by: 
 









• 𝝀𝒏,𝒊 represents the nth normal mode (the first 6 modes correspond to rotational 
and translational degrees of freedom and because of that they are not considered 
on the calculations. 
 




DUET is an integrated approach for predicting the effects of mutations on protein stability 
that takes advantage of two distinct techniques, SDM (4) and mCSM (5), by combining 
them in a consensus prediction (6). DUET unifies the results of the separate methods in 
an optimised predictor using Support Vector Machines (SVM) trained with Sequential 
Minimal Optimization (7). DUET predictions were more accurate than either method on 




A set of well-established and widely used performance metrics for evaluation regression 
models were used to evaluate DynaMut on both 10-fold cross validation and on blind 
tests. These metrics include Pearson’s Coefficient of Correlation (r) and Root Mean 
Squared Error (RMSE). 
 
 
Pearson’s Coefficient of Correlation 
 
The Pearson correlation coefficient, also known as the product moment correlation 
coefficient, is a measure of the linear correlation between two variables 𝑋 and 𝑌. The 
coefficient is measure on a scale with no units and can take values from -1, total negative 
linear correlation, to +1, total positive correlation. Values closer from 0 indicate that there 
is no linear correlation between 𝑋 and 𝑌. The mathematical definition of the Pearson's 
Correlation Coefficient is given by the covariance of the two variables divided by the 





   where: 
• 𝒄𝒐𝒗(𝑿,𝒀) is the covariance of 𝑿 and 𝒀; 
• 𝝈𝑿 is the standard deviation of the variable 𝑿; 
• 𝝈𝒀 is the standard deviation of the variable 𝒀; 
 
 
Root Mean Squared Error 
 
Root Mean Squared Error (RMSE) is the standard deviation of the predictions errors. This 
measure indicates how concentrated the predicted data points are from the line of best fit 
which represents the ideal perfect correlation between the actual observed values (𝑌) 
and the predicted values (?̂?) (9). RMSE is described by the formula below: 
 









• 𝒏 is the total number of instances; 
• (𝒀𝒊 − ?̂?𝒊)
𝟐 represents the squared errors between actual observed values and 




The Machine learning task used on this work was implemented on the Weka Tool Kit (10). 
 
Random Forest  
 
The Random Forest algorithm uses a set of decision tree predictors in a way that each 
tree relies on the values of a random vector sampled independently and with the same 
distribution for all trees in the set. The generalization error for forests converge to a limit 
as the number of trees in the set becomes large (11).  
 
This is a fast and easy to implement algorithm that produces highly accurate predictions 
and can handle a large number of input variables with low overfitting rates. Since all the 
trees are built from scratch without any previous information on the other trees (reason 
why the algorithm is called Random Forest) in the forest and also the final prediction is 
the average of all the predictions for each tree. 
  
TABLES 
Table S1 – Force Fields options for Normal Mode Analysis in DynaMut.  
Name Description 
C-alpha (12) 
Force field derived from fitting to the Amber94 all-atom 
potential. 
ANM (13) 
Anisotropic Network Model uses a simplified spring force 
constant based on the pair-wise distance. 
pfANM (14) 
parameter-free Anisotropic Network Model is variant from the 
ANM force field with interactions that fall off with the square 
of the distance. 
REACH (15) 
Realistic Extension Algorithm via Covariance Hessian is 
parameterized based on variance-covariance matrices 
obtained from MD simulations. 
sdENM (16) 
This force field employs residue specific spring force 
constants and it has been parameterized through a statistical 






Table S2 – Performance evaluation of DynaMut on training and comparison with other 
methods. 
Methods Pearson (r) RMSE 
DynaMut 0.67 1.31 
DUET (6) 0.41* 1.79 
SDM2 (4) 0.42* 1.93 
mCSM (5) 0.40* 1.83 
ENCoM (2) 0.05* 5.13 
FoldX (17) -0.05* 4.37 







Table S3 – Performance evaluation of DynaMut on identifying stabilizing mutations and 
comparison with other methods. 
Method 
Stabilising Destabilizing 
Person (r) RMSE Pearson (r) RMSE 
DynaMut 0.51 1.48 0.61 1.42 
I-Mutant (18) 0.07* 2.57 0.57 1.07 
Maestro (19) 0.43 2.22 0.45* 2.13 
DUET (6) 0.13* 2.4 0.64 1.04 
SDM2 (4) 0.26* 2.15 0.4* 1.83 
mCSM (5) 0.12* 2.53 0.63 1.02 
ENCoM (2) 0.37* 1.84 0.03* 4.36 
FoldX (17) -0.37* 2.34 -0.03* 5.21 






Figure S1 - DynaMut normal mode analysis input page. For the protein dynamics 
analysis, the server requires the user to input a protein structure by either uploading a file 
in PDB format or by providing the 4-letter accession code for any entry on the PDB 
database. In addition, users, are required to specify a force field that will describe the 
interactions between the atoms of the structure for the normal mode analysis. 
 
Figure S2 - DynaMut prediction input page. For assessing effects of mutations on protein 
dynamics and stability two different input options are available. The "Single mutation" 
option requires the user to provide a PDB file or PDB accession code, the point mutation 
specified as a string containing the wild-type residue one-letter code, its corresponding 
residue number and the mutant residue one-letter code. The "Mutation list" option allows 
users to upload a list of mutations in a file for batch processing. For both input options the 
user also is asked to specify the chain identifier in which the wild-type residue is located. 
 
 
Figure S3 - Porcupine Plots on DynaMut Normal Mode Analysis output page for the 
example (PDB: 1U46 – Tyrosine Kinase ACK1). Protein kinase transition state from active 
to inactive and vice-versa requires that the protein presents a minimum flexibility no 






Figure S4 - Modes Visualisation on DynaMut Normal Mode Analysis output page.  
 
 
Figure S5 - Deformation energies and atomic fluctuation on DynaMut Normal Mode 
Analysis output page.  
 
 




Figure S7 - Mutation effect prediction on DynaMut Prediction output page for the example 
(PDB: 1U46 – Tyrosine Kinase ACK1). The mechanisms by which the activating 
mutations affect kinases are associated with a restriction in the transition from active to 
inactive, resulting in one conformational state being favoured. This transitional state is 
directly affected by the molecule flexibility. The ΔΔG prediction outcome is shown on the 
top left of the page. Results for other predictive tools (NMA based and Other Structure-
based approaches) are also displayed. Visual representation of the Δ Entropy Energy in 
which the amino acids were coloured according to the vibrational entropy change upon 
mutation is shown on the bottom. Blue regions indicate rigidification and red a gain in 
flexibility. 
 
Figure S8 - Interatomic Interactions predictions of wild-type and mutant residues on 
output page of DynaMut. Wild-type and mutant residues are coloured in light-green and 
are also represented as sticks. A table with the colour definitions for each type of 
interaction is shown on top. 
  
Figure S9 - Atomic fluctuation and deformation energies of the wild-type and mutant 
structures on output page of DynaMut. Wild-type and Mutant sequence were extracted 
from their respective 3D structures and then aligned. The results of normal mode data for 
each of the sequences are displayed on top. Visual representation of atomic fluctuation 
and deformation energies for wild-type (left) and mutant (right) are shown below. The 
magnitude of the fluctuation and deformation is represented by thin to thick tube coloured 
blue (low), white (moderate) and red (high). 
 
Figure S10 – Results page of DynaMut for the Mutation list option. The server output is 
summarised as a downloadable table, and users have the option to analyse each 
mutation separately, similar to the analysis of a single mutation, by clicking on the “Detail” 
button of each mutation on the row. All resources generated on the analysis are also 
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Abstract
Predicting the effect of missense variations on protein stability and dynamics
is important for understanding their role in diseases, and the link between pro-
tein structure and function. Approaches to estimate these changes have been
proposed, but most only consider single-point missense variants and a static
state of the protein, with those that incorporate dynamics are computationally
expensive. H ere we present DynaMut2, a web server that combines Norma l
Mode Analysis (NMA) methods to capture protein motion and our graph-
based signatures to represent the wildtype environment to investigate the
effects of single and multiple point mutations on protein stability and dynam-
ics. DynaMut2 was able to accurately predict the effects of missense mutations
on protein stability, achieving Pearson's correlation of up to 0.72 (RMSE:
1.02 kcal/mol) on a single point and 0.64 (RMS E: 1.80 kcal/mol) on multiple-
point missense mutations across 10-fold cross-validation and independent
blind tests. For single-point mutations, DynaMut2 achieved comparable per-
formance with other methods when predicting variations in Gibbs Free Energy
( ) and in melting temperature (G Tm ). We anticipate our tool to be a valu-
able suite for the study of protein flexibility analysis and the study of the role
of variants in disease. DynaMut2 is freely available as a web server and API at
http://bios ig .unimelb.edu.au/dyna mut2.
K E Y W O R D S
dynamics, graph-based signatures, missense mutations, stability changes
1 | I N T R O D U C T I O N
Proteins are highly dynamic, metastable molecular
machines. Missense mutations are associated with more
than half of all known inherited diseases, however, they
are often associated with more subtle molecular effects
than mutations that lead to larger changes to the mature
peptide. These single amino acid changes can readily dis-
rupt the intricate network of intramolecular interactions,
affecting how a protein folds, its stability, dynamics, and
ultimately protein function. Beyond phenotypic
outcomes, 1 22– it also has direct implications for their
experimental study, protein engineering,23,24 drug
design, 25 30– and use in industrial processes. 31
A number of approaches have been developed to pre-
dict how missense mutations affect protein stability using
either sequence 32–34 or structural information.35–37 The
information from both approaches is often complementary;
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however, s tructural methods have generally assumed a pro-
tein is static and doe s not consider the implications o f a
mutation within its conformational lands cape. We previ-
ously showed that by considering both the mutation envi-
ronment and the protein dynamics, we could more
accurately predict the effects of single-point missense
mutations. 38
Most predicti ve tools, however, have been limited to
single point missense variants, and the inclusion of pro-
tein dyna mics computationa lly scales poorly with protein
size. Here we present DynaMut2, an enhanced server
that combines normal mode analysi s with our graph-
based representation of protein structure, to accurately
and quickly predict the effects of single and multiple
point mutations on protein stability and dynamics.
2 | R E S U L T S A N D D I S C U S S I O N
The DynaMut2 development workflow is summarized in
Figure 1. Data on single and multiple point mutations
were derived from ProTherm. 39 Given the wide range of
molecular mechanisms by which mutations can impact
protein function, we modeled the effects of each
m u t a t i o n u s i n g a ra n g e o f f e a t u r e s , i n c l u d i n g p r o t e i n
d y n a m i c s ( N M A ) , w  i l d - t y p  e r e s i d u e e n v i r o n m e n t , s u b -
s t i t u t i o n p r o p e n s i t i e s a n d c o n t a c t p o t e n t i a l s c o r e s , i n t e r -
a t o m i c i nt e r a c t i o n s 4 0 a n d a l s o o u r w e l l - v a l i d a t e d g r a p h -
b a s e d s i g n a t u r e s a p p r o a c h . 3 5 , 4 1–4 8 T h e s e w e r e t h e n u s e d
to tra in and te st mac hi ne l ear nin g alg ori thm s. Ou r pre-
d i c t i v e m o d e l s w e r e f u r t h e r e v a l u a t e d u s i n g i n d e p e n -
d e n t b l i n d t e s t s e t s .
2.1 Predicting the effects of single|
point mutations
We initially evaluated the performance of our app roach
to predict changes in stability caused by single point
mutations. DynaMut2 was able to achieve a Pearson's
correlation of = 0.72 (RMSE = 1.02 kcal/mol) for ther
dataset S4022, under 10-fold cross-validation, and
r = 0.68 on S611, our non-redundant independent test set
(RMSE = 1.14 kcal/mol) (Figure 2), outpe rforming all
other methods (Table 1). The compara ble performance
between cross-valida tion and non-redundant blind test
supports the generalizability of the final model. After
removing 10% of outliers, performance remained
F I G U R E 1 DynaMut2 workflow. The methodology for this work can be summarized into four steps: (1) data collection and curation of
single and multiple mutations, (2) feature engineering to model the effects of mutations, (3) supervised machine learning, and (4) the
predicted effects on stability and dynamics































































consistent for the training set with = 0.76r
(RMSE = 1.06), and increased to = 0.77 (RMSE = 1.07)r
on the test set. No significant differences in the distribu-
tions of properties were observed for the outliers com-
pared to the overall dataset.
Due to the natural imbalance between stabilizi ng and
destabilizing mutat ions present in the training and evalu-
ation data (Figure S1), we further analyzed performance
on the respective classes separately. Across the non-
redundant validation se S611, DynaMut2 achieved a
Pearson's correlation of = 0.62 (RMSE = 1.75) andr
r = 0.51 (RMSE = 1.88) on destabili zing and stabilizing
mutations, respectiv ely. The slightly lower performance
toward stabilizing mutations was expected due to the
imbalanced distribution of data but was significantly
improved compared to previous methods (Table 1). These
results remained consisten t when we compared the per-
formances using rank coefficient scores Kendall and
Spearman (Table S1). This was furth er reflected in the
ability of DynaMut2 to correctly classify stabilizing and
destabilizing mutations (AUC 0.68), outperforming previ-
ous approaches.
To further investigate potential biases in the predic-
tive performance, we evaluated the performance of
F I G U R E 2 Predictive performance of DynaMut2 on 10-fold cross-validation (a) and non-redundant test sets (b) for single point
mutations. 10% of outliers are shown as pink crosses
T A B L E 1 Comparative performance across the non-redundant test set S611
Method
Overall Stabilizing mutations Destabilizing mutations
AUCPearson ( ) RMSE (kcal/Mol) Pearson ( ) RMSE (kcal/Mol) Pearson ( ) RMSE (kcal/Mol)r r r
DynaMut2 0.68 1.14 0.51 1.02 0.62 0.91 0.68
DynaMut1 0.49* 1.38+ 0.47 1.24 0.55 1.01 0.62
SDM 0.35 * 1.93+ 0.15 * 2.00+ 0.36* 1.86 + 0.60 #
mCSM 0.46 * 1.42+ 0.11 * 1.81+ 0.56 0.98 0.56 #
DUET 0.48 * 1.40+ 0.09 * 1.75+ 0.58 1.00 0.56 #
ENCoM 0.14− * 2.03+ −0.01* 1.94+ −0.18* 2.09 + 0.41 #
Maestro 0.36− * 1.55+ 0.27 * 1.17 0.43* 1.81 + 0.46 #
I-mutant 0.33 * 1.47+ 0.03 * 1.83+ 0.49* 1.09 + 0.51 #
MUpro a 0.15* 1.71+ −0.05* 2.15+ 0.23* 1.21 + 0.50 #
*p Value < .05 compared with DynaMut2 using z test.
#p tValue < .05 compared with DynaMut2 using test.
+p Value < .05 compared with DynaMut2 using Diebold-Mariano test.
a 48 mutations were left out due to input issues.































































DynaMut2 on subsets derived from the O2567 dataset. 49
DynaMut2 showed significantly better performance than
all other approaches for mutations on buried residues
(RSA 30%; Table S2). A small deterioration in perf or-≤
mance is observed on mutations on exposed residues
(RSA > 30%; Table S3), likely to be related to the smaller
number features captured by the graph-based signatures
in DynaM ut2; however, our method still achieved compa-
rable result s to mCSM, MAESTRO and SDM, and out-
performed other approaches. Evaluating the performance
on different protein CATH classifications, DynaMut2 out-
performed other approaches across -sheet structuresβ
(Table S4), and -helix and -helix structures (Table S5).α β
The size of the protein being mutated did not affect per-
formance, with comparable performance between larger
proteins (>150 residues; Table S6) and small prote ins
(<150 residues; Table S7), outperforming all other evalu-
ated approaches. Similarly, DynaMut2 performance was
similar to mutations from large to small residues
(Table S8), from small to large residues (Table S9), or for
mutations between residues of comparable sizes
(Table S10). Encouragingly, DynaMut2 outperformed all
other approaches on mutations leading to a change in
volume and demonstrated comparable performance to
the top approaches for mutations between residues of
similar volume. Overall, this highlighted that DynaMut2
predictive performance across all single-point mutations
was significantly more balanced and less biased than all
other methods evaluated.
We further evaluated the performance of our model
across an additional independent test set, S276.
DynaMut2 achieved a Pearson's correlation of 0.52, com-
parable with the best-performing meth ods (Table 2) and
significantly better than MUpro. 50 Although not directly
comparable, as there is a correlation betwee n changes
upon mutation in stability ( ) and thermal stabilityG
(Tm),
51 the performance of DynaMut2 on predicting
changes in melting temperature was assessed using the
blind test set S173. Results were stratified by protein
structure and summarized in Table S11. Overall,
DynaMut2 ranks fourth among the methods evaluated;
however, perf ormances of all methods varied greatly
between structures. These result s indicate a possible chal-
lenge in accurately predicting the thermal stability effects
of mutations on a more diverse set of proteins.
2.2 Predicting the effects of multiple|
point mutations
The perf ormance of our approach to predict the effects of
multiple point mutations on protein stabil ity was then
assessed. DynaMut2 achiev ed a Pearson's correlation of
r = 0.71 (RMSE = 1.6 6 kcal/mol) under 10-fold cross-
validation and = 0.67 (RMSE = 1.79 kcal /mol) on ourr
non-redundant test set. The comparable performance
between cross-v alidation and blind test set again gave
confidence in the generalizabil ity of the approach. This
significantly outperformed the previously reported per-
formances of DDGun, DDGun3D, Maestro, and FoldX,
whose correlations ranged from 0.37 to 0.55 on the exper-
imental multiple point mutations in ProTherm. 52 Perfor-
mances were consistent when considering only 90% of
the data, with DynaMut2 achieving = 0.82r
(RMSE = 1.91) and = 0.80 (RMSE = 2.01) on 10-foldr
cross-validation and blind-test, respectively (Figure 3).
This indicates that outlier predictions were not having a
significant effect on the correlations.
The unbalanced nature of the training dataset was
evident when we analyzed the performance of our final
model on stabilizing and destabilizing multiple mutations
separately (Tab le 3). Overall, DynaMut2 was able to cor-
rectly classify 80% of multiple missense mutations (AUC
0.84) in the blind test set, including 93% of the
destabilizing mutations, providing confidence in the
ranking ability of the approach. As expected, however,
across our non-redundant test set DynaMut2 shows a bet-
ter performance toward predicti ng multiple mutations
with a destabilizing effect, achieving a Pearson's correla-
tion of = 0.56 (RMSE = 2.66), while for stabilizingr
entries the performance drops to = 0.42 (RMSE = 2.94).r
These results indi cate a need for new experimental data
on multiple point mutations, especially those with stabi-
lizing effects, since the use of hypothetical reverse muta-
tions is likely to add more uncertainty to the model.
2.3 Web server|
We have implemented DynaMut2 a s a freely available and
user-friendly web server (http://bio sig.unimelb.edu.au/










*p zValue < .05 compared with DynaMut2 using test.































































dynamut2/). Th e frontend was developed us ing Mat-
erializecss version 1.0.0 and the backend uses the Flask
module (1.0.2) from the Python programming language. T he
web server i s hosted on a Linux machine running Apache.
2.4 Input|
DynaMut2 can be used in three different ways 1:
predicting for single point mutations,G 2 predicting
G for multiple point mutations (up to three), and also
analysis of protein dynamics based on NMA. For
predicting single point mutations, similarly to our previ-
ous implementation of DynaMut, two different inputs are
available: Single mutation and List of Mutati ons . For“ ” “ ”
the Single Mutation option, users are required to provide
a protein structure on PDB format or provide a four-digit
code of an entry on the PDB, the chain identifier where
the muta tion occurs and the point mutation defined as
string comprising wild-type residue one-letter code, residue
position, and mutant residue one-letter code. For the List of
Mutations option, users must provide the structure of the
protein, similarly to the Single Mutation option, and also
upload a file with the list o f variants (one per line), follow-
ing the same mutation code previously defined.
For predicting the effects of multiple mutations, users
are required to provide the structure of the pro tein, as
previously described , and also the multiple mutations
separated by a comma. DynaMut2 also allows for submit-
ting a list of multiple point mutations to be analyzed in
batch. These can be input by uploading a file with one
entry of multiple mutations separated by comma per line.
Alternatively, for protein dynamic analysis, users are
required to input the prote in structure by uploading a file
using the PDB format or provide a valid four-digit code
for a PDB entry, and also select one of the force fields
available to guide structural interactions for NMA. A ll
force field options available are detailed in Table S12.
F I G U R E 3 Predictive performance of DynaMut2 on 10-fold cross-validation (a) and non-redundant test sets (b) for multiple point
mutations. 10% of outliers are shown as pink crosses
T A B L E 3 Comparative
performance on multiple mutations




rp Tau rs rp Tau rs rp Tau rs
DynaMut2 0.71 0.58 0.75 0.42 0.38 0.53 0.56 0.47 0.63
MAESTRO 0.19* 0.13+ 0.19# 0.12* 0.07+ 0.08# 0.21* 0.14 + 0.21 #
FoldX 0.33* 0.21+ 0.31# 0.04* 0.06+ 0.09# 0.30* 0.19 + 0.27 #
*p Value < .05 compared with DynaMut2 using Fisher r-to-z transformation.
+p Value <.05 by transforming tau-to-r followed by Fisher r-to-z transformation.
#p Value <.05 by transforming rho-to-r followed by Fisher r-to-z transformation.
































































For single point mutations on the Single Mutation“ ”
option, predicted is shown at the top with details ofG
users' input and also the wild-t ype residue en vironment
(Figure 4). All interatomi c contacts calculated with
Arpeggio are also displayed as an interactive viewer using
NGL viewer. 53 On the Mutation List option, the re sults“ ”
are displayed as a downloadable table with options to
view details of each variation separately, similarly to the
analysis provided by the Single Mutation , option.“ ”
The results for multiple mutations, predictions are
displayed at the top of the page with detailed information
for each mutation, if a list is provided these results are
F I G U R E 4 DynaMut2 results
page. The figure depicts the
prediction results page for single-
point mutations. The predicted
effect of a mutation in stability and
dynamics is given as the variation in
Gibbs Free Energy (in Kcal/mol)
(1), together with complementary
information about the mutation
provided (2). Users can inspect the
wild-type residue environment via
an interactive viewer (3), which also
allows the visualization of non-
covalent interactions established by
the mutated residue































































shown as a table. An interactive viewer allowing for the
analysis of residue contacts is also available.
For NMA submissions, the results are displayed on
three panels. The first two provide information on trajec-
tory representation of the molecule motion and por cu-
pine plots, summarizin g vector field representation, for
the first non-trivia l modes. Finally, the last panel displays
a residue correlation matrix and structural represent a-
tions using all modes.
2.6 API|
DynaMut2 conveniently offers an API (Application Pro-
gramming Interface) to assist users in integrating our pre-
dictive tool into their research p ipelines. All jobs submitted
to DynaMut2 are labeled with a unique identifier, which is
used to query the status of the job. Input fields follow the
same rules of our website implementation. A full descrip-
tion of these with examples using curl and Python are avail-
able at http://biosig.unimelb.edu.au/dynamut2/api.
2.7 Processing time|
Finally, we compared the performance of DynaMut2 with
our previous implementa tion, DynaMut, in terms of
processing time for single-point mutations on six differ-
ent protein structu res. For each struct ure, we submitted a
single-point mutat ion to each server and computed the
processing time in seconds. This procedure was repeated
10 times for each mutat ion and the results are summa-
rized in Table S13 and Figure S2. Clearly, the greater the
number of residues comprising the protein structure the
longer it takes for our NMA based methods to generate
predictions. However, DynaMut2 runs much faster than
DynaMut on all sets of experiments with very little differ-
ences in each repetition and an improvement of more
than six times in the worst-case scenario.
3 | C O N C L U S I O N
Here we present DynaM ut2, a tool that incorporates
information on protein dynamics and structural environ-
ment properties of wild-type residue with our graph-
based signatures approach to provide an accurate predic-
tion of mutation effects on stability and dynamics for sin-
gle and multiple point mutations. Our updated server has
shown to outperform other methods on predicti ng
changes in stability caused by single point mutations and
also comparable results for when used for estimating
Tm . In addition, our new approach was significantly
faster compared to the original DynaMut, which will be
of great benefit toward large scale analysis and large
structures. Finally, we have extended our method to pre-
dict the effects of multiple point mutations (double and
triple mutants) and an API, which conveniently enables
users to programmatically run predictions and represents
a great contribution in terms of a novelty for this type of
tool. We believe DynaMut2 represents an invaluable
resource for the study of protein dynamics and to help
understand the role of mutations in diseases. Web server
and API with examples are freely available at http://
biosig.unimelb .edu .au/dynamu t 2.
4 | M A T E R I A L S A N D M E T H O D S
4.1 Data set|
We have collected experimental data on 2,648 single
point mutations on 125 globular proteins from
Protherm. 39 Of these, 2,080 are destabilizing
( < 0.0 kcal/mol) and 568 stabilizingG
( > 0.0 kcal/mol) (Figure S1). To minimize theG
imbalanced nature of our dataset (Figure S1) and as a
sanity check evidenced by other studies, here we use
hypothetical reverse mutations. 36,54 However, different ly
from our previo us implementation of DynaMut, hypo-
thetical reverse mutations with more drastic changes on
Gibbs free energy ( < 2.0 kcal/mol orG −
G > 2.0 kcal/mol) were left out of our study due to
uncertainties about the qualit y and biological significance
of the modeled mutant. Our final dataset comprised
4,633 mutations (2,640 destabilizing and 1,993 stabiliz-
ing), which were split into 4,022 entries (S4022) for train-
ing our predictive model and a non-redundant test set
comprising 611 en tries (S611), following the protocol
from our initial version of DynaMut.38 For further perfor-
mance evaluation and comparison with other methods,
here we also consider a test set of 276 mutations (S276)
with low sequence identi ty to proteins in the origin al
ProTherm dataset, and an independent test set compris-
ing 173 variants (S173) in six prote ins with experimental
melting temperature changes available (Tm ). The latter
includes the structu re of guanylate kinase (GK) obtained
through homology modeling with Modeller 55 using the
mouse GK as a template (PDB: 1LVG), similarly to previ-
ous works.56,57
For the data on multiple point mutations, we were
able to extract 1,323 entries from ProTherm; however,
since the majority of entries were double and triple
mutants (Figure S3) and for the sake of simplicity, here
we only considered those two types. Our final dataset
comprised 1,098 entries (710 destabilizing and































































388 stabilizing) (Figure S4), which were randomly split
into train and test sets comprising 872 and 227 entries,
respectively.
In this study, we prioriti ze the use of biologica l
assembly structures author assigned, if not available, for
structures generated using NMR for instance, the asym-
metric unit was considered. All data used in this study is
freely available for download at http://biosig.unimelb.
edu.au/dy namut2/data .
4.2 Normal model analysis|
NMA provides a valuable approach for the study of
dynamics and accessibl e conformations in a system as an
alternative to time-consuming and computationally
expensive Molecular Dynamics simulations. Similarly
with our previous work, here we incorporated dynamics
properties extracted from the protein structure generated
with the module NMA of the bio3D tool. 58
4.3 Graph-based signatures|
Our in-house graph-b ased signatures approach to repre-
sent molecular structures 35,59 61– has proven to be success-
ful for a range of applications toward the study of protein
structure and changes carried out by missense
mutations, 35,37,41 48– including phenotypic changes.16,62,63
These signatures comprise physicochemical and geomet-
rical pro perties from the wild-type environment based on
distance patterns mined from the 3D structure by rep-
resenting atoms as nodes and their interactions as edges.
Physicochemical properties are then defined based upon
the amino acid properties, namely pharmacophore, and
distance patterns between atoms are summarized as
cumulative distribution functions.
4.4 Analysis of mutation effects|
Changes in Gibbs Free energy of folding can occur due to
a myriad of factors related and in order to incorporate
these properties, we used Arpeggio 40 to calculate the
number of hydrophobic contacts involvi ng the wild-type
residue and contact potential scores from AAINDEX
database. 64
4.5 Machine learning|
I n t h i s s t u d y , w e u s e d t h e i m p l e m e n t a t i o n o f t h e R a n -
d o m F o r e s t a l g o r i t h m a v a  i l a b l e o n t h e s c i k i t - l e a r n
P y t h o n l i b r a  r y f o r b o t  h t h e p r e d  i c t i o n o f G f o r s i n -
g l e a n d m u l t i p l e m u t a t i o n s . I n o r d e r t  o a v o i d t h e c u r s e
o f d i m e n s i o n a l i t y a n d i m p r o v e p e r f o r m a n c e , w e
s e l e c t e d o u r f e a t u re s u s i n g a n i n c re m e n t a l s t e p w i s e
g r e e d y a p p r o a c h .
5 | G E N E R A L S T A T E M E N T
Small changes in proteins can have large phenotypic out-
comes. By considering the chan ges of mutations within
the context of the protein 3D structure, we have been
able to accurately predict the molecular consequences of
single and multiple point mutations on prote in folding,
stability, and dynamics. We have made this tool available
through an easy to use website and API.
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Figure S1 - Proportion of stabilising and destabilising mutations on S2648 and ΔΔG 
distribution. A) highlights the unbalanced nature of the original dataset with a much greater 
number of destabilising mutations over the stabilising ones. B) depicts the proportions for each 
one of the classes after including the reverse mutations. C) and D) shows the distribution of 
ΔΔG values for S2648 and our final dataset used in this study. 
  
 
Figure S2 - Processing time of DynaMut and DynaMut2 on structures of different sizes. Here 
we show average values of processing time (in seconds) for Dynamut (blue) and DynaMut2 
(orange) after 10 repetitions across 6 different proteins. DynaMut2 has a much lower 
processing time than its previous implementation on all cases, including a decrease of more 
than 6 times on larger structures. Details on structures and mutations are shown in Table S13. 
  
 
Figure S3 - Distribution of number of point mutations from the original dataset extracted from 
Protherm. More than 80% of the entries in the dataset comprises double and triple mutants. 
  
 
Figure S4 - Distribution of ΔΔG values for our dataset of multiple mutations. 
Table S1 - Comparative performance on single-point mutation prediction on the test set S611 
using rank correlation coefficients. 
Methods 
Overall Stabilising Destabilising 
Kendall Spearman Kendall Spearman Kendall Spearman 
DynaMut2 0.42 0.58 0.22 0.27 0.39 0.56 
DynaMut 0.27* 0.37+ 0.11* 0.12+ 0.36 0.52 
DUET 0.25* 0.36+ 0.01* -0.01+ 0.35 0.50 
mCSM 0.23* 0.33+ 0.01* 0.01+ 0.33 0.47 
SDM 0.23* 0.32+ 0.09* 0.13+ 0.24* 0.35+ 
ENCoM -0.23* -0.33+ -0.11* -0.16+ -0.21* -0.32+ 
Maestro -0.15* -0.23+ -0.0660* -0.09+ -0.22* -0.33+ 
I-Mutant 0.15* 0.22+ -0.07* -0.11+ 0.31* 0.44+ 
MUpro 0.07* 0.11+ -0.05* -0.07+ 0.13* 0.21+ 
* p-value < 0.05 by transforming tau-to-r followed by Fisher r-to-z transformation 
+ p-value < 0.05 by transforming rho-to-r followed by Fisher r-to-z transformation  
  
Table S2 - Comparative performance for single-point mutations on buried residues (RSA ≤ 
30%) derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.41 1.42 
mCSM 0.24* 1.40 
FoldX 0.21* 2.09 
I-Mutant 3.0 0.14* 1.37 
PoPMuSiC 0.19* 1.49 
SDM 0.14* 1.55 
Maestro 0.25* 1.41 
CUPSAT 0.24* 1.87 
Automute 0.26* 1.28 




Table S3 - Comparative performance for single-point mutations on exposed residues (RSA > 
30%) derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.27 1.42 
mCSM 0.27 0.96 
FoldX 0.16* 1.41 
I-Mutant 3.0 0.15* 0.86 
PoPMuSiC 0.16* 0.94 
SDM 0.20 0.90 
Maestro 0.37* 0.83 
CUPSAT 0.16* 1.31 
Automute 0.14* 1.43 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S4 - Comparative performance for single-point mutations on β-sheet structures 
according to CATH and derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.45 1.53 
mCSM 0.21* 1.66 
FoldX 0.27* 2.23 
I-Mutant 3.0 0.02* 1.78 
PoPMuSiC 0.24* 1.66 
SDM -0.05* 1.89 
Maestro 0.26* 1.66 
CUPSAT 0.31* 2.05 
Automute 0.08* 1.51 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S5 - Comparative performance for single-point mutations on α-helix and β-helix 
structures according to CATH and derived from the O2567 non-redundant to training sets for 
each model. 
Tool Pearson MAE 
DynaMut2 0.37 0.99 
mCSM 0.25* 1.23 
FoldX 0.25* 1.65 
I-Mutant 3.0 0.24* 0.89 
PoPMuSiC 0.27* 1.22 
SDM 0.21* 1.34 
Maestro 0.32 1.22 
CUPSAT 0.23* 1.62 
Automute 0.24* 1.39 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S6 - Comparative performance for single-point mutations on proteins with greater than 
150 residues derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.43 1.47 
mCSM 0.18* 1.59 
FoldX 0.21* 1.98 
I-Mutant 3.0 0.11* 1.48 
PoPMuSiC 0.07* 1.85 
SDM 0.20* 1.61 
Maestro 0.28* 1.54 
CUPSAT 0.26* 2.06 
Automute 0.24* 1.50 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S7 - Comparative performance for single-point mutations on proteins with less than 150 
residues derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.40 1.02 
mCSM 0.27* 0.94 
FoldX 0.24* 1.59 
I-Mutant 3.0 0.27* 0.91 
PoPMuSiC 0.37 0.90 
SDM 0.23* 0.99 
Maestro 0.37 0.89 
CUPSAT 0.18* 1.32 
Automute 0.22* 1.30 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S8 - Comparative performance for single-point mutations from large to small residues 
(in terms of volume) derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.37 1.66 
mCSM 0.15* 1.59 
FoldX 0.21* 1.89 
I-Mutant 3.0 0.12* 1.63 
PoPMuSiC 0.07* 1.87 
SDM 0.25* 2.06 
Maestro 0.23* 1.67 
CUPSAT 0.03* 2.39 
Automute 0.21* 1.56 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S9 - Comparative performance for single-point mutations from small to large residues 
(in terms of volume) derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.47 1.40 
mCSM 0.09* 1.78 
FoldX 0.10* 2.53 
I-Mutant 3.0 -0.31* 1.52 
PoPMuSiC 0.11* 1.74 
SDM -0.11* 1.72 
Maestro 0.28* 1.82 
CUPSAT 0.43 1.81 
Automute 0.41 1.22 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
 
  
Table S10 - Comparative performance for single-point mutations from and to residues with 
similar volumes derived from the O2567 non-redundant to training sets for each model. 
Tool Pearson MAE 
DynaMut2 0.39 0.98 
mCSM 0.35 0.96 
FoldX 0.24* 1.60 
I-Mutant 3.0 0.33 0.89 
PoPMuSiC 0.38 0.91 
SDM 0.32 0.97 
Maestro 0.40 0.88 
CUPSAT 0.32 1.36 
Automute 0.23* 1.31 
* p-value < 0.05 compared with DynaMut2 using Fisher r-to-z transformation 
  
Table S11 - Pearson Correlation coefficient for performance over blind test S173 of 
experimental ΔTm. 
Method 1AQH 1H8V 1OSI 1XAS 2FJF GKa average 
DynaMut2 -0.33 0.25 0.23 0.35 0.40 0.45 0.23 
DeepDDG 0.69 0.16 0.25 0.56 0.76 0.50 0.49 
STRUM 0.24 0.09 0.30 0.34 0.62 0.39 0.33 
SDM -0.05 0.30 0.32 0.09 0.58 0.33 0.26 
DUET -0.43 0.33 0.36 0.41 0.39 0.37 0.24 
mCSM -0.55 0.22 0.32 0.33 0.34 0.34 0.17 
I-Mutant -0.29 0.03 0.32 0.30 0.25 0.30 0.15 
MUpro 0.31 0.12 0.18 -0.47 0.30 0.33 0.13 
DynaMut -0.63 0.21 0.23 0.12 0.29 0.33 0.09 
a Guanylate kinase 
 
  
Table S12 -  NMA force field options available on DynaMut2. 
Name Description 
C-alpha (1) Force field derived from fitting to the Amber94 all-atom potential 
ANM (2) Anisotropic Network Model uses a simplified spring force 
constant based on the pair-wise distance. 
pfANM (3) parameter-free Anisotropic Network Model is a variant from the 
ANM force field with interactions that fall off with the square of 
the distance. 
REACH (4) Realistic Extension Algorithm via Covariance Hessian is 
parameterized based on variance-covariance matrices obtained 
from MD simulations. 
sdENM (5) This force field employs residue specific spring force constants 
and it has been parameterized through a statistical analysis of 
1500 NMR ensembles. 
 
Table S13 - Summary of processing time for DynaMut and DynaMut2. Here we show average 
and standard deviation values after 10 repetitions for each mutation. Average values are 
shown with a confidence interval of 95%. 








1A43 G156A A 67.50 ± 0.67* 1.08 16.70 ± 1.17 1.89 
1AKY V8I A 212.90 ± 
1.53*  
2.47 22.00 ± 0.41 0.67 
1AMQ C270A A 373.60 ± 
2.67* 
4.33 43.25 ± 0.40 0.63 
1AON T516V A 466.30 ± 
5.27* 
8.50 81.40  ± 2.86 4.62 
2ZT8 T526V A 617.30 ± 
2.50* 
4.03 112.10  ± 1.28 2.07 
6M71 Y884K A 1460.50 ± 
6.02* 
9.71 231.90 ± 3.42 5.53 
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ABSTRACT
Protein–protein Interactions are involved in most fun-
damental biological processes, with disease caus-
ing mutations enriched at their interfaces. Here we
present mCSM-PPI2, a novel machine learning com-
putational tool designed to more accurately predict
the effects of missense mutations on protein–protein
interaction binding affinity. mCSM-PPI2 uses graph-
based structural signatures to model effects of vari-
ations on the inter-residue interaction network, evo-
lutionary information, complex network metrics and
energetic terms to generate an optimised predictor.
We demonstrate that our method outperforms pre-
vious methods, ranking first among 26 others on
CAPRI blind tests. mCSM-PPI2 is freely available as a
user friendly webserver at http://biosig.unimelb.edu.
au/mcsm ppi2/.
INTRODUCTION
Most biological processes, including cell proliferation (1),
signalling (2), host-pathogen interactions (3) and protein
transport (4), are intrinsically coordinated through complex
networks of protein–protein interactions. The diversity and
size of the interactome offers a highly selective and tunable
way to modulate protein activities and pathways (5). Ge-
netic variations leading to changes in the binding affinity
of these interactions can disrupt or directly affect the for-
mation of interacting complexes and consequently lead to
disease (6–16) and drug resistance (17–19).
Advances in next-generation sequencing techniques have
created an explosive increase in the number of genetic vari-
ants available in the literature. However, experimental tech-
niques to study these variants are still expensive and time
consuming. mCSM (20) was one of the first scalable compu-
tational tools to accurately predict the effects of mutations
on binding affinity. Previous methods were limited either in
terms of their throughput (21,22) or in terms of their perfor-
mance (23). Since then, significant efforts have been devoted
to computationally study the effects of mutations on protein
complexes (24,25) but their poor predictive performance on
new variants, particularly mutations that lead to increased
binding affinity of the complex, has limited their use. In ad-
dition, the increase in amount of experimental evidence of
effects of variants on binding affinity offers the opportunity
to develop new and more accurate methods.
Our previously described graph-based signatures concept
has proven to be a powerful approach and has been widely
applied to the study of protein structure, including how mu-
tations alter protein stability (20,26), dynamics (27) and in-
teractions with other molecules (20,28–34).
Here we introduce mCSM-PPI2, a webserver that inte-
grates our well-established mCSM graph-based based sig-
natures framework with evolutionary information, inter-
residue non-covalent interaction networks analysis and en-




The data used on this work was derived from the re-
cently updated version of the SKEMPI database (35), which
compiles experimental data on changes in thermodynamic
and kinetic parameters on mutation for protein–protein
complexes that have 3D structures deposited in the PDB.
SKEMPI 2.0 (36) includes new mutations identified in the
literature after its first release, including data available from
three other databases: ABbind (37), PROXiMATE (38) and
dbMPIKT (39). The average mutation effect was considered
for variants reported in multiple experiments when these
varied by less than 2.0 kcal/mol and discarded otherwise.
After filtering for only single-point mutations with available
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Correspondence may also be addressed to Douglas E.V. Pires. Email: douglas.pires@unimelb.edu.au
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experimental crystal structures of the wild-type, we were
able to collect 4169 (S4169) variants in 319 different com-
plexes. All protein structures were collected from the Protein
Data Bank and a series of pre-processing steps were per-
formed to account for the diversity of structures (see Sup-
plementary material).
The binding affinity of protein–protein complexes were
used to calculate the binding Gibbs free energy (G):
G = RT ln (KD)
where R = 1.985 × 10−3 kcal K−1mol−1 is the ideal gas
constant, T is the temperature (in K) and KD is the equilib-
rium dissociation constant of the protein–protein complex
(in molar). The change in binding affinity upon mutation
was calculated as follows:
Gwt−mt = Gwild−type − Gmutant
Since the Gibbs free energy formulation is a thermody-
namic state function a change in binding affinity of a muta-
tion from a wild-type protein to its mutant (GWT→MT)
should be equivalent to the negative change binding free
energy of the hypothetical reverse mutation, from the mu-
tant to the wild-type protein (–GMT→WT) (40). Given
the unbalanced nature of the original dataset collected from
SKEMPI 2.0, 901 variants increased (Gwt-mt ≥ 0) and
3268 decreased (Gwt-mt < 0) binding affinity, and in or-
der to build a more robust and balanced predictive method,
we also included the hypothetical reverse mutations. There-
fore, the final dataset for building mCSM-PPI2 predictive
model includes 8338 single-point mutations (S8338), which
represents an increase of up to three-fold in datapoints in
comparison with previous methods that used data from the
first version of SKEMPI with 2007 (S2007) (20,23), 1964
(S1964) (25), 1102 (S1102) (24) and 1327 (S1327) mutations
(41).
A subset of 487 mutations in 56 complexes (S487) con-
tained within S4169 and not in S2007 were recently curated
(24) and here we used as evidence to evaluate the perfor-
mance of mCSM-PPI2. A summary of different subsets de-
rived from SKEMPI is shown in Supplementary Table S1.
The datasets used in this work are freely available
for download at http://biosig.unimelb.edu.au/mcsm ppi2/
datasets.
Graph-based structural signatures
mCSM-PPI2 uses as one of its core components our well
established graph-based structural signatures (mCSM) to
represent the environment of the wild-type residue. This
approach models both the geometry and physicochemical
properties of the interactions and architecture of wild-type
structure and has been widely applied to the study of small
molecule and protein structure (20,26–34,42). Our signa-
tures represent atoms as nodes and their interactions as
edges, with their physicochemical properties encoded based
upon the amino acid residue properties, denoted by a phar-
macophore. From this representation of the residue envi-
ronment, distance patterns between atoms characterized by
their properties are summarized in concise signatures as cu-
mulative distribution functions.
Modelling effects of mutation
Single-point mutations can affect protein–protein interac-
tions via different molecular mechanisms, including chang-
ing folding free energy of interacting partners or disrupting
non-covalent interactions essential for complex formation
(6,43). In mCSM-PPI2, we have included six new distinct
types of features that were not used in our first method (Sup-
plementary Table S2). These were combined with our well-
established graph-based signatures as evidence for training
a machine learning algorithm (see Supplementary material)
to better explore the effects of mutations in protein–protein
binding affinity (Figure 1).
Wild-type residue environment. Based on 3D structures
collected from the Protein Data Bank (44), we were able to
calculate Relative Solvent Accessibility (RSA), torsion an-
gle PHI and residue depth for the wild-type residue using
BioPython (45) version 1.7. We also extracted information
on the amino acid content in the sequence of the chain in
which the mutation occurs using iFeature (46).
Nature of wild-type and mutant residues. The conforma-
tional flexibility of glycine side chains and the rigidity of
proline side chains are important for defining the backbone
flexibility. Mutations from and to these two amino acids can
lead to large structural effects. For our model we included
binary terms to capture if the mutation was from or to a
glycine or proline.
Evolutionary information. Binding regions are known to
be evolutionarily conserved, which has been exploited in
a variety of studies to identify potential protein interac-
tion interfaces. For mCSM-PPI2 we also harnessed this
information by using the Position Specific Scoring Ma-
trix (PSSM) scores. PSSM was calculated through PSI-
BLAST of BLAST 2.2.3 using the non-redundant Swiss-
Prot database of protein sequences and the sequence of the
chain in which the mutation occurs as the query parameter.
Non-covalent interaction network analysis. We performed
analysis of the non-covalent interactions for the wild-type
residue and for the closest interface using the contacts cal-
culated by Arpeggio (47). Here, we extracted two types of
information: the difference between the number of con-
tacts of wild-type and mutant residue for covalent, Van der
Waals’, aromatic and hydrogen bond contacts, and com-
plex network metrics for the contact graph of the closest
interface of interaction, from which we extracted central-
ity metrics, including closeness and central points (48). In
this work, we consider a residue to be at an interaction in-
terface if it is located at most 5 Å away from the interacting
partner, following previous studies. In addition, we included
three protein contact potentials scores from the AAindex
database (49) (Supplementary Table S3).
Energetic terms. Interaction energy information between
the two interacting chains were extracted from FoldX (22).
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Figure 1. mCSM-PPI2 methodology workflow. The method relies on graph-based signatures, which model distance patterns and encode geometrical and
physico-chemical properties on wild-type residue environment. Network analysis based on non-covalent interactions of wild-type residue and interacting
interface along with evolutionary information and energy terms are also used. All features are used as evidence to train, test and validate machine learning
algorithms.
Atomic fluctuation. We used the Bio3D R package (50)
to calculate the atomic fluctuations of the structure of
the monomer where the mutation occur using calpha
and pfanm force fields to account for effects on protein
flexibility/rigidity.
WEBSERVER
We have implemented mCSM-PPI2 as a user-friendly
and freely available webserver (http://biosig.unimelb.edu.
au/mcsm ppi2/). The server front end was built using Ma-
terialize framework version 1.0.0, while the back-end was
built in Python via the Flask framework (Version 1.0.2). It
is hosted on a Linux server running Apache.
Input
mCSM-PPI2 can be used in two different ways: to either as-
sess the effects of mutations specified by the user input or to
predict the effects of mutations at the protein–protein inter-
face in an automated manner. For user-specified variations
two options are available (Supplementary Figure S1). The
‘Single Mutation’ option requires one to provide a PDB file
or PDB accession code of the structure of the protein com-
plex, the point mutation specified as a string containing the
wild-type residue one-letter code, its corresponding residue
number and the mutant residue one-letter code. The ‘Muta-
tion List’ option allows users to upload a list of mutations in
a plain text file for batch processing. For both options, users
are also required to specify the chain identifier in which the
wild-type residues are located.
Alternatively, for assessing effects of mutations at
protein–protein interfaces the server requires the user to
provide a PDB file or PDB accession code and select one
of two options: alanine scanning (all interface residues are
mutated to an Alanine) or saturation mutagenesis (all inter-
face residues are mutated to every other amino acid) (Sup-
plementary Figure S2).
In order to assist users to submit their jobs for predic-
tions, sample submission entries are available in both sub-
mission pages and a help page is also available via the top
navigation bar.
Output
For the Single Mutation option (Supplementary Figure S3),
mCSM-PPI2 outputs the predicted change in binding affin-
ity (in kcal/mol) along with an interactive 3D viewer, built
using NGL viewer (51), showing non-covalent interactions,
generated with Arpeggio, at the mutated position. A set of
controllers are available for users to hide and show the dif-
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Figure 2. Performance evaluation on cross-validation. mCSM-PPI2 was able to achieve a Pearson’s correlation of 0.82 and RMSE 1.18 kcal/mol when
trained on the S8338 dataset applying 10-fold cross-validation 10 times (A). In low-redundancy sets, mCSM-PPI2 was able to achieve a correlation of 0.75
and 0.67 on leave-one-complex-out (B) and leave-one-binding-site-out (C), respectively.
type and mutant structures. In addition, a 2D viewer dis-
playing non-covalent interactions of wild-type and mutant
structures is also shown. Pymol sessions are available for
download. For the Mutation List option (Supplementary
Figure S4), the results are summarized in a downloadable
table from which users can access details for each single vari-
ant.
For the Alanine Scanning option on the interface anal-
ysis, the server first presents a table with all the interfaces
identified on the submitted structure, and it also allows for
inspection of the individual interfaces. On the results page
of each interface the server shows a downloadable table
with the prediction outcomes for each mutation, a bar chart
that summarizes the predicted changes in binding affinity
(Supplementary Figure S5) and an interactive 3D viewer
in which the residues are coloured according to the pre-
dicted value (Supplementary Figure S6). Similarly, for the
Saturation Mutagenesis option, mCSM-PPI2 outputs a ta-
ble with all the interfaces identified and allows the users to
access detailed information on each interface. For each in-
terface, the server outputs a table compiling the results for
all variants (Supplementary Figure S7), a heatmap of all in-
terface residues and their respective mutations (Supplemen-
tary Figure S8), and a 3D viewer in which the residues are
coloured according to the average prediction for each par-
ticular position (Supplementary Figure S9).
VALIDATION
Performance on cross-validation
In order to build a more robust and reliable predictive
model we performed four types of validation. Firstly, we
performed 10-times stratified 10-fold cross-validation, us-
ing 90% of our original dataset (S8338) for training and the
remaining as a blind test. Selection of the blind test was re-
peated 10 times in a stratified manner, with the model re-
trained on the remaining data, in order to test the robust-
ness of the model (see Supplementary material). For this
approach the hypothetical reverse mutations were kept in
either training or test sets during the splits according to
its counterpart original mutation. Our method was able to
achieve an average Pearson correlation ( ) of 0.82 with a
standard deviation () of 0.06 across the 10 runs (Figure
2A) showing a more balanced prediction when distinguish-
ing between mutations that increase binding affinity from
decreasing ones than other methods (Supplementary Ta-
ble S4). We also evaluate the performance of mCSM-PPI2
when trained only on the original subset of mutations from
SKEMPI2 (S4169) using the same procedure and obtained
a correlation of 0.76 and RMSE of 1.19 kcal/mol. These
results corroborate the use of reverse mutations in order
to improve performance and robustness of our predictive
model. Performance comparison between mCSM-PPI2 and
other methods on different versions of SKEMPI and per-
formance of individual types of attributes are shown in Sup-
plementary Tables S5 and S6, respectively.
We further evaluated the performance of our approach
on two low-redundancy sets; low redundant at the (i) com-
plex and (ii) interface level. The complex low redundancy
test was performed using leave-one-complex out cross-
validation, in which we trained our model on 318 com-
plexes of our dataset and evaluate the performance on the
one remaining complex. After repeating this procedure for
each complex we achieved  = 0.75 (Figure 2B) and Root
Mean Square Error (RMSE) of 1.30 kcal/mol, outperform-
ing MutaBind (25) ( = 0.68 and RMSE = 1.57 kcal/mol).
Similarly, we applied leave-one binding site out using the
‘hold-out’ information extracted from SKEMPI2. Here, we
removed all mutations located in identical binding sites for
testing and trained on the remaining data. mCSM-PPI2
achieved  = 0.67 (RMSE = 1.39 kcal/mol) (Figure 2C),
which was significantly higher (p-value < 0.0001 by Fisher
r-to-z transformation) than the results reported for Muta-
Bind when trained using only mutations from SKEMPI1 (
= 0.57 and RMSE = 1.57 kcal/mol).
In addition, we evaluated the performance of our ap-
proach on a subset of 472 mutations (S472) not present
within the first version of SKEMPI but included in
SKEMPI2. For this experiment, we trained a predictive
model using all variants from the first version of SKEMPI
(S1964). Our method achieved a correlation of 0.63 (RMSE
= 1.11 kcal/mol).
Validation on CAPRI
mCSM-PPI2 was further validated against the CAPRI (52)
round 26, which is composed of 1862 experimentally char-
acterised mutations in two de novo influenza inhibitor tar-
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Table 1. Comparative performance of mCSM-PPI2 on CAPRI and the blind test set for the complex MDM2-P53





(kcal/mol) ρ RMSE (kcal/mol)
mCSM-PPI2 0.42 2.55 0.32 4.06 0.40 0.36
mCSM (20) 0.16** 3.71 0.13** 4.15 0.23 0.83
MutaBind (25) 0.41 2.58 0.30 4.27 NA NA
iSEE (24) NA NA NA NA 0.24 0.81
BeAtMuSiC (23) 0.28** 3.04 0.30 4.06 −0.23* 0.91
FoldX (22) 0.12** 3.94 0.16** 4.33 −0.14*
0.90
MMPBSA (21) 0.19** 5.40 0.08** 28.04 NA NA
*p-value < 0.05 by Fisher r-to-z transformation test compared to mCSM-PPI2
**p-value < 0.05 by transforming tau-to-r followed by Fisher r-to-z transformation. NA: Data not available.
in T55 and 855 mutations at 45 different positions in T56).
The in vitro experimental measurements used the enrich-
ment values generated from deep sequencing and were cal-
culated based on the binary logarithm of the ratio of num-
ber of times the variant sequence was observed after and
before the selection for binding. Although the 3D struc-
tures for these two complexes were not available, struc-
tures of close homologues have been described (53,54) and
were used for generating homology model structures by in-
troducing point mutations using Modeller (55) (see Sup-
plementary Materials). mCSM-PPI2 was able to achieve a
Kendall’s score of up to 0.42 and 0.32 for mutations in T55
and T56, respectively, ranking first amongst 26 other meth-
ods (Supplementary Figure S10 and Table 1).
Blind test
The performance of mCSM-PPI2 was further evaluated on
a small set of 26 variants at the interface of interaction of
the MDM2-p53 complex (PDB 1YCR) (24). Our method
achieved a Pearson’s Correlation of 0.40 and an RMSE =
0.36 kcal/mol outperforming mCSM, iSEE, FoldX, BeAt-
MuSiC (23) (Table 1).
Finally, we looked at the ability of mCSM-PPI2 to ac-
curately identify PPI hotspots, residues that contribute
to the majority of the binding free energy of the inter-
action and have been recognized as important sites for
drug development (5). Here we evaluated the performance
of mCSM-PPI2 across a previously proposed set of 378
alanine-scanning experimental mutations within 19 differ-
ent protein–protein complexes (56,57) (Supplementary Ta-
ble S7). In order to minimize biases, for this experiment
we removed 232 variants from S8338 which were redun-
dant with our set of 378 alanine scanning mutations. Our
predictive model was was able to accurately distinguish
hot and not-hot spots (95% of hotspots and 92% of non-
hotspots were correctly predicted) outperforming the re-
sults reported for Robetta (precision of 79% and 68% when
predicting hotspots and non-hotspots, respectively). The
predicted changes in binding energy showed that mCSM-
PPI2 predictions correlated strongly with the experimen-
tal data (Pearson’s Correlation of 0.95 and RMSE of 0.25
kcal/mol; Supplementary Figure S11). These results indi-
cate that mCSM-PPI2 could also be a powerful tool for
hotspot identification.
CONCLUSION
Here, we introduce mCSM-PPI2, a web server that imple-
ments an integrated computation approach for predicting
effects of missense mutations in protein–protein affinity. By
consolidating our graph-based signatures framework with
evolutionary information, inter-atomic contacts and energy
terms our updated method has shown to perform better
than its previous version and other methods. In addition,
the use of hypothetical reverse mutations has shown to im-
prove the robustness of our predictive model allowing for
a more balanced prediction. mCSM-PPI2 is freely avail-
able as a user-friendly and easy to use web server at http:
//biosig.unimelb.edu.au/mcsm ppi2/.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
FUNDING
Australian Government Research Training Program Schol-
arship [to C.H.M.R and Y.M.]; Jack Brockhoff Founda-
tion [JBF 4186, 2016 to D.B.A.]; a Newton Fund RCUK-
CONFAP Grant awarded by The Medical Research Coun-
cil (MRC) and Fundação de Amparo à Pesquisa do Es-
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mCSM-PPI2 was built using the open source module Scikit-Learn version 0.20.1 (1). 
Scikit-Learn provides a collection of simple and powerful functions, tools and algorithms 
to perform machine learning and data analysis in Python. Our final model and the results 
presented in this work were generated based on the ExtraTrees algorithm, a tree-based 
ensemble method for supervised classification and regression tasks (2). This algorithm 
operates in a similar manner as the Random Forest algorithm with the difference that 
decisions boundaries used when splitting the nodes for building the trees are chosen 
randomly. When building our predictive models we used the default parameters defined 




Results for 10-fold cross-validation performance of mCSM-PPI2 were generated after 10 
times repetition of the traditional cross-validation in a stratified manner (pseudo-code 
below). The dataset used for training was divided in 10 subsets and for each repetition 
one subset was used for testing and the remaining data was used for training in which 
10-fold cross-validation was carried out. Therefore, every subset was used as test set 





Pseudo-code for stratified cross-validation: 
N = 10 
K = 10 
subsets = split(original_dataset, N) 
for each subset: 
 remaining_dataset = original_dataset - subset 
 performance_on_crossvalidation(original_dataset - subset, K) 
 model = train_predictive_model(remaining_dataset) 
 model.evaluate(subset) 
 
Homology Model Structures for CAPRI Dataset 
 
3D structures for the de novo designed influenza inhibitors (HB36.4 and HB80.3) in 
complex with hemagglutinin (HA), specified on the 26th round of CAPRI as targets T55 
and T56, were obtained via homology modelling using Modeller version 9.21 (3) and close 
homologues previously defined (4,5). The 3D structure for Target 55 were obtained by 
introducing a single point mutation (N64K) on the structure of HB36.3-HA (PDB: 3R2X). 
For Target 56, we used the crystal structure of the complex HB80.4-HA (PDB: 4EEF) as 
the template and introduced 5 point mutations (K12G, I17L, I21L, K35A, K42S). 
 
Pre-Processing of PDB Structures 
 
Due to limitations and eccentricities of the PDB format, we performed a series of steps 
to ensure that structures could be processed by external software. These are described 
as follows: 
• If an accession code for a protein structure on the Protein Data Bank is provided 
on the input page, mCSM-PPI2 will try to download the first author assigned 
biological assembly defined in the headers of the official structure. If no code is 
found (e.g., on NMR structures), mCSM-PPI2 will use the official structure file 
available on the Protein Data Bank. 
• Where multiple models were present in a structure (e.g., on NMR structures), 
only the first one was maintained, ensuring only a static state was compared 
when conducting large scale analysis. 
• Water molecules, ligands and non-standard compounds were removed. 
• For residues presenting multiple occupancy, only the most prevalent one was 
selected. 
• Given that some of the tools used by mCSM-PPI2 have difficulties dealing with 
structures with insertion codes, temporary files with residues renumbered 
sequentially (starting from 0) before running our calculations. 
• Missing atoms and residues were not modelled.  
TABLES 
 
Table S1 – Summary of datasets of experimental information on point mutations and their effects on binding 
affinity. 
Dataset Description Reference 
S4169 Variants extracted from Skempi2 (16) 
S8338 S4169 plus all reverse mutations (16) 
S2007 2007 variants extracted from Skempi1 (10,17,18) 
S1964 1964 variants extracted from Skempi1 (17,19) 
S1327 1327 variants extracted from Skempi1 (17,20) 
S1102 1102 variants extracted from Skempi1 (17,21) 
S472 472 variants contained in S4169 and not in S2007 (16,21) 
S378 Alanine scanning variants (22) 
 
Table S2 – Comparison of features used in mCSM-PPI1 and mCSM-PPI2. The first version of mCSM-PPI 
used our graph-based signatures to model the environment of the wild-type residue and pharmacophore 
to account for the effects of physicochemical changes caused by a point mutation as evidence to train a 
predictive model. In addition to those two types of features, mCSM-PPI2 also includes six new different 
classes of features that model different effects of single-point variants. 
Type of Feature Features Tool mCSM-PPI1 mCSM-PPI2 
Graph-based 
Signatures 




Negative, Hydrogen acceptor, 
hydrogen donor, aromatic, 
sulphur and neutral 
mCSM (10) Yes Yes 
Wild-type residue 
Environment 
Relative Solvent Accessibility, 
torsion angle Phi, Residue 
depth, amino-acid content of 
chain in which the wild-type 
resides in percentage: 
aliphatic, aromatic, positively 





Nature of Wild-type 
and Mutant 
Residues 
Is glycine? Is glycine and has 
a positive Phi torsion angle? 
Is proline? 
BioPython (11) No Yes 
Evolutionary 
Information 




Difference between contacts: 
Van der Waals’, aromatic and 
hydrogen bonds. Complex 
network metrics for the 
contact graph of the closest 
interface of interactions: 
betweenness, authority score, 
central points, number of 








Energetic Terms Electrostatic interaction 
between molecules, cost of 
FoldX (14) No Yes 
 
Table S3 - Protein contact potentials scores from the AAindex database (6) used for mCSM-PPI2 as part 
of its workflow. 
AAindex Code Description Reference 
MIYS960101 Quasichemical energy of transfer of amino acids from water to the 
protein environment. 
(7) 
SIMK990103 Distance-dependent statistical potential (contacts within 7.5-10 Å) (8) 
ZHAC000104 Environment-dependent residue contact energies (9) 
 
Table S4 - mCSM-PPI2 performance comparison on classification using two thresholds (0 and 0.2 
kcal/mol) in which ΔΔG >= threshold was considered to increase affinity and ΔΔG < threshold decrease 
affinity. The performance for each method was calculated over the performance on training. mCSM-PPI2 
shows a better and more balanced performance on increasing and decreasing affinity mutations than 
MutaBind. 
  |ΔΔG| > 0 kcal/mol |ΔΔG| > 0.2 kcal/mol 
Method Δ Affinity Precision Recall AUC Precision Recall AUC 
mCSM-PPI2 
Increase 0.90 0.87 0.88 0.89 0.85 0.84 
Decrease 0.87 0.90 0.88 0.79 0.84 0.84 
MutaBind 
Increase 0.62 0.24 0.60* 0.57 0.41 0.66* 
Decrease 0.81 0.96 0.60* 0.84 0.91 0.66* 
* p < 0.05 by z transformation test compared to mCSM-PPI2. 
 
Table S5 – mCSM-PPI2 training performance comparison across different subsets of variants derived 
from SKEMPI. The performance of mCSM-PPI2 was calculated after running 10-fold cross-validation 10 
times using 90% of the dataset for training and 10% for testing. 
SKEMPI Method Correlation (ρ) RMSE (kcal/mol) 
S2007 
mCSM-PPI2 0.83 1.02 
mCSM-PPI1 0.80* 1.25 
BeAtMuSiC 0.39* 1.81 
S1964 
mCSM-PPI2 0.82 1.08 
MutaBind 0.78 1.20 
FoldX 0.40* 2.12 
MMPBSA 0.44* 6.45 
S1327 
mCSM-PPI2 0.80 1.12 
SAAMBE 0.62* NA 
S1102 
mCSM-PPI2 0.81 1.19 
iSEE 0.80* 1.41 




having a cis peptide bond and 
Gibbs free energy change 
Atomic Fluctuation Score using calpha and 
pfanm force-fields 
Bio3D (15) No Yes 
Table S6 – Performance of predictive model across the different types of attributes used to build 
mCSM_PPI2. For this set of experiments the models were trained and performance evaluated on each type 
of feature separately. The performance was calculated after running 10-fold cross-validation 10 times using 
90% of the dataset S8338 and 10% for testing. 
Type of Feature Correlation (ρ) RMSE (kcal/mol) 
Graph-based signatures + pharmacophores 
changes 
0.57 2.75 
Wild-type residue Environment 0.28 3.13 
Nature of Wild-type and Mutant Residues 0.13 4.08 
Evolutionary Information 0.46 2.84 
Non-Covalent interaction network metrics 0.38 3.62 
Energetic Terms 0.40 3.53 
Atomic Fluctuation 0.11 5.43 
  
Table S7 – Distribution of mutations over protein-protein complexes for the dataset of alanine-scanning 
experimental mutations. 
 

























Figure S1 - Submission page for user-specified mutations. Two options are available. For the “Single 
Mutation” option mCSM-PPI2 requires one to specify a string containing the wild-type, wild-type residue 
one-letter code, the position in the structure, the mutant residue one-letter code and the chain identifier. 
For the “Mutation List” option users are asked to provide a file with a list of mutations for batch 
processing. For both options a PDB file is also required. 
 
 
Figure S2 - Input page for Interface analysis. For assessing the effects of mutations at protein-protein 
interfaces the server requires the user to provide a PDB file or a PDB accession code and select one of 
two options: alanine scanning (all interface residues are mutated to alanine) or saturation mutagenesis 
(all interface residues are mutated to every other amino acid). 
 
 
Figure S3 - Results page for “Single Mutation” option. mCSM-PPI2 outputs the change in binding free 
energy (in kcal/mol) on the top panel alongside with details on the input mutation. An interactive 3D 
viewer allows for analysis of non-covalent interactions at the position specified on input. Lastly, a 2D 
graph displays the interactions of wild-type and mutant residues. In both cases controllers are provided in 
order to hide or show specific interactions. 
 
Figure S4 - Results page for “Mutation List” option. The results are summarised in a downloadable table 
from which users can access details for each single mutation. 
 
 
Figure S5 - Table and Bar graph for Alanine Scanning results page. For each interface identified on the 
protein complex submitted, mCSM-PPI2 shows a downloadable table with all mutations and the results 




Figure S6 - 3D viewer for Alanine Scanning results page. A 3D viewer in which interface residues are 
coloured according to the predicted change in binding affinity is also shown at the bottom of the results 
page. A set of controllers are available for customising the structure according to the user’s need. 
 
 
Figure S7 - Table of results for Saturation Mutagenesis option. Similarly to the “Mutation List” and 
“Alanine Scanning”, for each interface identified on the Saturation mutagenesis option, the results are 
compiled in a downloadable table. 
 
 
Figure S8 - Heatmap for Saturation Mutagenesis option. The results compiled in the table for saturation 




Figure S9 - 3D viewer for Saturation Mutagenesis results page. mCSM-PPI2 also shows an interactive 
3D viewer for the saturation mutagenesis option in which the interface residues are coloured according to 
the average predicted change in binding affinity. 
 
 
Figure S10 - Performance comparison on CAPRI round 26th. mCSM-PPI2 (green) outperforms all other 
26 methods with a Kendall’s coefficient of 0.42 and 0.32 for datasets based on Targets T55 and T56, 
respectively. Bar coloured as blue indicate methods that used this same dataset as a benchmark on their 
studies. Other methods which participated on CAPRI by the time the dataset was released in 2012 were 
coloured in grey. 
 
 
Figure S11 - Density distribution of ΔΔG predictions by mCSM-PPI2 for mutations that were 
experimentally assigned as hotspots. While the majority of neutral mutations (blue) were predicted to 
have little impact, most of hotspots mutations (red) were predicted to have a significant decrease in the 
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ABSTRACT: Protein−protein interactions are promising sites for
development of selective drugs; however, they have generally been
viewed as challenging targets. Molecules targeting protein−protein
interactions tend to be larger and more lipophilic than other drug-
like molecules, mimicking the properties of interacting interfaces.
Here, we propose a machine learning approach that uses a graph-
based representation of small molecules to guide identification of
inhibitors modulating protein−protein interactions, pdCSM-PPI.
This approach was applied to 21 different PPI targets. We
developed interaction-specific models that were able to accurately
identify active compounds achieving MCC and F1 scores up to 1,
and Pearson’s correlations up to 0.87, outperforming previous
approaches. Using insights from these individual models, we
developed a generic protein−protein interaction modulator predictive model, which accurately predicted IC50 with a Pearson’s
correlation of 0.64 on a low redundancy blind test. Importantly, we were able to accurately identify active from inactive compounds,
achieving an AUC of 0.77 and sensitivity and specificity of 76% and 78%, respectively. We believe pdCSM-PPI will be an important
tool to help guide more efficient screening of new PPI inhibitors; it is freely available as an easy-to-use web server and API at http://
biosig.unimelb.edu.au/pdcsm_ppi.
■ INTRODUCTION
Protein−protein interactions (PPIs) play an essential role in
most key processes within the cell.1−4 Disruption of PPIs, often
caused by genetic mutations,5,6 are involved in the development
of many diseases, including cancer.7 Unlike traditional active site
drug targets that often share significant conservation with other
areas of the proteome leading to off-target effects, the broad
diversity of PPIs is of great interest for the development and
discovery of selective and specific drugs. PPI interfaces were
traditionally viewed as large, flat, and relatively featureless,8
making them not amenable to small molecule inhibition.
Subsequent work, however, has shown that many interfaces
can indeed be successfully modulated by small molecules,
especially through targeting hotspots at the interface.9 This has
been reflected in the successful design of inhibitors of PPIs, most
notably the development of small-molecule modulators of the
Bcl2/Bak complex.10
Despite these successes, developing PPI inhibitors is still a
challenging and time-consuming process.11,12 Several studies
focusing on chemical properties of known PPI inhibitors to
streamline the process of screening for new compounds have
been developed. These involved a range of machine learning
(ML) algorithms applied to limited data sets, including decision
trees to model chemical descriptors derived from 25 PPI
inhibitors13 and support vector machines (SVM) applied to 40
distinct compounds.14 Since then, many efforts to increase data
availability for small molecules targeting PPIs have been
proposed, most notably 2P2I-DB15 with over 274 inhibitors
targeting 27 different PPIs and iPPI-DB16 with over 2378
inhibitors acting on 46 PPI families. The emergence of large
collections of data prompted the development of more robust
data-driven methods such as PPIMpred17 and SMMPPI.18 The
former used 11 chemical descriptors with SVM to build
predictive models to identify inhibitors for three oncogenic
PPIs: Bcl2/Bak, mdm2/P53, and c-Myc/Max. More recently,
SMMPPI was developed as a two-stage classification workflow
based on chemical structure fingerprints, which at first identifies
small molecules more likely to inhibit PPIs and on stage 2
attempts to classify whether the compounds have inhibitory
activity against 11 different PPI complexes.
The ability to accurately predict compounds more likely to
target PPI interfaces can help understand better the complexity
and druggability of these regions.We have previously shown that
graph-based signature representation of small molecules is a
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powerful tool for providing novel insights into, and accurately
predicting, small molecule pharmacokinetic, toxicity, and
bioactivity properties.19−22 Here, we have explored the
application of this approach to the discovery of PPI inhibitors
(Figure 1). We have made our method, pdCSM-PPI, freely
available to assist with ongoing PPI inhibitor screening efforts.
■ RESULTS AND DISCUSSION
Common Properties of PPI Inhibitors.Most compounds
in our data set show physicochemical properties in agreement
with the widely used Lipinski Rule of Five (RO5) for orally
bioavailable drugs, with an average molecular weight of 483 Da,
four hydrogen acceptors, three donors, and logP of 3.90 (Figure
S1), presumably reflecting a natural bias in the screening
Figure 1.Methodology workflow of pdCSM-PPI. The development of pdCSM-PPI can be divided into four main steps. First, data on small molecules
with activity against PPIs, including IC50 values, were collected from the literature. In the second step, geometrical and physicochemical properties for
each compound were generated in the form of graph-based signatures. Additional molecular properties such as number of rotatable bonds, rings,
number of atoms, LogP value, and fragment-based descriptors, calculated via RDKit, were also included. These were then used to train and validate
supervised learning predictive models. Best performing models were selected and made available via a user-friendly web server and API for easy
integration with other analysis pipelines.
Table 1. Performances of 21 Target-Specific Predictive Modelsa
10-fold CV Blind test
PPI target MCC F1 AUC TP TN FP FN MCC F1 AUC TP TN FP FN
Bcl2-Like/Bak-Bax 0.94 0.97 0.98 184 192 2 10 0.99 0.99 1.00 65 64 1 0
Bromodomain/Histone 0.83 0.92 0.97 400 383 44 27 0.74 0.86 0.88 138 110 34 5
CD4/gp120 1.00 1.00 1.00 60 60 0 0 0.91 0.95 0.95 18 20 0 2
Cyclophilins 1.00 1.00 1.00 54 54 0 0 0.90 0.95 1.00 19 17 2 0
FKBP1a/FK506 1.00 1.00 1.00 67 67 0 0 0.92 0.96 1.00 23 21 2 0
HIF-1a/p300 0.97 0.98 0.99 60 60 1 1 0.91 0.95 0.98 20 20 1 1
Integrins 0.95 0.98 0.99 700 698 19 17 0.93 0.97 0.99 237 226 14 3
LEDGF/IN 0.87 0.93 0.97 91 78 13 0 0.77 0.87 0.90 23 31 0 8
LFA/ICAM 1.00 1.00 1.00 112 112 0 0 0.95 0.97 0.99 37 38 1 1
Mdm2-Like/P53 0.96 0.98 0.99 326 331 5 10 0.94 0.97 1.00 110 110 4 3
Ras/SOS1 0.95 0.98 0.99 41 41 1 1 0.87 0.93 0.99 14 12 2 0
WDR5/MLL 0.94 0.97 0.97 32 31 1 1 0.92 0.96 0.94 10 12 0 1
XIAP/Smac 0.98 0.99 0.99 132 134 0 3 0.89 0.94 0.94 40 45 0 5
Annexin A2/S100-A10 0.97 0.98 0.98 28 29 0 1 − − − − − − −
BRD2/Ack 1.00 1.00 1.00 32 33 0 0 − − − − − − −
CD80/CD28 1.00 1.00 1.00 35 35 0 0 − − − − − − −
IL2/IL2R 1.00 1.00 1.00 19 19 0 0 − − − − − − −
Keap1/Nrf2 0.96 0.98 0.98 26 28 0 1 − − − − − − −
MENIN/MLL 1.00 1.00 1.00 32 33 0 0 − − − − − − −
STAT3 1.00 1.00 1.00 21 21 0 0 − − − − − − −
TTR 1.00 1.00 1.00 35 35 0 0 − − − − − − −
aResults are shown in terms of Matthew’s correlation coefficient (MCC), F1 score, area under the ROC curve (AUC), true positives (TP), true
negatives (TN), false positives (FP), and false negatives (FN).
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libraries used to obtain these molecules. Interestingly, more
potent inhibitors (IC50 < 1 μm) presented a small deviation to
RO5 in terms of molecular weight, indicating that these could
have been elaborated/grown through medicinal chemistry to
achieve higher selectivity toward specific PPI interfaces (average
molecular weight of 513 Da, logP of 3.97, five hydrogen
acceptors, and three hydrogen donors). In fact, a certain degree
of flexibility to the rule is observed for small molecules within
our data set; for example, Navitoclax, a known potent inhibitor
for the Bcl2/Bak complex, has a molecular mass of 973 Da, 14
acceptors, two donors, and 9.6 logP. Furthermore, the most
potent molecules are enriched with complex ring substructures
(Figure S2), including biphenyls which have been previously
shown to be related to high levels of specificity.23 These findings
are also consistent with previous studies showing that PPI
inhibitors tend to have more aromatic rings than other
ligands.24,25
Identifying PPI-Specific Inhibitors. The identification of
chemical compounds that modulate PPIs to serve as probes for
guiding rational design of new and more potent small molecule
inhibitors is essential for accelerating drug discovery. Many
efforts have been implemented into compiling this information
into large publicly available databases, from libraries with a
broader range of small molecules, lipids and peptides,26,27 to
resources dedicated solely to compounds targeting PPIs.15,16,28
In this study, we manually curated data for small molecules
with experimental inhibitory activity for 21 distinct PPI targets
in Simplified Molecular-Input Line-Entry System (SMILES)
format. In order to complement and expand on previous works,
here we generated two sets of features for each compound,
namely, graph-based signatures19 and physicochemical descrip-
tors calculated via RDKit descriptors, which were then used as
evidence to train 21 different supervised learning predictive
models, one for each PPI target. Feature selection was carried
out via a greedy stepwise approach, and the best performing
models were selected. Performances on the training set under
10-fold cross-validation for all methods were given in terms of F1
score, area under the ROC curve (AUC) and Matthews
correlation coefficient (MCC) and are summarized in Table 1
and Figures S3−S5.
As eachmodel was trained individually, the optimal number of
features selected across all predictive models varied from 3 to 65.
However, we observed that the best performing models used
three main types of features which capture critical aspects of PPI
inhibitors extensively described in the literature: (1) Molecular
surface area descriptors (MOE), as evidenced by previous
studies, surface properties are key elements of more efficient PPI
inhibitors;29 (2) Distance patterns from graph-based signatures
involving atoms on aromatic ring structures emphasize the role
aromatic rings play on these types of compounds28 and are
consistent with the findings of our substructure mining
presented previously; (3) Fragment descriptors capture
common structural patterns for each PPI target (the number
of bicyclic fragments for example). Furthermore, analysis of
feature importance values output from the ExtraTrees algorithm
shows a balanced distribution of importance across all classifiers,
indicating a synergistic contribution by all features for the final
prediction (Tables S1−21, Supporting Information).
The performances of each target-specific predictive model
were further evaluated on nonredundant blind test sets, and
outcomes were compared with those reported for PPIM-pred17
and SMMPPI.18 PPIM-pred is a ML-based predictor for
inhibitors targeting three distinct PPIs: Bcl2/Bak, Mdm2/P53,
and c-Myc/Max. However, as machine learning is a data-driven
approach highly dependent on the amount of data used for
training a predictivemodel, and given the lack of data available in
our data set after removing redundancy for inhibitors of c-Myc/
Max (eight compounds), we are only able to compare the results
of two of our predictive models with PPIM-pred, namely, Bcl2/
Bak and Mdm2/P53. For a fair comparison between the two
methods, here we removed from our training set all compounds
with a Tanimoto similarity score greater than 0.8 from the test
set reported by PPIM-pred. As our method has been trained on a
larger data set of inhibitors for these two PPI targets using a
more diverse set of features, it is no surprise that our approach
significantly outperformed the metrics reported by PPIM-pred
(p-value < 0.05), showing a more balanced prediction for
inhibitors on both targets (Figure 2 and Table S22).
SMMPPI is a more recent ML-based method built on a more
robust data set of PPI inhibitors. The method proposes class-
specific predictors of inhibitors for 11 clinically important PPI
families, nine of which are included among those developed
using our approach. Here, we used the same test sets available on
the SMMPPI study for seven PPI targets, and test sets for the
Figure 2. Performance comparison of pdCSM-PPI with PPIM-pred. Both models were evaluated on their ability to distinguish between inhibitors and
noninhibitors of two distinct PPIs: (A) Bcl2/Bak and (B) mdm2/P53. pdCSM-PPI (orange) outperforms PPIM-pred (blue) in both cases (p-value
<0.05).
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WDR5/MLL1 and CD4/gp120 were used from our 75/25 split
as these were not available on SMMPPI. For the sake of
comparison, all small molecules with similarity greater than 0.8
were removed from our training set. Despite using a smaller
number of features for all predictors, our approach achieves
similar performance to those reported for SMMPPI for
inhibitors on all nine PPI targets in terms of MCC, F1 score,
and AUC (Table S23).
Finally, the 21 class-specific predictive models were used to
scan the NCI database with over 224,000 compounds, and
results are available at http://biosig.unimelb.edu.au/pdcsm_
ppi/data
Predicting PPI Inhibitor Potency.After demonstrating the
ability of our approach to classify molecules as either inhibitors
or noninhibitors, we investigated whether we could predict the
ability of small molecules to inhibit PPIs quantitatively, as a
regression task. New predictive models were trained and
evaluated using half maximal inhibitory concentration (IC50),
in a logarithmic scale, as outcomes. Here, we were able to
retrieve IC50 values for 3972 inhibitors fromTIMBAL and iPPI-
DB targeting 45 different PPIs. In order to minimize
redundancy, for each PPI target, we clustered compounds
with 0.8 Tanimoto similarity and selected one small molecule
per cluster. Similar to our criteria used for the classifiers, here we
chose nine PPI targets where the number of small molecules
after clustering was greater than 40 to proceed with the
regression task: Bcl2-Like/Bax-Bak, Bromodomain/Histone,
Cyclophilins, HIF-1a/p300, Integrins, LEDGF/IN, LFA/
ICAM, Mdm2-Like/P53, and XIAP/Smac. A summary of the
distribution of compounds across the 45 different PPI targets,
before and after clustering, is shown in Table S24. Data sets were
then split into 75% for training and 25% as a nonredundant blind
test using the same strategy previously described based on the
number of compounds per cluster. Here, the predictive models
were trained using the same set of features selected during our
classification task for each PPI target.
Performances on training under 10-fold cross-validation
ranged from Pearson’s and Kendall’s correlations of 0.33 and
0.21 (RMSE = 0.52) for inhibitors of the LEDGF/IN target to
Pearson’s and Kendall’s correlations of 0.91 and 0.60 (RMSE =
0.55) for Cyclophilins (Table 2). Surprisingly, the predictive
model for inhibitors targeting Integrins achieved Pearson’s and
Kendall’s correlations under 10-fold cross-validation of 0.59 and
0.39 (RMSE = 0.55), respectively, despite having the largest
number of entries available for training (680). On the
nonredundant blind test, the results remained consistent with
Pearson’s and Kendall’s correlations of 0.49 and 0.33 (RMSE =
1.31), respectively. Even though, the classifier for this PPI target
Table 2. Performance of Regression Models Predicting IC50 Values on Training under 10-Fold Cross-Validation and
Nonredundant Blind Test for Inhibitors of Nine Different PPI Targetsa
10-fold CV Blind test
PPI target ρ τ rs RMSE MAE ρ τ rs RMSE MAE
BCL2-Like/Bax-Bak 0.76 0.59 0.79 0.73 0.54 0.64 0.43 0.63 0.79 0.65
Bromodomain/Histone 0.68 0.46 0.63 0.88 0.69 0.44 0.34 0.51 0.84 0.61
Cyclophilins 0.91 0.60 0.81 0.55 0.41 0.87 0.48 0.67 0.57 0.39
HIF-1a/p300 0.51 0.36 0.57 0.90 0.63 0.28 0.09 0.13 0.83 0.62
Integrins 0.59 0.39 0.55 1.26 0.99 0.49 0.33 0.47 1.31 1.00
LEDGF/IN 0.33 0.21 0.31 0.52 0.41 −0.03 −0.02 −0.09 0.60 0.52
LFA/ICAM 0.71 0.48 0.65 0.69 0.50 0.67 0.37 0.59 0.85 0.65
Mdm2-Like/P53 0.76 0.56 0.74 0.79 0.60 0.63 0.45 0.61 0.76 0.61
XIAP/Smac 0.67 0.29 0.40 0.75 0.52 0.44 0.37 0.50 0.89 0.57
aResults are shown in terms of coefficients of correlation, namely, Pearson (ρ), Kendall (τ), Spearman (rs), and RMSE.
Figure 3. Performance evaluation of general predictor of PPI inhibitor potency. (A) Summary of performances on CV1 (80/20 split) and CV2 (50/50
split) for a general predictor in terms of Pearson’s Correlation. (B) Distribution of experimental inhibitory activity versus predictions on a blind test
(low redundant) at molecule similarity level of 0.80. IC50 values are shown on a log scale.
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achieved MCC values as high as 0.95 and 0.93 on training and
nonredundant test sets, respectively, with the same set of
features the distribution of IC50 values is the most diverse in the
data set (Figures S6−S14) making the regression task
significantly more difficult. Predictive models for inhibitors of
the LEDGF/IN and HIF-1a/IN complexes achieved the lowest
scores on the nonredundant blind tests, which is likely to be
related to the small number of entries available for each target,
68 for the former and 82 for the latter. The best performing
models with consistent predictions between 10-fold cross-
validation and nonredundant blind tests are the Bcl2-Like/Bax-
Bak, Mdm2-Like/P53, and Cyclophilins targets, the first two
being well studied oncogenic PPIs with great implications to
study of cancer therapies. The use of features for each target-
specific regression model is summarized as Gini importance
values output from the ExtraTrees algorithm in Tables S25−
S33. As observed for the classification models previously
described, overall importance for all regression models was
spread across the different features.
Building a General PPI Inhibitor Predictor. Leveraging
insights from the PPI-specific predictors, we developed a
predictive model capable of identifying generic PPI inhibitors.
For this purpose, we used all the available data from our original
data set of inhibitors with experimental IC50 values, comprising
3972 targeting 45 distinct PPIs. After selecting features using our
greedy stepwise approach (Table S34), performance was
assessed by randomly selecting 80% of compounds for training
the predictor and remaining 20% for testing, repeated 100 times
(CV1). Here, our method achieved an average Pearson’s
correlation of 0.74 (σ = 0.02) and RMSE = 0.95 (σ = 0.07).
On a similar configuration, but using a proportion of 50% of
molecules in each set (CV2), we were able to achieve similar
results with a Pearson’s correlation and RMSE of 0.70 (σ = 0.01)
and 1.07 (σ = 0.04), respectively, with small variations across
100 repetitions (Figure 3A).
Finally, we further evaluated our method on a low redundancy
set in terms of molecule similarity. Here, we split our data set
into 75% to train and remaining 25% as a test set, where all
compounds in our test set have a similarity coefficient no greater
than 0.80 (calculated via Tanimoto using Morgan fingerprints)
to any molecules in the subset used for training the predictive
model. This procedure resulted in a train set comprising 1581
small molecules and remaining 678 were used for validation.
The distribution of IC50 values on each subset is depicted in
Figure S15 in the Supporting Information. Under 10-fold cross-
validation, our predictor was able to achieve Pearson’s and
Kendall’s correlations of 0.75 and 0.56 (RMSE = 1.01),
respectively, which is consistent with the results for the two
cross-validation approaches discussed earlier (CV1 and CV2).
After removing 10% of the outliers, the performance reached
Pearson’s and Kendall’s correlations of 0.83 and 0.63 (RMSE =
0.86), respectively. On the low-redundant blind test set, our
approach was able to achieve Pearson’s and Kendall’s
correlations of 0.64 and 0.48 (RMSE = 1.08), respectively.
Figure 4. pdCSM-PPI web interface. (A) The submission page allows users to submit one single molecule as a SMILES string or upload a list of
molecules to be processed in batch. Accepted formats are plain text with one SMILES per line or SDF. For single molecules, users can also draw the
molecule using the Kekule.js editor. (B) Results are summarized as a downloadable table with predictions of IC50 (μM) and whether the compound is
likely to inhibit any of the 21 PPI complexes in this study. Other properties are also shown, and additional pharmacokinetic properties can be calculated
using pkCSM.
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After removing 10% of the outliers, represented mostly by
smaller compounds (average molecular weight of 425 Da), the
predictive model achieved Pearson’s and Kendall’s correlations
of 0.76 and 0.56 (RMSE = 0.74), respectively (Figure 3B).
Finally, we evaluated the performance of our regressor in
identifying more potent PPI inhibitors (IC50 < 1 μM) via
classification by regression, and our predictive model showed a
balanced prediction with an AUC of 0.77 and sensitivity and
specificity of 76% and 78%, respectively. While not providing a
definitive measurement of PPI affinity or inhibition constant, a
robust general predictor can further our understanding of what
makes a PPI inhibitor, also enabling complementary compound
prioritization and ranking.
pdCSM-PPI Web Server. pdCSM-PPI is freely available via
an easy-to-use web interface and API at http://biosig.unimelb.
edu.au/pdcsm_ppi. Users can query the website with a single
small molecule formatted as a SMILES string or provide a list of
SMILES, one per line in a plain text file (Figure 4) for batch
processing. For the single molecule submission, users have the
option to draw the molecule using the Kekule.js editor.30 On the
results page, users have the option of calculating pharmacoki-
netic properties of selected molecules using pkCSM19 and
visualize molecule depiction via SmilesDrawer.31 A full
description with examples is available in the help page, and
documentation for querying the web server using the API is
available at http://biosig.unimelb.edu.au/pdcsm_ppi/docs.
■ CONCLUSIONS
Here, we present pdCSM-PPI, a novel predictive method to
study the inhibitory activity of small molecules in PPI
complexes. By implementing our well-established graph-based
signatures framework with complementary physicochemical and
fragment-based descriptors, we were able to outperform existing
complex-specific methods in predicting inhibitors for nine
different PPI targets: Bcl2-Like/Bak-Bax, Bromodomain/
Histone, LEDGF/IN, LFA/ICAM, Mdm2-Like/P53, Ras/
SOS1, WDR5/MLL, XIAP/Smac, and CD4/gp120. Overall,
our approach can help identify PPI inhibitors for 21 different
PPI complexes, representing the most comprehensive computa-
tional platform to assist PPI inhibitor development to date.
Finally, we expanded our method into implementing a robust
general predictor for PPI inhibitor potency that will complement
compound prioritization. We anticipate pdCSM-PPI to be of
great value in helping a more efficient and rapid screening of
compounds targeting PPIs. The method is freely available as a
web server, including an API for easy integration with other
analysis pipelines, at http://biosig.unimelb.edu.au/pdcsm_ppi.
■ METHODS
Data Set. Experimentally characterized PPI inhibitors were
retrieved from TIMBAL,28 iPPI-DB,16 and 2P2I-DB v215
(Figure S16), comprising 4965 small molecules targeting 51
distinct PPIs (Table S35). Inhibitors for each PPI were clustered
separately using the Butina algorithm with a Tanimoto similarity
cutoff of 0.8, based on Morgan molecular fingerprints (1024
bits) with a radius size of 2,18 with one compound selected as a
cluster representative tominimize redundancy. PPIs with at least
20 nonredundant inhibitors were selected to build class-specific
predictors. In order to build more balanced and specific
classifiers, for each PPI target, noninhibitors were selected in
the same proportion as the number of inhibitors using the
following approach: 50% of noninhibitors were randomly
selected from compounds targeting single proteins on the
PubChem database,26 and the other half was randomly selected
from the inhibitor pool. In order to minimize biased predictive
models, data sets for 13 PPI targets with more than 40
nonredundant inhibitors were split based on ligand clustering,32
where compounds are selected from larger to smaller clusters
until 75% of entries in the data set were included in the training
set, and the remaining 25% of the compounds in smaller clusters
remained reserved as a blind test set. For 10 PPI targets where
the number of nonredundant inhibitors ranged from 19 to 35, all
the data were used for training the predictive models.
From the original data set, experimental half maximal
inhibitory concentration (IC50) values were retrieved from
TIMBAL and iPPI-DB for 3972 small molecules. After
clustering (using the aforementioned procedure), a total of
2259 nonredundant small molecules were selected to build a
general PPI inhibitor predictor. These were split into 75% for
training the predictive model and remaining 25% as a holdout
test set based on ligand clustering. All data used in this work are
publicly available at http://biosig.unimelb.edu.au/pdcsm_ppi/
data.
Graph-Based Signatures and Feature Engineering.We
have previously described graph-based distance patterns33,34 as a
resourceful representation for modeling the structural environ-
ment and studying the effects of single and multiple point
mutations on protein folding35−41 and interactions.42 Alter-
natively, these signatures have proven to be effective and
powerful for the study of toxicity and pharmacokinetics19−21 and
more recently for identification of compounds likely to be active
against specific Mycobacteria species.22 In this study, each small
molecule in the data set is modeled as an undirected, unweighted
graph, where atoms are represented as nodes and labeled
according to their properties as different pharmacophores
(hydrogen donor, acceptor, hydrophobic, aromatic, positive
ionizable, and negative ionizable). A distancematrix is calculated
for each graph/compound via all-pairs shortest paths (Johnson’s
algorithm) using the implementation available on the iGraph
library. The matrix is then used to extract cumulative
distribution of distances between nodes (for different
combinations of pharmacophore types) by varying a distance
cutoff by 1 unit. Finally, cumulative distributions for all possible
pairs of labels are compiled in a feature vector and used as
evidence to train machine learning algorithms. Additional
physicochemical properties and fragment-based descriptors
calculated using the RDKit library for cheminformatics were
included. Molecular substructure mining was implemented
using the program MoSS.43
Model Selection and Validation. For regression and
classification tasks presented in this study, we used the
ExtraTrees algorithm available on the scikit-learn Python library
with default parameters.44 Model interpretability was inves-
tigated based on feature importance scores which are measured
as the total reduction of the criterion brought by the feature
(known as Gini importance). The performance for regression
was evaluated using Pearson’s, Spearman’s, and Kendall’s
correlation coefficients, as well as root mean square error
(RMSE). The classification task was carried out for each of the
individual complexes in our data set, and performance was
assessed based on F1-score, Matthew’s correlation coefficient
(MCC), and area under the receiving operator curve (AUC).
Results are shown as 10-fold cross-validation on training and
nonredundant blind tests at small molecule level. The effect of
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outliers on regression was also investigated by assessing
performance on 90% of the data.
Finally, for each predictive model, in order to minimize noise
and identify an optimal combination of features, we performed
an incremental stepwise greedy approach. For each feature in a
signature vector, the performance is evaluated against the target
value. The best performing feature is selected and “fixed”. The
process is repeated for each of the remaining features in
combination with the previously selected in order to find the
best pair of features. The procedure continues until all features
are selected. For classification tasks, AUCwas used as the metric
to evaluate performance and Pearson’s correlation coefficient on
regression. In order to compare the number of features selected
and performance of our bottom-up approach, here we evaluated
the use of the recursive feature elimination (RFE)45 algorithm
using decision trees as the base learner for feature selection. For
all predictive models (PPI-specific models and general
regressor), the number of features selected using RFE was
greatly superior to those selected with our greedy approach, and
performance on the latter was overall better. Therefore, we
opted to use less complex models (Occam’s razor principle)
using a smaller number of features selected via our approach.
Web Server. The server front end was developed using
Materialize framework version 1.0.0, while the back end was
built using Python via the Flask framework (version 1.0.2). The
web server is hosted on a Linux server running Apache2.
■ DATA AND SOFTWARE AVAILABILITY
pdCSM-PPI predictive models were made freely available either
as a user-friendly web interface and as an API for programmatic
access at http://biosig.unimelb.edu.au/pdcsm_ppi. No login or
license is required. All data sets used to train and validate
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Table S1. Feature importance for predictive model of PPI inhibitors targeting the Bcl2/Bak complex. 
Feature Description Importance 
Aromatic_Count Number of atoms in aromatic rings 0.105 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe atoms within 4 
bonds 
0.055 
Chi2n Molecular connectivity index 0.052 
fr_sulfide Number of thioether 0.051 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.046 
fr_Ar_N Number of aromatic nitrogens 0.042 
fr_bicyclic Number of bicyclic structures 0.042 
SMR_VSA10 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.037 
Acceptor:Hydrophobe-3.00 Number of pairs of acceptor-hydrophobe atoms 
within 3 bonds 
0.028 
VSA_EState8 MOE-type descriptors, surface area contributions 
and EState indices 
0.027 
SlogP_VSA12 MOE-type descriptors, LogP and surface area 
contributions 
0.026 
SMR_VSA9 MOE-type descriptors, LogP and surface area 
contributions 
0.025 
SlogP_VSA10 MOE-type descriptors, LogP and surface area 
contributions 
0.022 
Donor:Donor-3.00 Number of pairs of hydrophobe atoms within 3 
bonds 
0.022 
fr_thiazole Number of thiazole rings 0.021 
Donor_Count Number hydrogen bond donors 0.020 
SMR_VSA5 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.019 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.019 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms within 
1 bond 
0.018 
Donor:Hydrophobe-3.00 Number of pairs of donor-hydrophobe atoms within 
3 bond 
0.018 
fr_pyridine Number of pyridine rings 0.017 
fr_phenol Number of phenolic OH excluding ortho 
intramolecular Hbond substituents 
0.017 
PEOE_VSA9 MOE-type descriptors, partial charges and surface 
area contributions 
0.016 
SlogP_VSA7 MOE-type descriptors, LogP and surface area 
contributions 
0.016 
Donor:Donor-6.00 Number of pairs of hydrogen donor within 6 bonds 0.016 
PosIonizable_Count Number of PosIonizable atoms 0.015 
fr_Ar_OH Number of aromatic hydroxyl groups 0.014 
Donor:Donor-1.00 Number of pairs of hydrogen donor atoms within 1 
bond 
0.012 
Aromatic:NegIonizable-4.00 Number of pairs of aromatic-negIonizable atoms 
within 4 bonds 
0.011 
fr_Imine Number of Imines 0.009 
fr_NH2 Number of Primary amines 0.009 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-negIonizable atoms 
within 4 bonds 
0.008 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonizable atoms 
within 1 bond 
0.008 
Acceptor:PosIonizable-4.00 Number of pairs of acceptor-posIonizable atoms 
within 4 bonds 
0.008 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonizable-negIonizable 
atoms within 1 bond 
0.008 
PosIonizable:PosIonizable-4.00 Number of pairs of posIonizable-posIonizable 
atoms within 4 bonds 
0.007 
fr_alkyl_halide Number of alkyl halides 0.007 
NegIonizable:NegIonizable-4.00 Number of pairs of negIonizable-negIonizable 
atoms within 4 bonds 
0.007 
fr_unbrch_alkane Number of unbranched alkanes of at least 4 
members (excludes halogenated alkanes) 
0.007 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonizable-negIonizable 
atoms within 2 bonds 
0.007 
NegIonizable:NegIonizable-5.00 Number of pairs of negIonizable-negIonizable 
atoms within 5 bonds 
0.006 
Donor:PosIonizable-3.00 Number of pairs of donor-posIonizable atoms 
within 3 bonds 
0.006 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonizable atoms 
within 3 bonds 
0.006 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonizable-posIonizable 
atoms within 3 bonds 
0.006 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonizable atoms 
within 1 bond 
0.005 
Hydrophobe:NegIonizable-4.00 Number of pairs of hydrophobe-negIonizable atoms 
within 4 bonds 
0.005 
fr_ketone Number of ketones 0.005 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonizable-posIonizable 
atoms within 2 bonds 
0.005 
Hydrophobe:NegIonizable-2.00 Number of pairs of hydrophobe-negIonizable atoms 
within 2 bonds 
0.005 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonizable atoms 
within 1 bond 
0.004 
fr_priamide Number of primary amides 0.004 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonizable atoms 
within 1 bond 
0.004 
Acceptor:NegIonizable-4.00 Number of pairs of acceptor-negIonizable atoms 
within 4 bonds 
0.004 
Acceptor:NegIonizable-2.00 Number of pairs of acceptor-negIonizable atoms 
within 2 bonds 
0.004 
Donor:NegIonizable-5.00 Number of pairs of acceptor-negIonizable atoms 
within 5 bonds 
0.004 
Tox_2 [CH]=[CH]O 0.004 
fr_thiophene Number of thiophene rings 0.003 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonizable atoms 
within 1 bond 
0.003 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonizable atoms 
within 1 bond 
0.003 
Donor:NegIonizable-3.00 Number of pairs of donor-posIonizable atoms 
within 3 bonds 
0.003 
fr_guanido Number of guanidine groups 0.001 
fr_lactone Number of cyclic esters (lactones) 0.001 
 
Table S2. Feature importance for predictive model of PPI inhibitors targeting the Bromodomain/Histone 
complex. 
Feature Description Importance 
Donor:Hydrophobe-4.00 Number of pairs of donor-hydrophobe atoms 
within 4 bonds 
0.044 
Kappa2 Molecular shape index 0.043 
fr_aryl_methyl Number of aryl methyl sites for hydroxylation 0.041 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.037 
BalabanJ Balaban's connectivity topological index 0.033 
fr_Al_COO Number of aliphatic carboxylic acids 0.024 
fr_halogen Number of halogens 0.024 
VSA_EState10 MOE-type descriptors surface area contributions 
and EState indices 
0.024 
Chi1v Molecular connectivity index 0.023 
SMR_VSA5 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.022 
fr_aniline Number of anilines 0.022 
Aromatic:Aromatic-5.00 Number of pairs of aromatic-aromatic atoms 
within 5 bonds 
0.021 
Aromatic:Donor-3.00 Number of pairs of aromatic-donor atoms within 3 
bonds 
0.021 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 4 bonds 
0.020 
fr_benzene Number of benzene rings 0.020 
VSA_EState8 MOE-type descriptors surface area contributions 
and EState indices 
0.018 
SlogP_VSA5 MOE-type descriptors, LogP and surface area 
contributions 
0.018 
PEOE_VSA2 MOE-type descriptors, partial charges and 
surface area contributions 
0.017 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe atoms 
within 1 bond 
0.017 
Acceptor:Aromatic-5.00 Number of pairs of acceptor-aromatic atoms 
within 5 bonds 
0.017 
SMR_VSA6 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.017 
Aromatic:Hydrophobe-5.00 Number of pairs of aromatic-hydrophobe atoms 
within 5 bonds 
0.017 
Aromatic_Count Number of atoms in aromatic rings 0.016 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.016 
SlogP_VSA10 MOE-type descriptors, LogP and surface area 
contributions 
0.016 
SMR_VSA10 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.015 
fr_NH0 Number of Tertiary amines 0.015 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 6 
bonds 
0.015 
SMR_VSA4 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.015 
Acceptor:Aromatic-4.00 Number of pairs of acceptor-aromatic atoms 
within 4 bonds 
0.015 
PEOE_VSA7 MOE-type descriptors, partial charges and 
surface area contributions 
0.014 
Acceptor:Aromatic-2.00 Number of pairs of acceptor-aromatic atoms 
within 2 bonds 
0.014 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 5 
bonds 
0.014 
PEOE_VSA3 MOE-type descriptors, partial charges and 
surface area contributions 
0.014 
PEOE_VSA9 MOE-type descriptors, partial charges and 
surface area contributions 
0.013 
SlogP_VSA1 MOE-type descriptors, LogP and surface area 
contributions 
0.013 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.013 
Aromatic:Donor-1.00 Number of pairs of aromatic-donor atoms within 1 
bond 
0.013 
PEOE_VSA11 MOE-type descriptors, partial charges and 
surface area contributions 
0.012 
PEOE_VSA4 MOE-type descriptors, partial charges and 
surface area contributions 
0.012 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.012 
Acceptor:Acceptor-5.00 Number of pairs of acceptor-acceptor atoms 
within 5 bonds 
0.012 
NegIonizable_Count Number of negIonizable atoms 0.011 
PosIonizable_Count Number of posIonizable atoms 0.010 
Donor:Donor-4.00 Number of pairs of donor-donor atoms within 4 
bonds 
0.010 
PEOE_VSA5 MOE-type descriptors, partial charges and 
surface area contributions 
0.009 
Aromatic:PosIonizable-6.00 Number of pairs of aromatic-posIonizable atoms 
within 6 bonds 
0.008 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.008 
fr_Imine Number of Imines 0.007 
fr_Ar_OH Number of aromatic hydroxyl groups 0.007 
fr_ketone Number of ketones 0.007 
fr_thiophene Number of thiophene rings 0.006 
Acceptor:PosIonizable-6.00 Number of pairs of acceptor-posIonazable atoms 
within 6 bonds 
0.006 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.006 
Aromatic:PosIonizable-5.00 Number of pairs of acceptor-posIonazable atoms 
within 5 bonds 
0.006 
Aromatic:PosIonizable-4.00 Number of pairs of acceptor-posIonazable atoms 
within 4 bonds 
0.006 
fr_unbrch_alkane Number of unbranched alkanes of at least 4 
members (excludes halogenated alkanes) 
0.005 
fr_nitrile Number of nitriles 0.005 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonazable atoms 
within 1 bond 
0.005 
fr_nitro_arom Number of nitro benzene ring substituents 0.004 
Tox_2 [CH]=[CH]O 0.004 
fr_nitro Number of nitro groups 0.004 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonazable 
atoms within 3 bonds 
0.004 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.004 
fr_azo Number of azo groups 0.004 
Donor:PosIonizable-4.00 Number of pairs of donor-negIonazable atoms 
within 2 bonds 
0.004 
PosIonizable:PosIonizable-5.00 Number of pairs of posIonazable-posIonazable 
atoms within 5 bonds 
0.004 
Acceptor:PosIonizable-3.00 Number of pairs of acceptor-posIonazable atoms 
within 3 bonds 
0.004 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.003 
Acceptor:PosIonizable-2.00 Number of pairs of acceptor-posIonazable atoms 
within 2 bonds 
0.003 
fr_hdrzone Number of hydrazone groups 0.003 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.003 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable atoms 
within 1 bond 
0.002 
Aromatic:NegIonizable-1.00 Number of pairs of aromatic-negIonazable atoms 
within 1 bond 
0.002 
fr_C_S Number of thiocarbonyl 0.002 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.002 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonazable atoms 
within 2 bonds 
0.002 
 
Table S3. Feature importance for predictive model of PPI inhibitors targeting the CD4/gp120 complex. 
Feature Description Importance 
fr_piperzine Number of piperzine rings 0.559 
PEOE_VSA13 MOE-type descriptors, partial charges and 
surface area contributions 
0.270 
fr_amide Number of amides 0.169 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-
posIonazable atoms within 1 bond 
0.002 
 
Table S4. Feature importance for predictive model of PPI inhibitors targeting the Cyclophilins complex. 
Feature Description Importance 
fr_amide Number of amides 0.102 
Aromatic:Donor-1.00 Number of pairs of aromatic-donor atoms within 
1 bond 
0.074 
fr_Ar_N Number of aromatic nitrogens 0.067 
Chi1n Molecular connectivity index 0.059 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.054 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 5 
bonds 
0.046 
SMR_VSA10 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.044 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.039 
fr_benzene Number of benzene rings 0.038 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic atoms 
within 3 bonds 
0.033 
fr_pyridine Number of pyridine rings 0.029 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe atoms 
within 1 bond 
0.027 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonizable-posIonizable 
atoms within 2 bonds 
0.027 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.027 
Aromatic:Hydrophobe-2.00 Number of pairs of aromatic-hydrophobe atoms 
within 2 bonds 
0.026 
SMR_VSA6 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.025 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.025 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms within 
1 bond 
0.023 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonizable-posIonizable 
atoms within 1 bond 
0.021 
Acceptor:Acceptor-4.00 Number of pairs of acceptor-acceptor atoms 
within 4 bonds 
0.021 
Hydrophobe:Hydrophobe-2.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 2 bonds 
0.019 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.019 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonizable atoms 
within 1 bond 
0.017 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.017 
Acceptor:Acceptor-2.00 Number of pairs of acceptor-acceptor atoms 
within 2 bonds 
0.016 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.015 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonizable atoms 
within 1 bond 
0.014 
Hydrophobe:NegIonizable-2.00 Number of pairs of hydrophobe-negIonizable 
atoms within 2 bonds 
0.012 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonizable 
atoms within 1 bond 
0.011 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonizable atoms 
within 2 bonds 
0.011 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonizable-negIonizable 0.008 
atoms within 1 bond 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonizable 
atoms within 1 bond 
0.006 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonizable atoms 
within 2 bonds 
0.006 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-posIonizable 
atoms within 2 bonds 
0.005 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonizable atoms 
within 1 bond 
0.005 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonizable 
atoms within 1 bond 
0.003 
Donor:NegIonizable-3.00 Number of pairs of donor-negIonizable atoms 
within 3 bonds 
0.003 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonizable atoms 
within 1 bond 
0.002 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonizable 
atoms within 2 bonds 
0.002 
Aromatic:NegIonizable-1.00 Number of pairs of aromatic-negIonizable 
atoms within 1 bond 
0.001 
 
Table S5. Feature importance for predictive model of PPI inhibitors targeting the Fkbp1a/Fk506 
complex. 
Feature Description Importance 
NHOHCount Number of NHs or OHs 0.103 
Acceptor:Acceptor-3.00 Number of pairs of acceptor-acceptor atoms 
within 3 bonds 
0.093 
PosIonizable_Count Number of posIonizable atoms 0.092 
fr_bicyclic Number of bicyclic structure 0.081 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.072 
Aromatic_Count Number of atoms in aromatic rings 0.059 
fr_methoxy Number of methoxy groups -OCH3 0.059 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.053 
fr_NH0 Number of Tertiary amines 0.051 
Aromatic:Hydrophobe-4.00 Number of pairs of aromatic-hydrophobe atoms 
within 4 bonds 
0.050 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.032 
Donor:Hydrophobe-5.00 Number of pairs of donor-hydrophobe atoms 
within 5 bonds 
0.029 
Hydrophobe:Hydrophobe-2.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 2 bonds 
0.028 
Acceptor:Aromatic-1.00 Number of pairs of acceptor-aromatic atoms 
within 1 bond 
0.024 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.023 
Donor:Hydrophobe-2.00 Number of pairs of donor-hydrophobe atoms 
within 2 bonds 
0.017 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms within 
1 bond 
0.016 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.013 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.012 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-posIonazable 
atoms within 2 bonds 
0.010 
Aromatic:PosIonizable-2.00 Number of pairs of aromatic-posIonazable atoms 
within 2 bonds 
0.010 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable atoms 
within 1 bond 
0.008 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-negIonazable 
atoms within 1 bond 
0.007 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-negIonazable 
atoms within 2 bonds 
0.006 
NegIonizable:NegIonizable-3.00 Number of pairs of negIonazable-negIonazable 
atoms within 3 bonds 
0.006 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 1 
bond 
0.005 
fr_oxazole Number of oxazole rings 0.005 
NegIonizable:NegIonizable-4.00 Number of pairs of negIonazable-negIonazable 
atoms within 4 bonds 
0.005 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-posIonazable 
atoms within 1 bond 
0.004 
fr_sulfone Number of sulfone groups 0.004 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonazable atoms 
within 1 bond 
0.004 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.003 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-posIonazable 
atoms within 2 bonds 
0.003 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-posIonazable 
atoms within 3 bonds 
0.003 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable atoms 
within 1 bond 
0.002 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.002 
Aromatic:NegIonizable-3.00 Number of pairs of aromatic-negIonazable atoms 
within 3 bonds 
0.002 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.001 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable atoms 
within 2 bonds 
0.001 
 
Table S6. Feature importance for predictive model of PPI inhibitors targeting the HIF1-alpha/p300 
complex. 
Feature Descriptor Importance 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.234 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.127 
RingCount Number of aromatic rings 0.126 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms 
within 1 bond 
0.100 
VSA_EState10 MOE-type descriptors, surface area 
contributions and EState indices 
0.081 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.061 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.049 
fr_Al_OH Number of aliphatic hydroxyl groups 0.046 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-negIonazable 
atoms within 2 bonds 
0.032 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-negIonazable 
atoms within 1 bond 
0.029 
Donor:PosIonizable-6.00 Number of pairs of donor-posIonazable atoms 
within 6 bonds 
0.027 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.021 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.018 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 1 
bond 
0.016 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.013 
Aromatic:NegIonizable-1.00 Number of pairs of aromatic-negIonazable 
atoms within 1 bond 
0.010 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.005 
fr_alkyl_carbamate Number of alkyl carbamates (subject to 
hydrolysis) 
0.002 
NegIonizable:PosIonizable-1.00 Number of pairs of negIonazable-posIonazable 
atoms within 1 bond 
0.001 
NegIonizable:PosIonizable-2.00 Number of pairs of negIonazable-posIonazable 
atoms within 1 bonds 
0.001 
 
Table S7. Feature importance for predictive model of PPI inhibitors targeting the Integrins complex. 
Feature Description Importance 
fr_Al_COO Number of aliphatic carboxylic acids 0.245 
PEOE_VSA14 MOE-type descriptors, partial charges and 
surface area contributions 
0.050 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonazable atoms 
within 2 bonds 
0.039 
fr_NH1 Number of Secondary amines 0.036 
PEOE_VSA12 MOE-type descriptors, partial charges and 
surface area contributions 
0.035 
Hydrophobe:NegIonizable-4.00 Number of pairs of hydrophobe-negIonazable 
atoms within 4 bonds 
0.035 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.033 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.031 
PEOE_VSA13 MOE-type descriptors, partial charges and 
surface area contributions 
0.031 
Hydrophobe:NegIonizable-2.00 Number of pairs of hydrophobe-negIonazable 
atoms within 2 bonds 
0.029 
Aromatic_Count Number of atoms in aromatic rings 0.024 
SlogP_VSA2 MOE-type descriptors, LogP and surface area 
contributions 
0.024 
MolWt Molecular weight 0.023 
PEOE_VSA2 MOE-type descriptors, partial charges and 
surface area contributions 
0.022 
fr_amidine Number of amidine groups 0.021 
SlogP_VSA5 MOE-type descriptors, LogP and surface area 
contributions 
0.020 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 4 bonds 
0.018 
HallKierAlpha Hall-Kier alpha value 0.016 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 
2 bonds 
0.014 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 
5 bonds 
0.014 
fr_pyridine Number of pyridine rings 0.014 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 
6 bonds 
0.013 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.013 
Acceptor:Aromatic-5.00 Number of pairs of acceptor-aromatic atoms 
within 5 bonds 
0.013 
SlogP_VSA4 MOE-type descriptors, LogP and surface area 
contributions 
0.012 
Acceptor:Acceptor-6.00 Number of pairs of acceptor-acceptor atoms 
within 6 bonds 
0.012 
Donor:Donor-4.00 Number of pairs of donor-donor atoms within 
4 bonds 
0.011 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 
3 bonds 
0.011 
FCount Number of fluorine atoms 0.010 
fr_barbitur Number of barbiturate groups 0.007 
fr_alkyl_halide Number of alkyl halides 0.007 
fr_Imine Number of Imines 0.007 
fr_sulfonamd Number of sulfonamides 0.007 
fr_piperdine Number of piperdine rings 0.007 
fr_imide Number of imide groups 0.007 
Aromatic:PosIonizable-6.00 Number of pairs of aromatic-posIonazable 
atoms within 6 bonds 
0.006 
fr_ArN Number of N functional groups attached to 
aromatics 
0.006 
Donor:PosIonizable-4.00 Number of pairs of donor-posIonazable atoms 
within 4 bonds 
0.005 
fr_Ndealkylation1 Number of XCCNR groups 0.005 
Donor:PosIonizable-6.00 Number of pairs of donor-posIonazable atoms 
within 6 bonds 
0.005 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posIonazable atoms within 2 bonds 
0.005 
Donor:PosIonizable-5.00 Number of pairs of donor-posIonazable atoms 
within 5 bonds 
0.005 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable atoms 
within 2 bonds 
0.005 
Acceptor:PosIonizable-6.00 Number of pairs of acceptor-posIonazable 
atoms within 6 bonds 
0.005 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-
posIonazable atoms within 1 bond 
0.005 
Hydrophobe:PosIonizable-5.00 Number of pairs of hydrophobe-posIonazable 
atoms within 5 bonds 
0.005 
Aromatic:PosIonizable-2.00 Number of pairs of aromatic-posIonazable 
atoms within 2 bonds 
0.004 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazble-posIonazable 
atoms within 3 bonds 
0.004 
Acceptor:PosIonizable-4.00 Number of pairs of acceptor-posIonazable 
atoms within 4 bonds 
0.004 
PosIonizable:PosIonizable-5.00 Number of pairs of posIonazble-posIonazable 
atoms within 5 bonds 
0.004 
PosIonizable:PosIonizable-6.00 Number of pairs of posIonazble-posIonazable 
atoms within 6 bonds 
0.004 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.003 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.002 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.002 
fr_nitrile Number of nitriles 0.002 
Tox_31 1~a~a~a~a2~a~1~a3~a(~a~2)~a~a~a~a~3 0.001 
fr_aldehyde Number of aldehydes 0.001 
NegIonizable:PosIonizable-2.00 Number of pairs of negIonazable- 0.001 
posIonazable atoms within 2 bonds 
fr_SH Number of thiol groups 0.001 
fr_lactone Number of cyclic esters (lactones) 0.001 
NegIonizable:PosIonizable-6.00 Number of pairs of negIonazable-
posIonazable atoms within 6 bonds 
0.001 
 
Table S8. Feature importance for predictive model of PPI inhibitors targeting the Ledgf/IN complex. 
Feature Description Importance 
Acceptor:Aromatic-4.00 Number of pairs of acceptor-aromatic atoms 
within 4 bonds 
0.059 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.052 
fr_C_O_noCOO Number of carbonyl O, excluding COOH 0.045 
fr_amide Number of amides 0.038 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.037 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.035 
Acceptor:Hydrophobe-4.00 Number of pairs of acceptor-hydrophobe atoms 
within 4 bonds 
0.035 
fr_pyridine Number of pyridine rings 0.032 
Acceptor:Acceptor-5.00 Number of pairs of acceptor-acceptor atoms 
within 5 bonds 
0.029 
PEOE_VSA2 MOE-type descriptors, partial charges and 
surface area contributions 
0.024 
Acceptor:Hydrophobe-5.00 Number of pairs of acceptor-hydrophobe atoms 
within 5 bonds 
0.024 
HallKierAlpha Hall-Kier alpha value 0.022 
Hydrophobe:Hydrophobe-3.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 3 bonds 
0.022 
PEOE_VSA10 MOE-type descriptors, partial charges and 
surface area contributions 
0.022 
Chi2n Molecular connectivity index 0.021 
Donor:NegIonizable-4.00 Number of pairs of donor-negIonazable atoms 
within 4 bonds 
0.021 
SlogP_VSA2 MOE-type descriptors, LogP and surface area 
contributions 
0.020 
SMR_VSA2 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.019 
SlogP_VSA4 MOE-type descriptors, LogP and surface area 
contributions 
0.019 
Chi0v Molecular connectivity index 0.019 
PEOE_VSA6 MOE-type descriptors, partial charges and 
surface area contributions 
0.019 
Chi0 Molecular connectivity index 0.018 
Kappa1 Molecular shape index 0.018 
Aromatic:Hydrophobe-4.00 Number of pairs of aromatic-hydrophobe atoms 
within 4 bonds 
0.017 
Chi1v Molecular connectivity index 0.017 
PEOE_VSA7 MOE-type descriptors, partial charges and 
surface area contributions 
0.015 
Donor:Hydrophobe-5.00 Number of pairs of donor-hydrophobe atoms 
within 5 bonds 
0.015 
PEOE_VSA12 MOE-type descriptors, partial charges and 
surface area contributions 
0.015 
Aromatic:Donor-3.00 Number of pairs of aromatic-donor atoms 
within 3 bonds 
0.015 
fr_nitrile Number of nitriles 0.013 
Acceptor:Donor-5.00 Number of pairs of acceptor-donor atoms 
within 5 bonds 
0.013 
Acceptor:Donor-2.00 Number of pairs of acceptor-donor atoms 
within 2 bonds 
0.013 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.012 
fr_Ndealkylation2 Number of tert-alicyclic amines (no 
heteroatoms, not quinine-like bridged N) 
0.011 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 5 
bonds 
0.011 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 6 
bonds 
0.011 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.010 
fr_C_S Number of thiocarbonyl 0.009 
fr_hdrzone Number of hydrazone groups 0.009 
fr_urea Number of urea groups 0.009 
fr_quatN Number of quarternary nitrogens 0.008 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 1 
bond 
0.008 
PEOE_VSA5 MOE-type descriptors, partial charges and 
surface area contributions 
0.008 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.008 
SlogP_VSA7 MOE-type descriptors, LogP and surface area 
contributions 
0.008 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-posIonazable 
atoms within 2 bonds 
0.007 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.006 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-posIonazable 
atoms within 1 bond 
0.006 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-posIonazable 
atoms within 3 bonds 
0.006 
fr_ArN Number of N functional groups attached to 
aromatics 
0.005 
fr_unbrch_alkane Number of unbranched alkanes of at least 4 
members (excludes halogenated alkanes) 
0.005 
fr_priamide Number of primary amides 0.005 
fr_alkyl_halide Number of alkyl halides 0.005 
fr_nitro_arom Number of nitro benzene ring substituents 0.005 
fr_nitro Number of nitro groups 0.005 
fr_ketone Number of ketones 0.005 
Tox_1 O=N(~O)a 0.005 
Tox_2 a[NH2] 0.004 
fr_Imine Number of Imines 0.004 
fr_Al_OH_noTert Number of aliphatic hydroxyl groups excluding 
tert-OH 
0.003 
Donor:NegIonizable-3.00 Number of pairs of donor-negIonazable atoms 
within 3 bonds 
0.003 
Tox_12 [OH,NH2][N,O] 0.002 
fr_azo Number of azo groups 0.002 
fr_Al_OH Number of aliphatic hydroxyl groups 0.002 
fr_oxime Number of oxime groups 0.002 
fr_thiazole Number of thiazole rings 0.002 
fr_nitro_arom_nonortho Number of non-ortho nitro benzene ring 
substituents 
0.001 
fr_Ndealkylation1 Number of XCCNR groups 0.001 
 
Table S9. Feature importance for predictive model of PPI inhibitors targeting the Lfa/Icam complex. 
Feature Description Importance 
VSA_EState8 MOE-type descriptors, surface area 
contributions and EState indices 
0.132 
SlogP_VSA10 MOE-type descriptors, LogP and surface 
area contributions 
0.121 
fr_amide Number of amides 0.115 
SMR_VSA5 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.089 
Kappa2 Molecular shape index 0.081 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.074 
fr_bicyclic Number of bicyclic structures 0.073 
SlogP_VSA5 MOE-type descriptors, LogP and surface 
area contributions 
0.072 
fr_imide Number of imide groups 0.065 
Acceptor:Donor-4.00 Number of pairs of acceptor-donor atoms 
within 4 bonds 
0.063 
fr_para_hydroxylation Number of para-hydroxylation sites 0.045 
Donor:Donor-1.00 Number of pairs of donor-donor atoms 
within 1 bond 
0.034 
fr_urea Number of urea groups 0.026 
fr_guanido Number of guanidine groups 0.009 
fr_term_acetylene Number of terminal acetylenes 0.002 
 
Table S10. Feature importance for predictive model of PPI inhibitors targeting the Mdm2-like/P53 
complex. 
Feature Description Importance 
VSA_EState10 MOE-type descriptors, surface area contributions 
and EState indices 
0.085 
fr_halogen Number of halogens 0.051 
SMR_VSA7 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.045 
Donor:Hydrophobe-4.00 Number of pairs of donor-hydrophobe atoms 
within 4 bonds 
0.040 
Aromatic:Aromatic-6.00 Number of pairs of aromatic-aromatic atoms 
within 6 bonds 
0.031 
Aromatic:Aromatic-5.00 Number of pairs of aromatic-aromatic atoms 
within 6 bonds 
0.026 
Chi4n Molecular connectivity index 0.025 
SMR_VSA9 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.023 
Aromatic_Count Number of atoms in aromatic rings 0.022 
Aromatic:Aromatic-4.00 Number of pairs of aromatic-aromatic atoms 
within 4 bonds 
0.021 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.020 
fr_aniline Number of anilines 0.020 
PEOE_VSA8 MOE-type descriptors, partial charges and 
surface area contributions 
0.018 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.018 
Chi3n Molecular connectivity index 0.018 
MolWt Molecular weight 0.017 
fr_NH1 Number of Secondary amines 0.017 
BalabanJ Balaban's connectivity topological index 0.017 
PEOE_VSA13 MOE-type descriptors, partial charges and 
surface area contributions 
0.017 
fr_bicyclic Number of bicyclic structures 0.016 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.015 
Acceptor:Aromatic-1.00 Number of pairs of acceptor-aromatic atoms 
within 1 bond 
0.015 
Chi0n Molecular connectivity index 0.014 
HeavyAtomCount Number of heavy atoms 0.014 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.014 
fr_aryl_methyl Number of aryl methyl sites for hydroxylation 0.013 
fr_C_O_noCOO Number of carbonyl O, excluding COOH 0.012 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.012 
Acceptor:Acceptor-3.00 Number of pairs of acceptor-acceptor atoms 
within 3 bonds 
0.012 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-posIonazable 
atoms within 4 bonds 
0.012 
Acceptor:Aromatic-3.00 Number of pairs of acceptor-aromatic atoms 
within 3 bonds 
0.012 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms within 1 
bond 
0.011 
SMR_VSA1 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.011 
Acceptor:Hydrophobe-6.00 Number of pairs of acceptor-hydrophobe atoms 
within 6 bonds 
0.011 
VSA_EState8 MOE-type descriptors surface area contributions 
and EState indices 
0.011 
PEOE_VSA14 MOE-type descriptors, partial charges and 
surface area contributions 
0.011 
fr_C_O Number of carbonyl O 0.011 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonazable 
atoms within 3 bonds 
0.011 
Kappa1 Molecular shape index 0.010 
fr_pyridine Number of pyridine rings 0.010 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-posIonazable 
atoms within 2 bonds 
0.010 
PEOE_VSA11 MOE-type descriptors, partial charges and 
surface area contributions 
0.010 
Acceptor:Hydrophobe-4.00 Number of pairs of acceptor-posIonazable atoms 
within 4 bonds 
0.009 
fr_morpholine Number of morpholine rings 0.009 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable atoms 
within 1 bond 
0.009 
VSA_EState9 MOE-type descriptors surface area contributions 
and EState indices 
0.009 
Donor_Count Number of hydrogen donors 0.008 
PEOE_VSA9 MOE-type descriptors, partial charges and 
surface area contributions 
0.008 
Aromatic:PosIonizable-3.00 Number of pairs of aromatic-posIonazable atoms 
within 3 bonds 
0.008 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 6 
bonds 
0.008 
fr_piperzine Number of piperzine rings 0.007 
Donor:Donor-4.00 Number of pairs of donor-donor atoms within 4 
bonds 
0.007 
Acceptor:PosIonizable-5.00 Number of pairs of acceptor-posIonazable atoms 
within 5 bonds 
0.007 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 0.006 
bonds 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.006 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-posIonazable 
atoms within 3 bonds 
0.006 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-negIonazable 
atoms within 2 bonds 
0.005 
fr_Ndealkylation1 Number of XCCNR groups 0.005 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.005 
fr_phenol Number of phenols 0.005 
FCount Number of fluorine atoms 0.005 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.004 
NegIonizable:NegIonizable-6.00 Number of pairs of negIonazable-negIonazable 
atoms within 6 bonds 
0.004 
Donor:PosIonizable-5.00 Number of pairs of donor-negIonazable atoms 
within 5 bonds 
0.004 
NegIonizable:NegIonizable-3.00 Number of pairs of negIonazable-negIonazable 
atoms within 3 bonds 
0.004 
fr_nitrile Number of nitriles 0.004 
fr_NH2 Number of Primary amines 0.003 
Donor:PosIonizable-3.00 Number of pairs of donor-posIonazable atoms 
within 3 bonds 
0.003 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonazable atoms 
within 1 bond 
0.003 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-negIonazable 
atoms within 1 bond 
0.003 
Tox_1 O=N(~O)a 0.003 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonazable atoms 
within 2 bonds 
0.003 
fr_imide Number of imide groups 0.002 
fr_nitro Number of nitro groups 0.002 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.002 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.002 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonazable atoms 
within 2 bonds 
0.002 
fr_nitro_arom Number of nitro benzene ring substituents 0.002 
Aromatic:NegIonizable-4.00 Number of pairs of aromatic-negIonazable atoms 
within 4 bonds 
0.002 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.002 
Aromatic:NegIonizable-3.00 Number of pairs of aromatic-negIonazable atoms 
within 3 bonds 
0.002 
Aromatic:NegIonizable-6.00 Number of pairs of aromatic-negIonazable atoms 0.002 
within 6 bonds 
fr_thiophene Number of thiophene rings 0.001 
fr_HOCCN Number of C(OH)CCN-Ctert-alkyl or 
C(OH)CCNcyclic 
0.001 
fr_tetrazole Number of tetrazole rings 0.001 
Tox_33 a1~a~a~a~a2~a~1~a~a3~a(~a~2)~a~a~a~a~3 0.001 




Table S11. Feature importance for predictive model of PPI inhibitors targeting the Ras/SOS1 complex. 
Feature Description Importance 
fr_aryl_methyl Number of aryl methyl sites for hydroxylation 0.080 
Acceptor:Hydrophobe-1.00 Number of pairs of acceptor-hydrophobe 
atoms within 1 bond 
0.075 
Acceptor:Hydrophobe-6.00 Number of pairs of acceptor-hydrophobe 
atoms within 6 bonds 
0.051 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe 
atoms within 1 bond 
0.047 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.046 
Aromatic_Count Number of atoms in aromatic rings 0.042 
SMR_VSA7 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.041 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 4 bonds 
0.037 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms 
within 1 bond 
0.037 
Donor_Count Number of hydrogen donors 0.035 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.034 
Aromatic:Aromatic-5.00 Number of pairs of aromatic-aromatic atoms 
within 5 bonds 
0.031 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic atoms 
within 3 bonds 
0.030 
fr_piperzine Number of piperzine rings 0.030 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.029 
Chi4n Molecular connectivity index 0.029 
Aromatic:Hydrophobe-5.00 Number of pairs of aromatic-hydrophobe 
atoms within 5 bonds 
0.027 
Aromatic:Aromatic-4.00 Number of pairs of aromatic-aromatic atoms 
within 4 bonds 
0.026 
fr_sulfide Number of thioether 0.018 
NegIonizable_Count Number of negIonizable atoms 0.016 
Donor:PosIonizable-5.00 Number of pairs of donor-posIonazable atoms 
within 5 bonds 
0.016 
fr_quatN Number of quarternary nitrogens 0.014 
Aromatic:Donor-1.00 Number of pairs of aromatic-donor atoms 
within 1 bond 
0.014 
fr_nitrile Number of nitriles 0.013 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 1 
bond 
0.010 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bond 
0.010 
Acceptor:PosIonizable-3.00 Number of pairs of acceptor-negIonazable 
atoms within 3 bonds 
0.010 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonazable 
atoms within 1 bond 
0.009 
Aromatic:PosIonizable-2.00 Number of pairs of aromatic-posIonazable 
atoms within 2 bonds 
0.009 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.009 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.008 
PosIonizable:PosIonizable-5.00 Number of pairs of posIonazable-posIonazable 
atoms within 5 bonds 
0.008 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable atoms 
within 2 bonds 
0.008 
fr_SH Number of thiol groups 0.007 
fr_ester Number of esters 0.007 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-
negIonazable atoms within 2 bonds 
0.007 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-posIonazable 
atoms within 1 bond 
0.006 
PosIonizable:PosIonizable-6.00 Number of pairs of posIonazable-posIonazable 
atoms within 6 bonds 
0.006 
fr_ketone_Topliss Number of ketones excluding diaryl, a,b-unsat. 
dienones, heteroatom on Calpha 
0.006 
NegIonizable:NegIonizable-3.00 Number of pairs of negIonazable-
negIonazable atoms within 3 bonds 
0.006 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.005 
Acceptor:NegIonizable-2.00 Number of pairs of acceptor-posIonazable 
atoms within 2 bonds 
0.005 
fr_hdrzine Number of hydrazine groups 0.005 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-posIonazable 
atoms within 2 bonds 
0.005 
fr_thiophene Number of thiophene rings 0.005 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.005 
fr_imidazole Number of imidazole rings 0.004 
fr_C_S Number of thiocarbonyl 0.004 
fr_urea Number of urea groups 0.004 
fr_nitro_arom Number of nitro benzene ring substituents 0.004 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonazable 
atoms within 2 bonds 
0.003 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.003 
Aromatic:NegIonizable-3.00 Number of pairs of aromatic-negIonazable 
atoms within 3 bonds 
0.002 
Aromatic:NegIonizable-1.00 Number of pairs of aromatic-negIonazable 
atoms within 1 bond 
0.002 
fr_imide Number of imide groups 0.002 




Table S12. Feature importance for predictive model of PPI inhibitors targeting the Wdr5/MLL complex. 
Feature Description Importance 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-
posIonazable atoms within 3 bonds 
0.344 
Aromatic:PosIonizable-6.00 Number of pairs of aromatic-posIonazable 
atoms within 6 bonds 
0.270 
Chi1v Molecular connectivity index 0.225 
Acceptor:PosIonizable-3.00 Number of pairs of acceptor-negIonazable 
atoms within 3 bonds 
0.160 
 
Table S13. Feature importance for predictive model of PPI inhibitors targeting the Xiap/Smac complex. 
Feature  Importance 
PosIonizable_Count Number of posIonazable atoms 0.119 
fr_amide Number of amides 0.087 
Acceptor:Donor-6.00 Number of pairs of acceptor-donor atoms 
within 6 bonds 
0.052 
SlogP_VSA11 MOE-type descriptors, LogP and surface area 
contributions 
0.035 
Aromatic:Donor-5.00 Number of pairs of aromatic-donor atoms 
within 5 bonds 
0.031 
SMR_VSA9 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.027 
VSA_EState8 MOE-type descriptors surface area 
contributions and EState indices 
0.026 
SMR_VSA10 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.024 
Aromatic_Count Number of atoms in aromatic rings 0.024 
Donor:Hydrophobe-2.00 Number of pairs of donor-hydrophobe atoms 
within 2 bonds 
0.020 
Acceptor:Acceptor-3.00 Number of pairs of acceptor-acceptor atoms 
within 3 bonds 
0.019 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 
2 bonds 
0.017 
PosIonizable:PosIonizable-6.00 Number of pairs of posIonazable-
posIonazable atoms within 6 bonds 
0.016 
NOCount Number of Nitrogens and Oxygens 0.016 
fr_quatN Number of quarternary nitrogens 0.015 
PEOE_VSA8 MOE-type descriptors, partial charges and 
surface area contributions 
0.015 
NegIonizable:NegIonizable-4.00 Number of pairs of negIonazable-
negIonazable atoms within 4 bonds 
0.015 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-
posIonazable atoms within 3 bonds 
0.015 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posIonazable atoms within 2 bonds 
0.015 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bond 
0.014 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.014 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-
negIonazable atoms within 2 bonds 
0.014 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-posIonazable 
atoms within 4 bonds 
0.014 
Acceptor:Hydrophobe-5.00 Number of pairs of acceptor-hydrophobe 
atoms within 5 bonds 
0.013 
Aromatic:PosIonizable-3.00 Number of pairs of aromatic-posIonazable 
atoms within 3 bonds 
0.013 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 
3 bonds 
0.013 
Aromatic:PosIonizable-2.00 Number of pairs of aromatic-posIonazable 
atoms within 2 bonds 
0.013 
fr_Ar_N Number of aromatic nitrogens 0.012 
NegIonizable:NegIonizable-3.00 Number of pairs of negIonazable-
negIonazable atoms within 3 bonds 
0.012 
PEOE_VSA3 MOE-type descriptors, partial charges and 
surface area contributions 
0.012 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.012 
fr_Ar_OH Number of aromatic hydroxyl groups 0.011 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic atoms 
within 3 bonds 
0.011 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-
posIonazable atoms within 1 bond 
0.011 
Donor:Hydrophobe-3.00 Number of pairs of donor-hydrophone atoms 
within 3 bonds 
0.011 
Acceptor:Hydrophobe-1.00 Number of pairs of acceptor-hydrophone 
atoms within 1 bond 
0.011 
Acceptor:Hydrophobe-4.00 Number of pairs of acceptor-hydrophone 
atoms within 4 bonds 
0.011 
Donor:Hydrophobe-4.00 Number of pairs of donor-hydrophone atoms 
within 4 bonds 
0.011 
Hydrophobe_Count Number of hydrophobe atoms 0.011 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophone 
atoms within 4 bonds 
0.010 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophone atoms 
within 1 bond 
0.009 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.009 
Acceptor:Hydrophobe-3.00 Number of pairs of acceptor-hydrophone 
atoms within 3 bonds 
0.009 
Acceptor:Aromatic-2.00 Number of pairs of acceptor-aromatic atoms 
within 2 bonds 
0.009 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophone 
atoms within 2 bonds 
0.008 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.008 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe 
atoms within 1 bond 
0.008 
Aromatic:Hydrophobe-2.00 Number of pairs of aromatic-hydrophobe 
atoms within 2 bonds 
0.008 
Acceptor:PosIonizable-3.00 Number of pairs of aromatic-posIonazable 
atoms within 3 bonds 
0.008 
Hydrophobe:Hydrophobe-3.00 Number of pairs of hydrophobe-hydrophone 
atoms within 3 bonds 
0.008 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophone 
atoms within 1 bond 
0.007 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 
1 bond 
0.007 
Acceptor:NegIonizable-2.00 Number of pairs of acceptor-negIonazable 
atoms within 2 bonds 
0.007 
fr_Ar_COO Number of Aromatic carboxylic acide 0.006 
fr_oxazole Number of oxazole rings 0.006 
Acceptor:PosIonizable-4.00 Number of pairs of acceptor-posIonazable 
atoms within 4 bonds 
0.006 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.004 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.004 
Donor:NegIonizable-4.00 Number of pairs of donor-negIonazable atoms 
within 4 bonds 
0.004 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-posIonazable 
atoms within 2 bonds 
0.004 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.003 
Hydrophobe:NegIonizable-2.00 Number of pairs of hydrophobe-negIonazable 
atoms within 2 bonds 
0.003 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.003 
Acceptor:PosIonizable-2.00 Number of pairs of acceptor-posIonazable 
atoms within 2 bonds 
0.003 
Donor:NegIonizable-2.00 Number of pairs of donor-posIonazable atoms 0.002 
within 2 bonds 
fr_priamide Number of primary amides 0.002 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.002 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonazable 
atoms within 2 bonds 
0.001 
Aromatic:NegIonizable-3.00 Number of pairs of aromatic-negIonazable 
atoms within 3 bonds 
0.001 
fr_ketone_Topliss Number of ketones excluding diaryl, a,b-
unsat. dienones, heteroatom on Calpha 
0.001 
fr_alkyl_carbamate Number of alkyl carbamates (subject to 
hydrolysis) 
0.001 
Aromatic:NegIonizable-1.00 Number of pairs of aromatic-negIonazable 
atoms within 1 bond 
0.001 
 
Table S14. Feature importance for predictive model of PPI inhibitors targeting the Annexin A2/S100-
A10 complex. 
Feature Description Importance 
Aromatic:Aromatic-4.00 Number of pairs of aromatic-
aromatic atoms within 4 bonds 
0.569 
Kappa1 Molecular shape index 0.355 
fr_piperdine Number of piperdine rings 0.076 
 
Table S15. Feature importance for predictive model of PPI inhibitors targeting the Brd2/Ack complex. 
Feature Description Importance 
Aromatic:Aromatic-4.00 Number of pairs of aromatic-aromatic atoms 
within 4 bonds 
0.619 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.121 
Donor:Hydrophobe-2.00 Number of pairs of donor-hydrophobe atoms 
within 2 bonds 
0.117 
fr_morpholine Number of morpholine rings 0.031 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-
posIonazable atoms within 3 bonds 
0.015 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.014 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-
negIonazable atoms within 2 bonds 
0.014 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bond 
0.012 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posIonazable atoms within 2 bonds 
0.011 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-
posIonazable atoms within 1 bond 
0.008 
fr_alkyl_carbamate Number of alkyl carbamates (subject to 
hydrolysis) 
0.008 
Donor:PosIonizable-1.00 Number of pairs of aromatic-aromatic atoms 0.007 
within 1 bond 
Hydrophobe:NegIonizable-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.007 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.005 
Acceptor:NegIonizable-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.005 
Hydrophobe:PosIonizable-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.004 
Donor:NegIonizable-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.002 
Aromatic:NegIonizable-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.001 
 
Table S16. Feature importance for predictive model of PPI inhibitors targeting the CD80/CD28 complex. 
Feature Description Importance 
Tox_30 a1~a~a~a2~a~1~a~a~a3~a~2~a~a~a~3 0.200 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.082 
fr_alkyl_halide Number of alkyl halides 0.081 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic atoms 
within 3 bonds 
0.072 
Aromatic:Donor-3.00 Number of pairs of aromatic-donor atoms within 
3 bonds 
0.068 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.064 
Aromatic:Donor-2.00 Number of pairs of aromatic-donor atoms within 
2 bonds 
0.056 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 1 
bond 
0.050 
Aromatic:Donor-1.00 Number of pairs of aromatic-donor atoms within 
1 bond 
0.042 
Acceptor:Aromatic-3.00 Number of pairs of acceptor-aromatic atoms 
within 3 bonds 
0.035 
Acceptor:Aromatic-2.00 Number of pairs of acceptor-aromatic atoms 
within 2 bonds 
0.024 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.023 
Acceptor:Aromatic-1.00 Number of pairs of acceptor-aromatic atoms 
within 1 bond 
0.017 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.017 
Aromatic:Hydrophobe-3.00 Number of pairs of aromatic-hydrophobe atoms 
within 3 bonds 
0.015 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe atoms 
within 1 bond 
0.013 
Donor:Hydrophobe-2.00 Number of pairs of donor-hydrophobe atoms 
within 2 bonds 
0.011 
Aromatic:Hydrophobe-2.00 Number of pairs of aromatic-hydrophobe atoms 
within 2 bonds 
0.011 
Acceptor:Donor-3.00 Number of pairs of acceptor-donor atoms within 
3 bonds 
0.011 
Acceptor:Acceptor-2.00 Number of pairs of acceptor-acceptor atoms 
within 2 bonds 
0.008 
Hydrophobe:Hydrophobe-2.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 2 bonds 
0.007 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.006 
Acceptor:Hydrophobe-3.00 Number of pairs of acceptor-hydrophobe atoms 
within 3 bonds 
0.006 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.005 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms within 
1 bond 
0.005 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.005 
Hydrophobe:Hydrophobe-3.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 3 bonds 
0.005 
Donor:Hydrophobe-3.00 Number of pairs of donor-hydrophobe atoms 
within 3 bonds 
0.005 
Acceptor:Acceptor-3.00 Number of pairs of acceptor-acceptor atoms 
within 3 bonds 
0.005 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-posIonazable 
atoms within 1 bond 
0.004 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.004 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.003 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.003 
Acceptor:Hydrophobe-1.00 Number of pairs of acceptor-hydrophobe atoms 
within 1 bond 
0.003 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-posIonazable 
atoms within 2 bonds 
0.003 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonazable 
atoms within 3 bonds 
0.003 
Aromatic:PosIonizable-2.00 Number of pairs of aromatic-posIonazable 
atoms within 2 bonds 
0.002 
Acceptor:Donor-2.00 Number of pairs of acceptor-donor atoms within 
2 bonds 
0.002 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-posIonazable 
atoms within 3 bonds 
0.002 
Donor:PosIonizable-3.00 Number of pairs of donor-posIonazable atoms 
within 3 bonds 
0.002 
Aromatic:PosIonizable-3.00 Number of pairs of aromatic-posIonazable 
atoms within 3 bonds 
0.002 
PosIonizable:PosIonizable-4.00 Number of pairs of posIonazable-posIonazable 0.002 
atoms within 4 bonds 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.001 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.001 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.001 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-negIonazable 
atoms within 2 bonds 
0.001 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-posIonazable 
atoms within 2 bonds 
0.001 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable atoms 
within 2 bonds 
0.001 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonazable atoms 
within 2 bonds 
0.001 
Acceptor:PosIonizable-2.00 Number of pairs of acceptor-posIonazable 
atoms within 2 bonds 
0.001 
Donor:NegIonizable-3.00 Number of pairs of donor-negIonazable atoms 
within 3 bonds 
0.001 
Acceptor:PosIonizable-3.00 Number of pairs of acceptor-posIonazable 
atoms within 3 bonds 
0.001 
 
Table S17. Feature importance for predictive model of PPI inhibitors targeting the IL2/IL2-R complex. 
Feature Description Importance 
PEOE_VSA11 MOE-type descriptors, partial charges and 
surface area contributions 
0.595 
Acceptor:Aromatic-4.00 Number of pairs of acceptor-aromatic atoms 
within 4 bonds 
0.284 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bond 
0.121 
 
Table S18. Feature importance for predictive model of PPI inhibitors targeting the Keap1/Nrf2 complex. 
Feature Description Importance 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.192 
Aromatic:NegIonizable-6.00 Number of pairs of aromatic-negIonazable 
atoms within 6 bonds 
0.159 
SMR_VSA6 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.110 
Kappa3 Molecular shape index 0.098 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.091 
Aromatic:Hydrophobe-6.00 Number of pairs of aromatic-hydrophobe atoms 
within 6 bonds 
0.077 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.077 
Donor:Hydrophobe-2.00 Number of pairs of donor-hydrophobe atoms 0.063 
within 2 bonds 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonazable 
atoms within 2 bonds 
0.044 
fr_nitrile Number of nitriles 0.031 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.028 
fr_tetrazole Number of tetrazole rings 0.012 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.005 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-posIonazable 
atoms within 2 bonds 
0.004 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-posIonazable 
atoms within 1 bond 
0.003 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.003 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.001 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.001 
 
Table S19. Feature importance for predictive model of PPI inhibitors targeting the Menin/MLL complex. 
Feature Descriptor Importance 
SMR_VSA10 MOE-type descriptors, molar refractivity and surface 
area contributions 
0.556 
fr_nitrile Number of nitriles 0.399 




Table S20. Feature importance for predictive model of PPI inhibitors targeting the STAT3 complex. 
Feature Descriptor Importance 
TPSA Topological polar surface area 0.588 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.321 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.090 
 
Table S21. Feature importance for predictive model of PPI inhibitors targeting the TTR complex. 
Feature Descriptor Importance 
Chi1n Molecular connectivity index 0.776 
SlogP_VSA7 MOE-type descriptors, LogP and surface area 
contributions 
0.141 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.051 
fr_hdrzine Number of hydrazine groups 0.032 
 
Table S22. Performance comparison of pdCSM-PPI and PPIM-pred on a non-redundant blind test. 
 pdCSM-PPI PPIM-pred 
PPI target F1 AUC Sensitivity Specificity F1 AUC Sensitivity Specificity 
Bcl2-Like / Bak-Bax 0.99 1.00 1.00 0.98 0.26 0.67+ 0.71* 0.67* 
Mdm2-Like / P53 0.97 1.00 0.97 0.96 0.45 0.84+ 1.00* 0.79* 
* p-value < 0.05 by McNemar’s Test compared to pdCSM-PPI 
+ p-value < 0.05  by z transformation test compared to pdCSM-PPI 
 
Table S23. Performance comparison of pdCSM-PPI and SMMPPI on non-redundant blind tests. 
 pdCSM-PPI SMMPPI 
PPI target MCC F1 AUC MCC F1 AUC 
Bcl2-Like / Bak-Bax 0.86 0.92 0.92 0.70 0.84 0.92 
Bromodomain / Histone 0.82 0.90 0.90 0.73 0.87 0.93 
LEDGF / IN 0.70 0.85 0.85 0.70 0.85 0.97 
LFA / ICAM 1.00 1.00 1.00 0.92 0.96 0.99 
Mdm2-Like / P53 0.88 0.93 0.93 0.79 0.89 0.93 
Ras / SOS1 0.57 0.73 0.75 0.52 0.71 0.82 
XIAP / Smac 0.89 0.94 0.94 0.89 0.95 0.97 
WDR5 / MLL 0.92 0.96 0.94 0.74 0.87 0.87 
CD4 / gp120 0.91 0.95 0.95 0.90 0.95 0.95 
 
Table S24. Distribution of compounds with experimentally determined inhibitory activity (IC50) across 
45 different PPIs, on the original dataset retrieved from TIMBAL and iPPI-DB, and after clustering using 
the Butina algorithm with Tanimoto similarity cutoff of 0.8. PPI targets with more than 40 inhibitors after 
clustering were further selected for building regression models. 
PPI # compounds # compounds (clustering 0.8) 
Integrins 1606 907 
Mdm2-Like / P53 685 400 
LFA / ICAM 277 150 
BCL2-Like / BAX-BAK 350 127 
Bromodomain / Histone 145 111 
HIF-1a / p300 121 82 
Cyclophilins 105 73 
LEDGF / IN 74 68 
XIAP / Smac 69 42 
CD80 / CD28 73 35 
BRD2 / Ack 47 32 
Annexin A2/S100-A10 44 29 
Neuropilin / VEGF 41 24 
FKBP1A/FK506 29 21 
STAT3 38 21 
TTR 19 17 
Transthyretin 16 16 
BRD4 / NUT 16 15 
BetaCatenin / Tcf4 and Tcf3 40 15 
IL2 / IL-2R 29 15 
Rac1 15 15 
Tubulin 14 14 
MENIN / MLL 20 12 
SPIN1 / H3 15 10 
E2 / E1 10 8 
MLLT1 / H3 16 8 
PCNA trimer 7 7 
c-Myc / Max 8 7 
SOD1 10 5 
RUNX1 / CBFb 4 4 
VEGF / VEGFR 4 4 
53BP1 / H4 3 3 
WD40 / H3 3 3 
CRM1 / Rev 2 2 
NRP / VEGF 2 2 
Ras / SOS1 2 2 
UPAR / UPA 3 2 
WDR5/MLL 3 2 
BRI1 1 1 
CD4 / gp120 1 1 
CD40 / CD154 1 1 
CaM / CaMBD2 1 1 
Rad51 1 1 
TNFa / TNFa 1 1 
Tak1 / Tab1 1 1 
 
Table S25. Feature importance for the regression model of PPI inhibitors targeting the BCL2-Like / 
BAX-BAK complex. 
Feature Description Importance 
SMR_VSA5 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.128 
SlogP_VSA7 MOE-type descriptors, LogP and surface area 
contributions 
0.104 
Chi2n Molecular connectivity index 0.096 
fr_Ar_N Number of aromatic nitrogens 0.083 
fr_bicyclic Number of bicyclic structures 0.042 
Donor_Count Number of hydrogen donors 0.042 
SMR_VSA10 MOE-type descriptors, molar refractivity and 0.037 
surface area contributions 
VSA_EState8 MOE-type descriptors, surface area 
contributions and EState indices 
0.036 
SlogP_VSA10 MOE-type descriptors, LogP and surface area 
contributions 
0.034 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 
1 bond 
0.032 
Acceptor:Hydrophobe-3.00 Number of pairs of acceptor-hydrophobe 
atoms within 3 bonds 
0.032 
PEOE_VSA9 MOE-type descriptors, partial charges and 
surface area contributions 
0.028 
fr_NH2 Number of Primary amines 0.028 
Aromatic_Count Number of atoms in aromatic rings 0.025 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe 
atoms within 2 bonds 
0.024 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 
6 bonds 
0.023 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 4 bonds 
0.021 
Donor:Hydrophobe-3.00 Number of pairs of donor-hydrophobe atoms 
within 3 bonds 
0.021 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.020 
fr_thiazole Number of thiazole rings 0.016 
SMR_VSA9 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.013 
SlogP_VSA12 MOE-type descriptors, LogP and surface area 
contributions 
0.010 
fr_unbrch_alkane Number of unbranched alkanes of at least 4 
members (excludes halogenated alkanes) 
0.008 
fr_alkyl_halide Number of alkyl halides 0.007 
Acceptor:PosIonizable-4.00 Number of pairs of acceptor-posIonazable 
atoms within 4 bonds 
0.007 
Donor:PosIonizable-3.00 Number of pairs of donor-posIonazable atoms 
within 3 bonds 
0.006 
PosIonizable_Count Number of posIonazable atoms 0.006 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-
negIonazable atoms within 2 bonds 
0.006 
PosIonizable:PosIonizable-4.00 Number of pairs of posIonazable-
posIonazable atoms within 4 bonds 
0.005 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-posIonazable 
atoms within 4 bonds 
0.005 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.005 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonazable 
atoms within 3 bonds 
0.004 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-
posIonazable atoms within 3 bonds 
0.004 
fr_sulfide Number of thioether 0.004 
fr_Ar_OH Number of aromatic hydroxyl groups 0.003 
Acceptor:NegIonizable-4.00 Number of pairs of acceptor-negIonazable 
atoms within 4 bonds 
0.003 
fr_pyridine Number of pyridine rings 0.003 
Acceptor:NegIonizable-2.00 Number of pairs of acceptor-negIonazable 
atoms within 2 bonds 
0.003 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bond 
0.003 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 
3 bonds 
0.003 
NegIonizable:NegIonizable-5.00 Number of pairs of negIonazable-
negIonazable atoms within 5 bonds 
0.002 
NegIonizable:NegIonizable-4.00 Number of pairs of negIonazable-
negIonazable atoms within 4 bonds 
0.002 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonazable 
atoms within 1 bond 
0.002 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.002 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.002 
Hydrophobe:NegIonizable-4.00 Number of pairs of hydrophobe-negIonazable 
atoms within 4 bonds 
0.002 
Donor:NegIonizable-3.00 Number of pairs of donor-negIonazable atoms 
within 3 bonds 
0.002 
Donor:NegIonizable-5.00 Number of pairs of donor-negIonazable atoms 
within 5 bonds 
0.002 
fr_phenol Number of phenols 0.002 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.001 
fr_ketone Number of ketones 0.001 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posIonazable atoms within 2 bonds 
0.001 
Aromatic:NegIonizable-4.00 Number of pairs of aromatic-negIonazable 
atoms within 4 bonds 
0.001 
Hydrophobe:NegIonizable-2.00 Number of pairs of hydrophobe-negIonazable 
atoms within 2 bonds 
0.001 
 
Table S26. Feature importance for the regression model of PPI inhibitors targeting the Bromodomain / 
Histone complex. 
Feature Description Importance 
Chi1v Molecular connectivity index 0.219 
BalabanJ Balaban's connectivity topological index 0.083 
Kappa2 Molecular shape index 0.075 
Tox_2 a[NH2] 0.054 
PEOE_VSA7 MOE-type descriptors, partial charges and 
surface area contributions 
0.039 
PEOE_VSA9 MOE-type descriptors, partial charges and 
surface area contributions 
0.039 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe atoms 
within 1 bond 
0.026 
SMR_VSA4 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.025 
Acceptor:Acceptor-5.00 Number of pairs of acceptor-acceptor atoms 
within 5 bonds 
0.025 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 4 bonds 
0.024 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.022 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.020 
PEOE_VSA2 MOE-type descriptors, partial charges and 
surface area contributions 
0.018 
Aromatic:Hydrophobe-5.00 Number of pairs of aromatic-hydrophobe atoms 
within 5 bonds 
0.018 
fr_NH0 Number of Tertiary amines 0.017 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.017 
VSA_EState10 MOE-type descriptors surface area contributions 
and EState indices 
0.017 
fr_benzene Number of benzene rings 0.015 
fr_Imine Number of Imines 0.014 
SMR_VSA6 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.014 
Aromatic_Count Number of atoms in aromatic rings 0.013 
SlogP_VSA10 MOE-type descriptors, LogP and surface area 
contributions 
0.011 
SlogP_VSA1 MOE-type descriptors, LogP and surface area 
contributions 
0.011 
SMR_VSA5 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.011 
fr_aniline Number of anilines 0.011 
Aromatic:Aromatic-5.00 Number of pairs of aromatic-aromatic atoms 
within 5 bonds 
0.010 
Acceptor:Aromatic-2.00 Number of pairs of acceptor-aromatic atoms 
within 2 bonds 
0.010 
VSA_EState8 MOE-type descriptors, surface area 
contributions and EState indices 
0.009 
Acceptor:Aromatic-5.00 Number of pairs of acceptor-aromatic atoms 
within 5 bonds 
0.009 
Acceptor:Aromatic-4.00 Number of pairs of acceptor-aromatic atoms 
within 4 bonds 
0.009 
PEOE_VSA3 MOE-type descriptors, partial charges and 
surface area contributions 
0.009 
fr_aryl_methyl Number of aryl methyl sites for hydroxylation 0.009 
Donor:Hydrophobe-4.00 Number of pairs of donor-hydrophobe atoms 0.008 
within 4 bonds 
Aromatic:Donor-3.00 Number of pairs of aromatic-donor atoms within 
3 bonds 
0.007 
SlogP_VSA5 MOE-type descriptors, LogP and surface area 
contributions 
0.007 
SMR_VSA10 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.006 
fr_thiophene Number of thiophene rings 0.006 
Acceptor:PosIonizable-6.00 Number of pairs of acceptor-posIonazable 
atoms within 6 bonds 
0.006 
PEOE_VSA11 MOE-type descriptors, partial charges and 
surface area contributions 
0.006 
PEOE_VSA5 MOE-type descriptors, partial charges and 
surface area contributions 
0.006 
Aromatic:PosIonizable-6.00 Number of pairs of aromatic-posIonazable 
atoms within 6 bonds 
0.005 
Aromatic:Donor-1.00 Number of pairs of aromatic-donor atoms within 
1 bond 
0.005 
PEOE_VSA4 MOE-type descriptors, partial charges and 
surface area contributions 
0.004 
Aromatic:PosIonizable-5.00 Number of pairs of aromatic-posIonazable 
atoms within 5 bonds 
0.004 
fr_Ar_OH Number of aromatic hydroxyl groups 0.003 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.003 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 6 
bonds 
0.002 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.002 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.002 
PosIonizable_Count Number of posIonazable atoms 0.002 
fr_halogen Number of halogens 0.002 
Donor:Donor-4.00 Number of pairs of donor-donor atoms within 4 
bonds 
0.002 
NegIonizable_Count Number of negIonazable atoms 0.001 
Acceptor:PosIonizable-2.00 Number of pairs of acceptor-posIonazable 
atoms within 2 bonds 
0.001 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 5 
bonds 
0.001 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonazable 
atoms within 3 bonds 
0.001 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.001 
Donor:PosIonizable-4.00 Number of pairs of donor-posIonazable atoms 
within 4 bonds 
0.001 
Aromatic:PosIonizable-4.00 Number of pairs of aromatic-posIonazable 
atoms within 4 bonds 
0.001 
PosIonizable:PosIonizable-5.00 Number of pairs of posIonazable-posIonazable 
atoms within 5 bonds 
0.001 
Acceptor:PosIonizable-3.00 Number of pairs of acceptor-posIonazable 




Table S27. Feature importance for the regression model of PPI inhibitors targeting the HIF-1a / p300 
complex. 
Feature Description Importance 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.464 
RingCount Number of rings 0.192 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.09 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms 
within 1 bond 
0.076 
fr_Al_OH Number of aliphatic hydroxyl groups 0.044 
Donor:PosIonizable-6.00 Number of pairs of donor-posIonazable atoms 
within 6 bonds 
0.044 
VSA_EState10 MOE-type descriptors, surface area 
contributions and EState indices 
0.041 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.025 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 
1 bond 
0.012 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.006 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.004 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bond 
0.001 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-
negIonazable atoms within 1 bonds 
0.001 
 
Table S28. Feature importance for the regression model of PPI inhibitors targeting the Mdm2-Like / 
P53 complex. 
Feature Description Importance 
PEOE_VSA13 MOE-type descriptors, partial charges and 
surface area contributions 
0.058 
Chi4n Molecular connectivity index 0.054 
VSA_EState8 MOE-type descriptors, surface area 
contributions and EState indices 
0.051 
fr_halogen Number of halogens 0.046 
VSA_EState10 MOE-type descriptors, surface area 
contributions and EState indices 
0.035 
PEOE_VSA9 MOE-type descriptors, partial charges and 0.035 
surface area contributions 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 6 
bonds 
0.031 
fr_bicyclic Number of bicyclic structures 0.030 
fr_NH1 Number of Secondary amines 0.029 
Chi0n Molecular connectivity index 0.026 
BalabanJ Balaban's connectivity topological index 0.023 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.023 
Chi3n Molecular connectivity index 0.023 
PEOE_VSA11 MOE-type descriptors, partial charges and 
surface area contributions 
0.021 
VSA_EState9 MOE-type descriptors surface area contributions 
and EState indices 
0.020 
Kappa1 Molecular shape index 0.018 
Donor_Count Number of hydrogen donors 0.018 
HeavyAtomCount Number of heavy atoms 0.018 
fr_aniline Number of anilines 0.017 
FCount Number of fluorine atoms 0.016 
MolWt Molecular weight 0.015 
PEOE_VSA8 MOE-type descriptors, partial charges and 
surface area contributions 
0.015 
SMR_VSA7 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.014 
Acceptor:Hydrophobe-4.00 Number of pairs of acceptor-hydrophobe atoms 
within 4 bonds 
0.012 
Donor:Donor-4.00 Number of pairs of donor-donor atoms within 4 
bonds 
0.012 
Donor:Hydrophobe-4.00 Number of pairs of donor-hydrophobe atoms 
within 4 bonds 
0.012 
fr_NH2 Number of Primary amines 0.011 
fr_C_O_noCOO Number of carbonyl O, excluding COOH 0.011 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.011 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms within 
1 bond 
0.011 
SMR_VSA1 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.011 
fr_C_O Number of carbonyl O 0.011 
Donor:NegIonizable-1.00 Number of pairs of donor-negIonazable atoms 
within 1 bond 
0.010 
Acceptor:Acceptor-3.00 Number of pairs of acceptor-acceptor atoms 
within 3 bonds 
0.010 
Acceptor:Aromatic-1.00 Number of pairs of acceptor-aromatic atoms 
within 1 bond 
0.010 
fr_HOCCN Number of C(OH)CCN-Ctert-alkyl or 0.009 
C(OH)CCNcyclic 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.009 
Acceptor:Hydrophobe-6.00 Number of pairs of acceptor-hydrophobe atoms 
within 6 bonds 
0.009 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.008 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.008 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.008 
PEOE_VSA14 MOE-type descriptors, partial charges and 
surface area contributions 
0.008 
fr_aryl_methyl Number of aryl methyl sites for hydroxylation 0.008 
Acceptor:Aromatic-3.00 Number of pairs of acceptor-aromatic atoms 
within 3 bonds 
0.008 
SMR_VSA9 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.007 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.006 
NegIonizable:NegIonizable-2.00 Number of pairs of negIonazable-negIonazable 
atoms within 2 bonds 
0.006 
Donor:PosIonizable-5.00 Number of pairs of donor-posIonazable atoms 
within 5 bonds 
0.006 
NegIonizable:NegIonizable-3.00 Number of pairs of negIonazable-negIonazable 
atoms within 3 bonds 
0.006 
fr_Ndealkylation1 Number of XCCNR groups 0.006 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.006 
Aromatic:Aromatic-4.00 Number of pairs of aromatic-aromatic atoms 
within 4 bonds 
0.005 
Aromatic:Aromatic-5.00 Number of pairs of aromatic-aromatic atoms 
within 5 bonds 
0.005 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-posIonazable 
atoms within 2 bonds 
0.005 
Aromatic:Aromatic-6.00 Number of pairs of aromatic-aromatic atoms 
within 6 bonds 
0.005 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonazable atoms 
within s bonds 
0.005 
Acceptor:PosIonizable-5.00 Number of pairs of acceptor-posIonazable atoms 
within 5 bonds 
0.005 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.005 
Aromatic_Count Number of atoms in aromatic rings 0.005 
fr_piperzine Number of piperzine rings 0.004 
NegIonizable:NegIonizable-6.00 Number of pairs of negIonazable-negIonazable 
atoms within 6 bonds 
0.004 
Donor:PosIonizable-3.00 Number of pairs of donor-posIonazable atoms 
within 3 bonds 
0.004 
fr_pyridine Number of pyridine rings 0.004 
NegIonizable:NegIonizable-1.00 Number of pairs of negIonazable-negIonazable 
atoms within 1 bond 
0.004 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable atoms 
within 1 bonds 
0.004 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.004 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-posIonazable 
atoms within 3 bonds 
0.004 
fr_ArN Number of N functional groups attached to 
aromatics 
0.004 
Aromatic:PosIonizable-3.00 Number of pairs of aromatic-posIonazable atoms 
within 3 bonds 
0.004 
Hydrophobe:PosIonizable-3.00 Number of pairs of hydrophobe-posIonazable 
atoms within 3 bonds 
0.004 
fr_nitro Number of nitro groups 0.003 
fr_morpholine Number of morpholine rings 0.003 
Hydrophobe:NegIonizable-1.00 Number of pairs of hydrophobe-negIonazable 
atoms within 1 bond 
0.003 
Tox_1 O=N(~O)a 0.003 
fr_nitro_arom Number of nitro benzene ring substituents 0.003 
fr_imide Number of imide groups 0.002 
Acceptor:NegIonizable-1.00 Number of pairs of acceptor-negIonazable 
atoms within 1 bond 
0.002 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-posIonazable 
atoms within 4 bonds 
0.002 
Aromatic:NegIonizable-6.00 Number of pairs of aromatic-negIonazable 
atoms within 63 bonds 
0.002 
fr_nitrile Number of nitriles 0.002 
fr_thiophene Number of thiophene rings 0.001 
fr_N_O Number of hydroxylamine groups 0.001 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonazable 
atoms within 2 bonds 
0.001 
Aromatic:NegIonizable-4.00 Number of pairs of aromatic-negIonazable 
atoms within 4 bonds 
0.001 
Aromatic:NegIonizable-3.00 Number of pairs of aromatic-negIonazable 




Table S29. Feature importance for the regression model of PPI inhibitors targeting the Integrins 
complex. 
Feature Description Importance 
fr_Al_COO Number of aliphatic carboxylic acids 0.067 
SlogP_VSA5 MOE-type descriptors, LogP and surface area 
contributions 
0.059 
fr_pyridine Number of pyridine rings 0.055 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 4 bonds 
0.049 
MolWt Molecular weight 0.044 
SlogP_VSA2 MOE-type descriptors, LogP and surface area 
contributions 
0.042 
Acceptor:Aromatic-5.00 Number of pairs of acceptor-aromatic atoms 
within 5 bonds 
0.040 
HallKierAlpha Hall-Kier alpha value 0.038 
Aromatic_Count Number of atoms in aromatic rings 0.034 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.033 
Acceptor:Acceptor-6.00 Number of pairs of acceptor-acceptor atoms 
within 6 bonds 
0.033 
fr_NH1 Number of Secondary amines 0.032 
fr_piperdine Number of piperdine rings 0.030 
SlogP_VSA4 MOE-type descriptors, LogP and surface area 
contributions 
0.027 
PEOE_VSA2 MOE-type descriptors, partial charges and 
surface area contributions 
0.026 
PEOE_VSA12 MOE-type descriptors, partial charges and 
surface area contributions 
0.026 
PEOE_VSA14 MOE-type descriptors, partial charges and 
surface area contributions 
0.023 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 
6 bonds 
0.023 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 
5 bonds 
0.021 
Hydrophobe:NegIonizable-2.00 Number of pairs of hydrophobe-negIonazable 
atoms within 2 bonds 
0.018 
Donor:Donor-4.00 Number of pairs of donor-donor atoms within 
4 bonds 
0.018 
PEOE_VSA13 MOE-type descriptors, partial charges and 
surface area contributions 
0.018 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.018 
Hydrophobe:NegIonizable-3.00 Number of pairs of hydrophobe-negIonazable 
atoms within 3 bonds 
0.017 
Hydrophobe:NegIonizable-4.00 Number of pairs of hydrophobe-negIonazable 
atoms within 4 bonds 
0.017 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 
3 bonds 
0.014 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 
2 bonds 
0.013 
fr_amidine Number of amidine groups 0.012 
Donor:NegIonizable-2.00 Number of pairs of donor-negIonazable atoms 
within 2 bonds 
0.012 
fr_sulfonamd Number of sulfonamides 0.011 
Hydrophobe:PosIonizable-5.00 Number of pairs of hydrophober-posIonazable 0.011 
atoms within 5 bonds 
Acceptor:PosIonizable-6.00 Number of pairs of acceptor-posIonazable 
atoms within 6 bonds 
0.010 
fr_Imine Number of Imines 0.009 
PosIonizable:PosIonizable-6.00 Number of pairs of posIonazable-
posIonazable atoms within 6 bonds 
0.008 
fr_alkyl_halide Number of alkyl halides 0.007 
fr_Ndealkylation1 Number of XCCNR groups 0.007 
Aromatic:PosIonizable-6.00 Number of pairs of aromatic-posIonazable 
atoms within 6 bonds 
0.007 
Donor:PosIonizable-6.00 Number of pairs of donor-posIonazable atoms 
within 6 bonds 
0.006 
Donor:PosIonizable-5.00 Number of pairs of donor-posIonazable atoms 
within 5 bonds 
0.006 
PosIonizable:PosIonizable-5.00 Number of pairs of posIonazable-
posIonazable atoms within 5 bonds 
0.006 
NegIonizable:PosIonizable-6.00 Number of pairs of negIonazable-
posIonazable atoms within 6 bonds 
0.005 
FCount Number of fluorine atoms 0.005 
fr_ArN Number of N functional groups attached to 
aromatics 
0.005 
Donor:PosIonizable-4.00 Number of pairs of donor-posIonazable atoms 
within 4 bonds 
0.004 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-
posIonazable atoms within 3 bonds 
0.004 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posIonazable atoms within 2 bonds 
0.004 
Acceptor:PosIonizable-4.00 Number of pairs of acceptor-posIonazable 
atoms within 4 bonds 
0.004 
Acceptor:PosIonizable-1.00 Number of pairs of acceptor-posIonazable 
atoms within 1 bond 
0.003 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable atoms 
within 2 bonds 
0.003 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-
posIonazable atoms within 1 bond 
0.003 
Aromatic:PosIonizable-2.00 Number of pairs of aromatic-posIonazable 
atoms within 2 bonds 
0.002 
NegIonizable:PosIonizable-2.00 Number of pairs of negIonazable-
posIonazable atoms within 2 bonds 
0.002 
fr_nitrile Number of nitriles 0.002 
fr_imide Number of imide groups 0.002 
fr_barbitur Number of barbiturate groups 0.001 
Hydrophobe:PosIonizable-1.00 Number of pairs of hydrophobe-posIonazable 
atoms within 1 bond 
0.001 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.001 
fr_term_acetylene Number of terminal acetylenes 0.001 
 
Table S30. Feature importance for the regression model of PPI inhibitors targeting the LFA / ICAM 
complex. 
Feature Description Importance 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-
hydrophobe atoms within 1 bond 
0.149 
VSA_EState8 MOE-type descriptors surface area 
contributions and EState indices 
0.145 
Kappa2 Molecular shape index 0.093 
SlogP_VSA10 MOE-type descriptors, LogP and surface 
area contributions 
0.091 
SlogP_VSA5 MOE-type descriptors, LogP and surface 
area contributions 
0.091 
fr_bicyclic Number of bicyclic structures 0.082 
SMR_VSA5 MOE-type descriptors, molar refractivity 
and surface area contributions 
0.078 
Acceptor:Donor-4.00 Number of pairs of acceptor-donor atoms 
within 4 bonds 
0.072 
fr_para_hydroxylation Number of para-hydroxylation sites 0.068 
fr_urea Number of urea groups 0.043 
fr_imide Number of imide groups 0.040 
fr_amide Number of amides 0.035 
Donor:Donor-1.00 Number of pairs of donor-donor atoms 




Table S31. Feature importance for the regression model of PPI inhibitors targeting the Cyclophilins 
complex. 
Feature Description Importance 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable 
atoms within 1 bond 
0.176 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posgIonazable atoms within 2 bonds 
0.135 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-
posIonazable atoms within 1 bond 
0.113 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-
posIonazable atoms within 2 bonds 
0.078 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable 
atoms within 1 bond 
0.075 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.071 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable 
atoms within 2 bonds 
0.070 
Acceptor:Acceptor-4.00 Number of pairs of acceptor-acceptor atoms 
within 4 bonds 
0.055 
Acceptor:Acceptor-2.00 Number of pairs of acceptor-acceptor atoms 
within 2 bonds 
0.047 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 
5 bonds 
0.040 
SMR_VSA6 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.019 
Chi1n Molecular connectivity index 0.019 
fr_amide Number of amides 0.015 
Acceptor:Donor-1.00 Number of pairs of acceptor-donor atoms 
within 1 bond 
0.012 
Donor:Hydrophobe-1.00 Number of pairs of donor-hydrophobe atoms 
within 1 bond 
0.009 
Aromatic:Donor-1.00 Number of pairs of aromatic-donor atoms 
within 1 bond 
0.009 
SMR_VSA10 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.008 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.008 
Acceptor:Acceptor-1.00 Number of pairs of acceptor-acceptor atoms 
within 1 bond 
0.006 
Hydrophobe:Hydrophobe-2.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 2 bonds 
0.005 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe 
atoms within 1 bond 
0.004 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic atoms 
within 1 bond 
0.004 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic atoms 
within 3 bonds 
0.004 
Aromatic:Hydrophobe-2.00 Number of pairs of aromatic-hydrophobe 
atoms within 2 bonds 
0.004 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic atoms 
within 2 bonds 
0.004 
fr_benzene Number of benzene rings 0.003 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe 
atoms within 2 bonds 
0.003 
fr_pyridine Number of pyridine rings 0.001 
fr_Ar_N Number of aromatic nitrogens 0.001 
 
Table S32. Feature importance for the regression model of PPI inhibitors targeting the LEDGF / IN 
complex. 
Feature Description Importance 
SlogP_VSA8 MOE-type descriptors, LogP and surface area 
contributions 
0.132 
Acceptor:Acceptor-5.00 Number of pairs of acceptor-acceptor atoms 
within 5 bonds 
0.065 
PEOE_VSA10 MOE-type descriptors, partial charges and 
surface area contributions 
0.059 
SlogP_VSA2 MOE-type descriptors, LogP and surface area 
contributions 
0.041 
PEOE_VSA6 MOE-type descriptors, partial charges and 
surface area contributions 
0.039 
Kappa1 Molecular shape index 0.034 
PEOE_VSA7 MOE-type descriptors, partial charges and 
surface area contributions 
0.029 
SlogP_VSA4 MOE-type descriptors, LogP and surface area 
contributions 
0.027 
Chi1v Molecular connectivity index 0.027 
PEOE_VSA5 MOE-type descriptors, partial charges and 
surface area contributions 
0.027 
Chi0v Molecular connectivity index 0.026 
Chi2n Molecular connectivity index 0.025 
PEOE_VSA2 MOE-type descriptors, partial charges and 
surface area contributions 
0.024 
Donor:Donor-3.00 Number of pairs of donor-donor atoms within 3 
bonds 
0.022 
fr_nitro_arom Number of nitro benzene ring substituents 0.021 
Donor:NegIonizable-4.00 Number of pairs of donor-negIonazable atoms 
within 4 bonds 
0.021 
fr_C_O_noCOO Number of carbonyl O, excluding COOH 0.021 
SMR_VSA3 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.020 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe atoms 
within 2 bonds 
0.020 
Chi0 Molecular connectivity index 0.019 
Tox_1 O=N(~O)a 0.019 
Donor:Donor-5.00 Number of pairs of donor-donor atoms within 5 
bonds 
0.018 
fr_nitro Number of nitro groups 0.018 
fr_hdrzone Number of hydrazone groups 0.018 
Donor:Donor-6.00 Number of pairs of donor-donor atoms within 6 
bonds 
0.017 
Donor:Hydrophobe-5.00 Number of pairs of donor-hydrophobe atoms 
within 5 bonds 
0.017 
Donor:NegIonizable-3.00 Number of pairs of donor-negIonazable atoms 
within 3 bonds 
0.016 
HallKierAlpha Hall-Kier alpha value 0.015 
Acceptor:Donor-2.00 Number of pairs of acceptor-donor atoms within 2 
bonds 
0.015 
Aromatic:Donor-3.00 Number of pairs of aromatic-donor atoms within 3 
bonds 
0.014 
Donor:Donor-1.00 Number of pairs of donor-donor atoms within 1 
bond 
0.012 
PEOE_VSA12 MOE-type descriptors, partial charges and 
surface area contributions 
0.012 
Aromatic:Hydrophobe-4.00 Number of pairs of aromatic-hydrophobe atoms 
within 4 bonds 
0.010 
Acceptor:Donor-5.00 Number of pairs of acceptor-donor atoms within 5 
bonds 
0.010 
fr_pyridine Number of pyridine rings 0.010 
Acceptor:Aromatic-4.00 Number of pairs of acceptor-aromatic atoms 
within 4 bonds 
0.010 
Hydrophobe:Hydrophobe-3.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 3 bonds 
0.009 
fr_ArN Number of N functional groups attached to 
aromatics 
0.007 
Acceptor:Hydrophobe-5.00 Number of pairs of acceptor-hydrophobe atoms 
within 5 bonds 
0.007 
SlogP_VSA7 MOE-type descriptors, LogP and surface area 
contributions 
0.007 
Acceptor:Hydrophobe-4.00 Number of pairs of acceptor-hydrophobe atoms 
within 4 bonds 
0.006 
fr_amide Number of amides 0.005 
Tox_2 a[NH2] 0.003 
PosIonizable:PosIonizable-1.00 Number of pairs of posIonazable-posIonazable 
atoms within 1 bond 
0.003 
Donor:Donor-2.00 Number of pairs of donor-donor atoms within 2 
bonds 
0.003 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-posIonazable 
atoms within 2 bonds 
0.002 
Tox_12 [OH,NH2][N,O] 0.002 
fr_furan Number of furan rings 0.002 
Donor:PosIonizable-1.00 Number of pairs of donor-posIonazable atoms 
within 1 bond 
0.002 
fr_azo Number of azo groups 0.002 
fr_ketone Number of ketones 0.002 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-posIonazable 
atoms within 3 bonds 
0.002 
Aromatic:PosIonizable-1.00 Number of pairs of aromatic-posIonazable atoms 
within 1 bond 
0.002 
fr_thiazole Number of thiazole rings 0.002 
fr_unbrch_alkane Number of unbranched alkanes of at least 4 
members (excludes halogenated alkanes) 
0.001 
fr_C_S Number of thiocarbonyl 0.001 
fr_amidine Number of amidine groups 0.001 




Table S33. Feature importance for the regression model of PPI inhibitors targeting the XIAP / Smac 
complex. 
Feature Description Importance 
fr_Nhpyrrole Number of H-pyrrole nitrogens 0.120 
Acceptor:Hydrophobe-5.00 Number of pairs of acceptor-hydrophobe 0.056 
atoms within 5 bonds 
SMR_VSA9 MOE-type descriptors, molar refractivity 
and surface area contributions 
0.055 
Acceptor:Donor-6.00 Number of pairs of acceptor-donor atoms 
within 6 bonds 
0.054 
Donor:Donor-3.00 Number of pairs of donor-donor atoms 
within 3 bonds 
0.052 
Donor:Donor-2.00 Number of pairs of donor-donor atoms 
within 2 bonds 
0.050 
NOCount Number of Nitrogens and Oxygens  0.044 
Hydrophobe:PosIonizable-2.00 Number of pairs of hydrophobe-
posIonazable atoms within 2 bonds 
0.042 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic 
atoms within 3 bonds 
0.040 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-
posIonazable atoms within 4 bonds 
0.036 
Aromatic:Aromatic-2.00 Number of pairs of aromatic-aromatic 
atoms within 2 bonds 
0.031 
Donor:Hydrophobe-3.00 Number of pairs of donor-hydrophobe 
atoms within 3 bonds 
0.030 
Donor:Hydrophobe-4.00 Number of pairs of donor-hydrophobe 
atoms within 4 bonds 
0.027 
Aromatic:Aromatic-1.00 Number of pairs of aromatic-aromatic 
atoms within 1 bond 
0.026 
SMR_VSA10 MOE-type descriptors, molar refractivity 
and surface area contributions 
0.025 
Aromatic:Donor-5.00 Number of pairs of aromatic-donor atoms 
within 5 bonds 
0.021 
Hydrophobe_Count Number of hydrophobe atoms 0.021 
Acceptor:Aromatic-2.00 Number of pairs of acceptor-aromatic 
atoms within 2 bonds 
0.021 
fr_priamide Number of primary amides 0.020 
Acceptor:Hydrophobe-4.00 Number of pairs of acceptor-hydrophobe 
atoms within 4 bonds 
0.020 
fr_amide Number of amides 0.018 
Aromatic:Hydrophobe-2.00 Number of pairs of aromatic-hydrophobe 
atoms within 2 bonds 
0.018 
Hydrophobe:Hydrophobe-1.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 1 bond 
0.018 
Hydrophobe:Hydrophobe-3.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 3 bonds 
0.018 
Aromatic_Count Number of atoms in aromatic rings 0.017 
Acceptor:Hydrophobe-3.00 Number of pairs of acceptor-hydrophobe 
atoms within 3 bonds 
0.016 
Hydrophobe:Hydrophobe-4.00 Number of pairs of hydrophobe atoms 
within 4 bonds 
0.015 
Aromatic:Hydrophobe-1.00 Number of pairs of aromatic-hydrophobe 
atoms within 1 bond 
0.011 
Acceptor:PosIonizable-2.00 Number of pairs of acceptor-posIonazable 
atoms within 2 bonds 
0.011 
PosIonizable_Count Number of posIonazable atoms 0.010 
PosIonizable:PosIonizable-3.00 Number of pairs of posIonazable-
posIonazable atoms within 3 bonds 
0.008 
Acceptor:PosIonizable-3.00 Number of pairs of acceptor-posIonazable 
atoms within 3 bonds 
0.006 
PEOE_VSA3 MOE-type descriptors, partial charges and 
surface area contributions 
0.006 
PEOE_VSA8 MOE-type descriptors, partial charges and 
surface area contributions 
0.005 
VSA_EState8 MOE-type descriptors, surface area 
contributions and EState indices 
0.005 
SlogP_VSA11 MOE-type descriptors, LogP and surface 
area contributions 
0.005 
fr_Ar_N Number of aromatic nitrogens 0.004 
Acceptor:Hydrophobe-2.00 Number of pairs of acceptor-hydrophobe 
atoms within 2 bonds 
0.004 
Acceptor:Hydrophobe-1.00 Number of pairs of acceptor-hydrophobe 
atoms within 1 bond 
0.004 
PosIonizable:PosIonizable-6.00 Number of pairs of posIonazable-
posIonazable atoms within 6 bonds 
0.004 
Donor:Hydrophobe-2.00 Number of pairs of donor-hydrophobe 
atoms within 2 bonds 
0.002 
Acceptor:Acceptor-3.00 Number of pairs of acceptor-acceptor 
atoms within 3 bonds 
0.002 
Acceptor:PosIonizable-4.00 Number of pairs of acceptor-posIonazable 
atoms within 4 bonds 
0.001 
 
Table S34. Feature importance for general predictive model of PPI inhibitors activity (IC50). 
Feature Description Importance 
BalabanJ Balaban's connectivity topological index 0.071 
NumHeteroatoms Number of heteroatoms 0.057 
fr_C_O Number of carbonyl O 0.046 
Chi4v Molecular connectivity index 0.044 
SlogP_VSA5 MOE-type descriptors, LogP and surface 
area contributions 
0.04 
fr_amide Number of amides 0.035 
PEOE_VSA3 MOE-type descriptors, partial charges and 
surface area contributions 
0.033 
PEOE_VSA10 MOE-type descriptors, partial charges and 
surface area contributions 
0.032 
Acceptor:Aromatic-6.00 Number of pairs of aromatic-aromatic atoms 
within 6 bonds 
0.031 
Aromatic:NegIonizable-2.00 Number of pairs of aromatic-negIonazable 
atoms within 2 bonds 
0.031 
Hydrophobe:Hydrophobe-6.00 Number of pairs of hydrophobe-hydrophobe 0.029 
atoms within 6 bonds 
Donor:Donor-6.00 Number of pairs of donor-donor atoms 
within 6 bonds 
0.029 
SMR_VSA7 MOE-type descriptors, molar refractivity and 
surface area contributions 
0.029 
SlogP_VSA10 MOE-type descriptors, LogP and surface 
area contributions 
0.028 
Donor_Count Number of hydrogen donors 0.028 
PEOE_VSA8 MOE-type descriptors, partial charges and 
surface area contributions 
0.028 
fr_NH0 Number of Tertiary amines 0.027 
Hydrophobe_Count Number of hydrophobe atoms 0.027 
Hydrophobe:Hydrophobe-5.00 Number of pairs of hydrophobe-hydrophobe 
atoms within 5 bonds 
0.027 
fr_bicyclic Number of bicyclic structures 0.023 
SlogP_VSA12 MOE-type descriptors, LogP and surface 
area contributions 
0.022 
Aromatic:Aromatic-3.00 Number of pairs of aromatic-aromatic atoms 
within 3 bonds 
0.02 
Aromatic:Aromatic-6.00 Number of pairs of aromatic-aromatic atoms 
within 6 bonds 
0.02 
PosIonizable:PosIonizable-2.00 Number of pairs of posIonazable-
posIonazable atoms within 2 bonds 
0.019 
fr_methoxy Number of methoxy groups -OCH3 0.019 
Aromatic:Aromatic-5.00 Number of pairs of aromatic-aromatic atoms 
within 5 bonds 
0.019 
SlogP_VSA8 MOE-type descriptors, LogP and surface 
area contributions 
0.018 
fr_amidine Number of amidine groups 0.018 
fr_unbrch_alkane Number of unbranched alkanes of at least 4 
members (excludes halogenated alkanes) 
0.017 
Donor:PosIonizable-6.00 Number of pairs of donor-posIonazable 
atoms within 6 bonds 
0.014 
Hydrophobe:PosIonizable-4.00 Number of pairs of hydrophobe-
posIonazable atoms within 4 bonds 
0.013 
fr_phenol Number of phenols 0.013 
fr_ketone Number of ketones 0.013 
Hydrophobe:PosIonizable-6.00 Number of pairs of hydrophobe-
posIonazable atoms within 6 bonds 
0.012 
fr_ester Number of esters 0.011 
fr_phos_ester Number of phosphoric ester groups 0.009 
fr_guanido Number of guanidine groups 0.009 
fr_sulfide Number of thioether 0.007 
Aromatic:PosIonizable-6.00 Number of pairs of aromatic-posIonazable 
atoms within 6 bonds 
0.007 
Aromatic:PosIonizable-4.00 Number of pairs of aromatic-posIonazable 
atoms within 4 bonds 
0.006 
fr_phos_acid Number of phosphoric acid groups 0.006 
Donor:PosIonizable-3.00 Number of pairs of donor-posIonazable 
atoms within 3 bonds 
0.006 
Donor:PosIonizable-2.00 Number of pairs of donor-posIonazable 
atoms within 2 bonds 
0.006 
fr_term_acetylene Number of terminal acetylenes 0.002 
 
Table S35. Distribution of PPIs inhibitors retrieved from 3 databases: TIMBAL, iPPI-DB, 2P2I-DB. 
Number of compounds per PPI target is shown before and after clustering with Tanimoto similarity cutoff 
of 0.8. 
PPI # compounds # compounds (clustering 0.8) 
Integrins 1606 907 
Bromodomain / Histone 680 501 
MDM2-Like / P53 768 440 
LFA / ICAM 277 150 
BCL2-Like / BAX-BAK 386 149 
LEDGF / IN 158 122 
HIF-1a 121 82 
Cyclophilins 105 73 
XIAP / Smac 99 68 
Ras / SOS1 64 55 
WDR5/MLL 39 37 
CD80 / CD28 73 35 
BRD2 / Ack 47 32 
MENIN / MLL 49 32 
Annexin A2/S100-A10 44 29 
Keap1 / Nrf2 31 26 
Neuropilin / VEGF 41 24 
FKBP1A/FK506 29 21 
STAT3 38 21 
IL2 / IL-2R 36 18 
TTR 19 17 
VHL / HIF1-alpha 33 17 
Transthyretin 16 16 
BRD4 / NUT 16 15 
BetaCatenin / Tcf4 and Tcf3 40 15 
Rac1 15 15 
Tubulin 14 14 
SPIN1 / H3 15 10 
CIAP1-BIR3/CASPASE-9 10 9 
E2 / E1 11 9 
MLLT1 / H3 16 8 
DCN1/UBC12 7 7 
PCNA trimer 7 7 
c-Myc / Max 8 7 
SOD1 10 5 
RUNX1 / CBFb 4 4 
TNFa / TNFa 5 4 
VEGF / VEGFR 4 4 
ZipA / ftsZ 4 4 
53BP1 / H4 3 3 
WD40 / H3 3 3 
CRM1 / Rev 2 2 
NRP / VEGF 2 2 
UPAR / UPA 3 2 
BRI1 1 1 
CD4 / gp120 1 1 
CD40 / CD154 1 1 
CaM / CaMBD2 1 1 
Rad51 1 1 
TNFR1A / TNFB 1 1 








Figure S1 - Distribution of experimental IC50 values and property distribution of PPI inhibitors. The top-
left histogram shows the distribution of experimental IC50 values for all inhibitors in the dataset after 
clustering with Tanimoto similarity of 0.8, , in terms of -log10(Molar). The remaining histograms depict 
the distribution of common physicochemical properties of the compounds, including molecular weight 
(in Da), logP, number of hydrogen acceptors and donors, and number of rings. 
 
 
Figure S2. Frequent substructures within the dataset of PPI inhibitors. More potent (IC50 < 1uM) 
compounds are enriched with ring substructures, including biphenyls.  
 
 
Figure S3. ROC curves for class-specific predictors during training under 10-Fold cross-validation and 
non-redundant test sets. 
 
 




Figure S5. ROC curves for class-specific predictors with a limited number of inhibitors. Given the lack 




Figure S6. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
BCL2-Like / BAX-BAK complex. A) depicts distribution on the set of molecules used for training the 
regression model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S7. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
Bromodomain / Histone complex. A) depicts distribution on the set of molecules used for training the 
regression model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S8. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
HIF-1a / p300 complex. A) depicts distribution on the set of molecules used for training the regression 
model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S9. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
Mdm2-Like / P53 complex. A) depicts distribution on the set of molecules used for training the 
regression model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S10. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
Integrins complex. A) depicts distribution on the set of molecules used for training the regression model 
and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S11. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
LFA / ICAM complex. A) depicts distribution on the set of molecules used for training the regression 
model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S12. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
Cyclophilins complex. A) depicts distribution on the set of molecules used for training the regression 
model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S13. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
LEDGF / IN complex. A) depicts distribution on the set of molecules used for training the regression 
model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S14. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors targeting the 
XIAP / Smac complex. A) depicts distribution on the set of molecules used for training the regression 
model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S15. Distribution of PPI half maximal inhibitory concentration (IC50) for inhibitors used to build 
the general predictor of PPI inhibitory activity. A) depicts distribution on the set of molecules used for 
training the regression model and B) on the non-redundant test set. IC50 values are shown as -log10. 
 
 
Figure S16. Distribution of PPI inhibitors retrieved from 3 different databases: TIMBAL, iPPI-DB and 
2P2I-DB. 
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ABSTRACT
Protein phosphorylation is tightly regulated due to
its vital role in many cellular processes. While gain
of function mutations leading to constitutive activa-
tion of protein kinases are known to be driver events
of many cancers, the identification of these muta-
tions has proven challenging. Here we present Kin-
act, a novel machine learning approach for predict-
ing kinase activating missense mutations using in-
formation from sequence and structure. By adapting
our graph-based signatures, Kinact represents both
structural and sequence information, which are used
as evidence to train predictive models. We show the
combination of structural and sequence features sig-
nificantly improved the overall accuracy compared to
considering either primary or tertiary structure alone,
highlighting their complementarity. Kinact achieved
a precision of 87% and 94% and Area Under ROC
Curve of 0.89 and 0.92 on 10-fold cross-validation,
and on blind tests, respectively, outperforming well
established tools (P < 0.01). We further show that
Kinact performs equally well on homology models
built using templates with sequence identity as low
as 33%. Kinact is freely available as a user-friendly
web server at http://biosig.unimelb.edu.au/kinact/.
INTRODUCTION
The ability of cells to recognize and correctly respond to
their microenvironment is crucial for survival. In order
to dynamically respond to cellular signals, fast dynamic
switches are required. Protein phosphorylation is the most
widespread type of post-translational modification, with
over one-third of the proteins in the human proteome phos-
phorylated (1). The dynamic equilibrium between phospho-
rylation and dephosphorylation is stringently regulated,
and provides a rapid mechanism to modulate protein be-
haviour and activity across most signalling pathways (2).
Loss of control over this regulation process, through the
introduction of dominant activating mutations in kinases
and the consequent hyperphosphorylation of their targets
can have many phenotypic consequences, including the de-
velopment and metastasis of many cancers (3–7), and the
development of other metabolic disorders (8).
Advances in next generation sequencing techniques are
leading to the identification of a range of novel mutations,
including in kinases. In the absence of experimental infor-
mation, it is currently challenging to identify mutations
that are likely to lead to constitutive activation of kinases.
While many computational approaches have been proposed
for predicting the effects of mutations that disrupt activity,
these approaches have been shown to be of limited success
to predict gain of function mutations, as also shown on this
work, despite the important roles they play in many dis-
eases, particularly in cancer.
To fill this gap, here we present Kinact, a machine
learning-based predictive model and web server. Using our
graph-based signatures, the method was tailored to accu-
rately identify kinase activating mutations from a combina-
tion of sequence and structural information.
MATERIALS AND METHODS
Data sets
Mutations were derived from three mutational databases
with experimental evidence of their functional consequence:
Kindriver (9); ClinVar (10); and Ensembl (11). Kinase mu-
tations were divided into two groups based upon the avail-
able experimental evidence: activating and non-activating
mutations. The non-activating group is represented by vari-
ations that either disrupt activity (inactivating) or have no
significant biological effect (neutral). The activating muta-
tions were defined by a significant experimentally measured
increase in kinase activity.
The complete data set contained 384 mutations (260 ac-
tivating and 124 non-activating) distributed across 42 pro-
teins, of which 256 (186 activating and 70 non-activating)
could be mapped onto experimentally solved 3D structures.
Supplementary Figures S1 and S2 of Supplementary Mate-
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rials summarises the composition and the class distribution
of mutations over the data set.
The dataset of mutations with experimental structures
available, which account for 256 mutations, was randomly
split into training and blind test sets. The proportion of ac-
tivating and non-activating mutations on training and blind
test sets is similar to observed on the original dataset as an
attempt to prevent bias on the final method. The training
set is comprised of 179 mutations (130 activating and 49
non-activating) that were used to train Kinact under 10-
fold cross validation. The remaining 77 (56 activating and
21 non-activating) were used as blind test for validating the
predictive model, minimizing the risk of overfitting. In or-
der to assess the quality of the sub sets selected for training
and blind test we repeated this process 20 times and the fi-
nal version of the web server was built using the predictive
model with best performance. Average and standard devia-
tion values are reported on Supplementary Materials.
In addition, 41 mutations (24 activating and 17 non-
activating in 14 kinases) that did not have experimentally
solved structures available, therefore were not part of the
original 256 mutations, had their structure modelled using
homology modelling for further evaluation of Kinact pre-
dictive performance as a blind test.
Feature engineering
The task of predicting and understanding the effects of mu-
tations in proteins at a molecular level has been tackled
by approaches using different biological features, each with
their own assumptions and limitations. Protein structural
and sequence features have been the two most popular cat-
egories of attributes used by these computational methods.
Sequence-based features have focussed predominantly on
the analysis of sequence residue conservation throughout
a protein family and homologs (12) and sequence compo-
sition (13). By contrast, previous studies have used a wide
range of structural features, including secondary structure,
solvent accessibility and dihedral angles (14,15). Significant
effort has also been employed on more computationally in-
tensive approaches to model mutation effects from the use
of force fields and energy terms, to molecular dynamics sim-
ulations (16,17).
As an alternative, the use of graph-based structural sig-
natures have been shown to be a scalable and effective
approach for modeling the residue environment, which
was successfully employed to train machine learning-based
methods to predict and elucidate effects of mutations on
protein stability and interactions with their partner (18–26).
Moreover, these have also been used to provide insights into
the molecular mechanisms of mutations and how they lead
to disease and disease predisposition (27–33) and drug re-
sistance (34–41). These graph-based signatures are predom-
inantly composed of distance patterns extracted from the
wildtype residue environment, which together with a phar-
macophore modelling of its components, has been shown
to be an effective way to model both geometry and physic-
ochemical composition of protein regions.
Despite these diverse range of approaches, a combina-
tion of sequence and structural information has also been
proven to be valuable when predicting damaging muta-
tions (42,43). Based on these assumptions, graph-based sig-
natures together with complementary sequence and struc-
tural information were used to build a predictive model.
This complementary information included: (a) wild-type
residue environment descriptors, (b) wild-type residue inter-
actions, (c) predicted stability changes upon mutation, (d)
sequence-based predicted effects on protein function and (e)
the mCSM mutation pharmacophore modelling. A total of
82 different attributes (72 structural and 10 sequence-based)
were calculated for each mutation in our dataset. These were
then provided as evidence to train and test supervised learn-
ing algorithms using the Weka Tool Kit (44). The attributes
used on this work were categorised into six different groups
and summarised in Supplementary Table S1 of Supplemen-
tary Materials.
WEB SERVER
We have implemented Kinact as a user-friendly, freely avail-
able web server (http://biosig.unimelb.edu.au/kinact/). The
server front end was built using Bootstrap framework ver-
sion 3.3.7, while the back-end was built in Python via the
Flask framework (Version 0.12.2). It is hosted on a Linux
server running Apache.
Input
The server provides two different input options for the user
(Supplementary Figure S4). The ‘Single mutation’ option
allows users to predict whether a given mutation will lead
to protein kinase activation or not. This option requires the
user to provide a PDB (45) file or PDB accession code of
the kinase, the point mutation specified as a string contain-
ing the wild-type residue one-letter code, its corresponding
residue number and the mutant residue one-letter code, and
the chain identifier of the wild-type residue. The primary
sequence of the kinase of interest in fasta format is also re-
quired. The ‘Mutation list’ option allows users to upload a
list of mutations in a file for batch processing. In order to
aid users to submit their jobs, sample submission entries are
available on the submission page and a help page is available
via the top navigation bar.
Output
For the ‘Single mutation’ option, as shown in Figure 1, the
web server displays in the output page the prediction out-
come of Kinact, the details of the user input data, such as
structure of wild-type and mutant residues, and also infor-
mation on the kinase group in which the submitted struc-
ture was assigned to, based on sequence similarity accord-
ing to the Standard Kinase Classification Scheme (46).
In addition, Kinact provides a set of analyses to help
users investigate in greater detail the impact of the mutation.
All resources displayed within the analysis section, includ-
ing Pymol Sessions and the Multiple Sequence Alignment
in fasta format, are made available for download.
The first item in the analysis section (Supplementary
Figure S5) allows users to explore the 3D structure and
the inter-residue interactions established by the wild-type
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Figure 1. Web server results page for a single mutation prediction. The predicted outcome is shown alongside with complementary information on the
submitted protein and the details of the mutation being evaluated. In addition, Kinact displays information on the group of homologue protein kinases
according to the Standard Kinase Classification Scheme. The effects of mutation on protein stability calculated by mCSM (21), SDM (43) and DUET (25)
are also shown.
also explore the conservation of residues with the struc-
ture of the wild-type kinase (Supplementary Figure S6).
The 3D structure of the kinase of interest is displayed
and colored according to conservation within the kinase
sub-group, from red (not conserved) to blue (conserved).
The structures are displayed in an interactive viewer imple-
mented with 3Dmol.js (48).
Finally, users can also explore, within the analysis sec-
tion, a multiple sequence alignment of the sequence of the
provided structure and those from the closest kinase group
according to the Standard Kinase Classification Scheme,
assigned by similarity (Supplementary Figure S7). Previ-
ously experimentally characterised point mutations within
any kinases of the group are highlighted, enabling users to
rapidly identify through homology the effect of mutations
at the corresponding residue position.
For the ‘Mutation list’ option, the server output is shown
as a downloadable table (Supplementary Figure S8) and
users also have the option to analyse each mutation sepa-
rately, similarly to what was described for the ‘Single muta-
tion’ option.
VALIDATION
In order to evaluate the quality of the training and blind
test sets used we performed a resampling of these subsets
20 times and evaluated the performance of the predictive
model on each split using AUC and precision. All values
for the blind tests are reported on Supplementary Materi-
als for each sample. Average and standard deviation are also
shown and no bias was identified. Here we compare the per-
formance of the best predictive model of Kinact with widely
used tools to study the effects of mutations in proteins func-
tions PolyPhen2 (42), SIFT (12) and wKinMut2 (49), a tool
to identify and interpret pathogenic variants in human pro-
tein kinases.
Performance on cross validation
In order to better evaluate the contribution of structure and
sequence-based attributes on the performance of supervised
learning algorithms, three different predictive models were
generated. The first model uses only attributes that rely on
protein sequence information, which include mutation tol-
erance predictions (12,42), as well as a pharmacophore dif-
ference vector between wild-type and mutant residues, as
proposed by the mCSM signatures (21), for this model we
used the complete original dataset of 384 mutations. The
second model uses only structural attributes calculated us-
ing the experimental structural data from the PDB. These
include the graph-based structural signatures and comple-
mentary descriptors described in Supplementary Table S1
of Supplementary materials. Finally, the third model was
constructed based on a combination of all attributes, us-
ing both sequence and structural data. For the models that
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Figure 2. Comparative performance of Kinact. The ROC curves obtained for the training data set for models using sequence information alone, structural
information alone, and the Kinact combined model is shown in (A). Kinact (AUC of 0.89), performs significantly better (P-value < 0.01) than the models
using either just sequence or structural data (AUC of 0.77 and 0.83, respectively). In order to compare the performance of Kinact against the widely
used tools SIFT, PolyPhen-2 and wKinMut2, a blind test (B) over a non-redundant test was evaluated and Kinact (AUC of 0.96) significantly (P-value <
0.01) outperformed all three methods (AUC of 0.54, 0.70 and 0.52, respectively). Using homology models (C), Kinact was also able to accurately identify
activating mutations (AUC of 0.77), and again outperformed the other methods.
dataset of mutations with experimental structure available,
which accounts for 256 mutations.
In order to run and assess the performance of the ma-
chine learning algorithms, we split each dataset into 70% of
the mutations for training and 30% for blind test. In that
sense, for the model that uses only sequence-based data we
used 268 mutations for training (182 activating and 86 non-
activating) and 116 for blind test (77 activating and 39 non-
activating). For the other two models that used structure-
based features 179 mutations were used for training and 77
mutations for blind test as previously described. All mod-
els were trained under 10-fold cross validation. Supplemen-
tary Figure S3 of Supplementary Materials summarises the
distribution of activating and non-activating mutations in
training and blind test sets for all models. Machine learning
methods, evaluation procedures and performance metrics
used are described in Supplementary Data.
A series of experiments were carried out to assess the per-
formance of Kinact to predict whether a given mutation
was likely to lead to constitutive activation of a kinase. The
ROC curves across the training data set for models using
sequence information alone, structure-based features alone,
and the Kinact model that combines both attribute classes
are shown in Figure 2. Details on the evaluation metrics
for each algorithm are summarised on Supplementary Ta-
bles S2-S4 in Supplementary materials. Across the complete
training set, Kinact achieved a Precision of 87% and Area
Under ROC Curve of 0.89, significantly higher than the
models using either just sequence or structural data (AUC
of 0.77 and 0.83, and Precision of 0.78 and 0.81, respec-
tively, P < 0.01). The final predictive models were trained
using the full training set and all the performance evalua-
tion metrics were calculated considering the average values
for all 10 folds from cross validation.
Blind test
In order to properly evaluate the method’s predictive per-
formance and generalization, Kinact was initially evaluated
against a separate, independent, non-redundant blind test
set comprised of 77 missense mutations in protein kinases
with available experimental structures, achieving a precision
of 97% and Area Under ROC Curve of 0.96. When compar-
ing with other methods, Kinact significantly outperformed
(Figure 2B) all three methods (P-value < 0.01). Looking
specifically at the activating mutations, SIFT predicted 55%
of mutations as deleterious (score < 0.05), PolyPhen-2 clas-
sified 84% as probably damaging (score > 0.85), and wKin-
Mut2 predicted 62% of mutations as disease related (score
> 0), while Kinact correctly classified 99% of them. Com-
parisons of Kinact with tools that assess the effects of mu-
tations on protein stability are described on Supplementary
Materials.
Homology models
The performance of the web server to accurately classifying
mutations using homology models was evaluated using a set
of 41 mutations in kinases without experimentally resolved
structures. Homology models of the kinases were generated
by Modeller (50) using experimentally resolved structures
down to 33% sequence identity. Using the homology mod-
els, Kinact was able to accurately identify activating muta-
tions (AUC of 0.77 and precision of 0.78), providing confi-
dence and robustness in the applicability of this approach
beyond experimental structures to those that are compu-
tationally modelled. This was also significantly better than
PolyPhen-2, SIFT and wKinMut2 (Figure 2C). When com-
paring the performance of the methods specifically at the
activating mutations, Kinact was able to classify correctly
100% of mutations, while SIFT predicted 75% as deleteri-
ous (score < 0.05), PolyPhen-2 classified 83% as probably
damaging (score > 0.85), and wKinMut2 predicted 77% as
disease related (score > 0).
CONCLUSION
We present here, Kinact, a predictive model and web server








127/5000015 by Alfred H
ealth user on 20 O
ctober 2020
Nucleic Acids Research, 2018, Vol. 46, Web Server issue W131
graph-based signatures, sequence and structural data. Kin-
act conveniently combines high-performance, open access,
web visualization tools to assist research on how mutations
affect protein kinases activity as well as prioritise mutations
for further investigation. Given the importance of these
variants in the context of many diseases, especially on the
development of many types of cancer, and also that widely
used tools have not been able to successfully predict gain of
function mutations, we believe Kinact will be a useful tool
to help identify and understand the role of these mutations.
The method is freely available as a user friendly and easy to
use web server at http://biosig.unimelb.edu.au/kinact/.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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EVALUATION METRICS
A set  of  well-established  and  widely  used  performance  metrics  for  classification
algorithms were used to evaluate Kinact on both 10-fold cross validation and on blind
tests. These metrics include Area Under ROC Curve (AUC), Precision, Recall and F-
Measure.  Such  measurements  are  expressed  based  on  the  values  of  a  binary
contingency table, also known as a confusion matrix (Figure S1), where the classes
are represented by convention as + (positive) and - (negative) signs.
Figure 1 - Confusion matrix (actual vs. predicted). True and False Positives (TP and FP) indicate the
number of predicted positives that were correctly and incorrectly classified, respectively.  Similarly,
True and False Negatives (TN and FN) refer to correct and wrong predictions for the negative class.
The sum TP+FP+TN+FN is equal to the total amount number of instances in the data set being used.
Area Under ROC Curve (AUC)
The measure of Area Under the ROC Curve (AUC or AUROC) considers the True
Positive Rate (TPR), also known as sensitivity, that corresponds to the proportion of
positive data points  that are correctly considered as positive; and also the False
Positive Rate (FPR) that corresponds to the proportion of negative data that are
wrongly  considered  as  positive,  regarding  all  negative  data  points.  A Receiver
Operating Curve (ROC) is then plotted using TPR versus FPR and the AUC is the
area under such curve (1). Like precision, recall and f-measure, AUC values range
from 0 to 1, which the later denoting a perfect classifier. A random binary classifier
would generate an AUC of 0.5.
Precision
Precision  denotes  the  proportion  of  Predicted  Positive  cases  that  are  Actual
Positives. It is defined by TP/(TP+FP).
Recall
Recall  is  defined  as  the  proportion  of  Predicted  Positives  cases  that  are  Actual
Positives over all Predicted Positives. Using the convention defined in Figure S1, it is
defined as TP/(TP+FN).
F-Measure






Several classification algorithms from different paradigms implemented on the Weka
Tool Kit (2) were considered during training. 
Random Forest
The Random Forest algorithm uses a combination of decision tree predictors such
that each tree depends on the values of a random vector sampled independently and
with the same distribution for all  trees in the “forest”. The generalization error for
forests converge to a limit as the number of trees in the forest become large (3). It is
a  fast  and  relatively  easy  to  implement  algorithm,  produce  highly  accurate
predictions and can handle a very large number of input variables without overfitting,
given that all the trees are built from scratch without any previous information on the
other  trees  in  the  forest  and  also  the  final  prediction  is  the  average  of  all  the
predictions for  each tree.  In fact,  it  is  considered to be on of  the most  accurate
general-purpose learning techniques available.
Classification by Regression with M5P
Classification via regression handles the discrete classes (nominal) of the data set
as continuous labels (probability)  in  a  probabilistic  classification manner  (4).  The
classification is achieved by defining a threshold, for example a prediction with a
probability  ŷ  <  0.5  indicates  non-activating and consequently  ŷ  >= 0.5  results  in
activating  output  prediction,  also  known  as  linear  decision  boundary.  Thus,
algorithms that use this type of classification seeks for a model that generates the
greatest approximate probability function that separates the classes in the dataset. In
this sense, for the scope of this work, we used the Decision Trees M5P (5).
MLP
Multi-Layer  Perceptron,  also  known  as  MLP,  is  a  feed-forward  neural  network,
consisting of many units, called neurons, which are connected by weighted links.
The units are organised in several layers, namely an input layer, one or more hidden
layers, and an output layer. The input layer receives an external activation vector,
and forwards it via weighted connections to the units in the first hidden layer. These
compute their activations and pass them to neurons in succeeding layers. From a
distal  point  of  view,  an  arbitrary  input  vector  is  propagated  forward  through  the
network,  finally  causing  an  activation  vector  in  the  output  layer  (6).  The  entire
network function, that maps the input vector onto the output vector is determined by
the connection weights of the network.
Decision Tree - J48
A decision tree is an algorithm that simulates trees that classify instances by sorting
them based on feature values. Each node in a decision tree represents a feature in
an instance to be classified, and each branch represents a value that the node can
assume. Instances are classified starting at the root node and sorted based on the
feature values. The basic assumption made in the decision trees is that instances
with different classes have different values in at least one of their features. One of
the most useful characteristics of such algorithm is their comprehensibility. One can
easily understand why the algorithm classifies an instance as belonging to a specific
class by just looking at the generated tree and analyzing its rules (7). In this sense,
the  J48  algorithm  is  a  variation  of  the  C4.5  and  ID3  algorithms  (8) that  uses
information theory principles to evaluate how “good” an instance is, in the sense that
it chooses the test that extract the maximum amount of information from a given set
of cases.
QUALITY ASSESSMENT OF TRAINING AND BLIND TEST SETS
In order to evaluate the quality of the training and blind test sets we performed a
resampling  of  these  subsets  20  times  and  evaluated  the  performance  of  the
predictive model on each split using AUC and precision. All values for the blind tests
are reported below with averages and standard deviations at the bottom of the table.
The split with best performance, which was the one used to build the final version of
the server is highlighted.
TABLE 1 – Performance evaluation for 20 resamplings of training and blind sets. AUC and Precision























Standard Deviation (σ) 0.02 0.02
COMPARISON WITH METHODS THAT ASSESS THE EFFECTS OF MUTATIONS 
ON PROTEIN STABILITY
In order to understand the relationship between the scores for predicted effects of
mutations on stability given by mCSM, SDM, DUET and I-Mutant2 and the validation
status  of  the  mutations  on  protein  kinases  in  our  dataset  (activating  and  non-
activating), also comparing their predictive performance with Kinact, the distributions
of all four scores for each status separately were analysed. We performed t-test with
a 95% confidence interval to evaluate whether a significant difference between the
scores for the two classes existed. No significant difference was observed. These
analyses were summarised on the figure below.
Figure 2 –  Distribution of values for mCSM, SDM, DUET and I-Mutant2 for each validation status
(Activating and Non-activating) on the blind test used to validate Kinact. T-test with 95% confidence
interval was performance and no significant difference was observed for none of the scores.
A similar analysis was performed for the subset of mutations on structures modelled
by  homology  modelling  and  again  no  statistical  difference  was  observed.  The
distributions for each score is represented on the boxplots on the figure below.
Figure 3 –  Distribution of values for mCSM, SDM, DUET and I-Mutant2 for each validation status
(Activating and Non-activating) on the set of mutations mapped on structures generated by homology
models, also used to validate Kinact. T-test with 95% confidence interval was performance and no
significant difference was observed for none of the scores.
In addition, as an attempt to compare Kinact predictive performance with these tools
using  AUC metric,  we considered stability  scores  below 0  as non-activating and
above 0 as activating. The performance of all methods on blind test set and also on
a set with homology models are shown on the figure below.
Figure 4 – Comparison of Kinact with well-established predictive methods that assess the effects of
mutations on protein stability. Scores below 0 were considered non-activating and above 0 activating
for mCSM, SDM, DUET and I-Mutant2.
Not surprisingly, Kinact outperformed all three methods on both test sets, given the
fact that it was built specifically for the identification of gain of function mutations in
protein kinases while the other tools were specifically built for the general purpose of
understanding the effects of mutations on protein stability. In that sense, we strongly
believe that Kinact and the other tools provide different information regarding the
effects of mutations on proteins kinases and can be valuable tools for the study of
these  variants  and  the  molecular  mechanism  of  activation  of  these  proteins.
Moreover, given the importance of these variants in the context of many diseases,
especially on the development of many types of cancer, we believe Kinact will be a
useful tool to help identify and understand the role of these mutations.
TABLES
Table S1 - Description of categories of attributes generated. The table presents a short summary of
the attributes and the data and tools used for their calculation. 
Category of attributes Attributes Rely on Tools
Wild-type  residue
environment 
type  of  secondary  structure,  solvent
accessibility,  residue  depth,  dihedral
angles,  flexibility,  minimum  distance  to






clash, covalent, Van der Waals clash, vdw,
proximal,  hydrogen  bond,  weak  hydrogen
bond, halogen bond, ionic, metal complex,
aromatic,  hydrophobic,  carbonyl,  polar
hydrogen bonds without angles, weka polar
weak hydrogen bonds without angles
Structure Arppegio
Structural signatures distance patterns among the atoms of the
structure based on graph modeling
Structure mCSM
Stability  change  upon
mutation













Table S2 - Results for all classifiers trained with sequence-based features in each one of the mutation
classes. Best performing model is highlighted.
Classifier Precision Recall F-Measure AUC Class
MLP 0,764 0,823 0,793 0,619 Activating
MLP 0,425 0,340 0,378 0,619 Non-activating
Regression (M5P) 0,730 0,915 0,812 0,617 Activating
Regression (M5P) 0,353 0,120 0,179 0,617 Non-activating
Random Forest 0,775 0,877 0,823 0,769 Activating
Random Forest 0,659 0,482 0,557 0,769 Non-activating
J48 Tree 0,750 0,877 0,809 0,531 Activating
J48 Tree 0,429 0,240 0,308 0,531 Non-activating
Table S3 - Results for all classifiers trained with structure-based features in each one of the mutation
classes. Best performing model is highlighted.
Classifier Precision Recall F-Measure AUC Class
MLP 0,784 0,790 0,787 0.775 Activating
MLP 0,602 0,600 0,600 0,755 Non-activating
Regression (M5P) 0,810 0,843 0,826 0,793 Activating
Regression (M5P) 0,722 0,665 0,692 0,793 Non-activating
Random Forest 0,873 0,862 0,867 0,833 Activating
Random Forest 0,715 0,680 0,697 0,833 Non-activating
J48 Tree 0,794 0,812 0,802 0,713 Activating
J48 Tree 0,659 0,613 0,635 0,713 Non-activating
Table S4 - Results for all  classifiers trained with the training test  of  mutations with structural and
sequence-based features. Results are presented for both classes of mutations. Best performing model
is highlighted.
Classifier Precision Recall F-Measure AUC Class
MLP 0,884 0,931 0,907 0,885 Activating
MLP 0,791 0,680 0,731 0,885 Non-activating
Regression (M5P) 0,885 0,939 0,911 0,883 Activating
Regression (M5P) 0,810 0,680 0,739 0,833 Non-activating
Random Forest 0,860 0,939 0,898 0,885 Activating
Random Forest 0,789 0,730 0,758 0,885 Non-activating
J48 Tree 0,874 0,901 0,887 0,783 Activating
J48 Tree 0,717 0,660 0,688 0,783 Non-activating
FIGURES
Figure S1  - Distribution of mutations and validations status. A) shows the distribution of mutations
regarding the subsets of origin (Kin-driver, Clinvar and Ensembl) that were used for data collection.
Most  of  the data  was obtained  from Kin-driver  followed by Ensembl  and Clinvar.  B)  depicts  the
distribution of validation status (activating, non-activating) of mutations across the entire data set.
Figure  S2 -  Summary  of  number  of  mutations  per  protein  within  the  data  set  of  384  mutations
collected for this work. The top 3 proteins with highest number of mutations are BRAF, EGFR and
CHK2 with 44, 36 and 30 mutations respectively. Bars are colored according to the class of mutations:
blue  bar  indicates  the  amount  of  non-activating  mutations  and  red  bar  indicates  the  amount  of
activating ones.
Figure S3 - Distribution of mutations in training and blind test sets used to build the final predictive
model.  The complete  set  of  mutations was divided into  two groups.  The first  comprising all  384
mutations identified during data collection. The second group contains only those mutations that had
their region mapped into structures on the PDB. Each group is split into data for training and blind test
of  the  machine  learning  algorithms.  A)  displays  the  distribution  of  the  two  classes  of  mutations
(activating and non-activating) over the set of mutations used in training for data without structural
mapping. B) presents the distribution of the two classes of mutations for the blind test on the same
type of data. C) and D) introduces the class distribution for training and blind test, respectively, for
mutations that had their region mapped into 3D structures of PDB.
Figure S4 – Input page of Kinact. The server provides two different input options for the user. The
"Single mutation" option allows users to predict whether a given mutation will lead to protein kinase
activation or not. Users are required to provide a PDB file or PDB accession code of the kinase, the
point mutation specified as a string containing the wild-type residue one-letter code, its corresponding
residue number and the mutant residue one-letter code, and also the chain identifier of the wild-type
residue. The primary sequence of the kinase of interest in fasta format is also required. The "Mutation
list" option allows users to upload a list of mutations in a file for batch processing.
Figure S5 - Interatomic Interactions of Wild-Type Residue on Kinact Results page. By default, the
molecule is displayed using the cartoon representation with the wild-type residue highlighted as stick
and labeled, as well as the surrounding residues that make interactions with it according to Arpeggio.
On the top of the page, a set of options allow the user to customise the viewer and a legend is also
provided for the binding types.
Figure S6 - Conservation analysis within Homologue Group of Kinases on Kinact Results page. 3D
structure  is  colored  according  to  residue  conservation  varying  from red  (not  conserved)  to  blue
(conserved). Wild-type residue is labeled.
Figure S7 - Multiple Sequence Alignment of Kinase Groupon Kinact Results page. This section shows
the Multiple Sequence Alignment with the proteins of the group in which the submitted molecule was
assigned according to Kinannote. All residues are colored by their type: Polar as pink, Hydrophobic as
light green, Charged as blue and Sulphur as orange. Activating mutations are highlighted with red
background. A legend is shown on top of the page.
Figure S8 - Kinact Results page for a list of mutations. A table with the prediction outcome for each of
the  submitted  mutations.  The  detail  button  allows  users  to  perform  analysis  for  each  mutation
individually, similar to those described for the ‘Single Mutation’ option.
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ABSTRACT
Protein–protein interactions play a crucial role in all
cellular functions and biological processes and mu-
tations leading to their disruption are enriched in
many diseases. While a number of computational
methods to assess the effects of variants on protein–
protein binding affinity have been proposed, they are
in general limited to the analysis of single-point mu-
tations and have been shown to perform poorly on
independent test sets. Here, we present mmCSM-
PPI, a scalable and effective machine learning model
for accurately assessing changes in protein–protein
binding affinity caused by single and multiple mis-
sense mutations. We expanded our well-established
graph-based signatures in order to capture physico-
chemical and geometrical properties of multiple wild-
type residue environments and integrate them with
substitution scores and dynamics terms from nor-
mal mode analysis. mmCSM-PPI was able to achieve
a Pearson’s correlation of up to 0.75 (RMSE = 1.64
kcal/mol) under 10-fold cross-validation and 0.70
(RMSE = 2.06 kcal/mol) on a non-redundant blind
test, outperforming existing methods. Our method
is freely available as a user-friendly and easy-to-use




Protein-protein interactions (PPIs) are a vital mechanism
for regulation and coordination of most biological pro-
cesses within the cell (1,2). Missense mutations are known
to directly contribute to function disruption and are en-
riched at their interacting interface in many diseases (3–
7). The ability to elucidate the underlying mechanisms by
which point mutations affect PPI interactions is therefore
essential for understanding how to modulate these interac-
tions and the development of therapeutics to target them.
Significant effort in the creation of manually curated
databases compiling experimental data on the effects of mu-
tations on protein stability and PPI binding affinity, most
notably ThermomutDB (8), ProTherm (9), PROXiMATE
(10) and SKEMPI (11,12), has greatly facilitated studies
aiming to understand and predict how missense mutations
affect PPIs. However, these have shown to perform poorly
on independent test sets and are usually limited to predict-
ing effects of single-point mutations. Furthermore, to the
best of our knowledge, little effort has been made towards
accessibility of these methods to help integration into other
analysis pipelines.
We have shown previously that representing protein
structure as a graph is a powerful method for extracting
structural signatures as distance patterns (13). These com-
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pile geometrical and physicochemical properties which can
further be mined and applied in a broad range of areas,
such as predicting the effects of single-point missense mu-
tations on protein stability (14–18), dynamics (16,17), inter-
actions (15,19–25), genetic diseases (26–38) and drug resis-
tance (39–53).
Here, we introduce mmCSM-PPI, a scalable and effec-
tive predictive model for assessing changes in PPI bind-
ing affinity caused by multiple missense mutations. We ex-
panded our well-established graph-based signatures to al-
low for capturing physicochemical and geometrical prop-
erties of multiple wild-type residue environments, and inte-
grate them with evolutionary scores, dynamics terms from
Normal Mode Analysis (NMA) and non-covalent interac-
tions for an accurate overall prediction (Figure 1).
MATERIALS AND METHODS
Data sets
The data used in this work was derived from SKEMPI2
(12), a manually curated database of experimental data
on thermodynamics and kinetic parameters for wildtype
and mutant protein–protein complexes which have been
mapped to protein structures available on the Protein Data
Bank (54). We were able to retrieve experimental informa-
tion on 1721 multiple mutations, ranging from 2 to 27 point
mutations, across 147 different protein–protein complexes
(Supplementary Table S1). These had been primarily exper-
imentally characterised by surface plasmon resonance and
fluorescence methods (Supplementary Table S2 and Supple-
mentary Figure S1).
Wild-type and mutant binding affinity parameters from
SKEMPI2 were used to calculate the Gibbs free energy of
binding as follows:
Gbinding = RTln (KD)
where R = 1.9872 cal/K·mol is the ideal gas constant, T is
the temperature (in K) and KD is the affinity of the protein–
protein complex.
The change in binding affinity upon mutation was
calculated with the formulation previously described in
SKEMPI2 and used in previous works:
Gbinding = GbindingWT − GbindingMT
With positive values denoting mutations leading to an
increased affinity and negative values denoting decreased
binding affinity, given in kcal/mol. As shown in Supplemen-
tary Figure S2, the majority of entries in our dataset (1126)
comprise double and triple mutants and for this work these
were used as evidenced to train our predictive model. Fur-
thermore, we explored the performance of our method on
low-redundancy sets at complex and binding interface level
according to the definition used in SKEMPI2. The remain-
ing 595 multiple point mutations (2 neutral, 153 increasing
and 440 decreasing affinity), ranging from 4–27 mutations,
were held out and used as a non-redundant blind test at mu-
tation level for performance comparison.
The distribution of Gbinding (Supplementary Figure
S3A) depicts a clear bias towards mutations that decrease
binding affinity (Gbinding < 0 kcal/mol) in the train-
ing set. To minimize the imbalance nature of the dataset
and how it would affect our predictive model, we also in-
cluded modelled hypothetical reverse mutations in the train-
ing set (55,56). Unlike previous implementations, however,
here we only modelled hypothetical reverse mutations for
entries where –0.5 kcal/mol < Gbinding < 0.5 kcal/mol
to minimize uncertainties about the quality and biological
implications of the modeled mutant structure (17). There-
fore, the final training set used in this study includes 1344
entries, 12 neutral (Gbinding = 0 kcal/mol), 347 increas-
ing (Gbinding < 0 kcal/mol) and 985 decreasing binding
affinity (Gbinding > 0 kcal/mol). All datasets used for
training and test are freely available at http://biosig.unimelb.
edu.au/mmcsm ppi/data.
Graph-based signatures
Our graph-based structural signatures framework is a well-
established approach used to represent physicochemical
and geometrical properties of protein structure and small
molecules. In the past decade, our method has been widely
used for assessing the effects of single point-mutations
on protein stability (14–16,18), PPI and antibody-antigen
binding affinity (15,19,23,25), and small molecules toxicity
(57–59). More recently, we have successfully expanded the
applicability of our approach to investigate the impact of
multiple point-mutations on protein stability (17) and on
antibody-antigen binding affinity (24).
In this work, for each point-mutation, our signatures rep-
resent atoms of the wild-type residues as nodes and their
interactions as edges, where their physicochemical prop-
erties are incorporated as labels according to amino acid
residue properties (pharmacophores). The representation
of the each wild-type residue environment is then used to ex-
tract distance patterns between atoms characterised by their
properties and compiled in signatures as cumulative distri-
butions. Finally, the cumulative distributions are averaged
based on the number of point-mutations (Supplementary
Figure S4).
Modelling multiple-mutation effects
Similarly to our previous implementation tackling the ef-
fects of single-point mutations on PPI binding affinity
(15,23), here we also incorporate complementary features
to account for the different mechanisms by which multiple
point mutations may affect PPIs. However, in this study, we
calculated the sum and average values of each property in
order to model the effects of multiple mutations. All fea-
tures generated can be broadly classified into 6 different
categories: (i) dynamics, obtained via normal mode anal-
ysis (60), (ii) residue environment properties (61), (iii) con-
servation, obtained by using scores from substitution tables
(62), (iv) non-covalent contacts involving wild-type residues
(63), (v) wild-type inter-residue distance and (vi) predicted
Gbinding for each single point mutation separately (23). A
summary of features for each category is available in Sup-
plementary Table S3.
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Figure 1. mmCSM-PPI methodology workflow. Experimental data on the effects of multiple missense mutations was collected from SKEMPI2 and
mapped on their respective protein structures on the PDB. These were then used to generate physicochemical and geometrical properties in the form of
graph-based signatures. In addition, six distinct types of complementary features were calculated to account for different mechanisms by which mutations
may affect PPIs: (i) dynamic properties from NMA; (ii) wild-type residues environments; (iii) evolutionary and contact potential scores; (iv) non-covalent
contacts; (v) wild-type inter-residue distances and (vi) the individual Gbinding for each point mutation. Feature selection was carried out with a stepwise
greedy approach to avoid the curse of dimensionality and the best performing supervised learning algorithm was fine-tuned using the GridSearch function
from the Scikit-learn Python library.
Machine learning
In this study we evaluated four distinct algorithms avail-
able on the scikit-learn Python library (64) on 10-fold cross-
validation: Extra Trees, Random Forest, Gradient Boosting
and XGBoost. The best performing algorithm used to build
the final model was Extra Trees, based on different corre-
lation coefficients (Pearson, Kendall and Spearman) and
RMSE. Supplementary Table S4 summarises the perfor-
mances of each algorithm. In order to avoid the curse of di-
mensionality and improve performance, we selected our fea-
tures using an incremental stepwise greedy approach. Hy-
perparameter tuning was performed using the Gridsearch
function also available on the scikit-learn library (Supple-
mentary Table S5). Feature importance for the final predic-
tive model is available on Supplementary Table S6. While
two classes of features, graph-based signatures and indi-
vidual mutation effects, were identified as contributing the
most to the final model (as shown in Supplementary Table
S7), their combination allowed for a significant increase in
performance in the final model (P-value < 0.05), indicating
they measure complementary aspects of mutation effects in
PPIs.
WEB SERVER
We have implemented mmCSM-PPI as a user-friendly and
freely available web server (http://biosig.unimelb.edu.au/
mmcsm ppi). The server front end was developed using
Materialize framework version 1.0.0, and the back end
was built using Python via the Flask framework (version
1.0.2). The web server is hosted on a Linux Server running
Apache2.
Input
mmCSM-PPI can be used to either predict the effects of a
list of mutations of interest or perform a systematic evalua-
tion of all double and triple multiple mutations at a protein–
protein interface (Supplementary Figure S5). In both cases,
users are required to upload a file in PDB format or provide
a valid PDB accession code with the structure of a protein–
protein complex. For user-specified variants, mutations can
be provided using a text field or uploaded as a plain text
file with one multiple mutation per line. Each entry must be
separated by a semicolon (;) and each point mutation must
be represented as the chain identifier, blank space, the one-
letter code for the wild-type, residue position and the one-
letter code for the mutant. For the systematic evaluation op-
tion, users must provide a chain identifier from which inter-
faces will be automatically identified and all possible per-
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mutations of double and triple mutations assessed. Exam-
ples and format descriptions are available in both submis-
sion page and help page via the top navigation menu.
An Application Programming Interface (API) to assist
users in integrating our predictive tool into their research
pipelines is also available. Input fields follow the same for-
mat previously described for our web server implementa-
tion. All jobs submitted are labelled with a unique identifier
which is used to query the status of the job. A full descrip-
tion of the API, including examples using curl and Python
are available at http://biosig.unimelb.edu.au/mmcsm ppi/
api.
Output
For both types of submissions, manual input and system-
atic evaluation, mmCSM-PPI outputs the predictions for all
entries as a downloadable table where the predicted effects
of multiple mutations on Gbinding is given in kcal/mol.
For the systematic evaluation option, the server shows the
top 100 increasing/decreasing affinity entries. Additionally,
individual predictions for each point mutation is available,
generated using mCSM-PPI2 (23), are also shown alongside
the average distance among the wild-type residues. Finally,
an interactive 3D viewer, built using the NGL viewer (65),
allows for the analysis of non-covalent interactions involv-
ing wild-type residues for each point mutation, calculated
using Arpeggio (63), for a particular entry. Users can alter-
nate the residues and interactions being displayed by select-




We evaluated the performance of mmCSM-PPI across 5 dif-
ferent types of cross-validations on our training set. First,
we randomly selected 80% of the data for training and re-
maining 20% for testing, repeated 100 times (CV1). Our
method achieved Pearson’s, Kendall’s and Spearman’s cor-
relations of 0.87, 0.68 and 0.85 respectively, with small de-
viations across repetitions ( = 0.02), and average RMSE
of 1.41 kcal/mol ( = 0.21). Using an analogous setup, but
varying the proportion of data split for train and test (50%
each set) (CV2), the performance was consistent with the
previous experiment, and the predictive model achieved a
Pearson’s, Kendall’s and Spearman’s correlations of 0.86,
0.66 and 0.84 ( = 0.01 for all coefficients), respectively
(Figure 2A), and RMSE = 1.55 kcal/mol ( = 0.14).
Since all the entries in our data set were not uniformly
distributed across all protein–protein complexes (Supple-
mentary Table S8), we evaluated the performance of our ap-
proach by randomly sampling up to 10 mutations per pro-
tein complex, repeated 10 times (generating 10 subsets), fol-
lowed by randomly selecting 80% of entries for training and
remaining 20% for testing, also repeated 10 times (CV3).
For this type of cross-validation, our predictive model was
able to achieve Pearson’s, Kendall’s and Spearman’s correla-
tions of 0.83, 0.63 and 0.81, again with small deviations over
the repetitions ( = 0.03) (Figure 2A), and average RMSE
= 1.85 kcal/mol ( = 0.40).
Finally, we assessed the robustness of mmCSM-PPI
on low-redundancy sets at complex (CV4) and interface
(CV5) levels. The former was implemented using leave-
one-complex-out cross-validation, where all mutations for
a particular complex were retained for test and the re-
maining for training the predictive model. Overall, our
predictive model achieved Pearson’s, Kendall’s and Spear-
man’s correlations of 0.76, 0.55 and 0.75 respectively, and
RMSE of 1.59 kcal/mol (Figure 2B). On leave-one-binding-
site-out (CV5), where all mutations for protein–protein
complexes sharing similar binding sites, according to data
on SKEMPI2, were used for testing and the remaining
for training, our method was able to achieve Pearson’s,
Kendall’s and Spearman’s correlations of 0.73, 0.54 and
0.74, respectively (RMSE = 1.40 kcal/mol).
Blind test
While mmCSM-PPI was trained using a subset containing
only double and triple mutants, the performance of our final
model was further evaluated using a non-redundant blind
set at the mutation level of experimentally measured effects
of 595 constructs with at least four point mutations, also
derived from SKEMPI2. Across this dataset, mmCSM-PPI
achieved Pearson’s, Kendall’s and Spearman’s correlation
coefficients of 0.70, 0.48 and 0.64, respectively, and RMSE
of 2.02 kcal/mol, significantly outperforming FoldX (66)
and Discovery Studio (P-value < 0.05, Table 1). After re-
moving 10% of outliers, the performance of our predic-
tive model increased to 0.81, 0.55 and 0.73 for Pearson’s,
Kendall’s and Spearman’s correlations, respectively, and
RMSE of 1.68 kcal/mol (Figure 2C). The majority of out-
liers (∼70%) comprise mutations with extreme effects to PPI
binding affinity (4 kcal/mol < |Gbinding| < 11 kcal/mol)
and entries with 10 or more point mutations. Reassuringly,
however, our final model demonstrated balanced predictive
performance across both stabilising and destabilising muta-
tions, achieving an overall accuracy of 87% and precisions
of 74% and 89% on mutations that increase and decrease
binding affinity, respectively.
Given the inherent imbalance between increasing and de-
creasing affinity mutations in the dataset, we further as-
sessed the performance of our method on these respective
classes separately. On mutations that decrease binding affin-
ity, mmCSM-PPI achieves Pearson’s, Kendall’s and Spear-
man’s correlations of 0.72, 0.46 and 0.64 respectively, with
an RMSE = 1.67 kcal/mol, outperforming FoldX and Dis-
covery Studio. For mutations that increase binding affinity
all three methods show similar performance (Supplemen-
tary Table S9). Finally, we tested the ability to use the pre-
dicted Gbinding values from mmCSM-PPI to differentiate
between mutations that increase from those that decrease
binding affinity (Supplementary Table S10). Overall, our
method has proven to be the most robust when compared
with FoldX and Discovery Studio, achieving an AUC and
MCC of 0.72 and 0.53, respectively, when evaluated on mu-
tations where |Gbinding| < 1 kcal/mol.
We further evaluated the generalisation capabilities of
our model on another independent test set, non-redundant
at the mutation level. Four hundred and ninety multiple-
point mutations were randomly selected across 81 differ-
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Figure 2. mmCSM-PPI performance on cross-validation and non-redundant blind-tests. (A) The performance of mmCSM-PPI on bootstrapped 5-fold
cross validation (CV1), using 50% of the data as a blind test (CV2) and limiting the number of mutations per complex (CV3). The robustness of mmCSM-
PPI was further assessed using low redundancy at the (B) complex level, (C) using all data with three or more mutations as a blind test, and (D) at the
mutation level. Outliers are shown as red crosses.
Table 1. Performance comparison of mmCSM-PPI2 on a non-redundant blind test comprising entries with four or more mutations
Method Pearson Kendall Spearman RMSE (kcal/mol) MCC AUC
mmCSM-PPI 0.70 0.48 0.64 2.02 0.53 0.72
Discovery Studio 0.39* 0.29# 0.41+ 3.07a 0.30 0.66
FoldX 0.39* 0.25# 0.37+ 5.27a 0.22 0.61b
*P-value < 0.05 by Fisher r-to-z transformation test.
#P < 0.05 by transforming tau-to-r followed by Fisher r-to-z transformation.
+P < 0.05 by transforming rho-to-r followed by Fisher r-to-z transformation.
aP < 0.05 by Diebold–Mariano test.
bP < 0.05 by t-test.
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ent PPI as a blind test, with the remaining being used for
training purposes. Across the non-redundant blind test,
mmCSM-PPI achieved Pearson’s, Kendall’s and Spear-
man’s correlations of 0.67, 0.47 and 0.67, respectively
(RMSE = 1.72 kcal/mol), performance consistent with
previous independent tests, highlighting robustness of the
method (Figure 2D).
The performance of mmCSM-PPI was compared to
Discovery Studio and FoldX (Supplementary Table S11),
which demonstrated that our approach significantly out-
performed both in all metric evaluations (Supplementary
Table S11). We also compared the performance of our
method with ZEMu (67), a tool that uses a dynamical
equilibration under a physics-based force field for a lim-
ited residue environment, followed by binding affinity eval-
uation with FoldX. In this case since ZEMu has only re-
ported predictions for multiple mutations on the first ver-
sion of SKEMPI, here we trained a predictive model with
all double and triple mutants except for those available on
the first release of SKEMPI. Therefore, the dataset used to
compare the two methods comprises 272 entries (1 neutral,
52 increasing and 219 decreasing binding affinity) across
24 protein–protein complexes, ranging from 2 to 15 point
mutations. mmCSM-PPI achieved Pearson’s, Kendall’s and
Spearman’s correlations of 0.73, 0.56 and 0.75 (RMSE =
1.72 kcal/mol), respectively, significantly higher (P-value <
0.05) than ZEMu (Pearson’s, Kendall’s and Spearman’s cor-
relations of 0.64, 0.46 and 0.65, respectively, and RMSE =
2.11 kcal/mol). On 90% of the dataset, our method achieves
up to 0.83, 0.65 and 0.84 on Pearson’s, Kendall’s and Spear-
man’s, respectively (RMSE = 1.49 kcal/mol).
CONCLUSION
Here, we present mmCSM-PPI, a web server that inte-
grates our well-established graph-based signatures frame-
work with evolutionary scores, dynamics properties and
non-covalent interactions for accurately predicting changes
in PPI binding affinity caused by multiple point mutations.
Our method has shown to be robust when evaluated across
different types of cross-validations and outperformed exist-
ing tools in a non-redundant blind test set. We anticipate
mmCSM-PPI to be of great value for the study of how mul-
tiple mutations affect PPI binding affinity and to a vari-
ety of applications, ranging from protein functional anal-
ysis, optimisation of binding affinity and understanding the
role of mutations in diseases. In addition, mmCSM-PPI
includes an API to assist users when integrating our pre-
dictions into their research pipelines. Our method is freely
available as a user-friendly and easy-to-use web server at
http://biosig.unimelb.edu.au/mmcsm ppi.
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Extracting Binding Free Energy values from FoldX and Discovery Studio 
 
In order to extract the effects of mutations on binding free energy from FoldX, we first 
generated mutant structures using the command BuildModel and then generated ΔGBinding 
for wild-type and mutant structures using the function AnalyseComplex. Information on the 
groups of molecules (chains) participating in the interaction and the change in binding free 
energy was then calculated using the definitions available in SKEMPI2: 
 
ΔΔGbinding = ΔGbindingWT - ΔGbindingMT 
 
For Discovery Studio, we obtained values for changes in binding free energy using the Pipeline 




Table S1 - Description of PPI structures present in the dataset used to build mmCSM-PPI. The majority 
of structures have been generated using X-ray crystallography and a minor fraction using Nuclear 
Magnetic Resonance (NMR). For the latter, resolution values have been set as “NA”.  
PDB ID Description Experiment Resolution 
1cz8 
Vascular endothelial growth factor in complex with 
an affinity matured antibody 
x-ray diffraction 2.40 
5m2o 
R. flavefaciens' third scab cohesin in complex with 
a group 1 dockerin 
x-ray diffraction 1.26 
4l3e 
The complex between high affinity tcr dmf5(alpha-
d26y,beta-l98w) and human class i mhc hla-a2 
with the bound mart-1(26-35)(a27l) peptide 
x-ray diffraction 2.56 
1mhp 
Crystal structure of a chimeric alpha1 integrin i-
domain in complex with the fab fragment of a 
humanized neutralizing antibody 
x-ray diffraction 2.80 
2c5d Structure of a minimal gas6-axl complex x-ray diffraction 3.30 
1yqv 
The crystal structure of the antibody fab hyhel5 
complex with lysozyme at 1.7a resolution 
x-ray diffraction 1.70 
3idx 
Crystal structure of hiv-gp120 core in complex 
with cd4-binding site antibody b13, space group 
c222 
x-ray diffraction 2.50 
2oob 
Crystal structure of the uba domain from cbl-b 
ubiquitin ligase in complex with ubiquitin 
x-ray diffraction 1.90 
4gnk 
Crystal structure of galphaq in complex with full-
length human plcbeta3 
x-ray diffraction 4.00 
1qab 
The structure of human retinol binding protein with 
its carrier protein transthyretin reveals interaction 
with the carboxy terminus of rbp 
x-ray diffraction 3.20 
1c1y 
Crystal structure of rap.gmppnp in complex with 
the ras- binding-domain of c-raf1 kinase (rafrbd). 
x-ray diffraction 1.90 
4b0m 
Complex of the caf1an usher domain, caf1m 
chaperone and caf1 subunit from yersinia pestis 
x-ray diffraction 1.80 
4g2v Structure complex of lgn binding with frmpd1 x-ray diffraction 2.40 
1tm1 
Crystal structure of the complex of subtilisin bpn' 
with chymotrypsin inhibitor 2 
x-ray diffraction 1.70 
3hg1 
Germline-governed recognition of a cancer 
epitope by an immunodominant human t cell 
receptor 
x-ray diffraction 3.00 
1dqj 
Crystal structure of the anti-lysozyme antibody 
hyhel-63 complexed with hen egg white lysozyme 
x-ray diffraction 2.00 
1n8z 
Crystal structure of extracellular domain of human 
her2 complexed with herceptin fab 
x-ray diffraction 2.52 
1ycs P53-53bp2 complex x-ray diffraction 2.20 
1y4a 
Crystal structure of the complex of subtilisin bpn' 
with chymotrypsin inhibitor 2 m59r/e60s mutant 
x-ray diffraction 1.60 
1dan 
Complex of active site inhibited human blood 
coagulation factor viia with human recombinant 
soluble tissue factor 
x-ray diffraction 2.00 
1yy9 
Structure of the extracellular domain of the 
epidermal growth factor receptor in complex with 
the fab fragment of cetuximab/erbitux/imc- c225 
x-ray diffraction 2.61 
4jfd 
Preservation of peptide specificity during tcr-mhc 
contact dominated affinity enhancement of a 
melanoma-specific tcr 
x-ray diffraction 2.46 
4jfe 
Preservation of peptide specificity during tcr-mhc 
contact dominated affinity enhancement of a 
melanoma-specific tcr 
x-ray diffraction 2.70 
1lfd 
Crystal structure of the active ras protein 
complexed with the ras- interacting domain of 
ralgds 
x-ray diffraction 2.10 
4ra0 
An engineered axl 'decoy receptor' effectively 
silences the gas6-axl signaling axis 
x-ray diffraction 3.07 
3uih 
Crystal structure of human survivin in complex 
with smac/diablo(1-15) peptide 
x-ray diffraction 2.40 
2pye 
Crystal structures of high affinity human t-cell 
receptors bound to pmhc revealnative diagonal 
binding geometry tcr clone c5c1 complexed with 
mhc 
x-ray diffraction 2.30 
3bdy Dual specific bh1 fab in complex with vegf x-ray diffraction 2.60 
1ak4 
Human cyclophilin a bound to the amino-terminal 
domain of hiv-1 capsid 
x-ray diffraction 2.36 
1gc1 
Hiv-1 gp120 core complexed with cd4 and a 
neutralizing human antibody 
x-ray diffraction 2.50 
3be1 
Dual specific bh1 fab in complex with the 
extracellular domain of her2/erbb-2 
x-ray diffraction 2.90 
4mnq 
Tcr-peptide specificity overrides affinity enhancing 
tcr-mhc interactions 
x-ray diffraction 2.74 
1E50 Aml1/cbfbeta complex x-ray diffraction 2.60 
2dvw 
Structure of the oncoprotein gankyrin in complex 
with s6 atpase of the 26s proteasome 
x-ray diffraction 2.30 
3qib 
Crystal structure of the 2b4 tcr in complex with 
mcc/i-ek 
x-ray diffraction 2.70 
1a4y Ribonuclease inhibitor-angiogenin complex x-ray diffraction 2.00 
1mq8 
Crystal structure of alphal i domain in complex 
with icam-1 
x-ray diffraction 3.30 
1gua 
Human rap1a, residues 1-167, double mutant 
(e30d,k31e) complexed with gppnhp and the ras-
binding-domain of human c-raf1, residues 51-131 
x-ray diffraction 2.00 
1rew 
Structural refinement of the complex of bone 
morphogenetic protein 2 and its type ia receptor 
x-ray diffraction 1.86 
4jeu 
Crystal structure of munc18a and syntaxin1 with 
native n-terminus complex 
x-ray diffraction 3.20 
1efn 
Hiv-1 nef protein in complex with r96i mutant fyn 
sh3 domain 
x-ray diffraction 2.50 
2o3b 
Crystal structure complex of nuclease a (nuca) 
with intra-cellular inhibitor nuia 
x-ray diffraction 2.30 
1kne 
Chromo domain of hp1 complexed with histone h3 
tail containing trimethyllysine 9 
x-ray diffraction 2.40 
2b2x 
Vla1 rdeltah i-domain complexed with a quadruple 
mutant of the aqc2 fab 
x-ray diffraction 2.20 
4uyq 
High resolution structure of the third cohesin scac 
in complex with the scab dockerin with a mutation 
in the c-terminal helix (in to si) from acetivibrio 
cellulolyticus displaying a type i interaction. 
x-ray diffraction 1.81 
4ftv 
The complex between the high affinity version of 
a6 tcr (a6c134) and human class i mhc hla-a2 
with the bound tax nonameric peptide 
x-ray diffraction 2.74 
1mah Fasciculin2-mouse acetylcholinesterase complex x-ray diffraction 3.20 
3d3v 
The complex between tcr a6 and human class i 
mhc hla-a2 with the modified htlv-1 tax (y5(3,4-
difluorophenylalanine)) peptide 
x-ray diffraction 2.80 
4ofy 
Crystal structure of the complex of syg-1 d1-d2 
and syg-2 d1-d4 
x-ray diffraction 3.30 
3l5x 
Crystal structure of the complex between il-13 and 
h2l6 fab 
x-ray diffraction 1.90 
1k8r Crystal structure of ras-bry2rbd complex x-ray diffraction 3.00 
3u82 Binding of herpes simplex virus glycoprotein d to x-ray diffraction 3.16 
nectin-1 exploits host cell adhesion 
5cyk 
Structure of ytm1 bound to the c-terminal domain 
of erb1-r486e 
x-ray diffraction 3.00 
3lzf 
Crystal structure of fab 2d1 in complex with the 
1918 influenza virus hemagglutinin 
x-ray diffraction 2.80 
3vr6 
Crystal structure of amp-pnp bound enterococcus 
hirae v1-atpase [bv1] 
x-ray diffraction 2.68 
1bd2 
Complex between human t-cell receptor b7, viral 
peptide (tax) and mhc class i molecule hla-a 0201 
x-ray diffraction 2.50 
2pcc 
Crystal structure of a complex between electron 
transfer partners, cytochrome c peroxidase and 
cytochrome c 
x-ray diffraction 2.30 
1gl0 
Structure of the complex between bovine alpha-
chymotrypsin and pmp-d2v, an inhibitor from the 
insect locusta migratoria 
x-ray diffraction 3.00 
1gl1 
Structure of the complex between bovine alpha-
chymotrypsin and pmp-c, an inhibitor from the 
insect locusta migratoria 
x-ray diffraction 2.10 
3mzg 
Crystal structure of a human prolactin receptor 
antagonist in complex with the extracellular 
domain of the human prolactin receptor 
x-ray diffraction 2.10 
5xco 
Crystal structure of human k-ras g12d mutant in 
complex with gdp and cyclic inhibitory peptide 
x-ray diffraction 1.25 
4gxu 
Crystal structure of antibody 1f1 bound to the 
1918 influenza hemagglutinin 
x-ray diffraction 3.29 
3sgb 
Structure of the complex of streptomyces griseus 
protease b and the third domain of the turkey 
ovomucoid inhibitor at 1.8 angstroms resolution 
x-ray diffraction 1.80 
3s9d Binary complex between ifna2 and ifnar2 x-ray diffraction 2.00 
1vfb 
Bound water molecules and conformational 
stabilization help mediate an antigen-antibody 
association 
x-ray diffraction 1.80 
1jtg 
Crystal structure of tem-1 beta-lactamase / beta-
lactamase inhibitor protein complex 
x-ray diffraction 1.73 
1he8 Ras g12v - pi 3-kinase gamma complex x-ray diffraction 3.00 
4k71 
Crystal structure of a high affinity human serum 
albumin variant bound to the neonatal fc receptor 
x-ray diffraction 2.40 
3kud Complex of ras-gdp with rafrbd(a85k) x-ray diffraction 2.15 
1xxm 
The modular architecture of protein-protein 
binding site 
x-ray diffraction 1.90 
2nyy 
Crystal structure of botulinum neurotoxin type a 
complexed with monoclonal antibody cr1 
x-ray diffraction 2.61 
1r0r 
1.1 angstrom resolution structure of the complex 
between the protein inhibitor, omtky3, and the 
serine protease, subtilisin carlsberg 
x-ray diffraction 1.10 
5tar 
Crystal structure of farnesylated and methylated 
kras4b in complex with pde-delta (crystal form ii - 
with ordered hypervariable region) 
x-ray diffraction 1.90 
3se4 Human ifnw-ifnar ternary complex x-ray diffraction 3.50 
3se3 Human ifna2-ifnar ternary complex x-ray diffraction 4.00 
2kso Epha2:ship2 sam:sam complex NMR NA 
1ppf 
X-ray crystal structure of the complex of human 
leukocyte elastase (pmn elastase) and the third 
domain of the turkey ovomucoid inhibitor 
x-ray diffraction 1.80 
4krl 
Nanobody/vhh domain 7d12 in complex with 
domain iii of the extracellular region of egfr, ph 6.0 
x-ray diffraction 2.85 
4kro 
Nanobody/vhh domain ega1 in complex with the 
extracellular region of egfr 
x-ray diffraction 3.05 
3eg5 
Crystal structure of mdia1-tsh gbd-fh3 in complex 
with cdc42-gmppnp 
x-ray diffraction 2.70 
2p5e 
Crystal structures of high affinity human t-cell 
receptors bound to pmhc reveal native diagonal 
binding geometry 
x-ray diffraction 1.89 
1ahw 
A complex of extracellular domain of tissue factor 
with an inhibitory fab (5g9) 
x-ray diffraction 3.00 
2ny7 
Hiv-1 gp120 envelope glycoprotein complexed 
with the broadly neutralizing cd4-binding-site 
antibody b12 
x-ray diffraction 2.30 
2g2u 
Crystal structure of the shv-1 beta-
lactamase/beta-lactamase inhibitor protein (blip) 
complex 
x-ray diffraction 1.60 
1fcc 
Crystal structure of the c2 fragment of 
streptococcal protein g in complex with the fc 
domain of human igg 
x-ray diffraction 3.20 
1brs 
Protein-protein recognition: crystal structural 
analysis of a barnase- barstar complex at 2.0-a 
resolution 
x-ray diffraction 2.00 
1a22 Human growth hormone bound to single receptor x-ray diffraction 2.60 
2vn5 
The clostridium cellulolyticum dockerin displays a 
dual binding mode for its cohesin partner 
x-ray diffraction 1.90 
1bj1 
Vascular endothelial growth factor in complex with 
a neutralizing antibody 
x-ray diffraction 2.40 
3ngb 
Crystal structure of broadly and potently 
neutralizing antibody vrc01 in complex with hiv-1 
gp120 
x-ray diffraction 2.68 
5e9d 
Rd-1 mart-1 high bound to mart-1 decameric 
peptide (ela) in complex with hla-a2 
x-ray diffraction 2.51 
4yh7 
Crystal structure of ptpdelta ectodomain in 
complex with il1rapl1 
x-ray diffraction 4.40 
1jrh Complex (antibody/antigen) x-ray diffraction 2.80 
1c4z 
Structure of an e6ap-ubch7 complex: insights into 
the ubiquitination pathway 
x-ray diffraction 2.60 
4uyp 
High resolution structure of the third cohesin scac 
in complex with the scab dockerin with a mutation 
in the n-terminal helix (in to si) from acetivibrio 
cellulolyticus displaying a type i interaction. 
x-ray diffraction 1.49 
1fss 
Acetylcholinesterase (e.c. 3.1.1.7) complexed with 
fasciculin-ii 
x-ray diffraction 3.00 
5c6t Crystal structure of hcmv glycoprotein b in x-ray diffraction 3.60 
complex with 1g2 fab 
4gu0 Crystal structure of lsd2 with h3 x-ray diffraction 3.10 
3uii 
Crystal structure of human survivin in complex 
with h3(1-10) peptide 
x-ray diffraction 2.60 
3aaa 
Crystal structure of actin capping protein in 
complex with v-1 
x-ray diffraction 2.20 
1b41 
Human acetylcholinesterase complexed with 
fasciculin-ii, glycosylated protein 
x-ray diffraction 2.76 
4nkq Structure of a cytokine receptor complex x-ray diffraction 3.30 
1cho 
Crystal and molecular structures of the complex of 
alpha-*chymotrypsin with its inhibitor turkey 
ovomucoid third domain at 1.8 angstroms 
resolution 
x-ray diffraction 1.80 
2wpt 
The crystal structure of im2 in complex with colicin 
e9 dnase 
x-ray diffraction 1.78 
2nz9 
Crystal structure of botulinum neurotoxin type a 
complexed with monoclonal antibody ar2 
x-ray diffraction 3.79 
4wnd 
Crystal structure of the tpr domain of lgn in 
complex with frmpd4/preso1 at 1.5 angstrom 
resolution 
x-ray diffraction 1.50 
3pwp 
The complex between tcr a6 and human class i 
mhc hla-a2 with the bound hud peptide 
x-ray diffraction 2.69 
4j2l 
Crystal structure of axh domain complexed with 
capicua 
x-ray diffraction 3.15 
1b2u 
Structural response to mutation at a protein-
protein interface 
x-ray diffraction 2.10 
1b2s 
Structural response to mutation at a protein-
protein interface 
x-ray diffraction 1.82 
1ao7 
Complex between human t-cell receptor, viral 
peptide (tax), and hla-a 0201 
x-ray diffraction 2.60 
1dvf 
Idiotopic antibody d1.3 fv fragment-antiidiotopic 
antibody e5.2 fv fragment complex 
x-ray diffraction 1.90 
2ccl 
The s45a, t46a mutant of the type i cohesin-
dockerin complex from the cellulosome of 
clostridium thermocellum 
x-ray diffraction 2.03 
1bp3 
The xray structure of a growth hormone-prolactin 
receptor complex 
x-ray diffraction 2.90 
2qj9 
Crystal structure analysis of bmp-2 in complex 
with bmpr-ia variant b1 
x-ray diffraction 2.44 
2noj Crystal structure of ehp / c3d complex x-ray diffraction 2.70 
5ufe Wild-type k-ras(gnp)/r11.1.6 complex x-ray diffraction 2.30 
1kbh 
Mutual synergistic folding in the interaction 




Structure of an antibody-antigen complex. crystal 
structure of the hy/hel-10 fab-lysozyme complex 
x-ray diffraction 3.00 
3qdg 
The complex between tcr dmf5 and human class i 
mhc hla-a2 with the bound mart-1(26-35)(a27l) 
peptide 
x-ray diffraction 2.69 
3qdj 
The complex between tcr dmf5 and human class i 
mhc hla-a2 with the bound mart-1(27-35) 
nonameric peptide 
x-ray diffraction 2.30 
4yfd 
Crystal structure ptp delta ig1-fn2 in complex with 
il-1racp 
x-ray diffraction 3.25 
2j0t 
Crystal structure of the catalytic domain of mmp-1 
in complex with the inhibitory domain of timp-1 
x-ray diffraction 2.54 
5ufq K-rasg12d(gnp)/r11.1.6 complex x-ray diffraction 2.20 
3mzw 
Her2 extracelluar region with affinity matured 3-
helix affibody zher2:342 
x-ray diffraction 2.90 
3g6d 
Crystal structure of the complex between cnto607 
fab and il-13 
x-ray diffraction 3.20 
4x4m 
Structure of fcgammari in complex with fc reveals 
the importance of glycan recognition for high 
affinity igg binding 
x-ray diffraction 3.49 
3m63 
Crystal structure of ufd2 in complex with the 
ubiquitin-like (ubl) domain of dsk2 
x-ray diffraction 2.40 
4myw Structure of hsv-2 gd bound to nectin-1 x-ray diffraction 3.19 
4e6k 
2.0 a resolution structure of pseudomonas 
aeruginosa bacterioferritin (bfrb) in complex with 
bacterioferritin associated ferredoxin (bfd) 
x-ray diffraction 2.00 
1b3s 
Structural response to mutation at a protein-
protein interface 
x-ray diffraction 2.39 
1z7x 
X-ray structure of human ribonuclease inhibitor 
complexed with ribonuclease i 
x-ray diffraction 1.95 
4jpk 
Crystal structure of the germline-targeting hiv-1 
gp120 engineered outer domain eod-gt6 in 
complex with a putative vrc01 germline precursor 
fab 
x-ray diffraction 2.40 
4rs1 Crystal structure of receptor-cytokine complex x-ray diffraction 2.68 
1emv 
Crystal structure of colicin e9 dnase domain with 
its cognate immunity protein im9 (1.7 angstroms) 
x-ray diffraction 1.70 
1sbb 
T-cell receptor beta chain complexed with 
superantigen seb 
x-ray diffraction 2.40 
1mlc 
Monoclonal antibody fab d44.1 raised against 
chicken egg- white lysozyme complexed with 
lysozyme 
x-ray diffraction 2.50 
1ohz 
Cohesin-dockerin complex from the cellulosome 
of clostridium thermocellum 
x-ray diffraction 2.20 
2abz 
Crystal structure of c19a/c43a mutant of leech 
carboxypeptidase inhibitor in complex with bovine 
carboxypeptidase a 
x-ray diffraction 2.16 
4cvw 
Structure of the barley limit dextrinase-limit 
dextrinase inhibitor complex 
x-ray diffraction 2.67 
4y61 
Crystal structure of the complex between slitrk2 
lrr1 and ptp delta ig1-fn1 
x-ray diffraction 3.36 
4g0n 
Crystal structure of wt h-ras-gppnhp bound to the 
rbd of raf kinase 
x-ray diffraction 2.45 
2qja 
Crystal structure analysis of bmp-2 in complex 
with bmpr-ia variant b12 
x-ray diffraction 2.60 
1wqj 
Structural basis for the regulation of insulin-like 
growth factors (igfs) by igf binding proteins 
(igfbps) 
x-ray diffraction 1.60 
2qjb 
Crystal structure analysis of bmp-2 in complex 
with bmpr-ia variant ia/ib 
x-ray diffraction 2.50 
4krp 
Nanobody/vhh domain 9g8 in complex with the 
extracellular region of egfr 
x-ray diffraction 2.82 
3bp8 Crystal structure of mlc/eiib complex x-ray diffraction 2.85 
 
 
Table S2 - Distribution of multiple point mutations across different experimental methods available in 
SKEMPI2 and used in this work. 
Acronym Technique # mutations 
SPR Surface Plasmon Resonance 599 
FL Fluorescence 355 
SFFL Stopped Flow Fluorescence 170 
ITC Isothermal Titration 138 
SP Spectroscopy 115 
IASP Spectroscopy Inhibition Assay 81 
ELISA ELISA 70 
RA Radioactive Ligand Binding 63 
IAFL Fluorescence Inhibition Assay 54 
KinExA Kinetic Exclusion Assay 47 
IARA Radioligand Inhibition Assay 11 
ELFA Enzyme-linked Functional Assay 10 
BI Biolayer Interferometry 3 
Other SE, IAGE and ESMA 3 
SPR,SFFL SPR,SFFL 2 
 
Table S3 - Complementary features used to model the effects of multiple point mutations on PPIs. 
Category Description Tool 
Normal Mode Analysis 
Deformation energy and atomic fluctuation 
across 4 different force-fields (C-alpha, ANM, 
pfANM, REACH, sdENM) 
Bio3D (1) 
Residue Environment 
Torsion angles (psi and phi), relative solvent 
accessibility and residue depth 
Biopython (2) 
Evolutionary and contact potential Scores from substitution tables 
AAINDEX (3), Blosum 
and PAM matrices 
Non-covalent contacts 
Hydrogen bonds, Hydrophobic contacts, PI 
stacking and Ionic interactions 
Arpeggio (4) 
Wild-type inter-residue distance 
Average, shortest and longest distances 
among wild-type residues being mutated 
Python 
Individual ΔΔGbinding 




Table S4 - Performance of mmCSM-PPI for different supervised learning algorithms. Evaluation metrics 
were calculated using 10-fold cross validation before feature selection. 
Algorithm Pearson Kendall Spearman RMSE 
(kcal/mol) 
Extra Trees 0.73 0.53 0.73 1.66 
Random Forest 0.70 0.52 0.72 1.75 
Gradient Boosting 0.69 0.50 0.70 1.79 
XGBoost 0.68 0.49 0.68 1.81 
 
Table S5 - Parameters used in the final predictive model for mmCSM-PPI using Extra Trees algorithm 








Table S6 - Feature importance from the Extra Trees algorithm used for the final model of mmCSM-PPI. 
Feature Score 
Sum of ΔΔGbinding for each single point mutation separately (mCSM-PPI2) 0.480 
Average graph-based signatures of wild-type residues 0.462 
Sum of scores from DOSZ010103 (AAINDEX) 0.015 
Average Pharmacophore changes (Positives) 0.007 
Average deformation energies of wild-type residues (Bio3D) 0.006 
Sum of Pharmacophore changes (Sulfurs) 0.005 
Sum of scores from RUSR970103 (AAINDEX) 0.004 
Sum of deformation energies of wild-type residues (Bio3D) 0.004 
Sum of Hydrophobic contacts of wild-type residues (Arpeggio) 0.003 
Average atomic fluctuation of wild-type residues (Bio3D) 0.003 
Average Weak Polar interactions of wild-type residues (Arpeggio) 0.003 
Sum of scores for MEHP950101 (AAINDEX) 0.003 
Shortest distance between wild-type residues 0.003 
Sum of Pharmacophore changes (Negatives) 0.002 
Average Phi torsion angle of wild-type residues 0.002 
 
Table S7 - Performance comparison of mmCSM-PPI and predictive models using only the most 
important features on a non-redundant blind test comprising entries with 4 or more mutations. 
 Pearson Kendall Spearman RMSE 
mmCSM-PPI 0.70 0.48 0.64 2.06 
Sum of Individual 
ΔΔGbinding  
0.61* 0.41# 0.57+ 2.55a 
Graph-based signatures  0.37* 0.26# 0.37+ 2.83a 
* p-value < 0.05 by Fisher r-to-z transformation test 
# p-value < 0.05 by transforming tau-to-r followed by Fisher r-to-z transformation 
+ p-value < 0.05 by transforming rho-to-r followed by Fisher r-to-z transformation 
a p-value < 0.05 by Diebold‐Mariano test 
 
Table S8- Distribution of multiple mutations across different protein-protein complex structures in the 
PDB extracted from SKEMPI2. 





















2G2U, 5XCO 18 
2WPT 17 
4NKQ, 3HFM, 1MLC, 1CZ8 16 
3KUD 15 
1HE8, 1VFB, 1BP3 14 
1EMV, 1DQJ, 1A4Y, 1DVF 13 
3VR6, 4MNQ, 1JRH, 1BJ1 12 
3IDX, 2NY7 11 
1QAB, 4K71, 4FTV 9 
3HG1, 4RS1, 4UYP, 4UYQ, 5E9D 8 
4RA0, 1AHW, 1MQ8, 5M2O, 1BD2 7 
3BE1, 3G6D, 2PCC, 2J0T, 4L3E 6 
2KSO, 2DVW, 2PYE, 4JFE, 4JFD, 1OHZ, 3BDY, 1YCS 5 
2OOB, 1FSS, 1Z7X, 1TM1, 2P5E, 1MAH, 3NGB 4 
2QJA, 5UFE, 1YY9, 4GNK, 2QJ9, 5CYK, 2QJB, 4YH7, 4E6K, 1GUA, 4J2L, 1C1Y, 
3D3V, 4B0M 
3 
3EG5, 1GC1, 1YQV, 2NYY, 4OFY, 1B41, 1N8Z, 3QIB, 5UFQ, 3QDG, 3QDJ, 
4YFD, 3SE4, 5C6T 
2 
2ABZ, 4KRL, 1FCC, 1E50, 1XXM, 3PWP, 1C4Z, 3BP8, 4JEU, 1EFN, 1AK4, 
4MYW, 4CVW, 4X4M, 1WQJ, 4GXU, 2NOJ, 1B2S, 2NZ9, 3AAA, 2O3B, 1B2U, 
4KRP, 4Y61, 4KRO, 4WND, 3UIH, 1GL0, 1GL1, 4G2V, 3LZF, 5TAR, 3U82, 
3MZG, 1K8R, 1Y4A, 4JPK, 4GU0, 3UII, 3M63, 2CCL, 1B3S, 1SBB 
1 
 
Table S9 - Performance comparison on increasing and decreasing mutations. 
 Decreasing affinity Increasing affinity 
Method Pearson Kendall Spearman RMSE Pearson Kendall Spearman RMSE 
mmCSM-PPI 0.72 0.46 0.64 1.67 0.16 0.21 0.31 2.93 
Discovery 
Studio 
0.30* 0.30# 0.44+ 4.84a 0.18 0.11 0.17 5.42 
FoldX 0.34* 0.21# 0.32+ 2.83a 0.23 0.20 0.32 2.83 
* p-value < 0.05 by Fisher r-to-z transformation test 
# p-value < 0.05 by transforming tau-to-r followed by Fisher r-to-z transformation 
+ p-value < 0.05 by transforming rho-to-r followed by Fisher r-to-z transformation 




Table S10 - mmCSM-PPI classification by regression using different thresholds. 
  |ΔΔGbinding| > 0.5 |ΔΔGbinding| > 1.0 |ΔΔGbinding| > 1.5 
Threshold Class Precision Recall MCC AUC Precision Recall MCC AUC Precision Recall MCC AUC 
ΔΔGmmCSM-PPI > -1.0 Increase 0.46 0.76 0.44 0.76 0.45 0.80 0.47 0.78 0.45 0.79 0.48 0.79 
ΔΔGmmCSM-PPI < -1.0 Decrease 0.92 0.75 0.44 0.76 0.94 0.77 0.47 0.78 0.95 0.80 0.48 0.79 
ΔΔGmmCSM-PPI > -0.50 Increase 0.52 0.61 0.43 0.73 0.53 0.65 0.48 0.76 0.52 0.65 0.48 0.76 
ΔΔGmmCSM-PPI < -0.50 Decrease 0.88 0.84 0.43 0.73 0.91 0.86 0.48 0.76 0.92 0.87 0.48 0.76 
ΔΔGmmCSM-PPI > 0 Increase 0.76 0.43 0.49 0.70 0.74 0.49 0.53 0.72 0.77 0.48 0.55 0.73 
ΔΔGmmCSM-PPI < 0 Decrease 0.86 0.96 0.49 0.70 0.89 0.96 0.53 0.72 0.90 0.97 0.55 0.73 
ΔΔGmmCSM-PPI > 0.50 Increase 0.94 0.29 0.46 0.64 0.94 0.36 0.53 0.68 0.96 0.39 0.57 0.69 
ΔΔGmmCSM-PPI < 0.50 Decrease 0.83 0.99 0.46 0.64 0.87 0.99 0.53 0.68 0.8 1.00 0.57 0.69 
ΔΔGmmCSM-PPI > 1.00 Increase 1.00 0.18 0.38 0.59 1.00 0.24 0.45 0.62 1.00 0.24 0.46 0.62 
ΔΔGmmCSM-PPI < 1.00 Decrease 0.81 1.00 0.38 0.59 0.84 1.00 0.45 0.62 0.86 1.00 0.46 0.62 
 
 
Table S11 - Performance comparison for blind-test non-redundant at the mutation level. 
Method Pearson Kendall Spearman RMSE (kcal/mol) 
mmCSM-PPI 0.67 0.47 0.67 1.72 
Discovery 
Studio 
0.36* 0.28# 0.38+ 2.74a 
FoldX 0.29* 0.26# 0.39+ 4.55a 
* p-value < 0.05 by Fisher r-to-z transformation test 
# p-value < 0.05 by transforming tau-to-r followed by Fisher r-to-z transformation 
+ p-value < 0.05 by transforming rho-to-r followed by Fisher r-to-z transformation 





Figure S1 - Distribution of experimental techniques used to generate the data set extracted from 
SKEMPI2. 5 experimental techniques represent the majority of the dataset (80%): surface plasmon 
resonance (SPR), fluorescence (FL), stopped flow fluorescence (SFFL), isothermal titration calorimetry 
(ITC) and spectroscopy. 
 
 
Figure S2 - Distribution of multiple mutations across the data retrieved from SKEMPI2. Double and 
triple mutants, which account for more than 65% (1126) of all entries, were used for training mmCSM-
PPI. The remaining 595 entries were held out and used as a non-redundant blind test at mutation level.  
 
 
Figure S3 - ΔΔGbinding distribution of training and blind test sets used in this work. A) depicts the 
distribution of changes in binding affinity for the original training set extracted from SKEMPI2. B) shows 
the distribution on the training set after including hypothetical reverse mutations. Finally, C) summarises 




Figure S4 - Graph-based signatures representation for multiple point mutations. For each point 
mutation, the residue environment is represented as a graph where surrounding residues are 
represented as nodes and their interactions as edges. Distance patterns between atoms characterised 
by their properties are compiled as cumulative distributions for each environment separately. Finally, 
the distributions are averaged based on the number of point mutations. 
  
 
Figure S5 - mmCSM-PPI submission page. Two predictive types are available: Manual input and 
Systematic evaluation. In both cases, users must provide the 3D structure of a protein complex by either 
uploading a file in PDB format or specifying a valid PDB accession code. For the Manual input option, 
a list of mutations of interest are required, represented as the chain identifier, the wild-type residue one-
letter code, the residue number and the mutant residue one-letter code, and with each point mutation 
separated by a semi-colon. For the Systematic evaluation option, users must specify a chain identifier 




Figure S6 - mmCSM-PPI results page. For both predictive options, manual input and systematic 
evaluation, results are shown as a downloadable table where predicted effects of multiple mutations in 
ΔΔGbinding and individual predicted effects for each single-point mutation are also available. In addition, 
an interactive 3D viewer is also available where interactions for an entry are displayed. Users can 
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Discussion and Conclusions 279
For the past decades, considerable attention has been given to PPIs, particularly aiming
to target and modulate them, given their selectivity and their widespread roles in cel-
lular processes. However, the design of drugs to target PPIs has been long considered
challenging, given the complex and diverse nature of these regions. In this context,
the identification and study of hotspots residues, and the emergence of publicly avail-
able libraries of compounds with experimental information to serve as probes, represent
considerable advances to support and accelerate drug discovery efforts.
In this work, I hypothesized that computational techniques can provide powerful and
valuable biological insight into the nature of PPIs and how they can be effectively mod-
ulated. In Chapter 2, I performed a large-scale analysis of the structural and chemical
properties of all PPI interfaces available on the PDB, and demonstrated that PPI in-
terfaces are not uniformly flat and featureless as has been previously described. In fact,
quantitative analysis of PPI use of concavity showed that while on average these re-
gions are flat, the majority of interfaces made use of small concavities, corroborating the
anchor residues hypothesis and the widespread occurrence of complemented pockets.
Furthermore, multi segmented interfaces utilising discontinuous binding regions were
not only larger than single segmented interfaces, but also less well packed and less
complementary in shape. These findings suggest that single interacting segments make
tight selective interactions with their globular partner, compared to looser interfaces in
larger multi segmented complexes. Surprisingly, single segment interfaces have shown
to be more planar than multi segmented interfaces. This observation may be related to
the potentially linear nature of peptide binding sites, binding across a small interface
surface area. While peptidic interfaces were overall more concave, their deviation from
a best-fit plane through the interface may have been smaller due to smaller interface
size. Au contraire, interfaces for non-identical and identical symmetric pairs were larger
and, on average, comprised multiple interacting segments, consequently increasing the
RMSD from an interface best-fit plane. From a druggability perspective, continuous
binding sites that make use of deeper binding pockets and significantly (ANOVA p-
value <0.5) more directional non-covalent interactions (hydrogen/polar bonds) may be
more immediately amenable for targeting than discontinuous interfaces. In addition, the
presence of completed sub-pockets across most globular interfaces may be explored by
small-molecule fragments.
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As discussed in Chapter 1, PPI interface regions are known to be enriched with disease-
mutations, and the ability to rapidly uncover the different mechanisms by which these
variants disrupt protein interactions is essential to help identify disease driver mutations
and hotspots, design of more stable complexes, and better understand disease develop-
ment. In Chapters 3, 4, 6 and 7, I have demonstrated that protein structure and sequence
can be used as rich sources of information from which computational approaches can be
developed. By employing machine learning techniques (Appendix A), I developed meth-
ods that contributed for a better understanding of how missense mutations affect PPIs.
To this date, the majority of methods currently available for assessing the effects of mis-
sense mutations on PPIs are known to perform poorly in new test sets, and are limited
to analysis of the effects of single point mutations. I have demonstrated in Chapters 3, 4
and 6 that my approaches outperformed many other alternative methods on estimating
these effects of single point mutations with more balanced predictions. Furthermore,
I extrapolated these approaches to analyse mutational effects on a multiple mutations
context (Chapters 3 and 7), which represented a considerable advance to the field.
Over the past 3 years, these mutational analysis methods have been applied into a variety
of projects, most notably the exploration of the mutation landscapes across all proteins
from the SARs-Cov-2 virus [89] and several other studies investigating this rapid mu-
tated virus [90–93]; antimicrobial drug resistance and pathogenicity (i.e., Mycobacterium
Tuberculosis) [94–96]; identification of hotspots at PPI interfaces which could, in turn,
be used to aid drug/vaccine design [97]; to investigate the role of mutations in cancer
[98, 99] and rare diseases [100, 101]. Overall, these studies showed that up to 60% of
mutations involved in drug resistance and disease phenotype would lead to significant
disruption of key protein-protein interactions. The findings described in Chapters 3,
4, 6 and 7 have paved the way to a new generation of tools that will greatly benefit
our understanding of how mutations affect protein interactions and how we can develop
drugs to selectively target them with implications in personalised medicine.
The variety of mechanisms by which mutations may affect protein function was also
represented in the diversity of features selected by the machine learning algorithms for
these predictive models. Overall, features representing geometrical and physicochemical
properties of wild-type residue environment (graph-based signatures), protein dynamics,
contact potentials and evolutionary scores from substitution matrices had greater impact
in method performance. Most notably, I demonstrated that extracting protein flexibility
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properties using NMA is a great alternative to computational and time consuming MD
simulations.
Protein dynamics plays an important role in molecular recognition with the occurrence
of PPIs where one one of the partners undergoes small or more drastic conformational
changes. Changes in protein flexibility, caused by point mutations, can directly affect
binding site regions involved in protein recognition, or even “lock” a protein in specific
conformations, as seen for mutations causing permanent activation of protein kinases
and consequent hyperphosphorylation of their targets. Geometric and physicochemical
changes relate to the ability of amino acid side chains to participate in non-covalent
interactions which are key components for the protein folding, kinetics of PPI binding
and also molecular recognition.
Finally, as we improve our understanding of the molecular properties at PPI interfaces,
a number of PPI inhibitors/modulators have been proposed, some of which are already
approved for clinical use, namely Venetoclax (ABT-199) [102] and others under clinical
trial. However, the complexity and diversity of PPI interfaces combined with the lack of
screening libraries dedicated specifically to PPIs, or yet limited to compounds targeting a
small number of protein complexes, still makes it difficult to identify potential inhibitors.
In Chapter 5, I showed that most PPI inhibitors used deviate from the Lipinski Rule
of Five (RO5) for bioavailable drugs, suggesting a natural bias in the screening libraries
used to obtain these molecules. Interestingly, most active compounds presented a larger
molecular weight than the threshold used in RO5, presumably the result of compound
optimisation via medicinal chemistry to generate small molecules with a higher selec-
tivity towards specific PPIs. Furthermore, more potent compounds were enriched with
complex ring structures, including biphenyls, consistent with previous studies demon-
strating that PPI inhibitors tend to have more aromatic rings than other ligands, and
possibly related to hotspots targeting as these are known to be predominantly aro-
matic residues. Furthermore, I explored the concept of graph-based signatures to model
small molecules inhibitors for targeting 3 oncogenic PPIs: Bcl2/Bak, mdm2/P53 and
c-Myc/Max. Using these as a baseline I was able to develop a generic method that
represents a major contribution into compound prioritisation/ranking and potentially
as an alternative to enrich screening libraries.
In future work, I would like to further assess the effects of mutations in the context
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of protein-protein interaction networks (PPINs), which could help in the identification
of adjacent proteins in the same network (i.e., same signalling pathway) that could be
more easily targeted for modulation. In addition, a broader mutational analysis of PPINs
could improve our understanding of how multiple variants affect more complex protein
assemblies and pathways. Furthermore, a previous study [37] has suggested the exis-
tence of perturbations patterns on PPINs across a variety of human Mendelian diseases,
and propose a characterisation of molecular interactions to help identify disease-causing
mutations. The application of the analysis and computational techniques presented in
this thesis can provide a deeper elucidation of how these perturbations patterns are
related to disease and consequently allow for a better understanding of the complex
genotype-phenotype relationship.
All methods/tools developed and described in this thesis were made freely available
via easy-to-use web servers and overall receive over 1 million hits per year. Tools and
third-party applications used for the development of these methods are summarised in
Appendix B. I strongly believe these represent invaluable resources that can help to
accelerate analysis in a broad range of fields, including, but not limited to, protein
functional analysis, understanding the role of mutations in diseases and more efficient




Machine learning (ML) is a branch of computer science that aims to use historical data
to derive a model that describes a phenomenon, aiming for its generalisation (applying
it in data never seen before), or to identify inherent patterns within a collection of data.
ML has been widely utilised for a variety of tasks such as speech/pattern recognition
[103, 104], prediction of phenotype diseases from variants [55] and binding site detections
[105]. In that sense, ML can be split into two categories depending on the type of data
that is being worked with: supervised and unsupervised learning.
Supervised learning task refers to inferring a mapping function between an input and an
output label, using labeled training data. The training data takes the form of a collection
of (X,y) pairs in which X is usually represented by a vector of features and y is the
known output label (either numerical or categorical) for a given X (Figure A.1A). The
goal is to produce a prediction in response to a query with an unknown outcome, based
on the information and patterns extracted from the training step [106]. This could also
be further divided into classification and regression.The former aims to identify patterns
within a dataset that could be used to assign a categorical value (class) to each data
point [107], while regression aims to estimate an actual numerical value based on a set
of input features.
Alternatively unsupervised learning is defined when the input data comprises a collection
of features that describe the dataset without a corresponding label/class associated to
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it [108]. In this case, the purpose of ML is to find inherent groupings in the data or to
identify relationships, also known as association rules, among the features. The patterns
discovered for this type of algorithms commonly have to be manually evaluated or via
application of a supervised learning (Figure A.1B)
Figure A.1: Supervised and Unsupervised learning workflows. ML algorithms for
supervised learning (A) are provided with data in which the outcome is previously
known. The ultimate goal is to identify patterns to help the algorithm predict the
outcome when new data is provided. For unsupervised learning on the other hand (B),
a random dataset is provided and the ML algorithms try to determine if any existing
latent patterns are present.
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A.2 Learning Algorithms
A great variety of ML algorithms have been proposed to address specific problems and
data formats. These range from more simple implementations, such as Support Vector
Machines and Decision Trees, to more complex and robust approaches (Neural Net-
works), exploring different approaches and capturing different patterns encoded within
a dataset.
Support Vector Machines (SVM) algorithm has also proven to be robust and efficient
when dealing with classification and regression problems. In classification, its prelim-
inary aim is to establish decision boundaries in the feature space which separate data
points belonging to different classes [109] (Figure A.2A). Its intent is to create an opti-
mal separating hyperplane between classes in order to minimize the generalization error
and thereby maximise the margin of separating between the classes. When dealing with
non-linear separable classes and high number of features, SVM can use non-linear kernel
functions to help map high-dimensional feature space. For regression tasks, SVM tries
to find the best fit line (hyperplane) that has the maximum number of points within a
threshold value (distance between hyperplane and boundary lines).
A Decision Tree is an algorithm that uses a tree-like representation of a dataset in which
individual or combination of features are defined as nodes and the possible outcome
values from these nodes (branches) are linked to other child nodes, in a process that is
repeated until a decision based on a target value can be made. The basic assumption
made in the decision tree is that the instances with different classes have different values
in at least one of their features. One of the most useful characteristics of such algorithms
is their comprehensibility. One can easily understand why the algorithm classifies an in-
stance as belonging to a specific class by just looking at the generated tree and analysing
the splitting rules on each node of the tree [107] (Figure A.2B).
Ensemble methods are techniques that combine the results from several machine learn-
ing algorithms (base learners) into one predictive model in order to decrease variance,
bias and consequently improve predictions. In this regard, Random Forest, one of the
most used algorithms in ML uses a combination of decision trees such that each tree
depends on the values of a random vector sampled independently and with the same
distribution for all trees in the “forest” [110] (Figure A.2D). It is a fast algorithm that
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produces highly accurate predictions and can handle a very large number of input vari-
ables without overfitting, given that all the trees are built from scratch without any
previous information on the other trees in the forest. The final prediction output is
given as a combination of the outputs for all the base learners decision trees.
Multi-Layer Perceptron [111], commonly known as MLP, is a feed-forward neural net-
work, consisting of a number of units (neurons), which are connected by weighted links.
The units are organized in several layers, namely an input layer, one or more hidden
layers, and an output layer. The input layer receives an external activation vector,
and forwards it via weighted connections to the units in the first hidden layer. These
compute their activations and pass them to the neurons in succeeding layers creating a
mapping of the input dataset onto the output vector based on connection weights of the
network (Figure A.2D.
Alternatively classification tasks may be addressed with the use of regression algorithms
that handle discrete classes (nominal) of the dataset as continuous labels (probability) in
a probabilistic classification manner [112]. The classification is then achieved by defining
a threshold T , also known as linear decision boundary, in which the predicted classes are
assigned. Algorithms that use this type of classification seek for a model that generates
the greatest approximate probability function that separates the classes in the dataset
[113].
A.3 Feature Selection
When dealing with datasets with a large number of features, precautions are necessary
in order to avoid the curse of dimensionality [114] and also model overfitting during the
step of training on supervised learning. These two issues introduce a negative effect not
only on model generalization but also on performance during training, which could make
the predictive task unfeasible [115]. Here, I describe the algorithms used to select the
most representative features of a dataset that will be used for this work, before feeding
them to the supervised learning algorithms.
Principal Component Analysis (PCA) [116] is a mathematical algorithm that applies
an orthogonal transformation in the data, in order to generate a new set of features
(principal components) that maximises the variance among the data. Dimensionality
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Figure A.2: Examples of Learning algorithms workflows. To this date, a variety of
ML algorithms have been proposed. More simplistic approaches such as SVM (A) and
Decision Tree (B), in particular the latter, are beneficial because, in most cases, they
provide a more straightforward and clear explanation of how the algorithm uses the
features to make the predictions. One of the most popular ML algorithms is Random
Forest, which implements a combination of n base learners decision trees, has proven
to be accurate and robust in many different applications. More complex approaches
such as Multi-Layer Perceptron are also available, however, in most cases it requires a
lot more data and computational power to converge to a non-overfitted solution, than
other algorithms.
reduction can then be achieved by selecting only a subset of components with maximal
variance (principal components). The latter are also the ones that minimize the mean
squared error [117].
Information gain is a technique which uses the assumption that attributes in a dataset
are independent and estimates the quality of each attribute by measuring how much in-
formation was available before adding that attribute value, and how much was available
after with respect to the class that is trying to be predicted [118, 119], commonly calcu-
lated in terms of information entropy (Equation A.1). The attributes are then ranked
and feature selection can be performed by choosing a subset of features based on their
position in the rank.
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IG(T,X) = Entropy(T ) − Entropy(T,X) (A.1)
where IG(T,X) represents the information gain towards the target T when adding the
attribute X.
More recently, Recursive Feature Elimination (RFE) has been proposed and it uses an
external estimator that assigns weights to features (e.g., coefficients of a linear model)
to select features by recursively considering smaller sets of features. First, the estimator
is trained on the initial set of features and the importance of each feature is obtained.
Then, the least important features are pruned from the current set of features [120]. This
procedure is recursively repeated on the pruned set until the desired number of features
to select is eventually reached. Alternatively, cross-validation may be performed on each
iteration of RFE to find the optimal number of features, also known as RFECV.
A.4 Validation
Predictive models built using ML algorithms aim to generalise from the training data
to any data from the problem domain which the model has never “seen” before [107].
This aspect of ML is directly related to the concepts of underfitting and overfitting,
which can cause a negative effect of a final predictive model. Underfitting refers to a
predictive model unable to identify patterns in the training data and is consequently
incapable of generalisation to new data [121]. The solution generally involves trying
different algorithms, collection of more data points or generating/modelling of new sets
of features. On the other hand, overfitting occurs when an algorithm models the training
data so well and is unable to generalise to new data.
The process of evaluating predictive models is crucial in order to obtain a model capable
of generalisation and also to estimate its future prediction performance. A commonly
used validation method for ML models is known as k-fold cross-validation (CV) [115,
122]. The workflow for this approach consists of randomly splitting a data set (D) into
k mutually exclusive subsets, known as folds, D1, D2, ..., Dk of approximately equal size.
Secondly, the learning algorithm is trained and tested k times; each time tE1, 2, ..., k, it
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is trained on D−Dt and tested on Dt. The overall performance of the predictive model
is then calculated based on the average of performances for each fold (Figure A.3).
Figure A.3: k -fold Cross-validation workflow. The process consists of randomly split-
ting a data set (D) into k mutually exclusive subsets, known as folds. The learning
algorithm is then trained and tested k times and overall performance is calculated based
on the average of performances for each fold.
In the case of a dataset with a small amount of data points, the value of k is set to the
total number of instances in the dataset, named leave-one-out or jackknife CV [122].
Here the testing set will comprise a single entry and the remaining data is used for
training purposes the algorithms. The process is repeated until all entries have been
used as a test set.
In addition, as an extra layer of validation for the predictive models independent blind
tests are used [51, 55, 73], allowing for the assessment of how likely the final model is to
generalise on new data. The proportion of data points on training and blind test sets is
directly related to the total size of the dataset.
A.5 Evaluation Metrics
When evaluating performance on classification tasks, a variety of metrics can be ex-
pressed based on the values of a contingency table, also known as confusion matrix.
Given a binary classification, in which the classes are represented with positive (+) and
negative (−), a 2 × 2 matrix (actual versus predicted class) uses the raw counts of the
number of times each predicted label is associated with each real class. As shown on
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Figure A.4: Confusion matrix.
True and False Positives (TP and
FP ) indicate the number of pre-
dicted positives that were correct
and incorrect, respectively. Simi-
larly, True and False Negatives (TN
and FN) refer to correct and wrong
predictions for negative class. The
sum TP+FP+TN+FN is equal to
the total amount number of instances
in the data set being used.
Figure A.4, True and False Positives (TP and FP ) indicate the number of predicted pos-
itives that were correct and incorrect, respectively. Similarly, True and False Negatives
(TN and FN) refer to correct and wrong predictions for the negative class.
Alternative metrics can be derived based on the values from the confusion matrix. Preci-
sion denotes the proportion of Predicted Positive cases that are Actual Positives (Equa-
tion A.2). On the other hand, Recall (Equation A.3) measures the proportion of Actual
Positives cases that are correctly Predicted as Positives [123]. Furthermore, a combi-
nation of Precision and Recall in a harmonic mean denotes another metric known as
F-measure or F-score (Equation A.4) [124]. Precision, Recall and F-score values range
from 0 to +1, the latter representing a perfect prediction for the class being evaluated.
By essentially evaluating only one of the classes, all of these metrics present biases
towards the predictions of the positive class and ignore the performance in correctly
predicting the negative class [124]. This problem can be overcome by a straightforward
approach, which consists of inverting the signs on the confusion matrix and recalculating
all metrics. In that case, the metrics can be evaluated for each class separately, allowing
a better interpretation of the overall predictions. In addition, one can explore a less
biased metric, such as the Area Under the ROC Curve (AUC) that considers the True
Positive Rate (TPR), also known as sensitivity, which based on the example described
previously, corresponds to the proportion of positive data points correctly classified; and
also the False Positive Rate (FPR) that corresponds to the proportion of negative data
that are wrongly considered as positive, regarding all negative data points. A Receiver
Operating Curve (ROC) is then plotted using TPR versus FPR and the AUC is the










Fmeasure = 2 × precision× recall
precision+ recall
(A.4)
In the context of regression tasks, Pearson Coefficient Correlation (ρ), Matthews Cor-
relation Coefficient (MCC) [125] and Root Mean Squared Error (RMSE) are three
well-established and widely used metrics.
ρ is a measure of the linear correlation between two variables X and Y . The coefficient
is measured on a scale without units and can take values from −1, total negative linear
correlation, to +1, total positive correlation, Values closer to 0 indicate that there is no
linear correlation between X and Y [126]. The mathematical definition of the Pearson’s
Correlation Coefficient is given by the covariance of the two variables divided by the






• cov(X,Y ) is the covariance of X and Y
• σX is the standard deviation of the variable X
• σY is the standard deviation of the variable Y
Similarly, MCC also measures the correlation between two variables and also uses the
same scale of ρ. MCC scores can be calculated directly from the confusion matrix using
the following formula (Equation A.6):
MCC =
(TP × TN) − (FP × FN)
(TP + FP ) × (TP + FN) × (TN + FP ) + (TN + FN)
(A.6)
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RMSE is the standard deviation of the predictions errors. This measure indicates how
concentrated the predicted data points are from the line of best fit which represents the
ideal perfect correlation between the actual observed values (Y ) and the predicted values






(Yi − Ŷi)2 (A.7)
where: n is the total number of instances; (Yi−Ŷi)2 represents the squared errors between
actual observed values (Y ) and the predictions (Ŷ );
Lastly, the quality of predictions for machine learning algorithms is directly related to the
distribution of the features on the dataset being analysed. In this regard, the existence of
data points that lie an abnormal distance from other instances of the data, also known as
outliers, can decrease the performance of predictive models. These outliers may indicate
a variability in the measurements or simply experimental errors. A common practice
for predictive methods is to report the performance of their models after removing the
outliers and investigate those separately, in order to identify how these abnormal data
points may be affecting the final predictions [55, 65].
Appendix B
Programming and Scripting Tools
Task Tool Description
Scripting Python A high-level programming and scripting language
used for general purpose programming. The main
Python components used include.
Scripting R Programming Language and environment for statis-
tical analysis.
Version Control Git A distributed version control system for software de-
velopment. Used to store and organise code via Bit-
bucket web service.
Data Manipulation Numpy Provides support for large, multi-dimensional arrays,
matrices and high-level mathematical functions in
Python.
Data Analysis Pandas Implementation of data structures and data analysis
tools using Python.
Data Analysis BioPython Collection of tools for computational biology and
bioinformatics in Python.




CD-hit A program for clustering and comparison of large
sets of next generation sequencing data.
Data Storage SQL Structured Query Language is a standard language
for storing, manipulating and retrieving data in re-
lational databases
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Web Framework Flask Python framework used for the development of web
servers.
Web Development HTML Hypertext Markup Language is the standard markup
language for creating web pages.
Web Development CSS Cascading Style Sheets used for designing an HTML
page.
Web Development JS JavaScript is used for controlling the behaviour of
elements on an HTML page.
Containers Anaconda A software distribution with a vast library of pre-
configured and pre-built Python packages for scien-
tific computing.
Containers Docker Docker provides a way to run applications securely




Used to run multiple serial computing jobs, such as
PDB calculations, in parallel across multiple com-




Spartan Cluster of computers that delivers high performance.
Spartan is a system operated by Research Platform
Services (ResPlat) at The University of Melbourne.
High Performance Com-
puting
Bio21 Cluster of computers that delivers high performance.
This system is operated by the Bio21 computer staff
at The University of Melbourne.
Table B.1: Programing and Scripting tools.
Appendix C
HGDiscovery: an online tool
providing functional and
phenotypic information on novel
variants of homogentisate 1,2-
dioxigenase
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Abstract 
Alkaptonuria (AKU), a rare genetic disorder, is characterized by the accumulation of 
homogentisic acid (HGA) in the body. Affected individuals lack enough functional levels of an 
enzyme required to breakdown HGA. Mutations in the HGD gene cause AKU and they are 
responsible for deficient levels of functional homogentisate 1,2-dioxygenase (HGD), which, in 
turn, leads to excess levels of HGA. Although HGA is rapidly cleared from the body by the 
kidneys, in the long term it starts accumulating in various tissues, especially cartilage. Over time 
(rarely before adulthood), it eventually changes the color of affected tissue to slate blue or 
black. Here we report a comprehensive mutation analysis of 111 pathogenic and 190 non-
pathogenic HGD missense mutations using protein structural information. Using our 
comprehensive suite of graph-based signature methods, mCSM complemented with sequence-
based tools, we studied the functional and molecular consequences of each mutation on 
protein stability, interaction and evolutionary conservation. The scores generated from the 
structure and sequence-based tools were used to train a supervised machine learning algorithm 
with 84% accuracy. The empirical classifier was used to generate the variant phenotype for 
novel HGD missense mutations. All this information is deployed as a user friendly freely 
available web server called HGDiscovery (http://biosig.unimelb.edu.au/hgdiscovery/). 
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Introduction 
Alkaptonuria (AKU) is a rare recessive metabolic disorder which was used by Sir Archibald 
Garrod in his Croonian lectures to describe inborn errors of metabolism [1]. It is a hereditary 
disorder, resulting from mutations in the enzyme homogentisate 1,2 dioxygenase (HGD) (EC 
1.13.11.5), responsible for the breakdown of  homogentisic acid (HGA) which is an intermediate 
metabolite in the tyrosine degradation pathway [2]. With blockage in tyrosine metabolism, 
elevated levels of HGA leads to deposition of its own polymers as an ochronotic pigment in the 
connective tissue including cartilage, heart valves, and sclera [3]. Manifestation of disease 
during early childhood is seen as “homogentisic aciduria”, which is darkening of the urine upon 
standing. Delayed symptoms can be seen after 30 years of age which involves “ochronosis” – 
pigmentation of collagenous tissues like cardiac valves, eyes, ears and skin [4]. Current 
estimates of the disease occurrence in the Unites States obtained from the National 
Organisation of Rare Disorders is 1 in 250,000 – 1,00,000 live births [5].  
 
HGD gene located on chromosome 3q21-q23 [6], is a single copy gene composed of 14 exons 
[7]. Due to compound heterozygosity or homozygosity of HGD gene variants, the enzymatic 
defect in HGD is autosomal recessive [6, 8]. Information on all variants identified till date 
globally have been documented in the HGD mutation database (http://hgddatabase.cvtisr.sk/).  
The experimental crystal structure of the HGD protein has been solved (PDB code 1EY2 and 
1EYB) in 2000. The HGD protein protomer (NP_000178.2), is composed of 445 amino acids, 
which includes a 280 residue N-terminal domain, a central β-sandwich  and a 140 residue C-
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terminal domain [8]. It is a complex hexameric protein arranged as a dimer of trimers [9]. It is 
principally expressed in osteoarticular compartment cells (i.e. chondrocytes, synoviocytes and 
osteoblasts) [10] and in prostate, small intestine, colon, kidney and liver [7]. The spatial 
structure of the protomer, two-disc like trimers and the hexamer are maintained by an intricate 
network of non-covalent inter and intra-molecular interaction. This makes the protein structure 
extremely vulnerable to mutations [11].  
 
The major obstacle in studying an ultra-rare and complex disease like AKU is the lack of a 
standardized methodology to assess disease severity and response to treatment [12], which is 
complicated by the fact that AKU symptoms differ from one individual to another. Detailed 
evaluation and comparison of clinical and genomic data of AKU patient can play a key role to 
understand AKU variability. An in-depth molecular characterization of the disease is needed in 
pharmacogenomics prediction for suitable medical treatment. To address the issue we 
developed ApreciseKUre platform, which includes data on potential biomarkers, patients’ 
quality of life, biochemical outcomes and clinical information facilitating their integration and 
analysis in order to shed light on pathological characterization of every AKU patient in a typical 
Precision Medicine perspective [13-16] .  
 
We wanted to further elaborate and build a new database which would complement the 
existing ApreciseKUre database. The new database would provide the necessary underlying 
molecular information for novel and known clinical HGD variants. We have tried to exploit 
structural and sequence based information to build a predictive tool using supervised machine 
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learning algorithm. The model has been implemented through the webserver HGDiscovery, 
providing functional and phenotypic consequences of HGD non-synonymous variations to 




After removal of duplicate mutations, we curated a dataset composed of 301 non-synonymous 
substitutions. It included 190 non-pathogenic non-synonymous variations retrieved from 
gnomAD v.3 (Genome build GRCh38/hg38, Ensembl gene ID: ENSG00000113924.11, Region 
3:120628173-120682571) [17] and 111 AKU-causing clinical mutations. The 111 variants were 
first described in the study of Ascher et al. 2019 [18] and included in HGD Mutation Database 
(http://hgddatabase.cvtisr.sk) [19], which summarizes results of mutation analysis from 
approximately 530 AKU patients reported so far.  
HGD protein structure 
The X-ray crystallographic 3D structure of Homo sapiens holo-HGD (holo-HGDHs, PDB ID: 1EY2) 
is incomplete; thus, it needed structural reconstruction of the missing residues of the monomer 
and then of the whole hexamer in order to be able to perform a complete evaluation of 
variants effect on protein stability and flexibility. The missing loop in the human protein 
structure (residues 348–355) was reconstructed by homology modeling using the Pseudomonas 
putida HGD (HGDPp) structure. By using protein BLAST [20] software we found three structures 
belonging to Pseudomonas putida with a sequence identity (the amount of characters which 
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match exactly between two different sequences) larger than 49% and with root-mean-square 
deviation (RMSD) amounting to 1.8 Å for Cα [21]. We opted for HGDPp, with PDB ID 4AQ2 
since, similarly to 1EY2, as it had no substrate. The structures of holo-HGDHs (PDB ID: 1EY2) and 
its homologous HGDPp (PDB ID: 4AQ2) were retrieved from the Protein Data Bank (PDB) [22]. 
Thereafter at the 1EY2 and 4AQ2 sequences alignment on BLAST web server [20], we modelled 
the missing residues. The modelling of the loop 348-355 was carried out using a homology 
model approach in which an elucidated structure of HGDPp loop was employed as template to 
model the structure of the protein of interest. The completed monomer structure served as a 
starting point for the reconstruction of the whole HGDHs oligomeric protein on the template of 
the asymmetric units of PDB entry 1EY2. The structure reliability was validated using PROCHECK 
[23]. Additionally, the energy minimization of the hexameric protein was performed using 
GROMACS 5.0.2 [24] in order to obtain an optimized 3D structure, a relaxation of the highly 
energetic conformations and a correct geometry for the following simulations (for additional 
information see Supplementary Methods in [18]). 
Biophysical and evolutionary score generation 
A thorough structural and sequence based assessment was performed for all the HGD variants 
to account for the potential effects of AKU-causing mutations. Variations in protein-protein 
interactions between the different monomers of the hexamer HGD upon mutation was 
determined using mCSM-PPI2 [25]. Changes in protein stability and folding were determined 
using our in-house tools like mCSM-Stability [26], SDM [27] and DUET [28] and conformational 
flexibility changes using the normal mode analysis tool called DynaMut [29]. Effects of 
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mutations on binding affinity of HGD to its substrate homogentisic acid were analyzed using 
mCSM-Lig [30]. All these are novel machine learning approaches that use graph-based 
signatures to represent the structural and biochemical environment of the wild-type 3D 
structure of a protein to quantitatively predict the effects of point mutation. To complement 
the above methods we used sequence based feature like SNAP2 (Screening for Non-Acceptable 
Polymorphisms) [31], ConSurf [32] and Provean (Protein Variation Effect Analyzer) [33] which 
provides valuable evolutionary information.  To enrich the analysis we included protein’s wild 
type structural information such as residue depth, dihedral angles of the HGD chain φ (phi) and 
ψ (psi), relative solvent accessibility and secondary structure information. We calculated 
changes in molecular interactions such as hydrophobic, ionic, van der Waals’, halogen and 
hydrogen bonds and π interactions (cation–π, donor–π, halogen–π, carbon–π, π–π) between 
the wild type and mutant structures using Arpeggio [34]. We also included population-based 
variability using the missense tolerance ratio (MTR) [35] scoring system. 
Supervised Machine learning for empirical model building 
We evaluated different supervised machine learning algorithms for classification which is 
available within the scikit-learn Python library. These include – K-Nearest Neighbors (KNN), 
Random Forest, Decision Trees, Extra Trees, AdaBoost, Gradient Boosting, SVM, Gaussian Naïve 
Bayes, and Stochastic Gradient Descent. The best performing model was chosen by assessing 
metrics like Matthews correlation co-efficient (MCC), Receiver Operating Characteristic 
(AUROC) curve, accuracy, F1-score and precision. The model was trained using stratified 10-fold 
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cross validation. We carefully split the train and blind test dataset non-redundantly with respect 
to the amino acid residue position.  
To address the issue of imbalance between the pathogenic and non-pathogenic mutations in 
the data, we evaluated the model performance by both under-sampling the non-pathogenic 
mutations and oversampling pathogenic mutations in the train dataset [36]. The performance 
was compared for above mentioned scenario and the normal dataset and best results were 
obtained when the pathogenic mutations were oversampled using the Extra Tree algorithm. 
Extremely randomized tree classifier (or Extra Tree) is an ensemble machine learning algorithm 
and a variation of the random forest algorithm. The empirical binary classifier built using this 
algorithm highlights a set of structural and evolutionary features which can be used to 
discriminate between AKU-causing and non-pathogenic variations. 
Webserver development 
We have implemented HGDiscovery as a user-friendly and freely available webserver 
(http://biosig.unimelb.edu.au/hgdiscovery/). The front-end of the server was developed using 
Materializecss framework version 1.0.0, while the back-end was built in Python using the Flask 
framework version 1.0.2. The server is hosted on a Linux server running Apache 2. 
Results 
In this work we have used the 3D protein structure to understand the functional and molecular 
consequences of mutations in HGD leading to AKU disease and using the information generated 
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from these analyses we have trained a supervised machine learning algorithm to develop a 
predictive tool to determine novel variants which could lead to AKU manifestation. Figure 1 
depicts the novel methodological pipeline we have developed. 
 
Figure 1: HGDiscovery workflow. The first step involves scoping published literature and clinical 
databases to prepare a curated list of non-synonymous HGD mutations.  The second step 
involves generating various structure and sequence-based features for the curated missense 
mutations. In the third step, we use these features in a supervised machine learning algorithm 
to build a binary classifier, which can distinguish between pathogenic and non-pathogenic 
missense mutations. Finally, we develop a free available user-friendly webserver which contains 
phenotypic information on all HGD variants. 
Sequence-based analysis of HGD variants 
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ConSurf, SNAP2 and PROVEAN are sequence-based predictors and consider evolutionary 
information to predict functionally important non-synonymous mutation. The prediction helps 
us understand the biological impact of a mutation on the protein structure. A consistent 
pattern was observed from all of the sequence based features. The pathogenic mutations were 
associated with deleterious scores and the non-pathogenic mutations scored neutral. All the 
features were statistically significant to be used to train the predictive algorithm to build the 
empirical tool (p-values SNAP2: 4.6 e-14, PROVEAN: 1.1 e-9, ConSurf: 2.4 e-10). Population-based 
variability was considered using the missense tolerance ratio (MTR) scoring system. Majority of 
the pathogenic mutations were in the bottom 25th percentile, reflecting intolerance and hence 
associated with altering protein function. 
Wild-type environment analysis 
The wild-type environment analysis includes data on relative solvent accessibility (RSA), residue 
depth, dihedral angles and secondary structure information for both pathogenic and non-
pathogenic variants. Looking into the relative solvent accessibility values for the pathogenic and 
non-pathogenic mutations (p-value: 2.2 e-8), we see pathogenic mutations tend to be more 
exposed than non-pathogenic variants. It has been previously described that the HGD protomer 
structure constitutes of a pore in which the side chains of large number of residues are exposed 
[21]. These residues are thought to play an important part in the complex HGD catalytic 
function and we see subtle changes in the side chains as non-synonymous substitution can 
affect the active site functionality [18]. The residue depth values reveal pathogenic mutations 
are more buried than non-pathogenic mutations. This observation is congruous with earlier 
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observation where point mutations on the surface were better tolerated in the globular 
hexameric HGD protein structure. 
Structural and Biophysical analysis 
Our in-house biophysical tools mCSM-Stability [26], DUET [28] and DynaMut [29] were used to 
study and understand the impact of missense mutations on protein stability, folding and 
conformational flexibility. These tools are novel machine-learning algorithms which rely on 
graph-based signatures to calculate changes in Gibb’s free energy upon non-synonymous 
mutations. We observed pathogenic mutations to be associated with highly destabilizing scores 
affecting protein stability and dynamics. The effects of mutation on the substrate binding 
affinity to active site were determined using mCSM-Lig [30]. Pathogenic mutations altered the 
active / substrate binding pocket. mCSM-PPI2 [25] was used to assess changes in protein-
protein interaction and we observed pathogenic mutations hindered the formation of the 
symmetrical homohexamer. Therefore, pathogenic mutations either reduced or disrupted the 
HGD protein activity. 
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Figure 2: Boxplot representation of features. A) Structural features. B) Sequence-based 
features. C) Wild-type environment features. The non-pathogenic mutations (NP) are 
represented as sea green and pathogenic mutations (P) as dark orange. (*** p < 0.0001, ** p < 
0.001, Welch two sample t-test). 
Supervised machine learning algorithm: Extra Tree  
Our features could be grouped into eight distinct categories – protein stability, protein-protein 
interactions, ligand affinity, evolutionary conservation scores, distance parameters, MTR scores, 
molecular interaction and backbone geometry. Each category of features was initially used to 
build and evaluate the performance of the predictive model. After a thorough analysis of the 
individual features, we combined them together to see if there is a pattern which could be used 
to distinguish pathogenic from non-pathogenic HGD mutations. We observed that when 
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different categories of features were combined together, in addition to using stratified 10-fold 
cross validation with Extra Tree algorithm, yielded a more robust and balanced performance. 
The Extra Tree algorithm  implements a meta estimator that fits randomized decision trees on 
various sub-samples of the dataset and uses averaging to improve the predictive accuracy and 
reduces over-fitting [37].  
 
Figure 3: Empirical model performance trained on individual class of features. The Extra Tree 
algorithm was trained using stratified 10-fold cross validation using eight distinct class of 
features (first eight bars from left to right; dark blue bars) and with a combination of all features 
(red bar). The AUC score is low when a single class of feature is used for training the binary 
classifier, however, a significant improvement is noticed when all the eight different features are 
combined to build the model. 
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190 non-pathogenic and 111 pathogenic mutations were split into non-redundant train and 
blind test datasets with respect to their amino acid position. Initially we observed poor 
performance on the model’s ability to predict pathogenic mutation. We concluded that the 
train data set was imbalanced as there were more non-pathogenic mutations than pathogenic 
mutations. We improved the metric scores by oversampling (duplicating) [36] the pathogenic 
mutations in the train dataset. The final model correctly classified 84% and 73% of mutations in 
the train and blind test datasets respectively. 
 
Figure 4: Receiver Operating Characteristic (ROC) curves of HGD classifier.  The evaluation 
metrics shown for train and test dataset where pathogenic mutations are represented in dark 
orange and non-pathogenic mutations in sea green. (AUC = area under the curve). 
HGDiscovery Webserver 
HGDiscovery allows for users to query for a single point mutation or submit a list of mutations 
to be analysed in batch. For the “Single Mutation” option users are asked to provide the point 
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mutation as a string containing the wild-type reside one-letter code, its corresponding residue 
number and the mutant residue one-letter code. The “Mutation List” option requires that a text 
file is submitted with the list of mutations (one per line). 
The results page for the “Single Mutation” option displays the predicted outcome on the top 
alongside with details of the input mutation, wild-type residue environment, the variables and 
scores used by our predictive model and external links to experimental evidence (when 
available). An interactive 3D viewer using the NGL-viewer [38] shows the molecular contacts 
generated by Arpeggio [34] for wild-type and mutant structures. 
On the “Mutation List” option, the results are displayed as a downloadable table. Individual 
analysis for each variant on the table can be analysed similarly to “Single Mutation” option by 
clicking the “Details” button. An interactive viewer is also shown at the bottom of the page 
highlighting Pathogenic and Non-pathogenic mutations on the 3D structure. 
Discussion 
Here we present an empirical classifier HGDiscovery, which has phenotypic information on all 
variants of homogentisate 1,2 dioxygenase, (EC 1.13.11.5), an enzyme involved in the 
metabolism of tyrosine, whose deficiency leads to Alkaptonuria [OMIM 203500]. We combine 
structural, evolutionary and molecular information from known HGD variations and look to 
investigate a pattern to distinguish non-pathogenic from AKU-causing non-synonymous 
variants. So along with physiological information from ApreciseKUre platform, we have an 
additional AKU-dedicated database which provides new insight into functional and phenotypic 
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consequences of novel HGD non-synonymous variations, crucial for a genetic disease like AKU 
to support clinical decisions. 
The 3D crystal structure of the HGD active form reveals a highly complex and dynamic 
hexameric organization comprising two disk-like trimers [9]. An intricate network of 
noncovalent interactions is needed to maintain the spatial structure firstly of the protomer, the 
trimer and then the hexamer. This delicate structure presents a very low tolerance to mutations 
and can be easily disrupted mainly by missense variants compromising enzyme function. In case 
of HGD, missense variants represent approximately 65% of all known AKU substitutions [4, 11, 
39] and 93 distinct amino acid residue positions within the structure are affected by the 111 
AKU-causing missense changes. Recent studies on evolutionary conservation revealed that AKU 
variants were mainly located at more conserved residue positions [18] and, consequently, 
HGD missense changes can influence protein folding and stability or interactions with other 
protomers or substrate. Specifically, they can decrease stability of individual protomers, disrupt 
protomer–protomer interactions, or modify residues in the active-site region. Thus, when a 
novel HGD missense mutation is identified, it is important to distinguish causal AKU variants 
from non-pathogenic ones.  
With sequence-based tools such as ConSurf, SNAP2 and PROVEAN we have evaluated 
evolutionary information in order to predict functionally important non-synonymous mutations 
and the biological impact of a mutation on HGD protein structure. The obtained results 
supported our hypothesis: the pathogenic mutations were associated with deleterious scores 
whereas the non-pathogenic mutations with neutral scores. Additionally, using MTR score 
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system we have analyzed population-based variability and most of the pathogenic mutations 
resulted to be in the bottom 25th percentile, reflecting intolerance and alteration of protein 
function. With the help of biophysical tools (i.e. mCSM-Stability, DUET and DynaMut) we 
investigated the impact of missense mutations on protein stability, folding and conformational 
flexibility. AKU-causing mutations appear to reduce or disrupt the HGD protein activity by 
destabilizing its structure and altering the active site/substrate binding pocket. 
It is not uncommon that AKU patients carry compound heterozygotes for two HGD gene 
variants. In such cases, the estimation of the role of each missense variant is not trivial, since 
the hexamer could be assembled with monomers all affected by the same variant (homo-
oligomer) or by two different ones (heterooligomer) [40]. Variants affecting two different 
regions could have additive destructive effect, on the contrary, the effects could partially 
compensate for those that belong to the same region. However, we do not have any tools able 
to evaluate such events so far [12]. Compound heterozygosity could have even interfered with 
our analysis, where a variant labelled as non-pathogenic could actually be pathogenic. This was 
the limitation of our study. But with increasing availability of genomic and clinical data after 
patient analysis in future, we can always update our tool and re-label the mislabeled non-
synonymous variants. 
 
The information available from the above study can be used to develop new treatment 
strategies, for example, use of small molecules. We know that a pathogenic mutation with 
destabilizing scores for stability and flexibility leading to reduced enzyme activity can be 
rescued partially or totally with the help of a small molecule and hence might decrease the 
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severity of the disease [18]. Moreover, understanding the protein structure and function would 
also help in designing tailored drugs and therapies.  
Therefore, this framework may represent an online tool that can be turned into a best practice 
model for Rare Diseases. We believe this is not limited to the study of AKU, but it represents a 
proof of principle study that could be applied to other rare diseases, allowing data 
management, analysis and interpretation. We applied this novel methodological pipeline to 
understand and determine novel drug resistant mutations in tuberculosis [41, 42] and even 
performed a real-time analysis [43] on tuberculosis patient. Hence, HGDiscovery is a user 
friendly freely available tool which could help with faster and more accurate diagnosis of AKU.  
 
Acknowledgements 
M.K and C.H.M.R were funded by Melbourne Research Scholarships. D.B.A. was funded by a 
Newton Fund RCUK-CONFAP Grant awarded by The Medical Research Council and Fundacao de 
Amparo a Pesquisa do Estado de Minas Gerais(FAPEMIG) [MR/M026302/1]; the Jack Brockhoff 
Founda-tion [JBF 4186, 2016]; and an Investigator Grant from the National Health and Medical 
Research Council of Australia[GNT1174405]. Supported in part by the Victorian Government’s 
OIS Program. 
  
.CC-BY-NC-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.441386doi: bioRxiv preprint 
   
 
   
 
References 
1. Garrod, A.E., The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical 
article]. The Yale journal of biology and medicine, 2002. 75(4): p. 221-231. 
2. Phornphutkul, C., et al., Natural history of alkaptonuria. N Engl J Med, 2002. 347(26): p. 2111-
21. 
3. Damarla, N., et al., Alkaptonuria: A case report. Indian journal of ophthalmology, 2017. 65(6): p. 
518-521. 
4. Zatkova, A., L. Ranganath, and L. Kadasi, Alkaptonuria: Current Perspectives. Appl Clin Genet, 
2020. 13: p. 37-47. 
5. Disorders, N.O.f.R., NORD, 2019. https://rarediseases.org/rare-diseases/alkaptonuria/. 
6. Pollak, M.R., et al., Homozygosity mapping of the gene for alkaptonuria to chromosome 3q2. Nat 
Genet, 1993. 5(2): p. 201-4. 
7. Fernandez-Canon, J.M., et al., The molecular basis of alkaptonuria. Nat Genet, 1996. 14(1): p. 
19-24. 
8. Janocha, S., et al., The human gene for alkaptonuria (AKU) maps to chromosome 3q. Genomics, 
1994. 19(1): p. 5-8. 
9. Titus, G.P., et al., Crystal structure of human homogentisate dioxygenase. Nat Struct Biol, 2000. 
7(7): p. 542-6. 
10. Laschi, M., et al., Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: 
implications in alkaptonuria. J Cell Physiol, 2012. 227(9): p. 3254-7. 
11. Nemethova, M., et al., Twelve novel HGD gene variants identified in 99 alkaptonuria patients: 
focus on 'black bone disease' in Italy. Eur J Hum Genet, 2016. 24(1): p. 66-72. 
12. Ranganath, L.R. and T.F. Cox, Natural history of alkaptonuria revisited: analyses based on scoring 
systems. J Inherit Metab Dis, 2011. 34(6): p. 1141-51. 
13. Cicaloni, V., et al., Interactive alkaptonuria database: investigating clinical data to improve 
patient care in a rare disease. Faseb j, 2019. 33(11): p. 12696-12703. 
14. Spiga, O., et al., Machine learning application for development of a data-driven predictive model 
able to investigate quality of life scores in a rare disease. Orphanet J Rare Dis, 2020. 15(1): p. 46. 
15. Spiga, O., et al., A new integrated and interactive tool applicable to inborn errors of metabolism: 
Application to alkaptonuria. Comput Biol Med, 2018. 103: p. 1-7. 
16. Spiga, O., et al., ApreciseKUre: an approach of Precision Medicine in a Rare Disease. BMC Med 
Inform Decis Mak, 2017. 17(1): p. 42. 
17. Lek, M., et al., Analysis of protein-coding genetic variation in 60,706 humans. Nature, 2016. 
536(7616): p. 285-91. 
18. Ascher, D.B., et al., Homogentisate 1,2-dioxygenase (HGD) gene variants, their analysis and 
genotype-phenotype correlations in the largest cohort of patients with AKU. Eur J Hum Genet, 
2019. 27(6): p. 888-902. 
19. Zatkova, A., et al., Identification of 11 Novel Homogentisate 1,2 Dioxygenase Variants in 
Alkaptonuria Patients and Establishment of a Novel LOVD-Based HGD Mutation Database. JIMD 
Rep, 2012. 4: p. 55-65. 
20. Altschul, S.F., et al., Basic local alignment search tool. J Mol Biol, 1990. 215(3): p. 403-10. 
21. Jeoung, J.-H., et al., Visualizing the substrate-, superoxo-, alkylperoxo-, and product-bound states 
at the nonheme Fe(II) site of homogentisate dioxygenase. Proceedings of the National Academy 
of Sciences, 2013. 110(31): p. 12625. 
22. Berman, H.M., et al., The Protein Data Bank. Nucleic Acids Res, 2000. 28(1): p. 235-42. 
.CC-BY-NC-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.441386doi: bioRxiv preprint 
   
 
   
 
23. Laskowski, R., et al., PROCHECK: A program to check the stereochemical quality of protein 
structures. Journal of Applied Crystallography, 1993. 26: p. 283-291. 
24. Berendsen, H.J.C., D. van der Spoel, and R. van Drunen, GROMACS: A message-passing parallel 
molecular dynamics implementation. Computer Physics Communications, 1995. 91(1): p. 43-56. 
25. Rodrigues, C.H.M., et al., mCSM-PPI2: predicting the effects of mutations on protein–protein 
interactions. Nucleic Acids Research, 2019. 47(W1): p. W338-W344. 
26. Pires, D.E.V., D.B. Ascher, and T.L. Blundell, mCSM: predicting the effects of mutations in proteins 
using graph-based signatures. Bioinformatics (Oxford, England), 2014. 30(3): p. 335-342. 
27. Pandurangan, A.P., et al., SDM: a server for predicting effects of mutations on protein stability. 
Nucleic Acids Res, 2017. 45(W1): p. W229-w235. 
28. Pires, D.E.V., D.B. Ascher, and T.L. Blundell, DUET: a server for predicting effects of mutations on 
protein stability using an integrated computational approach. Nucleic acids research, 2014. 
42(Web Server issue): p. W314-W319. 
29. Rodrigues, C.H.M., D.E.V. Pires, and D.B. Ascher, DynaMut: predicting the impact of mutations 
on protein conformation, flexibility and stability. Nucleic Acids Research, 2018. 46(W1): p. W350-
W355. 
30. Pires, D.E., T.L. Blundell, and D.B. Ascher, mCSM-lig: quantifying the effects of mutations on 
protein-small molecule affinity in genetic disease and emergence of drug resistance. Sci Rep, 
2016. 6: p. 29575. 
31. Hecht, M., Y. Bromberg, and B. Rost, Better prediction of functional effects for sequence 
variants. BMC Genomics, 2015. 16 Suppl 8: p. S1. 
32. Ashkenazy, H., et al., ConSurf 2016: an improved methodology to estimate and visualize 
evolutionary conservation in macromolecules. Nucleic Acids Res, 2016. 44(W1): p. W344-50. 
33. Choi, Y. and A.P. Chan, PROVEAN web server: a tool to predict the functional effect of amino acid 
substitutions and indels. Bioinformatics, 2015. 31(16): p. 2745-2747. 
34. Jubb, H.C., et al., Arpeggio: A Web Server for Calculating and Visualising Interatomic Interactions 
in Protein Structures. Journal of molecular biology, 2017. 429(3): p. 365-371. 
35. Traynelis, J., et al., Optimizing genomic medicine in epilepsy through a gene-customized 
approach to missense variant interpretation. Genome Res, 2017. 27(10): p. 1715-1729. 
36. Krawczyk, B., Learning from imbalanced data: open challenges and future directions. Progress in 
Artificial Intelligence, 2016. 5(4): p. 221-232. 
37. Geurts, P., D. Ernst, and L. Wehenkel, Extremely randomized trees. Machine Learning, 2006. 
63(1): p. 3-42. 
38. Rose, A.S. and P.W. Hildebrand, NGL Viewer: a web application for molecular visualization. 
Nucleic Acids Research, 2015. 43(W1): p. W576-W579. 
39. Zatkova, A., An update on molecular genetics of Alkaptonuria (AKU). J Inherit Metab Dis, 2011. 
34(6): p. 1127-36. 
40. Gallagher, J.A., et al., Alkaptonuria: An example of a "fundamental disease"--A rare disease with 
important lessons for more common disorders. Semin Cell Dev Biol, 2016. 52: p. 53-7. 
41. Karmakar, M., et al., Structure guided prediction of Pyrazinamide resistance mutations in pncA. 
Scientific Reports, 2020. 10(1): p. 1875. 
42. Karmakar, M., et al., Empirical ways to identify novel Bedaquiline resistance mutations in AtpE. 
PLoS One, 2019. 14(5): p. e0217169. 
43. Karmakar, M., et al., Analysis of a Novel pncA Mutation for Susceptibility to Pyrazinamide 
Therapy. Am J Respir Crit Care Med, 2018. 198(4): p. 541-544. 
 
.CC-BY-NC-ND 4.0 International licenseavailable under a
was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made 
The copyright holder for this preprint (whichthis version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.441386doi: bioRxiv preprint 
Appendix D
MTR3D: Identifying regions
within protein tertiary structures
under purifying selection
316
MTR3D: Identifying regions within protein tertiary structures under purifying selection 
Michael Silk1,2,3, Douglas Pires1,2,3,4, Carlos M. Rodrigues1,2,3, Elston N. D’Souza1,2,3, Moshe 
Olshansky1, Natalie Thorne5, David B. Ascher1,2,3,6,* 
 
1 Computational Biology and Clinical Informatics, Baker Heart and Diabetes Institute, Melbourne, Australia 
2 Structural Biology and Bioinformatics, Department of Biochemistry and Molecular Biology, University of Melbourne, 
Melbourne, Melbourne, Australia 
3 Systems and Computational Biology, Bio21 Institute, University of Melbourne, Melbourne, Australia 
4 School of Computing and Information Systems, University of Melbourne, Melbourne, Australia 
5 Melbourne Genomics Health Alliance, Melbourne, Australia 
6 Department of Biochemistry, University of Cambridge, Cambridge, UK 
 
* To whom correspondence should be addressed D. B. A. Tel: +61 90354794; Email: david.ascher@unimelb.edu.au.  
 
Abstract 
The identification of disease-causal variants is non-trivial. By mapping population variation from 
over 448,000 exome and genome sequences to over 81,000 experimental structures and 
homology models of the human proteome, we have calculated both regional intolerance to 
missense variation (Missense Tolerance Ratio, MTR), using a sliding window of 21-41 codons, 
and introduce a new 3D spatial intolerance to missense variation score (3D Missense Tolerance 
Ratio, MTR3D), using spheres of 5-8 Å. We show that the MTR3D is less biased by regions with 
limited data and more accurately identifies regions under purifying selection than estimates relying 
on the sequence alone. Intolerant regions were highly enriched for both ClinVar pathogenic and 
COSMIC somatic missense variants (Mann-Whitney U test p < 2.2 x 10-16). Further, we combine 
sequence- and spatial-based scores to generate a consensus score, MTRX, which distinguishes 
pathogenic from benign variants more accurately than either score separately (AUC = 0.85). The 
MTR3D server enables easy visualisation of population variation, MTR, MTR3D and MTRX 
scores across the entire gene and protein structure for >17,000 human genes and >42,000 
alternative alternate transcripts, including both Ensembl and RefSeq transcripts. MTR3D is freely 
available by user-friendly web-interface and API at http://biosig.unimelb.edu.au/mtr3d/ . 
 
Keywords: Diagnostic tool, mutational analysis, missense variant intolerance, population 
variation; in silico score; missense constraint 
 
Key Points: 
- MTR3D captures spatial-based intolerance to identify regions mapped to protein 3D 
structures under purifying selection enriched for disease-causing missense variants and 
functionally important regions 
- A consensus score combines sequence-based and spatial-based intolerance and 
achieves greater predictive power of disease variants 
- The MTR3D web-server provides an easy-to-use tool to view MTR3D scores across 
experimental and homology modelled protein structures, with the Ensembl and RefSeq 







Advancements in our ability to distinguish between pathogenic and benign variants using both 
experimental and computational methods have proven greatly beneficial in our ability to diagnose 
genetic diseases. In silico predictors of deleteriousness have been successfully used to prioritise 
likely disease-causative variants (1-3), and have proven greatly beneficial in a number of disease 
cohorts, such as epilepsy, to identify genes enriched for pathogenic variation (4). Despite the 
accuracy of these methods improving, it remains challenging to identify causative variants due to 
the diverse effects that a mutation can have on the resulting protein. 
 
Large publicly available datasets of observed variation within the population provide the means 
to identify regions under purifying selection that are intolerant to genetic change. Several methods 
have been used to measure this using sequence-based approaches, including RVIS (5), MPC (6) 
and MTR (7), which have shown that patient-ascertained causative variants are preferentially 
found within intolerant regions. These provide differing scores depending on whether they are 
per-gene or regional scores, the sample sizes involved, and the statistical methods used to 
summarise the degree of depletion. Several tools exist that utilise sequence-based information 
mapped to protein tertiary structures in order to analyse the impact of mutations (8,9). When 
examining intolerance scores across a gene’s protein tertiary structure, intolerant regions have 
been observed to cluster within 3D space, but this has not been systematically and 
comprehensively investigated.  
 
To form a more accurate estimate of missense intolerance, and to systematically investigate 
genetic intolerance in the tertiary protein space, we introduce the MTR3D, a means of evaluating 
missense variant deleteriousness based on its spatially measured intolerance. The MTR3D 
provides both experimental structures from the Protein Data Bank (PDB) and available homology 
models where a transcript (Ensembl or NCBI RefSeq) could be aligned to a high-quality template. 
 




Population variation was combined from gnomAD v2.1.1 (10) (125,748 exomes, 15,708 
genomes), gnomAD v3 (76,156 genomes overlapping with gnomAD v2.1.1), the DiscovEHR 
dataset (11) (50,000 exomes) and UK Biobank (12) (200,000 exomes). Genomic coordinates of 
DiscovEHR and gnomAD v2.1.1 variants were converted from GRCh37 to GRCh38 reference 
assembly using LiftOver (13). Variants were then filtered to those single nucleotide variants 
(SNVs) passing each dataset’s quality control filters, annotated using the Variant Effect Predictor 
(VEP) (Release 101) (14) for positions within Ensembl transcripts and consequence for filtering 
to synonymous and missense only. 
 
Ensembl transcripts were downloaded from the Ensembl database (v101) (15) using the 
Bioconductor’s biomaRt (16) package. RefSeq transcripts were downloaded from NCBI RefSeq 
(17) using the biomartr() (18) package for NM mRNA transcripts, NP coding sequences and 
paired with Ensembl transcripts with identical Consensus CDS (CCDS) (19) sequence identifiers. 
A simulated set of all possible variants was generated by considering every possible single 
nucleotide substitution (3 variants per nucleotide in the sequence), filtered to missense and 
synonymous variants, and annotated using VEP to calculate the expected proportion of missense 
variants. 
 
For validation purposes, ClinVar (20) missense variants were retrieved from the NCBI FTP server 
and subset based on their labels to pathogenic, likely pathogenic, benign and likely benign 
variants. Catalogue of Somatic Mutations in Cancer (COSMIC) v92 (21) variants were 
downloaded from their website and filtered to confirmed somatic missense variants. The 
FATHMM SwissProt/TrEMBLdisease variants dataset and FATHMM cancer-associated 
missense variants datasets were also retrieved for additional comparisons (22). 
 
Sequence-based MTR scores can also be viewed in MTR3D, calculated using window sizes of 
21, 31 and 41. MTR v1 refers to the MTR scores calculated using gnomAD v1 (23). MTR v2 refers 
to the current sequence-based MTR scores derived from variation from gnomAD v2 and v3, UK 
Biobank and DiscovEHR (7).  
 
Calculation of the MTR scores across gene sequences 
 
Missense Tolerance Ratio (MTR) scores were calculated using a sliding window of 21, 31 and 41 
codons across each Ensembl and RefSeq transcript by comparing the observed proportion of 
missense variants to the expected proportion of variants (Equations 1-3). 
 
For a given window 𝑊𝑖
𝐻,𝐽
 and with selected window size 𝑤, the window is defined as: 
where 𝑖 =  residue position 
𝐻 = max (1, 𝑖 −
𝑤−1
2
)          (1) 






Within each window, the missense and synonymous variants are summed at each amino acid 
position yi for both the observed and expected datasets (Equation 2), and the ratio is taken 
(Equation 3). 
 
𝑦𝑖 =  ∑ 𝑥𝑚𝑥𝑚∈{𝑊𝑖
𝐻,𝐽
}
                                                                                   




𝑀𝑇𝑅𝑖 =  
𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑜𝑏𝑠𝑖 / (𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑜𝑏𝑠𝑖  + 𝑠𝑦𝑛𝑜𝑛𝑦𝑚𝑜𝑢𝑠_𝑜𝑏𝑠𝑖)
𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑒𝑥𝑝𝑖 / (𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑒𝑥𝑝𝑖 + 𝑠𝑦𝑛𝑜𝑛𝑦𝑚𝑜𝑢𝑠_𝑒𝑥𝑝𝑖)
     (3) 
 
 
Alignment of transcripts to protein tertiary structures 
 
UniProtKB’s ID mapping table was used to identify pairings between Ensembl and RefSeq 
transcripts with their corresponding experimental and homology modelled PDB structures and 
chains (24). Experimentally determined protein structures were downloaded from RCSB Protein 
Data Bank (25), selecting only the primary biological assembly for each structure. Homology 
models of Ensembl or RefSeq transcripts were generated using SWISS-MODEL (26) and an in-
house homology modelling pipeline using Modeller (27). We considered all potential templates 
with at least 30% identity for alignments longer than 100 residues and at least 70% identity for 
alignments shorter than 100 residues. Following minimization in Foldx, the quality of the homology 
models was assessed using Procheck (28), Molprobity (29) and WHATIF (30). The distribution of 
QMEAN Z-scores for the homology models was examined, revealing that over 76.9% of models 
have a Z-score above -4.0, indicating structural features of the homology models are comparable 
to what would be expected from high resolution X-ray structures (Figure S1).  
 
Ensembl and RefSeq transcripts were aligned to protein tertiary structures in R. Transcripts, 
metadata and sequences were parsed using data.tables, PDB files were parsed using bio3d (31) 
and aligned using a ClustalW (32) pairwise alignment via the msa package (33). To take into 
consideration added and omitted residues (for example unresolved loops) and partial structures 
(where the experimental structure was generated from a region of the gene, for example a single 
domain), the alignment was then split where there were gaps of at least 3 residues. These were 
then considered separately for congruence of >50% and minimum length of 5 residues in order 
to allow unaligned regions to be discarded. 42,312 Ensembl transcripts and 32,845 RefSeq 
transcripts were aligned to 40,277 unique RCSB PDB structures, 41,861 unique SWISS-MODEL 
homology models and 43,477 unique homology models generated using Modeller. 
 
Calculation of the MTR3D scores 
 
Population variation and simulated data of all possible variants, as described above, were 
mapped to residues within the PDB structure files. At each residue position, in x,y,z coordinates 
in angströms, missense and synonymous variants were summed based on any residue within a 
distance of 5, 6 and 8 Å respectively. Proximal residues with at least one atom within each of 
these spheres were considered (Figure S2). 
 
For a given window 𝑊𝑖
(𝑥1,𝑥2),(𝑦1,𝑦2),(𝑧1,𝑧2) as a sphere of distance 𝑤, taken from the defined 𝑥, 𝑦, 𝑧 
coordinates of a residue (Equation 4), 
where 
𝑖 =  residue position 
 𝑥1 = 𝑥 − 𝑤; 𝑥2 = 𝑥 + 𝑤 
𝑦1 = 𝑦 − 𝑤; 𝑦2 = 𝑦 + 𝑤                      (4) 
𝑧1 = 𝑧 − 𝑤; 𝑧2 = 𝑧 + 𝑤 
 
Observed and expected missense and synonymous variants were summed for each window at each 
residue y.i (Equation 5). 
 









𝑀𝑇𝑅𝑖 =  
𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑜𝑏𝑠𝑖 / (𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑜𝑏𝑠𝑖  + 𝑠𝑦𝑛𝑜𝑛𝑦𝑚𝑜𝑢𝑠_𝑜𝑏𝑠𝑖)
𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑒𝑥𝑝𝑖 / (𝑚𝑖𝑠𝑠𝑒𝑛𝑠𝑒_𝑒𝑥𝑝𝑖 + 𝑠𝑦𝑛𝑜𝑛𝑦𝑚𝑜𝑢𝑠_𝑒𝑥𝑝𝑖)
    (6) 
 
 
The MTR3D was then calculated at each position, considering only positions with at least 3 
observed variants (Equation 6). 
 
MTR3D scores for both ClinVar and COSMIC missense variants were also compared at the 
different radii of 5 Å, 6 Å and 8 Å, and separately for experimentally determined and homology 
modelled structures (Figure S3 and S4). This revealed that the 5 Å window size was most 
informative. 
 
Additionally, both the MTR and MTR3D were calculated for specific populations using a subset of 
the gnomAD database with sufficient representation of a given population (Admixed American 
(AMR), Non-Finnish European (NFE) and South Asian (SAS). 
 
MTRX Consensus score 
 
To assess the extent to which the combination of MTR and MTR3D scores are able to distinguish 
between pathogenic and non-pathogenic variants, a machine learning model was trained. 
Uniquely observed missense variants from ClinVar with no conflicting evidence of pathogenicity 
were assigned the class labels “P”, where clinical significance was denoted “Pathogenic” or 
“Likely pathogenic”, or “B” for “Benign” or “Likely benign”. 
 
To develop the MTR consensus score, we considered the missense tolerance scores from 
MTR3D (using a radius of 5 Å), and the previous sequence-based scores from MTR v1 and MTR 
v2. The performance of each score was considered individually and in combination. In addition, 
general structural properties including measures of depth, residue solvent accessibility (RSA) and 
Psi/Phi angles at each residue position, calculated using DSSP 3.0 (34) and Biopython (35), were 
also considered. 
 
Selecting the most informative features based on predictive performance (Table S1), a classifier 
was generated using Random Forest Classification (trees=100, depth=unlimited, number of 
features=unlimited) with the scikit-learn Python toolkit (36) and evaluated under 10-fold cross-
validation, with the best performing model selected based on the Area Under the ROC curve 
(AUC) and Matthew’s Correlation Coefficient (MCC). The final classifier MTRX uses MTR3D, 
MTR v2 21-codon windows, MTR v1 41-codon windows and RSA as evidence to distinguish 






We have implemented MTR3D as a user-friendly and freely available web-server application 
(http://biosig.unimelb.edu.au/mtr3d). The server front end was developed using Materialize 
framework version 1.0.0, and the back end was built using Python 2.7 via the Flask framework 




MTR3D can be used to either browse a table of the full set of available gene transcript – PDB 
structure – chain pairings (Figure S5), or to search for a specific gene or transcript directly. Names 
are not case-sensitive. 
 
On the viewer page (Figure 1) after making a selection, users may select alternate transcripts or 
alternate structures available for the current transcript or select between different distance 
calculations from a set of pre-computed options. Sequence-based MTR scores including 
population-specific MTRs can also be visualised directly on the structure. Users may also submit 
a protein position or list of protein residues to be highlighted on the structure, based on the 




A line graph using Bokeh is displayed to show the currently selected MTR scores as a 2D 
representation. This also provides a visualisation of which protein positions of the transcript are 
present in the currently viewed protein structure. Low scoring MTR3D scores indicate intolerance 
and purifying selection acting on that region, while high MTR3D scores indicate tolerance and, 
where MTR3D > 1.0, indicate that variation may be positively selected for in this region. 
 
A viewer to interact with the protein structure is provided, displaying MTR scores mapped onto 
the structure, where blue coloured regions indicate tolerance and red regions indicate intolerance. 
The structure can be rotated, zoomed and translated. Individual residue information is displayed 
when hovering over the structure.  
 
If residues have been selected, a red dot denotes their positions is highlighted on the line graph, 
and their side chains are displayed in stick format on the structure view. 
 
Both the line graphs and structure representations can be downloaded as image files as currently 
displayed. A table of MTR scores with alignments between transcript protein positions and 
structure residue numbers can also be downloaded as a CSV file, as well as the currently 




An Application Programming Interface (API) implementation is also available for the MTR3D 
scores for facilitating integration of our method with other systems and applications. Users may 
query an Ensembl transcript, RefSeq transcript, or HGNC symbol, and may optionally specify a 
protein position, specific PDB:chain identifier and specific score name. If no specific PDB:chain 
is supplied, the API will default to the structure with the most coverage for that transcript’s 
alignment to the structure. If no protein position is supplied, the API will return all scores across 
the currently selected structure. If a specific score is selected, the API will only return values for 




A bulk download is available via the web-server to download the full set of scores for Ensembl 
and RefSeq transcripts mapped to the experimental and homology structures. ClinVar disease 
variants, COSMIC somatic variants and DiscovEHR population control variants used for validation 





Performance on disease-ascertained variants 
 
MTR3D was assessed for its ability to differentiate pathogenic from non-pathogenic variants by 
comparing MTR3D scores across the ClinVar dataset. For each ClinVar gene transcript, a single 
protein structure with the greatest number of matching residues was selected, then ClinVar 
variants were filtered to uniquely observed variants by removing duplicate observations in order 
to prevent bias towards gene symbols with many transcripts or overrepresented variants. Note 
that validation could only be performed on ClinVar genes with a valid structure (2,752 
experimental structures, 6,333 homology modelled structures). Performance of experimentally 
determined protein structures was assessed separately to the homology modelled structures to 
assess whether both show similar enrichment of pathogenic variants within intolerant regions 
(Figure S3).  
 
Intolerant regions were found to be significantly enriched for ClinVar non de novo pathogenic 
variants (n = 14,547) and de novo pathogenic variants (n = 725) than benign variants (n = 7,086) 
for both experimentally determined and homology modelled structures (Figure 2A; Mann-Whitney 
U test p < 2.2 x 10-16 and p < 2.2 x 10-16, respectively). At a MTR3D (5 Å) less than 0.5, which we 
consider to be intolerant, 537 of 725 ClinVar de novo pathogenic and 5,030 of 14,547 ClinVar non 
de novo pathogenic variants were observed, while only 856 of 7,086 benign variants were found 
here. The MTR3D scores was further assessed using the FATHMM SwissProt/TrEMBL training 
dataset and found to perform similarly (Mann-Whitney U test p < 2.2 x 10-16). 
 
Performance on cancer-ascertained variants 
 
COSMIC unique somatic missense variants from cancer samples were compared with 
DiscovEHR population variants to determine whether there is significant enrichment of COSMIC 
variants within intolerant regions compared with standing variation within the population (Figure 
2B). We defined a proposed cutoff of 0.75 to denote intolerance, however the ideal cutoff will vary 
depending on the gene under investigation. Over two thirds of COSMIC variants (18,981 / 27,520) 
were found to have a MTR3D below  0.75. A significant enrichment was found in both 
experimentally determined and homology models for COSMIC variants (Figure S4; Mann-
Whitney U test p < 2.2 x 10-16 and p < 2.2 x 10-16, respectively). Using the FATHMM cancer-
associated training dataset, we find similar enrichment for cancer-associated variants within 
intolerant regions (Mann Whitney U-test p < 2.2 x 10-16). 
 
Interestingly, when we compared the intolerance scores of variants in tumour suppressor (n = 116 
genes) and oncogenes (n = 91 genes) separately, while background control variation did not 
reveal any significant difference, cancer-ascertained variants in oncogenes were associated with 
significantly lower MTR3D scores than those in tumour suppressors (Figure S6). This is likely due 
to the larger effect of purifying selection of dominant variants. 
 
Performance of the MTRX consensus score 
 
A consensus score, MTRX, was built using the MTR3D scores, together with sequence-based 
MTR scores and general structural properties, using the ClinVar database (n = 23,406 variants). 
The MTRX represents a likelihood of a variant being pathogenic [0-1]. The distribution of MTRv1, 
MTRv2, MTR3D and RSA across the dataset shows clear differences between benign and 
pathogenic variants (p-value < 0.0001, Figure S7), and interestingly there is not a strong 
correlation between the spatial and sequence based scores (Figure S8). The overlap in intolerant 
regions between the spatial and sequence based scores, indicated that while there was significant 
agreement, over 18% of the intolerant regions under selective pressure were identified by only 
the spatial based scores, in particular in sequence based windows with limited data (Figure S9).  
 
Table 1 shows the predictive performance of individual scores and their combination under 10-
fold cross validation. Individually, MTR scores achieved AUCs of 0.63 (MTR3D; 5 Å), 0.64 (MTR 
v2; 21 codons) and 0.67 (MTR v1; 41 codons), respectively (Figure 2D). While individual features 
only presented a modest ability of distinguishing between pathogenic and benign variants, a 
significant improvement in performance (p-value < 0.001) is observed when scores are combined 
in a consensus, achieving an AUC of 0.85 and MCC of 0.49, demonstrating the complementary 
nature of the scores. Performance is further improved when structural properties (residue relative 
solvent accessibility) is also considered (Figure 2D; AUC of 0.90 and MCC of 0.62). An analysis 
of feature importance also showed a high level of complementarity between MTR scores and the 
selected structural property (Figure S10). 
 
Exploring the learned trees further, we observe that the top of the majority of the decision trees 
uses as first branching point an RSA of 20.7% (Figure 2C). Interestingly, this is consistent with 
general thresholds for considering residues as either buried (RSA <20%) or exposed (RSA >20%) 
(37,38). For buried residues, MTRX considered a variant pathogenic if the MTR3D score was 
below 0.73 or the MTRv1 score below 0.68 (Figure 1A). For exposed residues, variants were 
considered pathogenic if their MTR3D score was below 0.58, indicating the need for stronger 
evidence of intolerance to label exposed residues as pathogenic than buried residues. These two 





The MTR3D application provides an intuitive and programmable interface to explore intolerance 
and purifying selection within protein tertiary structures and across the flat sequence. The MTR3D 
and MTR consensus scores are versatile metrics to assess the likelihood of pathogenicity in 
patient-ascertained variants, as well as measures to identify novel important regions within protein 
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Figure 1. MTR3D viewer page. (A) Users may select between different structures and sequence-
based, spatial-based and consensus scores for the currently selected transcript. Users may also 
select between window sizes and population estimates. (B) Line graph showing the alignment of 
scores to the currently selected transcript and structure. Gaps in the plot indicate regions not 
congruent or not present in the protein tertiary structure. Horizontal lines indicate MTR percentiles 
for the current transcript at 5th, 25th, 50th and MTR = 1. (C) The selected protein structure is 
displayed and coloured by the currently selected MTR score, where red and blue represent 
intolerance and tolerance respectively. (D) Download links for the MTR scores for the currently 
selected structure or the currently shown PDB.  
 
Figure 2: Performance of MTR3D and consensus score on identification of disease and 
cancer-ascertained variants. Comparison of the spatial- and sequence- based MTR scores 
using disease-associated variants. (A) Cumulative distribution graph comparing MTR3D (5 Å) and 
MTR v2 (31 codons) in ClinVar de novo pathogenic missense variants (purple, blue respectively), 
ClinVar not de novo pathogenic missense variants (orange, brown respectively) and ClinVar 
benign missense variants (black, grey respectively). (B) Cumulative distribution graph comparing 
COSMIC somatic missense variants MTR3D (5 Å) scores (red), MTR v2 (31 codons) scores 
(orange), with DiscovEHR population missense variants observed within the same genes (black, 
grey respectively). (C) Decision tree representation of the most informative scores used in the 
generation of the consensus metric calculated using a Random Forest model. Cut-offs were 
determined based on 10-fold cross-validation. (D) Area under the Curve (AUC) plot showing 
classification specificity/sensitivity for MTR3D (5 Å) (red), MTR v2 21 codons (green), MTR v1 41 
codons (blue), MTR consensus using MTR3D (5 Å) + MTR v2 21 + MTR v1 41 (purple), and with 
RSA included (black).  
TABLES 
 
Table 1: Predictive performance of MTRX consensus scores on ClinVar variants 
 
Score TP rate FP rate Precision Recall AUC MCC 
MTR3D 5 Å 0.64 0.57 0.60 0.64 0.63 0.10 
MTRv2 (21 codons) 0.64 0.55 0.60 0.64 0.64 0.12 
MTRv1 (41 codons) 0.65 0.49 0.63 0.65 0.67 0.17 
MTR3D + MTRv2 + 
MTRv1 
0.77 0.30 0.77 0.77 0.85 0.49 
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Background. Asymptomatic left ventricular dysfunction (LVD) has management 
implications, but routine echocardiography is not undertaken in subjects at risk of heart 
failure. Signal processing of the surface ECG using continuous wave transforms (CWT) can 
identify abnormal myocardial relaxation. We sought whether machine-learning from CWT-
processed “energy waveform” ECG (ewECG) could be integrated with echocardiographic 
assessment of subclinical systolic and diastolic LVD.  
Methods. EwECG and echocardiography were undertaken in 398 participants at risk of HF. 
Reduced global longitudinal strain (GLS≤16%)), diastolic abnormalities (E/e’>15, left atrial 
enlargement with E/e’>10 or impaired relaxation) or LV hypertrophy defined LVD. EwECG 
feature selection and supervised machine-learning by Random Forest (RF) classifier was 
undertaken with 643 CWT-derived features and the Atherosclerosis Risk in Communities 
(ARIC) heart failure risk score.  
Results. The ARIC score and 18 CWT features were selected to build a RF predictive model 
for LVD in a training data set (n=287, 60% female, median age 71(68-74) years). Model 
performance was tested in an independent group (n=111, 49% female, median age 61(59-66) 
years), demonstrating 85% sensitivity and 72% specificity (AUC 0.83,95% CI 0.74-0.92). 
With ARIC score removed, sensitivity was 88% and specificity, 70% (AUC 0.78,95% CI 
0.70-0.86). RF models for reduced GLS and diastolic abnormalities including similar features 
had sensitivities that were unsuitable for screening. Conventional candidates for LVD 
screening (ARIC score, NT-proBNP and standard automated ECG analysis) had inferior 
discriminative ability. Integration of EwECG in screening of people at risk of HF would 
reduce need for echocardiography by 56% while missing 12% of LVD cases.    
Conclusion. Machine-learning applied to ewECG is a sensitive screening test for LVD and 
its integration into screening of patients at risk of HF would reduce the number of 
echocardiograms by over half.  
 
Keywords: Left ventricular dysfunction, electrocardiography, machine-learning, screening   
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The echocardiographic recognition of structural and functional cardiac abnormalities 
among patients with HF risk factors identifies asymptomatic LV dysfunction (LVD), and 
thereby guides therapy (1). Despite this, routine echocardiography is rarely performed in 
people with HF risk factors, other than in coronary artery disease (CAD) (2). No viable 
screening test has evolved to better direct selection for echocardiography.  
Standard 12-lead electrocardiography (ECG) is a potential initial investigation in 
people with HF risk factors. A range of ECG abnormalities, e.g. arrhythmias, conduction 
disturbances and voltage patterns, may relate to underlying LV dysfunction. The potential for 
a form of signal processing, known as continuous wavelet transform (CWT), to reveal 
abnormalities in a standard ECG signal has been recognized for over 20 years (3,4). 
However, only recently have patterns in CWT-processed ECG signals or ‘energy waveform 
ECG (ewECG)’ been demonstrated to predict functional LV abnormalities, specifically 
abnormal relaxation (5,6). Recording an ewECG requires no additional time or expertise and 
simultaneously displays a standard 12-lead ECG trace, making it a feasible test for use in the 
community. However, although there is an association between repolarization measures and 
abnormal myocardial relaxation (7), whether prior findings in populations presenting for 
echocardiography (6) extend to the detection of asymptomatic systolic LV dysfunction in 
community populations at risk of HF is unknown. Indeed, the most appropriate use of this 
technology would be to guide definitive echocardiographic assessment as part of a screening 
process.  We hypothesized that machine-learning algorithms applied to ewECG data could 
identify LVD in a community population at risk of HF, and that depolarization and 







Study participants. Participants were recruited from the community as part of the ongoing 
Victorian Study of Echocardiographic detection of Left ventricular dysFunction (Vic-ELF; 
ACTRN 12617000116325), in Melbourne, Australia. Participants were aged ≥65 years with 
at least one of the following HF risk factors; obesity (BMI ≥30 kg/m2), type 2 diabetes 
mellitus or hypertension (systolic blood pressure ≥140mmHg or on medication). Exclusion 
criteria included LV ejection fraction (LVEF) ≤40%, known symptomatic heart failure (or 
diagnosed at baseline screening), known coronary artery disease (CAD; excluded due to the 
routine use of echocardiographic assessment in this group), moderate or greater valvular heart 
disease, renal impairment and symptoms of HF.  
The testing dataset comprised an analogous group of 111 prospectively recruited 
asymptomatic people without established cardiovascular disease, with the same inclusion 
and exclusion criteria, in Canberra (Australian National University Medical School), 
Australia (n=79); New York, NY (Icahn School of Medicine), and Morgantown, WV 
(University of West Virginia), USA (n=32). This geographical heterogeneity aimed to test 
model generalizability. The relevant institutional review boards approved the study and 
participants gave written informed consent.  
Clinical measures. Baseline measures and procedures pertinent to this sub-study included: 
body mass index, resting averaged systolic blood pressure (SBP) and diastolic blood pressure 
(DBP), heart rate (HR), documentation of cardiovascular risk factors, comorbidities and 
medications. Clinical data were used to calculate the 4 year risk of incident symptomatic HF 
using the Atherosclerosis Risk in Communities (ARIC) HF risk score, which has 
demonstrated utility in risk stratification in subclinical HF (8). Biochemical markers of renal 




Standard electrocardiography and energy waveform ECG. After standard ECG lead 
placement, subjects underwent ewECG evaluation using a device that is CE-marked but not 
approved for use in the USA (MyoVista Version 2.0, HeartSciences, Southlake, TX). The 
MyoVista ewECG interface displays a standard 12-lead, ECG trace as well as an automated 
diagnostic interpretation based on the University of Glasgow 12-lead ECG interpretive 
analysis algorithm, which provides both quantitative parameters and qualitative 
interpretations (9,10). The ECG signal is deconstructed and presented graphically in an 
energy scalogram (red [high energy] to blue [low energy]) depicting an energy distribution by 
time (x-axis) and frequency (y-axis) (the “energy waveform”) (Figure 1). As described 
previously (5), energy is expressed as coefficients reflecting agreement between wavelet and 
signal at varying scales, rather than a discrete energy measurement (11). A total of 643 CWT 
features (energies, frequencies and ratios) at defined points in the cardiac cycle are generated 
by proprietary software throughout the cardiac cycle. As our prior work demonstrated the 
existing automated interpretative algorithms to be insufficiently sensitive to detect LVD (12), 
we used the complete CWT output.  
Echocardiography. On the same day as ewECG a transthoracic 2-D and Doppler 
echocardiographic study was performed using standard equipment (ACUSON SC2000, 
Siemens Healthcare USA, Mountain View, CA) and transducer (4V1c, 1.25 to 4.5 MHz; 
4Z1c, 1.5 to 3.5 MHz) in accordance with American Society of Echocardiography guidelines. 
LV systolic function was assessed by global longitudinal strain (GLS) computed using 
speckle-tracking (Syngo VVI, Siemens Healthcare USA, Mountain View, CA). GLS was the 
average of regional strains in the apical 2-chamber, 4-chamber and long axis views.  Diastolic 
function was assessed by measuring mitral inflow peak early diastolic velocity (E), peak late 
diastolic velocity (A), E/A ratio, septal and lateral mitral annular early diastolic velocities (e’) 




biplane images and indexed to body surface area; LA enlargement was defined as LAVi >34 
ml/m2. Left ventricular hypertrophy (LVH) was defined as LVMi >95 g/m2 in women and 
>115 g/ m2 in men. LVD was defined by either i) abnormal structure (LVH), ii) abnormal 
GLS ≤16%, or borderline GLS (17-18%) with impaired relaxation (IR) or left atrial 
enlargement (LAE), iii) diastolic dysfunction (E/e’ >15 or E/e’>10 with LAE or IR with 
LAE).  
We developed predictive models for: a) LVD, b) systolic dysfunction (GLS≤16%), c) 
diastolic dysfunction.  
Machine-learning classification model. A supervised machine-learning approach was used 
to predict LVD status. We used the Random Forest (RF) classifier algorithm in the module 
Scikit-learn (Python Software Foundation, https://www.python.org/) (13). All 
hyperparameters for the algorithm were entered according to the library’s documentation and 
have been summarised in Table 5 in the Supplemental material. Given the high 
dimensionality of the data, including the fact that ewECG features were more numerous than 
subjects, we undertook a process of feature selection to identify those features with the most 
predictive information relevant to LVD (Supplemental material, Figure 1). All CWT features 
plus the ARIC HF risk score were offered in feature selection. The ARIC score was included, 
so as to evaluate importance of this easily attainable clinical variable against ewECG.  
The feature selection approach evaluated the performance of all individual features 
(N), using area under the ROC curve, and selected the best performing in the first round. 
Then, each of the remaining (N-1) features was paired with the selected one to identify the 
pair that gave the best performance. This process was repeated until all features were selected 
and the combination of features that provided the best performance was ascertained. Other 
approaches were tested but were less successful (Supplemental material Table 1). We also 




importance). This indicates the contribution made by each feature to the model's predictive 
performance. Practically, higher importance means that the decision-making error associated 
with a feature in the nodes across all decision trees in the forest is less than using other 
features in other nodes. 
A 5-fold cross validation on the training data set was used to internally validate model 
performance with subsequent external validation on the separate/test dataset. The output of 
the RF model is a continuous probability score with a threshold of 50% for dichotomising 
predicted outcome e.g. LVD vs. no LVD. When evaluating the performance on the external 
dataset, modification of this probability threshold was investigated to see if performances 
could be optimised. Unless otherwise stated, the 50% threshold was found to be optimal.  
Statistical analysis. Continuous data are presented as mean ± standard deviation (SD) or 
median and interquartile range (IQR) depending on distribution after visual assessment. 
Between group differences for categorical data were tested using Pearson’s chi-square, and 
for continuous variables the independent t-test or Wilcoxon rank-sum test was used 
depending on normality of distribution. Because the most important characteristic of a 
screening test is high sensitivity, cut-points were selected with the minimal number of false 
positives at a sensitivity closest to 90%. Discriminatory performance predictive models were 
assessed using area under receiver operating characteristic curve (ROC AUC). To evaluate 
the incremental utility of the machine learning models compared with the ARIC HF risk 
score as a base model, continuous net reclassification improvement (cNRI) and integrated 
discrimination improvement (IDI) were calculated. CNRI measures improvements in 
probabilities within events (i.e. increased probability) and non-events (i.e. decreased 
probabilities), with the addition of, in this case, the machine-learning models (14). IDI 
reflects the difference in discrimination slopes (probabilities for events minus non-events) 




significance was defined as a two-tailed p value <0.05. Analyses were conducted using 
STATA 15.1 (StataCorp, College Station, TX). 
 
Results 
Participants: Overall we included 398 participants (57% female, median age 69 (66-73) 
years) and of these, 171 (43%) had LVD. Baseline characteristics by HF stage are shown in 
Table 1. Compared with people with only risk factors, LVD was associated with older age, a 
higher proportion of hypertension, T2DM, increased heart rate and systolic blood pressure, 
and higher ARIC HF risk score. The proportion of an ‘abnormal’ Glasgow ECG analysis 
summary was 15% and 36% for people with risk factors and LVD, respectively (p<0.001). 
All echocardiographic measures differed significantly between HF stages.  
Prediction of LVD by conventional methods. The ARIC HF risk score had an AUC of 0.72 
(95% CI 0.67-0.77) for LVD discrimination.  An optimized cut-point for sensitivity was 
identified as an ARIC HF risk score of 2.6, providing 90% sensitivity and 40% specificity. 
Similarly, the AUC for NT-proBNP was 0.53 with an optimized cut-off of 21pg/ml providing 
a sensitivity of 88% and specificity of 14%. Lastly, an abnormal ECG by Glasgow analysis 
had a sensitivity and specificity of 36% and 85%, respectively. In those with available NT-
proBNP, adding NT-proBNP to ARIC HF risk score (AUC 0.65 [95% CI 0.59-0.71]) did not 
significantly improve discriminatory ability vs. ARIC alone (AUC 0.63 [95% CI 0.56-0.69], 
p=0.18). Furthermore, the addition of both NT-proBNP and abnormal ECG by Glasgow 
analysis did not significantly improve discriminatory ability (AUC 0.67 [95% CI 0.61-0.74], 
p=0.06) (Supplemental material, Figure 2).  
Prediction of LVD by Random Forest classifier using ewECG. Of the 398 subjects, 287 
(72%) were used to train the RF prediction model and 111 (28%) were used to test model 




significantly younger and there was a lower proportion of females, as well as participants 
with hypertension and diabetes. Furthermore, SBP, DBP and ARIC HF risk were 
significantly lower. The prevalence of the LVD composite was 23% in the test dataset 
compared to 51% in the training dataset (p<0.001) and a similar pattern was observed for 
abnormal GLS and diastolic abnormalities (Table 2).  
The ARIC HF risk score was selected during feature selection along with 18 CWT 
features to train an RF model (Table 3). At a probability threshold of 0.51 (optimized for 
sensitivity), the sensitivity and specificity of the model for prediction of LVD on the test 
dataset were 85% and 72%, respectively (ROC AUC 0.83 (95% CI 0.74-0.92) (Table 4). 
With ARIC removed from the model, the optimized sensitivity and specificity for detection 
of LVD were 88% and 70%, respectively (ROC AUC 0.78 (95% CI 0.67-0.88), p=0.32 for 
difference between models) (Table 3, Figure 2). For a prevalence of 43%, this corresponded 
to a negative predictive value of 89% (95% CI 78-95%) and positive predictive value of 69% 
(95% CI 60-77%).  
Incremental improvements in prediction were seen for both RF models compared with 
the ARIC HF risk score alone, as assessed by cNRI and IDI. For the RF model incorporating 
ARIC, cNRI was 0.79 (95% CI 0.23-1.17) and IDI 0.09 (95% CI 0.012-0.24). For the model 
incorporating only ewECG features cNRI was 0.94 (95% CI 0.46-1.29) and IDI 0.11 (0.017-
0.255).  
The RF classifiers were inspected to reveal their node features. For the LVD 
predictive model, features were temporally associated with both depolarization and 
repolarization and included several features derived from the energy/power spectrum i.e. 
certain ratios of harmonics within the power spectrum throughout cardiac cycles (Table 3). 
Prediction of low global longitudinal strain by ewECG, using the Random Forest 




predictive model for low GLS (≤16%), this was not able to identify any cases of low GLS 
(supplemental material, Table 2). After repeating feature selection, 16 features were found to 
confer peak predictive power (supplemental material, Table 3), and performance on the test 
dataset showed a sensitivity of 57% and a specificity of 90% (Table 4).  However, the 
proportion with low GLS in the test dataset (6%) was significantly lower than the training 
dataset (19%, p=0.002), which is of significance in interpreting model performance. The 
CWT features selected for the low GLS model were predominantly power spectrum and 
repolarization features (ARIC HF risk score was not selected). Nine out of the 16 features 
were chosen for the LVD model. 
Prediction of diastolic abnormalities by ewECG, using the Random Forest classifier. 
Overall, 91 (23%) exhibited diastolic abnormalities, with a significantly lower proportion in 
the test versus training dataset (13% vs. 27%, p=0.002, respectively [Table 2]). Again, 
features from the LVD predictive model trained for diastolic abnormalities were unable to 
discriminate (Supplemental material, Table 2). After repeated feature selection, a model with 
14 features produced a sensitivity of 50% and a specificity of 90% (Table 4). Features 
selected for inclusion in the model included power spectrum and repolarization features as 
well as one depolarization-related features that also occurred in the LVD model (ARIC HF 
risk score was not selected) (supplemental material, Table 4). Ten out of the 14 features were 
also chosen for the LVD model. 
Impact of ewECG on a screening process for LVD. On the basis of greatest sensitivity for 
LVD identification, the RF ewECG model without the ARIC HF risk score was considered 
most optimal. Use of this ewECG-based model to select people for echocardiography could 
reduce the number of echocardiograms by 56% ([true negatives + false negatives]/total 
screened x 100). However, 12% of cases of LVD would be missed. Alternatively, the RF 




echocardiograms but would miss 16% of cases of LVD. By comparison, using the best of the 
conventional methods i.e. ARIC HF risk score ≥2.6, echocardiograms would be reduced by 
only 27% and 11% of LVD cases would be missed (Central illustration).  
 
Discussion 
The application of signal processing (CWT), to a conventionally acquired ECG signal 
provides a viable screening test that can be integrated with echocardiographic screening for 
LV dysfunction. In our cohort of people at-risk of HF, our machine-learning (RF) algorithm 
provided 88% sensitivity and 70% specificity for detection of LVD, outperforming a clinical 
risk score, biomarkers and an established automated ECG analysis algorithm. Furthermore, 
we highlighted that CWT features required for identification of LVD differed slightly 
according to LV abnormality e.g. reduced systolic function or diastolic abnormality. The 
best-performing model was for prediction of a composite measure of LVD. There was no 
significant difference between a machine-learning model that incorporated clinical 
information i.e. the ARIC HF risk score, compared with ewECG features alone. If 
implemented in combination with echocardiography as a screening test, ewECG could reduce 
echocardiograms by 56% in screening for LVD. This is important given the 82% prevalence 
of subclinical HF in the community in those over 67 years (16). For the United States this 
would mean approximately 40 million people would be eligible for screening and ewECG 
could reduce the number of echocardiograms by around 23 million (17). Even if such a 
screening program did not eventuate, ewECG may serve as a gatekeeper to the 
echocardiography lab in high risk but asymptomatic individuals.  
Electrocardiography and myocardial dysfunction. Structural and metabolic cardiac 
pathology manifesting as electrocardiographic abnormalities is well accepted. However, 




(9). Accordingly, a recent study used artificial intelligence (AI) (convolutional neural 
networks) applied to standard ECG digital data to predict LVD (defined as LV ejection 
fraction ≤ 35%) with a sensitivity of 89%, specificity of 83% and AUC of 0.93 (18). 
Interestingly, those with a “false positive” result were 4 times as likely to develop LVD 
during 4-year follow-up, suggesting the AI could recognize early abnormalities. Another 
approach extracted advanced ECG (A-ECG) parameters (3D ECG parameters, QRS/T wave 
complexity parameters) including variability analysis (5-minute high fidelity ECG recording) 
as well as conventional ECG measures to devise a prediction score for myocardial disease 
(19). The authors demonstrated that a 5-parameter A-ECG score (derived using a feature 
selection technique and logistic regression) had 83% sensitivity and 93% specificity for LVD 
(LVEF<50%) in a group of predominately male subjects with either CAD or LVH. 
Interestingly, none of the features used in this score required an extended duration, high 
sample rate recording, and as such could be attained from a conventionally recorded ECG, 
after advanced analytics. These works and ours, demonstrate a growing body of evidence 
supporting the feasibility of electrocardiographic identification of LVD. 
Continuous wavelet transforms processing and cardiac disease. Wavelet transforms have 
been applied to the ECG signal for measurement of intervals, noise reduction and importantly 
identification of abnormalities (20). One of the first applications was identification of 
ventricular late potentials (VLPs), microvoltage deflections after (and sometimes within) the 
QRS complex that are often obscured by noise (4,20). The detection of VLPs using CWT 
improved prediction of post-infarction ventricular arrhythmias from 52-72% and 64-76% for 
inferior and anterior infarctions, respectively, compared to standard signal filtering (21). 
Wavelet transforms have also revealed electrical similarities (abnormal frequency content) 
within the QRS complex in congenital and acquired long QT syndrome, providing insight 




While CWT-processed ECG has demonstrated value by revealing known or suspected 
electrical abnormalities, there are limited data on a direct association between CWT-
processed ECG features and cardiac function. Associations between standard ECG features 
and cardiac dysfunction has focused on long QT syndrome, which is associated with 
increased isovolumetric relaxation time, altered tissue Doppler velocity profiles and 
mechanical dispersion (23,24). Furthermore, the interval from T-wave peak to T-wave end 
(TpTe) is increased in DD assessed by mitral inflow and tissue Doppler velocities (7). At the 
molecular level, DD is partly related to low amplitude calcium transients secondary to 
reduced calcium uptake into, and leakage from, the sarcoplasmic reticulum (25,26). Given 
calcium is a key modulator of the action potential duration, disturbances in the electrical 
signal on the surface ECG may be apparent in LV dysfunction. It follows that detailed 
decomposition of the ECG signal from a diseased myocardium may reveal characteristic 
abnormalities, and indeed, the machine-learning model using only ewECG features provided 
accurate detection of LVD. Recently CWT-processed ECG (as used in our study) has shown 
80% sensitivity and 84% specificity for abnormal relaxation, assessed by low e’ (AUC 0.9) in 
a cohort of patients presenting with symptoms of CAD (5). As in our study, a machine 
learning approach (random forest classifier) was used but with far more features (n=257), 
owing to different methodologies. Furthermore, in a larger patient cohort with similar 
characteristics (e.g. suspected CAD or indication for LV function evaluation) (n=1202), a 
machine learning algorithm was trained with ewECG features to quantitatively predict e’ (6).  
This algorithm was able to discriminate guideline-defined thresholds with an AUC of 0.84, 
and given the model generated a continuous output for e’, inaccuracies associated with age-
based declines could be avoided. While we chose cut-offs, there is no suggestion that in 
normal aging GLS declines (27), and our definition of diastolic dysfunction would be 




that our study population is the most appropriate choice for testing and application of this 
technology i.e. where echocardiography may not be strictly indicated.   
The benefit of our machine-learning method, as opposed to an AI approach (e.g. 
neural networks), is the potential for interrogation of the model to provide mechanistic 
insight. We were interested to see whether systolic dysfunction was exclusively, temporally 
associated with depolarization features, which it was not. This may not be surprising for two 
reasons: 1) the surface ECG is a simplification of electrical activity spreading across the 
complex 3D structure of the heart and body and 2) early LV systolic dysfunction and 
diastolic dysfunction often coexist (28,29). The predictive model for diastolic abnormalities 
included measures from depolarization as well as repolarization, and most of the features 
within the low GLS and diastolic models also appeared in the composite LVD model. 
Clearly, investigation concerning the association between LV dysfunction and specific CWT 
signatures is in its infancy and is likely to be facilitated by machine-learning algorithms.  
Screening for LV dysfunction. The detection of subclinical LVD fulfills some but not all 
criteria for screening (30). On an individual and population health level, HF is burdensome, 
and its natural history involves an early asymptomatic stage that is readily detected by 
abnormal GLS and DD, which carry risk of symptomatic HF and mortality (31-34), 
analogous to standard markers of impaired LV function (34,35). In terms of treatment, 
guideline-advocated therapies (ACE-I, ARBs and beta-blockers) significantly improve 
outcomes (36,37), not only in populations with ischemic cardiomyopathy with reduced 
ejection fraction (EF), but also in subjects with reduced GLS and diastolic abnormalities with 
preserved EF, where intensification of cardioprotective therapies may reduce progression to 
symptomatic HF (38).  
Although echocardiography is safe and accurate, cost and access may be problematic. 




the number of patients going to echocardiography, while at the same time minimizing the 
numbers of false negatives who do not proceed.  The test is low risk and acceptable to 
patients. The sensitivity of ewECG in our study is superior to the fecal occult blood test for 
colorectal cancer screening, although specificity is lower (39). However, the risks associated 
with further testing after a positive ewECG (i.e. echocardiography) are far lower than for 
colonoscopy, for example. Nonetheless, further work with ewECG will need to include 
integration of machine-learning algorithms into the device’s software to enable immediate 
interpretation and guide decision-making, and integration of ewECG into clinical workflows.  
The alternative is the use of natriuretic peptides (NP) (e.g. BNP ≥50 pg/ml) to guide 
therapy. Intensification of RAAS and beta-blockade in diabetics with NT-proBNP >125 
pg/ml has been shown to reduce cardiovascular (CV) hospitalizations compared with usual 
care (RR 0.52, 95% CI 0.4-0.68) (40). However, although previous work has shown NP-
based therapy reduces asymptomatic LVD in individuals >40 years with CV risk factors 
(adjusted OR 0.6, 95% CI 0.39-0.93), that study showed no significant difference in HF 
hospitalization over the 4.2 year mean follow-up (41). Indeed, we found that NT-proBNP had 
poor screening performance. An inherent problem of BNP in this setting is that levels are 
artefactually reduced in the setting of obesity. Thus, the role of NT-proBNP in a screening 
role in this population remains unclear. 
Limitations. Machine-learning models are inherently limited by the amount of data available 
to train the algorithm. Continued acquisition of ewECG data will continue to improve our 
models. We demonstrated that models differ between targets; performance for one cardiac 
abnormality in one population should not be extrapolated to others. The poor performance of 
ewECG for diastolic and early systolic dysfunction abnormalities observed for are likely due 
to the small number of abnormal studies available for the algorithm to train; as well as the 




be predicted. More developmental work is needed to apply ewECG in these settings. Our 
study is cross-sectional and therefore we do not know what proportion will go on to develop 
symptomatic heart failure, or whether ewECG varies between those who do or do not 
progress. Furthermore, it is unknown whether ewECG can reveal abnormalities before the 
onset of early LVD or in the subset of patients who fail to exhibit resting echocardiographic 
abnormalities prior to manifesting HF.  
The definition of diastolic dysfunction used in this paper is not conventional. We chose not to 
use the standard criteria because many subjects are identified as indeterminate.  To create a 
definition suitable for screening, we used clear criteria of raised LA pressure (E/e’ with 
LAE), or if ambiguous (eg isolated LAE), partnered that with another diastolic dysfunction 
marker. Hence there were three criteria: E/e’ >15, E/e’>10 with LAE or impaired relaxation 
and LAE.  
Conclusion. Patients with subclinical LV dysfunction are at increased risk of HF, which may 
be prevented by initiation of cardioprotective therapy. However, there is currently no 
consensus as to whether (or how) subclinical LV dysfunction should be detected. Advanced 
analysis of a routinely acquired ECG using CWT signal processing and machine learning 
would be a suitably sensitive first step in a selective echocardiographic screening process for 
detection of LVD. Should such screening be adopted, it could reduce the number undergoing 







Clinical Competency (Systems-based practice). The detection of LV dysfunction by 
echocardiography in asymptomatic people with heart failure (HF) risk factors identifies a 
group who are at increased risk of HF. However, echocardiographic screening of the 
population provides logistic and financial challenges. A selection process for 
echocardiography would make detection more feasible. 
Translational Outlook. This study provides data to support the use of “energy waveform” 
(ew) ECG to identify people at low risk. This could reduce the need for echocardiography by 
>50%, while at the same time missing a minimal number of patients with LVD. Further 
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Figure 1: Conventional ECG traces and corresponding ewECG scalograms after signal 
processing using CWT. a) a normal ewECG [determined by MyoVista proprietary software 
and our machine-learning algorithm]. Echocardiogram was normal. b) Predicted abnormal by 
our machine-learning algorithm. Participant had abnormal systolic function (GLS 15%), of 
potential significance is the lower energy associated with the QRS and c) Predicted abnormal 
by our machine-learning algorithm. Participant had diastolic dysfunction, note low energy 
associated with the T wave.  
 
Figure 2: Performance of the random forest classifier model utilizing energy waveform 
ECG features for prediction of LV dysfunction. The area under the receiver operator 
characteristic (ROC) curves were similar for ewECG features combined with the ARIC-HF 
risk score (blue AUC 0.83, sensitivity 85% specificity 72%) and with ewECG alone (red 
AUC 0.78, sensitivity 88% specificity 70%). 
 
Central illustration: Comparison of strategies for LVD screening. The use of an echo 
screening strategy in all people with risk factors would identify almost 50% of the population 
as having LVD. A combination of clinical scoring and BNP would reduce echocardiography 
by about 1/3rd, and miss few people with LVD. However, the use of ew-ECG would reduce 






Table 1: Baseline characteristics by subclinical heart failure stage.  






Clinical and biomarkers    
Age, yrs. (IQR) 68 (62-71) 71 (68-75) <0.001 
Gender (% female) 137 (60) 90 (40) 0.08 
Hypertension (%) 185 (82) 152 (90) 0.04 
Type II Diabetes Mellitus (%) 41 (18) 60 (35) <0.001 
Atrial fibrillation (%) 9 (4) 13 (8) 0.12 
    
Systolic BP, mmHg (SD) 138 (15) 142 (15) 0.01 
Diastolic BP, mmHg (SD) 82 (9) 83 (11) 0.13 
Heart rate, beats per min (SD) 63 (9) 66 (10) 0.002 
BMI, g/m2 (SD) 31 (5) 32 (6) 0.09 
ACE-I/ARB* (%) 118 (75) 118 (73) 0.64 
Beta-Blockers* (%) 17 (11) 25 (15) 0.22 
NT-proBNP†, pg/ml (IQR) 51 (30-94) 59 (33-101) 0.39 
ARIC HF risk score (IQR) 3.6 (1.22-
6.6) 
7.1 (3.8-12.9) <0.001 
Standard ECG abnormalities    
Atrial fibrillation (%) 1 (0.4) 4 (2.3) 0.09 
LBBB (%) 0 (0) 3 (1.6) 0.05 
LV hypertrophy (%) 7 (3) 10 (6) 0.18 
Abnormal ECG (per Glasgow 
analysis) (%) 
35 (15) 62 (36) <0.001 
Echocardiographic measures    
LV mass index, g/m2 (SD) 67 (16) 71 (22) 0.01 
LV ejection fraction, % (SD) 64 (6) 61 (7) <0.001 
Global longitudinal strain, % (IQR) 20 (18.9-
21) 
17 (15.4-18.6) <0.001 
E/A ratio (SD) 0.95 (0.28) 0.80 (0.24) <0.001 




Average E/e’ (IQR) 8.3 (7.2-
9.8) 
9.3 (7.3-11.7) 0.003 
LAVI, ml/m2 (IQR) 30 (25-34) 37 (29-42) <0.001 
HF – heart failure, LV – left ventricular, BP – blood pressure, BMI – body mass index, ACE-
I/ARB – angiotensin converting enzyme inhibitor/receptor blocker, NT-proBNP – N terminal 
pro B-type natriuretic peptide, ARIC – Atherosclerosis Risk In Communities, LBBB – left 
bundle branch block, LAVI – left atrial volume indexed to body surface area. *not available 



































Age, yrs. (IQR) 71 (68-74) 61 (59-66) <0.001 
Gender (% female) 171 (60) 54 (49) 0.05 
Hypertension (%) 252 (88) 85 (77) 0.005 
Type II Diabetes Mellitus (%) 92 (32) 9 (8) <0.001 
Systolic BP, mmHg (SD) 142 (14) 134 (16) <0.001 
Diastolic BP, mmHg (SD) 84 (9) 79 (10) <0.001 
Heart rate, beats per min (SD) 65 (9) 64 (10) 0.48 
BMI, g/m2 (SD) 32 (6) 31 (5) 0.23 
ARIC HF risk score (IQR) 6.3 (3.8-10.6) 1.2 (0.8-2.6) <0.001 
    
Standard ECG abnormalities    
Atrial fibrillation (%) 5 (1.7) 0 (0) 0.16 
LBBB (%) 3 (1)  0 (0) 0.28 
LV hypertrophy (%) 15 (5) 2 (1.8) 0.13 
Abnormal ECG (per Glasgow 
analysis) (%) 
81 (28) 16 (14) 0.004 
    
Echocardiographic measures    
LV mass index, g/m2 (SD) 68 (20) 69 (17) 0.53 
LV hypertrophy (%) 17 (6) 4 (4) 0.35 
LV ejection fraction, % (SD) 63 (7) 62 (5) 0.65 
Global longitudinal strain, % 
(IQR) 
19 (17-20) 20 (18-21) <0.001 
GLS ≤ 16% (%) 54 (19) 7 (6) 0.002 
E/A ratio (SD) 0.83 (0.22) 1.03 (0.33) <0.001 
Average e’, cm/s (SD) 7.8 (1.9) 7.4 (1.7) 0.03 
Average E/e’ (IQR) 8 (7-10) 9 (8-11) 0.001 
LAVI, ml/m2 (IQR) 35 (30-41) 25 (22-31) <0.001 
Diastolic abnormality (%) 77 (27) 14 (13) 0.002 
    
LV dysfunction (%) 146 (51) 25 (23) <0.001 
LV – left ventricular, BP – blood pressure, BMI – body mass index, ARIC – Atherosclerosis 
Risk In Communities, HF – heart failure, LBBB – left bundle branch block, LAVI – left atrial 





Table 3: Model features and relative importance (as a proportion of 1) for predicting 
LV dysfunction.  
 
CWT feature description ECG Lead(s) Variable 
importance 
  0.004 
Repolarization late measure (RV) (programmed cut-
off) 
 0.01 
Repolarization early measure (RV) (programmed 
cut-off) 
 0.01 
Repolarization late measure (programmed ratio)  0.002 
Depolarization measure averaged from Q, R and S 
waves 
aVF 0.1 
Minimum energy in early repolarization V5 0.098 
Minimum energy in early repolarization, associated 
frequency 
V5, V6 0.056, 
0.055 
Minimum energy at peak repolarization II 0.095 
Maximum energy in early repolarization, associated 
frequency 
V6 0.09 
Minimum energy in late repolarization, associated 
frequency 
V4, II  0.051, 
0.065 
Repolarization late measure, associated frequency I, aVF 0.086, 
0.092  
Relative deflection of R and S waves  aVR 0.012 
Power spectrum (harmonic) ratio feature 
(LOA sign) 
II, V1 0.008, 0.01 
Power spectrum (harmonic) ratio feature 
(HIA sign)  




Power spectrum (harmonic) ratio feature  
(P43 sign) 
aVF, V5 0.018, 
0.015 
Power spectrum (harmonic) ratio feature  
(P51 sign) 







Power spectrum (harmonic) ratio feature 
(P53 sign) 
V4, V6 0.011, 
0.009 
Power spectrum (harmonic) ratio feature 
(LO1 sign) 
V2, V3 0.007, 
0.012 
Power spectrum (harmonic) ratio feature 
(LO3 sign)  
I, aVL 0.011, 
0.015 
LV – left ventricular, CWT – continuous wave transform, ECG – electrocardiogram, RV – 







Table 4: Performance of random forest classifier models for predicting LV dysfunction, 
low global longitudinal strain (GLS) alone and diastolic abnormalities.  
 
Prediction target: LV dysfunction 
Model components: ewECG features + ARIC HF risk score 
 Training (n=287) Test (n=111) 
Sensitivity 67% 85% 
Specificity 68% 72% 
ROC AUC (95% CI)  0.71 (0.64-0.77)  0.83 (0.74-0.92) 
F-score 0.68 0.60 
Prediction target: LV dysfunction 
Model components: ewECG features  
 Training  Test 
Sensitivity 66% 88% 
Specificity 60% 70% 
ROC AUC (95% CI) 0.66 (0.59-0.72) 0.78 (0.67-0.88) 
F-score 0.64 0.59 
Prediction target: Low GLS 
 Training  Test 
Sensitivity  35% 57% 
Specificity 95% 90% 
ROC AUC (95% CI) 0.67 (0.58-0.76) 0.65 (0.37-0.93) 
F-score 0.45 0.36 
Prediction target: Diastolic abnormalities  
 Training  Test 
Sensitivity  36% 50% 
Specificity 94% 90% 
ROC AUC 95% (CI)  0.69 (0.62-0.76)  0.62 (0.42-0.82) 
F-score 0.47 0.45 
LV – left ventricular, ewECG – energy waveform electrocardiogram, ARIC – Atherosclerosis 
Risk in Communities, HF – heart failure, ROC – receiver operating characteristic curve, 
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Exploring the structural distribution of genetic 
variation in SARS-CoV-2 with the COVID-3D 
online resource
The emergence of the COVID-19 pandemic has spurred a global rush to uncover basic biological mechanisms to 
inform effective vaccine and drug development. Despite the novelty of the virus, global sequencing efforts have 
already identified genomic variation across isolates. To enable easy exploration and spatial visualization of the 
potential implications of SARS-CoV-2 mutations in infection, host immunity and drug development, we have 
developed COVID-3D (http://biosig.unimelb.edu.au/covid3d/).
Stephanie Portelli, Moshe Olshansky, Carlos H. M. Rodrigues, Elston N. D’Souza, Yoochan Myung, 
Michael Silk, Azadeh Alavi, Douglas E. V. Pires and David B. Ascher
Declared a global pandemic on 11 March 2020, COVID-19 has become the most recent modern-day 
global health challenge, infecting 10 
million people and claiming more than 
500,000 lives within 6 months of being 
reported to the World Health Organization. 
Consequently, the scale of its humanitarian 
and economic impact has driven academic 
and pharmaceutical efforts to develop 
vaccines and antiviral treatments. Current 
efforts include more than 118 active vaccine 
candidates and numerous additional 
endeavors to identify biologics and 
small-molecule treatments.
One further challenge in controlling 
COVID-19 is the accumulation of variation 
across genes. Sources indicate that 
SARS-CoV-2 is mutating at approximately 
two variants per month, but the potential 
effects of the accumulation of these 
variants (Supplementary Fig. 1) on 
molecular diagnostics and the development 
of candidate vaccines and treatments 
remain poorly explored. Fortunately, the 
continual rapid increase in the amount of 
SARS-CoV-2 genome sequence data and 
structural information available provides 
an opportunity to analyze both data sources 
concomitantly, thus presenting a unique 
opportunity to not only understand how 
variants might affect patient outcomes, 
but also anticipate and minimize their 
potential roles in viral escape through early 
incorporation of this information within the 
development pipeline.
To facilitate such an understanding, we 
have developed a comprehensive online 
resource, COVID-3D, to enable analysis 
and interpretation of more than 11,000 
variants detected in circulating SARS-CoV-2 
genomic sequences (Supplementary Fig. 2). 
We have mapped these circulating variants 
and their frequencies to the corresponding 
protein sequences (Supplementary Table 1)  
and structures of the SARS-CoV-2 proteins 
derived from available experimental 
information (Supplementary Table 2), 
thus permitting direct comparison of 
variant clustering between the sequence 
and structural representations, along 
with the identification of coevolutionary 
relationships and potential compensatory 
mutations. Beyond these circulating 
variants, we have identified mutations 
from the longer-circulating related viruses 
BAT RaTG13 and SARS-CoV, to enable 
further investigation of the mutations 
that drove the species jump from RaTG13 
and that increased the infectivity and 
mortality beyond those of SARS-CoV. Our 
interactive three-dimensional viewer enables 
fast and intuitive spatial visualization of 
SARS-CoV-2 variants, highlighting their 
potential effects on protein structure 
and interactions1–7 (Supplementary Figs. 
3–6). This viewer is particularly useful for 
analyzing sites that are currently being 
targeted by potential therapeutics. A built-in 
mutation-analysis tool allows users to 
contrast properties and identify patterns 
in the data, plotting correlations and 
distributions (Supplementary Fig. 7).
To further enhance therapeutic discovery 
efforts, we have included maps of the 
fragment-binding hotspots to capture 
likely drug-binding sites8,9, as well as 
predicted antigenicity maps10,11 on the 
structures, which permit rational selection 
of target sites and compound design, 
specifically avoiding already circulating 
variants (Supplementary Fig. 4). Finally, 
combining this structural information 
with evolutionary and population variation 
analysis can further aid in identifying sites 
that are relatively less likely to accommodate 
mutations in the future. To facilitate this 
analysis, COVID-3D also allows users to go 
from analyzing a protein pocket to virtual 
screening in several clicks12. In an illustrative 
example, we have used COVID-3D 
to provide insights into the two main 
therapeutic targets: the spike protein and 
main proteinase.
The SARS-CoV-2 spike protein 
binds human angiotensin-converting 
enzyme 2 (ACE2), which mediates cell 
entry. Subsequently, the spike protein’s 
ACE2-receptor-binding domain has been 
the main target of most vaccine programs. 
Measures of selective pressure suggest 
that the spike protein is one of the viral 
proteins most tolerant to the introduction 
of mutations13,14 (Supplementary Table 1). 
Closer inspection (http://biosig.unimelb.edu.
au/covid3d/protein/QHD43416/CLOSED) 
indicates that although SARS-CoV-2 
was discovered only 6 months before the 
time of analysis, substantial variation can 
already be seen across the protein surface, 
including in predicted epitope regions in the 
receptor-binding domain (Fig. 1). Of these 
variants, QHD43416 p.Asp614Gly is present 
in two-thirds of the sequenced strains, 
although its actual importance remains 
unclear, despite initial suggestions that it 
may increase transmissibility15. The residue 
is located far from the ACE2 interface  
(73 Å) and has been predicted to have a 
mildly stabilizing effect on protein stability 
(0.5 kcal mol–1 according to DUET3 and 2.3 
kcal mol–1 according to SDM2 analyses) and 
hence a minimal fitness cost16. However, it 
has been predicted to alter protein dynamics 
and the interactions between the subunits 
(4.4 Å from the interface; –0.5 kcal mol–1 for 
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the closed form versus –0.35 kcal mol–1 for 
the open form, according to mCSM-PPI2 
analysis6), thus potentially affecting the 
equilibrium between open and closed states.
Interestingly, when we examined 
population-specific variants across ACE2, 
we observed several population-specific 
variants across the interface recognized 
by the spike protein (Fig. 1a). Evaluation 
of the consequences of these variants with 
mCSM-PPI6, which has been experimentally 
validated on this protein system17, shows 
potential significant effects on the binding 
affinity of spike protein, thus paving the way 
for further work exploring the influence of 
these variants on COVID-19 severity and 
progression.
Apart from the spike protein, the 
main proteinase (http://biosig.unimelb.
edu.au/covid3d/protein/QHD43415_5/
APO) has also attracted many therapeutic 
development efforts as a target for the 
development of small-molecule inhibitors. 
The main proteinase, however, is not 
particularly intolerant to missense variants 
(Supplementary Table 1), thus potentially 
promoting the emergence of resistant 
variants. The structures show that several 
circulating variants already present in 
the drug-binding site may have effects on 
efficacy (Fig. 2a). Using COVID-3D, we 
leveraged the abundance of SARS-CoV-2 
genomic sequences to calculate measures 
of mutational tolerance, and we identified 
several genes under strong purifying 
selection (Supplementary Table 1). These 
include the genes encoding helicase, RNA 
polymerase, NSP4, NSP9 and ExoN, which 
may serve as novel, promising drug targets 
with few circulating variants seen near the 
druggable pockets (Fig. 2b).
COVID-3D provides an easy-to-use 
bridge between genomic information and 
structural insights to better guide biological 
understanding and treatment efforts. The 
data and code (http://biosig.unimelb.edu.
au/covid3d/code) are freely available via 
the web interface (http://biosig.unimelb.
edu.au/covid3d/). As new structural and 
sequence data become available, COVID-3D 
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Mutations in the spike–ACE2 complex
Mutation mechanism effects
Interface residue (4.4 Å)
p.Asp614
mCSM-PP12: –0.5 kcal mol–1
Variant analysis (p.Asp614Gly)
Fig. 1 | Population variation across the spike–ace2 complex. a, Lollipop plots of circulating missense variants in the SARS-CoV-2 spike protein and 
population-specific missense variants in human ACe2 illustrate the broad distribution of variants across the proteins. b, When visualized spatially, several 
variants seen at the ACe2–spike interface are predicted to affect the binding affinity. One of the most prevalent circulating SARS-CoV2 spike variants, 
p.Asp614Gly, is located far from the ACe2 interface but close to the spike-trimer interface and is predicted to lead to structural perturbations.
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their integration into ongoing efforts to 
understand and combat SARS-CoV-2. ❐
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Fig. 2 | Visualization of sars-coV-2 circulating variants relative to druggable pockets. a, The gene 
encoding the main proteinase is neutral to the introduction of missense variants, with an overall 
missense tolerance score (MTR) and residual variation intolerance score (RVIS) both indicating that the 
gene is tolerant to genetic variation. Some circulating variants (red sticks) have already been observed 
to lead to alterations near binding sites of known inhibitors (boceprevir shown in yellow) and are likely 
to affect drug binding. Therefore, resistance mutations could be selected for with widespread use. b, The 
gene encoding helicase is among the SARS-CoV-2 genes most intolerant to missense variation, with low 
MTR and RVIS scores. Mapping the fragment-binding hotspots of the protein shows pockets with apolar 
(yellow), hydrogen-bond-donor (blue) and hydrogen-bond-acceptor (red) potential. Although some 
variation has been observed near this region, optimization of interactions to avoid these sites could 
decrease the potential for future resistance.
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ABSTRACT
Significant efforts have been invested into un-
derstanding and predicting the molecular conse-
quences of mutations in protein coding regions, how-
ever nearly all approaches have been developed us-
ing globular, soluble proteins. These methods have
been shown to poorly translate to studying the ef-
fects of mutations in membrane proteins. To fill
this gap, here we report, mCSM-membrane, a user-
friendly web server that can be used to analyse the
impacts of mutations on membrane protein stability
and the likelihood of them being disease associated.
mCSM-membrane derives from our well-established
mutation modelling approach that uses graph-based
signatures to model protein geometry and physico-
chemical properties for supervised learning. Our sta-
bility predictor achieved correlations of up to 0.72
and 0.67 (on cross validation and blind tests, respec-
tively), while our pathogenicity predictor achieved
a Matthew’s Correlation Coefficient (MCC) of up to
0.77 and 0.73, outperforming previously described
methods in both predicting changes in stability and
in identifying pathogenic variants. mCSM-membrane
will be an invaluable and dedicated resource for in-
vestigating the effects of single-point mutations on
membrane proteins through a freely available, user
friendly web server at http://biosig.unimelb.edu.au/
mcsm membrane.
INTRODUCTION
Integral membrane proteins play an essential role as the
gateway to the cell, mediating transport, signalling and ad-
hesion amongst many other functions. Mutations in mem-
brane proteins are associated with a wide variety of com-
mon diseases, including heart disease, and consequently
have been the site of action for over 50% of small molecule
drugs (1). While they represent 20–30% of the genes in the
human genome (2–4), they can be challenging to exper-
imentally characterise as they tend to be unstable when
extracted from the lipid bilayer. Consequently, less than
0.5% of experimentally determined structures are of inte-
gral membrane proteins.
There is therefore an increasing demand for methods ca-
pable of identifying mutations that might improve stabil-
ity, to facilitate structural and functional characterization,
and to identify novel disease-causing variants. Increasing
computational power offers new opportunities to address
these challenges, however most tools have been built using
experimental information on predominantly globular, solu-
ble proteins, and that have been shown to poorly translate
to predicting the effects of mutations in membrane proteins
(5).
The need for methods tailored for investigating mutation
effects on transmembrane proteins becomes evident when
considering the differences in residue environment in com-
parison with globular proteins. While many studies involv-
ing globular proteins have shown that solvent accessibil-
ity and residue depth correlates with mutation effects (6),
for example buried and deep residues tend to be more con-
served and mutations tend to have larger effects in stability,
these might not be applicable for integral membrane pro-
teins. To circumvent this, sophisticated ways to describe and
represent residue environments are necessary.
We have previously tackled this task by developing the
concept of graph-based signatures and showed they can
provide powerful insights into understanding and predict-
ing the effects of mutations on protein structures, including
how mutations alter protein stability (6–8), dynamics (8), in-
teractions with other molecules (7–14) and their relation to
emergence of genetic diseases (15–27) and drug resistance
(10,19,28–38).
Here we introduce mCSM-membrane, a web server that
adapts and optimizes our well-established mCSM graph-
based signatures framework in order to provide improved
*To whom correspondence should be addressed. David B. Ascher. Tel: +61 90354794; Email: david.ascher@unimelb.edu.au
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predictive performance of the molecular consequences of
mutations in membrane proteins.
MATERIALS AND METHODS
Data sets
The general workflow of mCSM-membrane is shown in
Figure 1. mCSM-membrane was trained using two sep-
arate data sets of experimentally characterized mutations
in transmembrane proteins, for which 3D structures were
available.
The first data set contained experimentally measured ef-
fects of mutations on protein stability. This was obtained
from (5) and encompasses 223 single-point missense mu-
tations on 7 different proteins with experimental crystal
structures available in the Protein Data Bank. The mu-
tation effects were obtained in terms of the difference in
Gibbs free energy of folding (G = GWT – GMT, in
Kcal/mol), with negative values denoting destabilising mu-
tations and positive values denoting stabilising mutations,
consistent with previously published methods. As discussed
in previous works (8,10,13,14), the original data set was bi-
ased towards destabilising mutations (Supplementary Fig-
ure S1), which tend to affect machine learning methods.
To circumvent this sampling limitation, we have modelled
the hypothetic reverse mutations via comparative homol-
ogy modelling and assigned the same G value as the
forward mutation, with the opposite signal, in other words:
GWT→MT = –GMT→WT. Only reverse mutations with
a measured effect in stability <2 kcal/mol were consid-
ered, in order to avoid situations where the reverse muta-
tion could potentially compromise protein folding. Struc-
tures for reverse mutations were generated using the mu-
tate function within Modeller (39) followed by refinement.
A total of 181 reverse mutations were modelled, leading to
a final data set of 404 mutations with associated stability ef-
fects (Supplementary Figure S1). Forward and reverse mu-
tations pairs were kept together either in training or test
sets. This was further divided into training (342 missense
mutations occurring in 4 proteins, PDB IDs 2XOV, 1PY6,
3GP6 and 1QD6; 156 decreasing stability (G < −0.4
kcal/mol), 56 neutral, 130 increasing stability (G > 0.4
kcal/mol) and independent blind test (62 mutations occur-
ring in the remaining three proteins, PDB IDs 1QJP, 2K73
and 1AFO, 28 decreasing stability, 14 neutral, 20 increasing
stability). Training and test sets used in mCSM-membrane
were non-redundant in terms of protein identity (<16% se-
quence identity – Supplementary Table S1) The proteins
were also assessed in terms of their structural similarity us-
ing TMAlign and shared no more than 64% similarity.
The second data set was selected in order to train
a structure-based model for predicting disease-associated
mutations tailored for transmembrane proteins and was
collected from (40). It comprises 539 single-point missense
mutations in 62 different proteins, labelled either as be-
nign or pathogenic, from the UniProtKB/Swiss-Prot vari-
ant database (41) This dataset was also further divided in
training set (485 mutations, 347 pathogenic, 138 benign)
and independent blind test (54 mutations, 38 pathogenic,
16 benign) for validation purposes, consistent with the data
set defined by the BORODA-TM method for comparison
purposes. Seven mutations described in the original data
set, on two different residues of protein 4ZWJ could not
be mapped to the structure available and therefore were re-
moved from the training set. These compose non-redundant
datasets, with sequence identity levels less than 50% and less
than 75% structural similarity (calculated using TMalign).
The data sets used to develop mCSM-membrane are
available to download at http://biosig.unimelb.edu.au/
mcsm membrane/data.
Modelling effects of mutations
Single-point mutations can lead to a range of structural
and functional changes. To try to encapsulate and explore
the effects of single-point mutations on membrane proteins,
we used two classes of structural features, in addition to
sequence-based calculations.
Graph-based structural signatures
One of the core components of mCSM-membrane is our
well-established approach of using the concept of graph-
based structural signatures (mCSM) to represent the en-
vironment of the wild-type residue (7) and describe both
its geometry and physicochemical properties. Our approach
aims to model wild-type residue environments as graphs,
where atoms are represented as nodes (labelled based on
their properties, i.e. pharmacophores) and their interactions
as edges. By varying a distance cut off, different graphs are
induced and cumulative distributions of distances for dif-
ferent pharmacophore/interactions generated, composing
a concise and effective representation of the residue envi-
ronment. This information is then used as evidence to train
and test predictive methods using supervised learning.
Molecular interactions
To capture information on whether, and how, a single-point
mutation disrupted the intricate molecular interaction net-
work, intra-molecular interactions were calculated using
Arpeggio (42).
Pharmacophore modelling and sequence-based features
The effect of the mutation on the residue environment
is modeled using a pharmacophore representation for
residues as previously described (7). Sequence-based fea-
tures describing protein properties and amino acid com-
position were also calculated using the BioPython python
library (43). These include AAindex amino acid mutation
matrices and indexes representing physicochemical prop-
erties (44) and ProtParam, for calculating general protein
sequence properties, including amino acid composition,
molecular weight, isoelectric point, and hydropathicity (45).
Differently from globular proteins, neither residue depth,
nor solvent accessibility, showed a significant correlation
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Figure 1. mCSM-membrane workflow. The first methodological step on mCSM-membrane was data collection. Experimentally validated effects of mu-
tations on protein stability and pathogenicity were obtained for transmembrane proteins with available structures. During feature engineering, three main
classes of features are generated: (i) graph-based signatures of the wild-type residue environment, (ii) a pharmacophore modelling of mutation effects
(together with sequence-based properties) and (iii) the inter-residue interactions established. These are then used as evidence to train and test supervised
learning algorithms. Random Forest for classification and Extra Trees for regression were the best performing and, therefore, selected methods.
WEB SERVER
We have implemented mCSM-membrane as a user-friendly
and freely available web server (http://biosig.unimelb.edu.
au/mcsm membrane/). The Bootstrap framework version
3.3.7 was used to develop the server front end, while the
back-end was built in Python using the Flask framework
version 1.0.2. The server is hosted on a Linux server run-
ning Apache 2.
Input
mCSM-membrane can be used in two different ways: to ei-
ther assess the effects of mutations on membrane protein
stability, or to assess their pathogenicity (Supplementary
Figure S3). For user-specified variations two options are
available. The ‘Single Mutation’ option requires users to
provide a PDB file or PDB accession code of the structure of
the protein, the point mutation specified as a string contain-
ing the wild-type residue one-letter code, its corresponding
residue number (consistent with the provided structure) and
the mutant residue one-letter code. Alternatively, the ‘Mu-
tation List’ option allows users to upload a list of muta-
tions in a file for batch processing. For both options, users
are also required to specify the chain identifier in which the
wild-type residues are located as well as the Uniprot acces-
sion code for the protein of interest or provide its sequence
in FASTA format. For homo-oligomers, mCSM-membrane
will only consider the mutation in the provided chain, how-
ever the overall environment (oligomer) will be considered
for feature generation.
In order to assist users to submit their jobs for predic-
tions, sample submission entries are available in both sub-
mission pages and a help page is also available via the top
navigation bar.
Output
For the Stability option, mCSM-membrane outputs
the predicted change in membrane protein stability (in
kcal/mol), while for the Pathogenicity option mCSM-
membrane outputs whether the mutation is predicted as
Benign or Pathogenic.
With the Single Mutation option, mCSM-membrane
outputs the prediction along with an interactive 3D viewer
showing the wildtype residue environment and a depiction
of the predicted transmembrane topology using Protter (46)
(Supplementary Figure S4). In addition, all non-covalent
interactions, generated using Arpeggio, made by the wild-
type residue are available for download as a Pymol session
file. For the Mutation List option, the results are summa-
rized in a downloadable table from which users can access
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VALIDATION
Predicting effects of mutations on transmembrane protein
stability
In order to build a robust and reliable model for predict-
ing the effects of mutations on transmembrane stability,
mCSM-Membrane was trained using a stratified 10-fold
cross-validation approach with 10 bootstrap repetitions. Se-
lection of the blind test was repeated 10 times in a stratified
manner, with the model assessed on the remaining data us-
ing 10-fold cross-validation, in order to evaluate the robust-
ness of the model. Our method achieved an average Pear-
son, Spearman and Kendall correlations of 0.72, 0.72 and
0.53, respectively, with a standard deviation of 0.09 across
the 10 runs (Figure 2A). We then evaluated the ability of
the model to capture destabilizing and stabilizing muta-
tions, using a classification by regression approach. mCSM-
Membrane achieved a Mathew’s Correlation Coefficient of
0.65 and F1-score of 0.81, correctly capturing 82% of stabi-
lizing and 83% of destabilizing mutations. The effect of con-
sidering reverse mutations in the data set was also assessed.
When only forward mutations are considered (i.e. remov-
ing reverse mutations from training and test sets), perfor-
mance drops considerably, achieving a Pearson’s correlation
of 0.58 and a Mathew’s Correlation Coefficient of 0.79 and
F1-score of 0.72, highlighting the importance of consider-
ing reverse mutations to balance the data set.
mCSM-Membrane was further evaluated using a blind
test set of 62 mutations across 3 proteins, not present in
our original training data sets. Our model achieved Pear-
son, Spearman and Kendall correlations of 0.67, 0.62 and
0.45 (Figure 2B), respectively, consistent with training per-
formance, providing confidence in the generalizability and
robustness of our model. Despite the low level of similar-
ity between proteins in training and test sets, and to elimi-
nate any potential selection bias while training and validat-
ing our method, we also evaluate the process of selecting
an independent test set in a bootstrapped manned 100×,
and evaluated the performance of the method on cross val-
idation and test set. mCSM-membrane achieved a correla-
tion of 0.68 (sd = 0.02) on 10-fold cross validation and 0.67
(sd = 0.07) on tests, demonstrating the robustness of the
method. Additionally, mCSM-Membrane was compared to
well established tools designed to predict the effects of mu-
tations on protein stability. mCSM-Membrane significantly
outperformed all tools tested (P < 0.05 by Fisher r-to-z
transformation test, Table 1). Consistent with previous re-
sults, the other stability predictive tools tested were only
weakly predictive across these mutations in transmembrane
proteins (Table 1).
Application to homology models
Experimentally solving structures of transmembrane pro-
teins is particularly challenging. The evolution of compar-
ative homology and threading algorithms, however, has al-
lowed for data augmentation for modelled structures at a
proteome-scale (47). To assess the performance of mCSM-
membrane on homology models, we have generated models
using templates with no more than 37% identity for three
Table 1. Comparative performance of mCSM-membrane across training







FoldX 0.48* 1.18 0.57 1.25
iMutant 0.27* 1.29 0.37* 1.41
CUPSAT 0.01* 1.34 0.15* 1.50
AUTOMUTE (RepTree) 0.17* 1.32 0.05* 1.52
AUTODMUTE (SVM) 0.14* 1.33 0.04* 1.52
MAESTRO 0.20* 1.16 0.17* 1.09
SDM 0.01* 1.34 − 0.14* 1.51
mCSM 0.21* 1.31 0.59 1.23
DUET 0.18* 1.32 0.47* 1.34
Dynamut 0.31* 1.27 0.62 1.19
mCSM-membrane 0.72 0.93 0.67 1.13
*P-value < 0.05 by Fisher r-to-z transformation test compared to mCSM-
membrane
different proteins, originally selected as the blind test of our
stability predictor. Supplementary Table S2 shows the infor-
mation on templates used in this process.
Performance on blind test using the homology models
deteriorates only slightly (r = 0.63. Supplementary Figure
S6), compared to performance on experimental structures (r
= 0.68), highlighting the robustness of the model and abil-
ity to accurately predict effects of mutations on homology
models. This defines a simple guideline for using mCSM-
membrane on homology models.
Identifying pathogenic mutations in transmembrane proteins
The second predictive mode for mCSM-membrane is a
predictor capable of accurately distinguishing between
pathogenic and benign mutations tailored for transmem-
brane proteins (Table 2). This predictor was trained and
assessed on 10-fold cross validation, with its performance
compared to alternative methods available. Our pathogenic-
ity predictor achieved an Mathew’s Correlation Coefficient
(MCC) of 0.77 and F1-score of 0.91 significantly outper-
forming SIFT (0.43 and 0.85), PolyPhen2 (0.54 and 0.89)
PROVEAN (0.48 and 0.85), MutPred2 (0.48 and 0.79),
PON-P2 (0.38, 0.71). The only method that achieved a
higher performance than mCSM-membrane during cross
validation was BORODA-TM (0.87 and 0.96). However,
the discrepancy between the reported performance in cross
validation and blind test for BORODA-TM (on blind it
achieves an MCC of 0.46 and F1 of 0.78) is a strong indica-
tion of overfitting.
Our predictor was further validated via a blind test
achieving an MCC of 0.73 and F1-score of 0.89, per-
formance compatible with cross validation, outperform-
ing alternative methods and demonstrating the efficacy
of a transmembrane-specific predictor no identifying
pathogenic mutations. Figure 2C and D shows the ROC
curves comparing the performance of the four methods
during cross validation and blind tests, with our predictor
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Figure 2. Performance evaluation of mCSM-membrane on cross validation and blind tests. (A) shows the performance of mCSM-membrane on predicting
effects of mutations on stability for transmembrane proteins during 10-fold cross validation, achieving a Pearson’s correlation of 0.72 (0.83 on 90% of the
data). During blind test (B), mCSM-membrane achieved a correlation of 0.67 with experimental data. For the pathogenicity predictor, (C) and (D) show
the performance of mCSM-membrane in comparison with well-established methods as ROC plots on cross validation and blind test, respectively. Our
method achieved AUC of 0.89 and 0.95.
Table 2. Performance assessment of mCSM-membrane in predicting pathogenic mutations across training and test data sets, in comparison with alternative
methods.
Training Test
Method AUC F1 MCC AUC F1 MCC
PolyPhen2 0.79 0.79 0.47 0.73 0.75 0.40
SIFT 0.80 0.77 0.43 0.82 0.84 0.63
PROVEAN 0.80 0.79 0.48 0.79 0.75 0.40
SNAP2 0.67 0.70 0.26 0.73 0.66 0.21
MutPred2 0.75 0.79 0.48 0.75 0.82 0.57
PON-P2 0.83 0.71 0.38 0.88 0.78 0.53
BORODA-TM* - - - 0.96 0.87 - - - 0.78 0.46
mCSM-membrane 0.89 0.91 0.77 0.95 0.89 0.73
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CONCLUSION
Here, we introduce mCSM-membrane, a web server that
uses our graph-based signatures to predict the effects of
single-point missense mutations on the stability of trans-
membrane proteins and the likelihood of them being dis-
ease associated. The method represents a significant ad-
vance upon our current predictive platform, outperforming
previous methods, which had been built using globular sol-
uble proteins.
mCSM-membrane is freely available as user-friendly
and easy to use web server at http://biosig.unimelb.edu.au/
mcsm membrane/.
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Supplementary Data are available at NAR Online.
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Abstract
Summary: EasyVS is a web-based platform built to simplify molecule library selection and virtual screening. With
an intuitive interface, the tool allows users to go from selecting a protein target with a known structure and tailoring
a purchasable molecule library to performing and visualizing docking in a few clicks. Our system also allows users
to filter screening libraries based on molecule properties, cluster molecules by similarity and personalize docking
parameters.
Availability and implementation: EasyVS is freely available as an easy-to-use web interface at http://biosig.unimelb.
edu.au/easyvs.
Contact: douglas.pires@unimelb.edu.au or david.ascher@unimelb.edu.au
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Structure-based virtual screening has been widely and successfully
used in early stages of drug development, aiding in the identification
of potential hits and guiding further experimental validation (Cheng
et al., 2012). Molecular docking is one of the most widely used vir-
tual screening approaches, which uses the three-dimensional struc-
ture of a target protein to predict the predominant binding mode of
a small molecule with the target of interest. In this way, docking can
be used to evaluate a large library of molecules and identify those
most likely to interact with the target in the desired manner. This
has been a powerful tool in the identification of initial hits, signifi-
cantly reducing the chemical space to experimentally test and
increasing the proportion of positive compounds being screened.
Significant improvements in docking protocols (Di Muzio et al.,
2017), scoring functions (Pires and Ascher, 2016) and molecule
libraries (Sterling and Irwin, 2015), and the greater availability of
computational power, have made virtual screening a more tractable
and reliable hit identification strategy. Despite this, current virtual
screening approaches typically require specialist computational and
technical expertise.
In order to make virtual screening more friendly and accessible
to a wider audience, we propose EasyVS (http://biosig.unimelb.edu.
au/easyvs), a web-based, efficient and intuitive system that allows
users to go from defining a protein structure and molecule library to
performing docking in a few clicks. Our system allows users to opti-
mize their screening library based on their properties (and define a
chemical space of interest). Through a molecule clustering approach,
we can more rapidly screen a larger chemical space, and present the
top solutions to the user.
2 Platform description
Initially users are asked to define their target of interest by either
uploading a structure of interest, or using the biological assembly of
VC The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 4200
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a previous experimental structure deposited in the Protein Data
Bank by providing the PDB accession code.
The selected structure is then analyzed using Ghecom
(Kawabata, 2010) to identify druggable pockets. While by default
the largest pocket is chosen for docking, users may select another
pocket of interest for screening, and can refine the boundaries and
docking parameters used (Supplementary Fig. S1). These parameters
include box size and position (which can be set to any of the identi-
fied pockets and finely adjusted by the user) and depth of the search.
In the next step, users are asked to define the set of molecules to
be assessed via docking. EasyVS currently supports the small molecule
databases ChEMBL 24_1 (Gaulton et al., 2017), HMDB 4.0 (Wishart
et al., 2018a), Drugbank 5.0 (Wishart et al., 2018b), Maybridge
(https://www.maybridge.com), Super Natural II (Banerjee et al.,
2015), Chembridge (Desai et al., 2004) and Zinc15 (Sterling and
Irwin, 2015), which together comprise over 16 million molecules.
There are many filters available for refining these molecular libra-
ries, including by molecular weight, number of acceptors or donors of
hydrogen, logP (or only selecting Lipinski’s Ro5 molecules), frag-
ments or natural products (Fig. 1A). Once the molecule library has
been selected, users have the option to cluster molecules by similarity
to improve screening performance. If users opt to perform clustering,
one representative molecule from each group is randomly selected for
docking. Users have the option to select the level of similarity used
during clustering, which will change the number of clusters and, there-
fore, the number of molecules that will proceed for docking stages.
Molecule docking of the selected compound library is then per-
formed using Autodock Vina (Trott and Olson, 2010). Users can
also rapidly rescore selected poses using NNScore (Durrant and
McCammon, 2011) or CSM-Lig (Pires and Ascher, 2016), analyze
the intramolecular interactions using Arpeggio (Jubb et al., 2017)
and predict pharmacokinetic properties of top hits using pkCSM
(Pires et al., 2015). While the docking is running, users can view the
results in real time to analyze best poses of selected molecules
(Fig. 1B) as well as include additional molecules for docking.
Further exploration of the chemical space of top docked ligands is
available by an additional round of virtual screening, using com-
pounds that are structurally similar to the ligand of interest.
The EasyVS docking protocol was validated using two different
benchmarks. We performed a redocking procedure for a selection of
eight G-protein-coupled receptors (GPCR)-ligands complexes with
available crystallographic structures. Ligands have been successfully
redocked with an average root-mean-square deviation (RMSD) of
0.98 Å (Supplementary Table S1). We have also created decoy libra-
ries using DUD-e (Mysinger et al., 2012) for the same set of proteins
considered for redocking. The docking scores for real ligands were
considerably higher than those obtained for the decoys (P-value
<0.001, Supplementary Table S2), demonstrating the robustness of
the EasyVS docking protocol. We have evaluated the system’s ability
to process multiple submissions, demonstrating the system’s respon-
siveness (Supplementary Fig. S2).
3 Conclusions
Here, we present EasyVS, a freely available, user-friendly platform
for simplifying molecule library construction and docking. EasyVS
allows users to choose molecules from well-established and diverse
databases, including fragments, approved drugs and natural prod-
ucts, and perform the docking with just a few clicks. We also show
EasyVS was successful in identifying GPCR ligands (Supplementary
Materials) as a case study.
We believe this will be an invaluable tool for the exploratory
stages of hit identification, allowing for the selection either stringent
or very diverse sets of molecules for virtual screening and the intelli-
gent assessment of different small molecule chemical spaces.
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Fig. 1. EasyVS web interface. Once a protein target is selected, (A) users are
prompted to select a molecule library from available databases and property filters.
(B) Docking will be performed on the selected target/library set and best poses
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Abstract
Clinical resistance against Bedaquiline, the first new anti-tuberculosis compound with a
novel mechanism of action in over 40 years, has already been detected in Mycobacterium
tuberculosis. As a new drug, however, there is currently insufficient clinical data to facilitate
reliable and timely identification of genomic determinants of resistance. Here we investigate
the structural basis for M. tuberculosis associated bedaquiline resistance in the drug target,
AtpE. Together with the 9 previously identified resistance-associated variants in AtpE, 54
non-resistance-associated mutations were identified through comparisons of bedaquiline
susceptibility across 23 different mycobacterial species. Computational analysis of the
structural and functional consequences of these variants revealed that resistance associ-
ated variants were mainly localized at the drug binding site, disrupting key interactions with
bedaquiline leading to reduced binding affinity. This was used to train a supervised predic-
tive algorithm, which accurately identified likely resistance mutations (93.3% accuracy).
Application of this model to circulating variants present in the Asia-Pacific region suggests
that current circulating variants are likely to be susceptible to bedaquiline. We have made
this model freely available through a user-friendly web interface called SUSPECT-BDQ,
StrUctural Susceptibility PrEdiCTion for bedaquiline (http://biosig.unimelb.edu.au/suspect_
bdq/). This tool could be useful for the rapid characterization of novel clinical variants, to
help guide the effective use of bedaquiline, and to minimize the spread of clinical resistance.
Introduction
Tuberculosis (TB) is the leading cause of infectious disease death worldwide, with over 10 mil-
lion new cases and 1.6 million deaths in 2017 [1]. A disproportionate burden arises from the
estimated 558,000 annual cases of rifampicin resistant TB (RR-TB) with 82% being multi-drug
resistant (MDR), which is associated with lengthy, toxic therapy and high rates of mortality
[1]. With limited therapeutic options available, especially for MDR-TB and extensively drug-
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resistant (XDR) TB, the introduction of new treatment options is urgently required. Bedaqui-
line, a new anti-TB drug with a novel mechanism of action, targeting the c-ring of ATP
synthase (AtpE) [2], was approved for treatment for MDR-TB in 2012 [3, 4]. This innovative
drug is potent against both actively replicating and dormant bacilli and has been shown to
increase culture conversion in patients with MDR-TB [5]. The use of bedaquiline has
expanded considerably in recent years, and has been recommended for more routine use in
MDR-TB regimens [6], however clinical failures have already been observed [7, 8]. This neces-
sitates a better understanding of how variants result in resistance to aid in the early detection
of resistance.
Phenotypic, and increasingly genotypic, drug susceptibility testing (DST) is recognized as
essential for effective individualization of TB therapy. However, while progress has been made
in strengthening laboratory diagnostics, the TB community is still struggling to build up labo-
ratory networks with the needed capacity for routine culture and DST [7, 9]. The World
Health Organization (WHO) has strongly urged the development of accurate and reproducible
DST for bedaquiline and recommended that in the absence of specific DST, bedaquiline resis-
tance should be monitored through MIC assessment [10] with resistance development evalu-
ated in patients with treatment failure or relapse. Early characterization of drug resistance
mutations would assist TB patient management and avoid treating individuals with ineffective
toxic regimens [11, 12], but capacity for rapid genotypic prediction of bedaquiline resistance is
limited by the identification of few known resistance associated variants [13].
In an era of rapidly expanding use of molecular technologies, including whole genome
sequencing, tools for evaluating the impact of novel mutations are increasingly vital, particu-
larly for drug resistance to novel and emerging medications such as bedaquiline. Though cul-
ture-based detection of resistance will remain the gold standard, in silico analyses can support
informed decision-making. We have previously shown that the analysis of how variants can
affect protein structure and function can be used to reliably characterize how variants lead to
drug resistance [14–18]. Using this approach, we have shown that drug resistant mutations
can be rapidly, accurately and pre-emptively predicted, guiding drug development [19–22]
and clinical diagnosis [23].
In-vitro selection [24] and clinical studies [25] have shown that variants in the atpE gene
can lead to bedaquiline resistance. To support rapid identification of potential bedaquiline
resistance mutations, we considered whether structural information of the drug target could
help guide clinical inference on genomic variants. Using a suite of well-established computa-
tional tools for characterizing the molecular consequences of mutations on protein structure
and function, we have assessed the effects of mutations on the biophysical changes of AtpE
folding, stability and on drug binding affinity. This was used to characterize how mutations in
AtpE lead to resistance, and to train a predictive multilayer perceptron (feedforward artificial
neural network) algorithm to characterize novel AtpE variants.
Methods
Data sets
Resistant variants from in-vitro selection studies were curated [13, 24, 26] along with a natural
variant [4, 27] and used for model development. Susceptible variants were identified using a
novel homology approach, where the genomes of all mycobacteria species sensitive to the drug
[28] were aligned, therefore inferring that any present variants were likely to be susceptible.
Clinically observed bedaquiline resistant atpE variants were curated from published reports
[25]. The Vietnam dataset consists of whole genome sequences of 1635 Mycobacterium tuber-
culosis (Mtb) strains isolated from patients with pulmonary TB in Ho Chi Minh City, Vietnam.
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Homology modeling of AtpE
The structure of Mtb AtpE was modelled with MODELLER [30] using the experimental crystal
structure of Mycobacterium phlei (M. phlei) AtpE (PDB ID: 4V1F). The model was then mini-
mized in Prime and bedaquiline docked into the apo structure using Glide (Schrödinger
Suite).
Modelling the biophysical consequences of missense variants
The structural consequences of the AtpE polymorphisms were assessed to account for all the
potential effects of the mutations. The effects of mutations on protein folding and stability
were assessed using SDM [31], mCSM-Stability [32] and DUET [33], and their effects on pro-
tein flexibility and conformation was predicted using normal mode analysis by DynaMut [34].
The effect of the difference on the protein-protein interactions between the protomers of AtpE
were predicted using mCSM-PPI [32]. The effect of the changes on the binding affinity of
bedaquiline towards AtpE were predicted using mCSM-Lig [35–37]. These approaches are
novel machine-learning algorithms that use graph-based signatures to represent the structural
and chemical environment of the wild-type 3D structure of a protein to quantitatively predict
the effects of point mutations. Additionally, SNAP2 [38] was used to provide additional evolu-
tionary based information.
Machine learning
To build the binary classifier, a multilayer perceptron neural network algorithm was trained,
based on the implementation available through the Weka toolkit [39]. The resistant variants
were up-sampled to create a more balanced model [40]. The training dataset constituted of 50
non-resistant associated variants and 5 resistant associated variants, while the blind test dataset
constituted of 4 non-resistant associated variants and 4 resistant associated variants. To avoid
over-biasing, the train and blind test dataset were non-redundant with respect to residue posi-
tion. The model was trained and evaluated using jackknife [41] and leave-one-residue-posi-
tion-out validation. The classification model was evaluated based on metrics, including the
Area Under the ROC curve (AUC), precision and accuracy. Statistical analysis was performed
using RStudio (version 3.1.1).
Webserver development
The server front-end was built using materialize CSS framework version 1.0.0, while the back-
end was built in Python via the Flask framework (version 0.12.2). It is hosted on a Linux server
running Apache.
Results
We used a structure-guided approach to understand the protein structure of the drug target
AtpE and machine learning to build an empirical tool that could identify likely resistant muta-
tions. The pipeline used to analyze the variants and train a multilayer perceptron neural net-
work algorithm is shown in Fig 1.
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE
PLOS ONE | https://doi.org/10.1371/journal.pone.0217169 May 29, 2019 3 / 14
Structural information: The drug binding domain
A homology model of Mtb H37Rv AtpE was built using the existing experimental crystal struc-
ture of AtpE from Mycobacterium phlei (PDB ID: 4V1F) [42], which shares a high sequence
identity with the Mtb protein (84.9%). The protomer model was an alpha helical hairpin struc-
ture comprising two membrane-spanning helices connected by a hydrophilic loop. The homo-
oligomeric construct was built using the M. phlei structure as a guide, as the Mtb protein has
been previously shown to assemble as a homo-nonamer [43] (Fig 2A and 2B). The cylindrical
palisade model contained an internal hydrophobic cavity where phospholipid had been pro-
posed to bind. The conserved proton binding residue (E61) was located sandwiched between
adjacent protomers and equidistantly distributed along the center of the hydrophobic mem-
brane bilayer.
The top docking poses of bedaquiline with the nonamer homology model identified a pose
consistent with that observed in the M. phlei structure. The drug binding cleft was located at
the interface of two protomers, with amino acid residues E61, A62, Y64, F65 from one proto-
mer and I66 from the adjacent protomer defining the drug binding cleft. Analysis of the
molecular interactions with Arpeggio [44] highlighted a strong network of polar interactions
between the drug and AtpE (Fig 2C). Of particular interest, the diethylaminomethyl group of
bedaquiline specifically interacted with the conserved proton binding residue E61, making
Fig 1. Methodology. This workflow highlights important steps in the methodology and how the main components of
the algorithms are computed. In our analysis we used 54 non-resistant associated mutations and 9 resistant mutations
for the biophysical analysis, followed by training and validation of our empirical model using a supervised machine
learning algorithm.
https://doi.org/10.1371/journal.pone.0217169.g001
Fig 2. Structure and sequence information. (A) ConSurf analysis of AtpE (M. tuberculosis) where the evolutionary
rates of conservation are color-coded on to the structure. (B) The experimental crystal structure of AtpE bound to
Bedaquiline (purple). (C) The key molecular interaction between Bedaquiline (ball and stick representation; purple)
and AtpE: ionic bond (yellow), π-interactions (green), proximal hydrogen bond (red) and weak polar van der Waal
clashes (orange). The known resistance mutations are shown as salmon red (sticks) on the cartoon representation of
the AtpE structure.
https://doi.org/10.1371/journal.pone.0217169.g002
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tight ionic and hydrogen bonds with the carboxyl group of E61 (S1 Fig). In the docked model,
bedaquiline also made strong π-interactions with residues Y64 and I66, and a hydrogen bond
to A62.
Variant calling
We identified 9 previously published bedaquiline resistant non-synonymous single nucleotide
variants (nsSNVs) from in-vitro selection experiments [4, 13, 24, 26]. To identify AtpE muta-
tions not associated with drug resistance, we examined sequence variation amongst AtpE
sequences from 23 mycobacterial species that have been shown to be phenotypically sensitive
to the drug [27, 45–49] (Fig 3). Due to the high degree of sequence conservation across myco-
bacterial AtpE sequences (~ 66% sequence homology; Clustal Omega), variations between
strains shown to be susceptible to bedaquiline were inferred to not be associated with drug
resistance. Through comparison against the Mtb sequence (highlighted in yellow in Fig 3), 54
non-resistance-associated variants were identified (shown in teal in Fig 3).
Understanding the structural basis of resistance is important to facilitate the rapid identifi-
cation of novel resistance variants, aiding efforts to minimize the rapid development of resis-
tance [23]. The 54 non-resistance-associated variants (“S”) and 9 resistant variants (“R”) were
mapped on the protein structure of AtpE (Fig 1). Most of the non-resistance-associated muta-
tions were located on the N-terminal surface exposed inner loop of AtpE. Conserved regions
(highlighted red in Fig 3) were evident, mainly on the C-terminal or the outer loop and
embedded in the lipid bilayer of the membrane. All resistance-associated mutations were local-
ized within 5 Å of the known drug binding site, which we refer to as the “resistance hotspot”.
Structural and biophysical consequences of AtpE variants
The resistant associated variants were all predicted by SNAP2 [38] to be more functionally del-
eterious than the non-resistance associated variants, reflecting the resistant associated variants
are in a more conserved region of the protein. In order to better understand the molecular
consequences of the mutations on AtpE structure and function, the mutations were analyzed
in the context of both the apo and complexed protomeric structures. The impact of resistant
and non-resistant associated mutations on protein folding, stability and conformation were
assessed using SDM [31], mCSM-Stability [32], DUET [33] and DynaMut [34]. The effect of
the variants on the affinity of the protomers to form the cylindrical palisade homo-oligomer
were examined using mCSM-PPI [32], and the effect of the variants on the binding affinity for
bedaquiline were assessed using mCSM-Lig [37].
Fig 3. Non-resistant associated variant assignment. This image highlights the sequence alignment of 23
mycobacterial species sensitive to Bedaquiline. Residues that were different to the reference M.tuberculosis sequence
(in yellow) are highlighted in teal, and were chosen as non-resistant associated variants for building the empirical
model. The conserved residues are shown in red. The secondary structure of the AtpE protein is shown above the
sequences in blue (α = alpha helix, η = loop). This image was created using ESPript 3 [56].
https://doi.org/10.1371/journal.pone.0217169.g003
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Analysis of the variant effects on protomer stability and the formation of the cylindrical pal-
isade did not reveal statistically significant differences between resistant and non-resistance-
associated variants (Fig 4). This is consistent with recent work that showed in order to mini-
mize fitness costs, resistant associated variants in drug targets tended to have mild effects on
protein stability [50]. The largest destabilizing effect observed amongst the resistance-associ-
ated variants using mCSM-Stability and DUET was for the conservative mutation E61D
(ΔΔG = -1.1 Kcal/mol), however normal mode analysis by DynaMut suggested that the E61D
mutation would not destabilize the structure and was only associated with mild conforma-
tional changes (S1 Fig). Examination of residue conservation across 150 homologous
sequences using ConSurf [51] showed the equivalent residue position in many species was an
Asp, suggesting its introduction is unlikely to have a large structural or functional effect.
While all nine resistant variants were within 5Å of the ligands, five in particular, A63M,
A63P, E61D, L59V and I66M, were within 2.5Å and making direct interactions with bedaqui-
line. Modelling of these mutations revealed that most of them would result in complete loss of
these intermolecular interactions (S2 Fig). For example, E61 upon mutation to Asp would
result in loss of these strong ionic and hydrogen bonds with bedaquiline. Interestingly, the
mutation of I66 to Met and L59 to Val mutation revealed the formation of new interactions,
although the overall binding affinity was predicted to be lower by CSM-lig. Most of the non-
resistant associated variants were located distal to the bedaquiline binding site.
Analysis of predicted changes in bedaquiline binding affinity upon mutation using mCSM-
Lig revealed a significant difference between variants associated with resistance or not associ-
ated with resistance (Fig 4). The non-resistance associated variants were associated with mild
mCSM-Lig predicted changes in bedaquiline binding affinity (average of -0.25 log affinity fold
change). This would be consistent with the mutations leading to minimal change in, or even
increasing, drug binding affinity. The average predicted log fold change in binding affinity
obtained for the 9 resistant mutations, by contrast, was -1.29 log affinity fold change, indicating
that they would likely disrupt bedaquiline binding. Among them, all four D28 resistant variants
were predicted to the largest destabilising effect on bedaquiline binding (-2.5 log affinity fold
change on average). D28 is positioned on the inner helix of the protomer and is 4.7Å from the
drug binding site. When D28 was substituted with either Ala or Gly, a loss in inter-helical inter-
actions and a gain in flexibility was observed, and when substituted to Pro and Val it led to a
gain in intra-molecular interactions and rigidification of the AtpE structures (S2 Fig).
Fig 4. PCA analysis. Boxplot representation of all the features used to build the predictive model. The resistant
associated mutations (R) are represented as red and the non-resistant associated mutations (S) as teal. (� p<0.05, ��
p<0.005, ��� p<0.0001, NS p>0.5 by Welch two sample t-test).
https://doi.org/10.1371/journal.pone.0217169.g004
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Machine learning algorithm: Multilayer perceptron network
Building on this structural analysis, we tested whether these structural features could be used
to train a supervised machine learning algorithm capable of accurately predicting resistant
associated variants. To avoid over-training, the 54 non-resistant and 9 resistant variants were
split into a training and blind test dataset. Our training dataset constituted of 50 non-resistant
associated variants and 5 resistant associated variants (A63V, A63P, I66M, L59V, E61D). Due
to the small sample size, to balance the dataset, the resistant variants in the training dataset
were oversampled (duplicated). The remaining 4 resistant (all D28 mutations) and 4 non-resis-
tant associated (I11L, L15T, A34Q and A45S) variants in the blind test were positioned non-
redundant with those in the training.
A list of features tested in method development is described in S1 Table. As discussed
above, the features that best distinguished between the classes include distance from ligand
binding site (“Distance from Ligand”, p< 0.0001), mCSM-Lig (p = 0.026) and SNAP2
(p< 0.0001) (Fig 4). Using jackknife and leave-one-residue-position-out validation, models
trained using multilayer perceptron neural networks yielded the strongest balanced perfor-
mance. The final model correctly classified 93.33% and 100% of variants in the training and
blind test datasets respectively (Fig 5, Table 1). The comparative performance across iterative
non-redundant blind datasets suggested that the model was not over-fitted.
The classifier revealed that variants with mild effects on protein stability and conformation
(DynaMut < 0.28 Kcal/mol and DUET < -1.65 Kcal/mol), located close to the docked beda-
quiline (distance from ligand < 6.36 Å) were likely to be associated with resistance. A closer
examination of the four incorrectly classified non-resistant associated variant in the train data-
set revealed that three of them, G58S, A63T and L68V, were positioned very close to the beda-
quiline binding site (< 2.5 Å) and N33A had a large predicted change in binding affinity (-1.4
log affinity fold change); indicating that these mutations might have direct consequences on
bedaquiline binding.
Fig 5. Evaluation metric. The ROC curve shows that using the structural and functional consequences of the variants,
we were able to accurately identify resistant (red) and non-resistant associated (teal) variants.
https://doi.org/10.1371/journal.pone.0217169.g005
Table 1. Evaluation metrics of the train and blind test dataset.
Multilayer Perceptron (MLP) Precision score Recall F-measure ROC area PRC area
Train Dataset 0.952 0.933 0.938 0.970 0.967
Blind test Dataset 1.000 1.000 1.000 1.000 1.000
https://doi.org/10.1371/journal.pone.0217169.t001
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Clinically identified resistance associated variants
Using a model trained without the D28 variants, we analyzed the recently reported clinical
atpE bedaquiline resistant variants [25]. Both D28N and A63V were both predicted by the
model to lead to bedaquiline resistance, consistent with the clinical data. Looking at these
mutations within the structure, the mutation at D28 would disrupt interactions made by the
wild-type residue to bedaquiline, consistent with the mCSM-Lig predictions that it would lead
to a significant reduction in ligand binding affinity (S3 Fig; -1.87 log affinity fold change).
Interestingly, while A63 did not make interactions directly with bedaquiline, the mutation to
Val would lead to steric clashes with the bound ligand and prevent bedaquiline binding (S3
Fig).
Vietnam data analysis
We also used this approach to predict the sensitivity of two atpE nsSNVs, I16V and P52L,
identified through whole genomic sequencing of Mtb strains isolated from 1635 TB patients in
Vietnam [15]. The predictive tool classified the reported nsSNPs to be non-resistant associated
variants. These variants were located approximately 10 Å away from the bedaquiline binding
site, and mutations at these residues were not predicted to disrupt any interactions with beda-
quiline (S4 Fig). As these samples had been collected from patients that had not been adminis-
tered bedaquiline, it provided confidence that in our large analysis of patients in Vietnam
there were no circulating strains likely to be resistant to bedaquiline.
SUSPECT-BDQ webserver
We have implemented SUSPECT-BDQ as a user-friendly, freely available web server http://
biosig.unimelb.edu.au/suspect_bdq/. SUSPECT-BDQ provides two different input options.
The “Single Mutation” option allows users to predict whether a mutation will be characterized
as either Resistant or Susceptible. For this option, the server requires the point mutation to be
specified as a text string containing the wild-type residue one-letter code, its corresponding
position on the structure and the mutant one-letter code. The “Mutation List” option allows
the user to upload a file with a list of mutations in a file for batch processing. In order to assist
users to submit their mutations for analysis, sample submission entries are available for both
input options and a help page is also available via the top navigation bar.
For the “Single Mutation” option, the web server displays the prediction outcome of SUS-
PECT-BDQ alongside with details of the user input data, information on the residue environ-
ment and parameters used on the prediction (S5 Fig). In addition, an interactive 3D viewer,
built using NGL [52] allows for analysis of non-covalent inter-residue interactions for the posi-
tion specified in the input calculated with Arpeggio [44] for wild-type and mutant structures.
For the “Mutation List” option, the results are summarized in a downloadable table from
which users can access details for each single mutation. A 3D viewer is also shown and each
wild-type residue from the input list is colored according to the predicted effect.
Discussion
Early genomic detection of resistance is crucial for tailoring individual therapy and preventing
the onward transmission of resistant infection. This is especially of importance to limit the
spread of resistance to bedaquiline, one of the few treatment options for XDR-TB. While sig-
nificant progress has been made in terms of innovative tools to understand and quantify the
different range of effects in which a mutation or a set of mutations can give rise to a drug-resis-
tant phenotype, a gap still exists when integrating these predictions and drawing conclusions
Empirical ways to identify novel Bedaquiline resistance mutations in AtpE
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regarding causality and the strength of associations observed. This is compounded by the need
for detailed information regarding the system/protein. The availability of scalable, effective
computational methods to assess mutational effects creates new opportunities for developing
integrated approaches and deciphering complex genomic background patterns, shedding light
on their role in the emergence of a given phenotype and molecular mechanisms of action [19].
Here we have used a computational approach to better understand the molecular mecha-
nism of drug resistance within the context of the protein’s 3D structure. A machine learning
algorithm was used to build a predictive tool which could pre-emptively determine novel beda-
quiline resistant mutations within atpE. We began our investigation by studying the interac-
tion dynamics between the c-ring of ATP synthase bound to bedaquiline. The correlations of
conformational changes and Gibb’s free energy provided novel molecular insights into how
resistance variants affected bedaquiline binding but led to minimal disruption of protein fold-
ing and dynamics. Mapping of all the mutations on the crystal structure helped us identify the
“mutational hotspot” for AtpE, which was in proximity to the drug binding site. We saw that
resistance associated variants were more likely to be located within this resistance hotspot, and
lead to a significant disruption in bedaquiline binding. Interestingly, the characterized resis-
tant variants did not lead to large changes in protein folding, stability or oligomeric state,
which would impose a larger fitness penalty [50].
This in silico biophysical information was used to build a predictive algorithm that accu-
rately identified resistant mutations. We then prepared a comprehensive mutational dataset
that contained the predictions of all possible mutations in AtpE, which we have made available
through a web-based interface: SUSPECT_BDQ (http://biosig.unimelb.edu.au/suspect_bdq/).
These analyses highlight the power of considering the structural environment of a mutation to
understand the molecular and biological consequences [53]. As a relatively novel drug, there is
still a paucity of reliable information regarding resistance mutations. While limited by the rela-
tively small available datasets, repeated stratified non-redundant blind testing revealed the
model was very robust. This associative approach thus helped us establish a set of guidelines
which adds to the missing information in the database for new TB drugs like bedaquiline. It
also provides a molecular understanding of how variants in AtpE affect ligand binding, leading
to resistance, providing insight to guide development of second-generation inhibitors.
We intend further development of this tool through expanded genomic targets, and evalua-
tion using additional clinical isolates. In particular we intend to extend SUSPECT_BDQ to
include non-target based resistance to bedaquiline, which has been linked to mutations in
Rv0678 [54], a transcriptional repressor of the gene encoding the MmpS5-MmpL5 efflux
pump, and pepQ (Rv2535c) [55], a putative Xaa-Pro aminopeptidase. Both are associated with
low-level of resistance and therefore we did not include them in the study. However, low level
resistance may have clinical significance in some settings, and future work will further evaluate
other potentially important loci. Additionally, testing this tool on further clinical isolates will
enhance the efficiency of the tool to predict the consequences of novel mutations.
Conclusion
This novel computational approach can enhance the impact of genome sequencing in identify-
ing and characterizing variants more accurately and may therefore assist in guiding optimal
usage of bedaquiline. The results obtained from our empirical tool is promising and should
help facilitate routine genotypic drug susceptibility testing for bedaquiline and stimulate fur-
ther research to help avoid the emergence of resistance to this new treatment through early
detection.
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Supporting information
S1 Table. The list of different features used to build the empirical model for predicting
novel resistance associated mutations in bedaquiline.
(PDF)
S1 Fig. Detailed molecular interactions between the key proton binding residue E61, and
upon its mutation to Asp, with bedaquiline. The wild-type residue is shown in cyan and
mutant in salmon red in ball and stick representation. Bedaquiline is shown in purple (ball
and stick representation). Hydrogen bonds are shown as orange dashes and ionic bond in yel-
low.
(TIF)
S2 Fig. Images of intermolecular interactions made by the wild-type residue (shown as
cyan) and the mutant amino acid (shown as salmon red). Hydrogen bonds are shown in
red, halogen bonds in blue, ionic bonds in yellow, hydrophobic bonds in green, π bonds in
grey.
(TIF)
S3 Fig. Detailed molecular interactions between two clinically observed bedaquiline resis-
tant variants, with the drug. The wild type residue is shown in cyan and mutant in salmon
red in ball and stick representation. Bedaquiline is shown in purple (ball and stick representa-
tion). Halogen bonds are represented in blue dashes (amide-amide interaction) and π-bond as
grey dashes.
(TIF)
S4 Fig. The localization of two circulating atpE variants relative to the bedaquiline binding
pocket. The wild type residues are shown in cyan and mutant in salmon red in ball and stick
representation. Bedaquiline is shown in purple (ball and stick representation).
(TIF)
S5 Fig. SUSPECT-BDQ webserver. Web-server results page for a single point mutation pre-
diction. The predicted outcome is shown alongside with complementary information on the
submitted mutation. An interactive 3D viewer allows for analysis of non-covalent interactions
for both the wild type and mutant residue. In both cases controllers are provided in order to
hide or show specific interactions and customize molecule representation.
(TIF)
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Chapter 9
Exploring Protein Supersecondary Structure Through
Changes in Protein Folding, Stability, and Flexibility
Douglas E. V. Pires, Carlos H. M. Rodrigues, Amanda T. S. Albanaz,
Malancha Karmakar, Yoochan Myung, Joicymara Xavier,
Eleni-Maria Michanetzi, Stephanie Portelli, and David B. Ascher
Abstract
The ability to predict how mutations affect protein structure, folding, and flexibility can elucidate the
molecular mechanisms leading to disruption of supersecondary structures, the emergence of phenotypes, as
well guiding rational protein engineering. The advent of fast and accurate computational tools has enabled
us to comprehensively explore the landscape of mutation effects on protein structures, prioritizing muta-
tions for rational experimental validation.
Here we describe the use of two complementary web-based in silico methods, DUET and DynaMut,
developed to infer the effects of mutations on folding, stability, and flexibility and how they can be used to
explore and interpret these effects on protein supersecondary structures.
Key words Missense mutations, Protein stability and folding, Machine learning, Normal mode
analysis, Graph-based signatures, DUET, DynaMut
1 Introduction
Proteins are marginally stable, versatile macromolecules involved in
a large variety of biochemical processes which are strictly linked and
regulated by their native conformation. Mutations leading to
changes in protein folding, stability, and conformation can have
large phenotypic consequences, responsible for the development of
many genetic disorders [1–14], including cancers, and even respon-
sible for changes in drug susceptibility [15–27]. While these effects
are commonly thought about in terms of reduced protein stability,
mutations leading to increased stability and rigidification of the
molecule can be equally deleterious. Maintaining, or enhancing,
protein stability, and the identification of mutations that do not
negatively affect protein stability, also remains one of the most
difficult and important challenges in protein engineering.
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While experimental validation of protein thermodynamic para-
meters remains a laborious task, the development of novel robust
and scalable computational methods (Table 1) has allowed for the
evaluation of the complete landscape of structural effects of muta-
tions in a protein system and their effects on protein stability and
flexibility within minutes, enabling rapid mutation prioritization.
Using the concept of graph-based signatures, we have devel-
oped robust methods for quantitatively analyzing effects of single
missense mutations on protein stability, flexibility, and interactions
[9, 28–37]. DUET [37] (http://biosig.unimelb.edu.au/duet) is a
machine learning-based approach that integrates and optimizes two
complementary methods in an optimized predictor (mCSM-
Stability [36] and SDM [38]) using support vector machines.
This method enables the accurate assessment of the effects of
mutations on protein folding and stability. DynaMut [28]
(http://biosig.unimelb.edu.au/dynamut) is a novel method that
takes into account molecular motions and, by combining the
graph-based signatures with coarse-grained normal mode analysis,
generates a consensus prediction of effects of mutations on the
protein conformational repertoire. These methods together com-
pose a powerful platform that allows users to navigate the landscape
of mutations effects on folding, stability, and flexibility.
2 Materials
DUET and DynaMut are structure-based methods for assessing
effects of single-point missense mutations on protein stability/
folding and protein flexibility/conformation, respectively. For
both methods, users are required to provide:
1. Wild-type protein structure in PDB format: For both methods,
a wild-type structure of the protein of interest in the Protein
Data Bank [39] format (.pdb) must be provided to perform the
predictions. This can be either (a) an experimentally solved
structure, with previously solved structures available in the
Protein Data Bank, or (b) a model, for instance, obtained via
comparative homology modeling (see Note 1 on how to deal
with oligomeric structures). We have previously shown that
using homology models built using templates down to 25%
sequence identity does not significantly reduce predictive per-
formance of either method (seeNote 2). Users have the option
to either upload the structure file or provide the PDB accession
code when they wish to use an experimental structure previ-
ously deposited into the PDB (http://www.rcsb.org or http://
www.ebi.ac.uk/pdbe/) (see Note 3).
2. Mutation information: The user also needs to supply informa-
tion on the mutation or mutations they wish to analyze,
174 Douglas E. V. Pires et al.
Table 1
List of freely available webservers and software for predicting effects of single-point mutations on
protein folding, thermostability, and flexibility




























































































































































including (1) the chain identifier (one-letter code of the chain,
which corresponds to the 22nd column of the coordinate
section in the PDB file where the mutation occurs) (see Note
1) and (2) the mutation code, which consists of the one-letter
amino acid residue code of the wild-type residue, the residue
number position as in the PDB file (columns 23–26 of the
coordinate section), and the one-letter code of the mutated
residue (e.g., R282W denotes a mutation from arginine to




of Mutation on Protein
Stability and Folding
with DUET
1. DUET is freely available as a user-friendly web interface and is
compatible with most operating systems and browsers. Open
up the prediction server, http://biosig.unimelb.edu.au/duet/
stability, on a web browser of your preference.
2. Provide the wild-type protein structure of interest by either
uploading a PDB file or supplying a valid four-letter PDB
accession code (Fig. 1a).
3. DUET offers users the option of two prediction modes,
(a) assessing stability effects of a single mutation or
(b) systematically evaluating all possible mutations at a given
residue position. For a single mutation, users need to provide
the mutation information and the mutation chain. For system-




1. If a single mutation is provided, after processing, the results
page is shown (Fig. 1b), which includes information about the
mutation and the predicted effects on stability for DUET and
for the individual methods (mCSM-Stability and SDM). An
interactive molecular visualization is also shown, allowing users
to inspect the wild-type residue environment.
2. For systematic evaluation of a given residue, the predicted
effects on protein stability for all 19 possible mutations are
shown in tabular format (Fig. 1c).
3. Predicted effects are given as the change in Gibbs Free Energy,
ΔΔG (kcal/mol), with negative values denoting destabilizing
mutations and positive values, stabilizing ones. While users
should interpret the values in the context of the protein system
being studied, previous studies have used a rule of thumb that
highly destabilizing/stabilizing mutations are those with a pre-
dicted |ΔΔG| > 1.0 kcal/mol; and moderately destabilizing/
stabilizing mutations are those with a predicted |ΔΔG| between
0.5 and 1.0. SeeNotes 4 and 5 for further information on how
to interpret results.
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Fig. 1 DUET submission and results web interface. (a) The submission page allows users to either provide its
own PDB file or inform an accession code of a protein of interest (1). Users have the option to analyze a







1. As with DUET, DynaMut predicted changes upon mutation in
protein stability are presented as a change in the Gibbs Free
Energy of folding and stability (ΔΔG in kcal/mol), calculated
as the difference between the wild-type and mutant proteins:
ΔΔG ¼ ΔGwt  ΔGmt. A positive value denotes a stabilizing
mutation, while a negative value denotes a destabilizing one.
The DynaMut consensus prediction uses both normal mode
analysis and graph-based signatures to more accurately identify
stabilizing mutations, a limitation of other published
approaches (Fig. 2b).
2. DynaMut is also freely available for use freely as a user-friendly
web interface. In order to run a prediction, open up the Dyna-
Mut prediction page at http://biosig.unimelb.edu.au/
dynamut/prediction on a web browser of your preference
(the web server is compatible with the most common operating
systems and browsers).
3. Users have the option to either evaluate a single mutation or
provide a text file with a list of mutations to be evaluated in the
same format discussed above to run DUET (Fig. 2a). There are
no limits on the number of mutations that can be analyzed.
4. For both predictions modes, users are required to provide the
wild-type protein structure of interest by either uploading a
PDB file or supplying a valid four-letter code PDB accession
code of a deposited experimental structure (Fig. 2a).
3.4 DynaMut
Prediction Output
1. Prediction results: DynaMut will present the results under
three main separate tabulated headings: (1) variation of Gibbs
Free Energy predictions, (2) interatomic interactions, and
(3) deformation/fluctuation analysis. See Notes 4 and 5 for
further information on how to interpret results.
2. DynaMut also graphically displays the resulting change in
vibrational energy between the wild-type and mutant struc-
tures (Fig. 2b). This highlights regions predicted to be more
flexible (red) or less flexible (blue) upon mutation. All calcula-
tions and representations can be downloaded through links
located at the bottom of the results page.

Fig. 1 (continued) specific mutation or perform a systematic analysis of all mutations for a given residue (2).
(b) For single-mutation prediction, the mutation identification (3) and the predicted effects on stability are
shown (4), as well as an interactive molecular visualization (5). (c) For systematic evaluation of mutation on a
given residue, the results are shown in tabular format
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3. When multiple mutations are analyzed, these results are pre-
sented in a tabulated format, where users are able to open up
and analyze each mutation within the single-mutation analysis
result interface.
Fig. 2 DynaMut submission and results web interface. (a) The submission page allows for the analysis of a
single-point mutation (1) or a list of mutations (2). The main results page (b) depicts the predicted effect of
mutation by DynaMut (3) as well as predicted effects by its individual components (4). A depiction of the
calculated different in vibration entropy (5) is also shown




1. DynaMut also enables visualization of the effects of a mutation
within the wild-type and mutant protein structure (Fig. 3).
2. The interatomic interactions made by the wild-type andmutant
residues, calculated using Arpeggio [30] (http://biosig.
unimelb.edu.au/arpeggioweb/), are visually shown. This
enables the user to identify how the mutation will affect the
local interaction network—important for maintaining protein
stability (Fig. 3a).
3. The normal mode analysis predictions are also shown, high-
lighting changes in vibrational energy between the wild-type
and mutant structures (Fig. 3b).
4. All these representations are downloadable as Pymol session
files from links at the bottom of the results page.
4 Notes
1. It is important to notice that both methods, DUET and Dyna-
Mut, were conceived to analyze monomer structures. In case of
analysis of oligomers, users are advised to filter their PDB files
prior to submission, filtering chains of interest (for instance,
using the PDBest software [40]). The servers will consider all
chains submitted; however, a warning message is exhibited.
When considering the effects of mutations on oligomeric struc-
tures, it is also important to consider the effects of the muta-
tions on the affinity of the monomers to form the oligomer.
This can be assessed using mCSM-PPI (http://biosig.unimelb.
edu.au/mcsm/protein_protein).
2. The chain ID for the provided PDB file is a mandatory field,
and blank characters are not allowed. Some homology model-
ing tools do not automatically add a chain ID. If this is the case,
the user will need to modify the PDB file prior to submission to
the servers. There are several tools available to perform this
task.1
3. Another source of error comes from structures with multiple
models. It is an important practice to filter NMR structures,
selecting a single model.
4. Special cases: Mutations to and from prolines. Prolines are the
only amino acid whose amino group is connected to the side
chain, which in the context of the peptide bond greatly limits
torsional angles. The nature of this residue, therefore, needs to
be taken into account while analyzing mutation effects. For
instance, (1) mutations to prolines in the middle of alpha-
helices can introduce kinks, affecting local structure, and
1 http://www.canoz.com/sdh/renamepdbchain.pl
180 Douglas E. V. Pires et al.
Fig. 3 DynaMut secondary results web interface. (a) A depiction of the calculated interatomic interactions (1)
for wild-type and mutant proteins is shown, with interactions identified by color (2). (b) Depicts visualizations
of the deformation and fluctuation analysis as fluctuation plot per residue (3) and atomic fluctuation in the
context of the structures (4). Figure and individual files (pymol files for molecular visualization) are available for
download
(2) since prolines are commonly found in turns and loops, their
substitution might interfere with the formation of superse-
condary structures such as hairpin loops.
5. Special cases: mutations of positive-phi glycines. Similarly to
prolines, positive-phi glycines, while rare in experimental struc-
tures, should also be given special consideration due to its
torsional angles. Glycines are the only residues capable of
adopting positive-phi angles. These glycines are usually con-
served across evolution, meaning that mutations of positive-phi
glycines tend to be destabilizing.
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Abstract
Motivation: A lack of accurate computational tools to guide rational mutagenesis has made affinity maturation a re-
current challenge in antibody (Ab) development. We previously showed that graph-based signatures can be used to
predict the effects of mutations on Ab binding affinity.
Results: Here we present an updated and refined version of this approach, mCSM-AB2, capable of accurately model-
ling the effects of mutations on Ab–antigen binding affinity, through the inclusion of evolutionary and energetic
terms. Using a new and expanded database of over 1800 mutations with experimental binding measurements and
structural information, mCSM-AB2 achieved a Pearson’s correlation of 0.73 and 0.77 across training and blind tests,
respectively, outperforming available methods currently used for rational Ab engineering.
Availability and implementation: mCSM-AB2 is available as a user-friendly and freely accessible web server provid-
ing rapid analysis of both individual mutations or the entire binding interface to guide rational antibody affinity mat-
uration at http://biosig.unimelb.edu.au/mcsm_ab2
Contact: david.ascher@unimelb.edu.au or douglas.pires@unimelb.edu.au
Supplementary information: Supplementary data are available at Bioinformatics online.
1 Introduction
Antibodies (Abs) are central components of our immune system that
bind specifically to their target antigens in order to elicit an immune
response. This interaction between an Ab and its antigen is mediated
by a myriad of non-covalent interactions made by the complementary
determining regions (CDRs) of the Abs with a specific epitope on an
antigen. This ability to bind to a wide variety of targets, including
those traditionally considered undruggable, in a highly specific and
selective manner has led to increasing interest in their use as therapeu-
tics for a broad range of diseases including several types of cancer
(Elgundi et al., 2017) and rheumatoid arthritis (Tanaka et al., 2014).
Since the first approval of monoclonal Ab, the significant improve-
ment in Ab engineering has led Abs to become best-selling drugs
accounting for over half of the therapeutic market (Urquhart, 2018).
Ab development often requires optimization of its stability, solu-
bility, selectivity, affinity and immunogenicity. Achieving the desired
properties can often become a major challenge, considering the large
number of possible variations in Abs, and with each potentially
affecting multiple biological properties. One of the early steps in the
development of effective Ab therapies is the engineering of binding
specificities and selectivities, which has traditionally been inspired
by the natural biological process of affinity maturation, with rounds
of mutations within the CDR loops explored. This process can be
time-consuming, and is inherently a random and error-prone pro-
cess. Recent examples, however, have shown how the computation-
ally guided rational engineering of Ab-binding affinities can
dramatically improve this process (Kiyoshi et al., 2014; Sefid et al.,
2019).
A number of different computational approaches which use an
available crystal structure to guide Ab design and optimization have
been developed (Roy et al., 2017). A systematic evaluation of the ac-
curacy of these approaches to predict the change upon mutation in
binding affinity highlighted the limited performance of existing
tools, and the challenging nature of this problem.
In a previous work, we have adapted the concept of graph-based
signatures which can efficiently represent the physicochemical proper-
ties and geometry of surrounding environment of the wild-type and
mutant residues to accurately predict the effects of mutations in terms
of protein stability (Pandurangan et al., 2017a; Pires et al., 2014a, b;
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Rodrigues et al., 2018b) and interactions with other proteins (Pires
et al., 2014b; Rodrigues et al., 2019), nucleic acids (Pires et al.,
2014b; Pires and Ascher, 2017), small molecules (Pires et al., 2015;
Pires and Ascher, 2016a) and metal ions (Pires et al., 2016b). These
have been successfully used to provide valuable insights into genetic
diseases (Albanaz et al., 2017; Andrews et al., 2018; Ascher et al.,
2019; Casey et al., 2017; Hnizda et al., 2018; Jafri et al., 2015; Jubb
et al., 2017; Nemethova et al., 2016; Pandurangan et al., 2017b;
Ramdzan et al., 2017; Rodrigues et al., 2018a; Silvino et al., 2016;
Soardi et al., 2017; Traynelis et al., 2017; Trezza et al., 2017; Usher
et al., 2015), drug resistance (Ascher et al., 2015; Hawkey et al.,
2018; Holt et al., 2018; Karmakar et al., 2018, 2019; Phelan et al.,
2016; Pires et al., 2016a, b; Portelli et al., 2018; Vedithi et al., 2018)
and rational protein engineering. We have also successfully applied
our graph-based signatures to the prediction of changes in Ab–antigen
binding affinity and showed that this outperformed existing methods,
although there was still significant room for improvement (Pires and
Ascher, 2016b). The release of SKEMPI2.0 containing information of
the effects of new mutations on Ab–antigen binding affinity, allowed
us to not only assess earlier approaches based on new unseen experi-
mental data, but to also build a predictive model across a more com-
prehensive set of Ab–antigen complexes and mutations. In particular,
mCSM-AB only considered structural information, however evolu-
tionary information and energetic terms have been shown to help pre-
dict the effect of a mutation on Ab-binding affinity, as variants which
have destabilizing effects on proteins are less likely to be conserved
from an evolutionary perspective (Gonzalez-Munoz et al., 2012). In
addition, Ab–antigen interfaces are enriched with specific type of
amino acids such as Tyr and Ser (Jubb et al., 2015; Van Regenmortel,
2014) compared with other protein–protein complexes, and different
modes of interatomic interaction may be important to explain
whether the mutation is favourable in its surroundings.
A powerful and scalable model for predicting the effects of mis-
sense mutations on Ab-binding affinity could hold enormous poten-
tial for guiding rational Ab development. Here we introduce
mCSM-AB2, an updated and optimized version of our previous
method, trained on a larger and more comprehensive dataset, which
uses not only graph-based signatures but also interatomic inter-
action, evolutionary and energy-based features to capture additional
structural and sequence-based information to more accurately pre-
dict Ab–antigen affinity changes upon mutation. We show that
mCSM-AB2 significantly outperforms existing methods, and has po-
tential to guide rational Ab engineering.
2 Materials and methods
The general mCSM-AB2 workflow is depicted in Figure 1. It is com-
posed of three main steps including: (i) dataset acquisition, which
refers to collecting experimental evidence from the literature on
effects of mutations in Ab–antigen binding affinity complexes with
solved structures; (ii) feature engineering, which encompasses the
generation and evaluation of features selected to model different
aspects involved in Ab–antigen recognition and effects of mutations
Fig. 1. Overview of the mCSM-AB2 workflow. In data collection, after data acquisition, hypothetical reverse mutations are considered to avoid the natural bias of mutations
reducing affinity. From the complete dataset (1810 mutations), a range of different features are calculated to be used as evidence to train predictive models using machine learn-
ing algorithms. Among the feature classes, graph-based signatures are used to describe the wild-type residue environment and its geometry and physicochemical properties.
Other structural attributes aiming to model other relevant aspects driving Ab-antigen affinity were also considered, including the variation in the distance to the antigen upon
mutations, solvent accessible area, as well as energetic terms and interatomic interactions. Additionally, an evolutionary score (derived from PSSM) was also used to model
mutation tolerance throughout evolution. All features are then used to build predictive models through a series of training and blind-test validation procedures. The best model
was then made available as an easy-to-use web server at http://biosig.unimelb.edu.au/mcsm_ab2
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on these complexes and (iii) machine learning, which aims to train,
test and validate an accurate predictive model via supervised learn-
ing, using the computed features and experimental effects of muta-
tions, as evidence.
2.1 Datasets
To develop our predictive model, we collected binding affinity
data with experimentally determined structures from the AB-BIND
(Sirin et al., 2016), PROXiMATE (Yugandhar et al., 2017) and
SKEMPI2.0 (Jankauskaite et al., 2018) databases to train and test
mCSM-AB2. Compared with the earlier AB-BIND dataset used for
mCSM-AB, we discarded 3 redundant mutations and 27 mutant
non-binders, which led to a dataset of 558 mutations that was
used as the training set. SKEMPI2.0 contained 830 single point
mutations from Ab–antigen complexes, which were filtered using
‘Hold_out_type’ and ‘Hold_out_proteins’ information, to avoid re-
dundancy during training. Of these 830 instances, there were
102 mutations that had more than one experimentally measured
binding affinity for the same mutation, for which we preferentially
kept direct binding assays such as SPR or ITC, leading to a group of
728 mutations. Within the 728 mutations selected from
SKEMPI2.0, we also disregarded 32 mutant non-binders, leaving a
total of 696 mutations in Ab–antigen complexes. Comparing to AB-
BIND, our filtered SKEMPI2.0 dataset contained 377 new muta-
tions in unique complexes not present in the original training set.
CD-HIT (Huang et al., 2010) was used to cluster interfaces with a
similarity threshold of 90%. The new SKEMPI2.0 dataset contained
unique interfaces not present in the original AB-BLIND dataset, and
was hence used as a non-redundant blind test and comparative tool
to evaluate previous methods built using AB-BIND. In total, our
train/blind-test datasets are composed of 905 single mutations and
the mutations from 11 out of 60 Ab–antigen complexes are present
in both training (AB-BIND) and blind test sets (Supplementary
Table S1). This represents not only a significant increase over the
558 mutations used to train mCSM-AB spanning across more than
twice the number of 25 Ab-antigen complexes, but also a non-
redundant experimental blind test set (377 mutations) which allows
us to explicitly compare the performance of our new approach to
mCSM-AB and other methods.
Due to the nature of experimental affinity maturation, these
datasets were unbalanced, with 652 destabilizing (DDGAffinity< 0),
196 stabilizing (DDGAffinity> 0) and 57 neutral (DDGAffinity¼ 0) sin-
gle point mutations (Supplementary Figure S1, left). As has been pre-
viously proposed (Thiltgen and Goldstein, 2012), to avoid any
subsequent bias in our predictive model we also considered the
hypothetical reverse mutations, using mutant structures generated
by FoldX (Eswar et al., 2006). This gave a final dataset of 1810 sin-
gle point mutations (Supplementary Figure S1, right), of which 1056
were used for training, and a non-redundant set of 754 mutations
were used as a blind test set to avoid overtraining and to benchmark
the performance of mCSM-AB2. We also used an additional blind
test set of 87 mutations across five homology models as proposed
previously (Pires and Ascher, 2016b). The datasets used to train and
validate mCSM-AB2 are available on the mCSM-AB2 web server.
2.2 Feature engineering
Three main classes of features were used in mCSM-AB2 as evidence
to train and test predictive models via supervised learning—struc-
tural, evolutionary and energy-based terms. Graph-based signature
are calculated to model the wild-type residue environment.
These represent distance patterns between different atom types
as cumulative distributions of distances, which we previously show
encode both its physicochemical aspects and geometry (Pires et al.,
2014a, 2016a; Pires and Ascher, 2016a, 2017; Rodrigues et al.,
2018a). In order to calculate structure-based features for mutants,
we implemented BuildModel of FoldX for high quality models.
Additionally, the changes in pharmacophores due to the mutation
are also modelled as a feature vector. These pharmacophore changes
calculated the difference in atom counts per class (hydrophobic,
positive charge, negative charge, hydrogen acceptor, hydrogen
donor, aromatic, sulphur and neutral) between wild-type and mu-
tant residues. Additional structural information was also taken into
account, including the change in molecular interactions upon muta-
tion as calculated by Arpeggio (Jubb et al., 2017), the distance
change of the mutation to the Ab–antigen interface, and the change
of relative solvent accessible (RSA) area upon mutation using DSSP
(Touw et al., 2015). Evolutionary-based information was integrated
by calculating the difference of evolutionary scores between wild-
type and mutant using PAM30-based position-specific scoring
matrices (PSSM) (Altschul et al., 1997). An energy-based term was
also generated using FoldX (Stricher et al., 2005) force fields to cal-
culate the difference upon mutation in potential energy between the
wild-type and mutant structures, expressed in kcal/mol.
2.3 Machine learning methods
Using the collected experimental data describing the effects of mis-
sense mutations on Ab–antigen affinity and calculated features, dif-
ferent supervised learning algorithms available on the Scikit-learn
library for Python (Pedregosa et al., 2011) were evaluated, including
Extra Trees (Geurts et al., 2006), Random Forest (Breiman, 2001),
Gradient Boost (Friedman, 2002) and XGBoost (Chen and
Guestrin, 2016) regression. Predictive models were trained using
five times stratified 10-fold cross-validation to avoid sampling bias,
followed by a blind test. A leave-one-complex out cross-validation
procedure was also implemented to assess performance variations
for different Ab–antigen complexes. The final model showed com-
parable performances across the different training schemes including
5-fold, 10-fold, leave-one-complex-out and Jackknife (Wager et al.,
2014) validation, as shown in Supplementary Table S2.
2.4 Evaluation metrics
The performance of individual models was assessed using the
Pearson’s correlation coefficient and root mean square error
(RMSE), considering performances on both cross-validation and
blind tests. The performance of the model was also assessed on 90%
of the data after removing 10% of worst predicted cases to evaluate
effects of outliers on model accuracy.
3 Results
In order to evaluate the performance of mCSM-AB2, we devised a
series of experiments. The first aim was to assess the contribution of
individual feature components to predictive performance as well as
their combination. mCSM-AB2 was further tested on blind tests and
its performance was compared with available methods.
3.1 Quantitative assessment of Ab–antigen affinity
changes upon mutation
Building upon the previous version of mCSM-AB, we have inte-
grated new structure-based features, energy-based terms and evolu-
tionary scores with our graph-based signatures to better model the
changes of topological and physicochemical properties on Ab–anti-
gen affinity induced by missense mutations. Supplementary Table S2
shows the predictive performance of the individual feature classes,
given as Pearson’s correlation coefficient, for different validation
procedures, including 5- and 10-fold cross-validation, as well as
Jackknife validation.
The best performing individual class of features was the graph-
based signatures, contributing to a correlation of q ¼ 0.65 (RMSE
of 2.14 kcal/mol) on 10-fold cross-validation, followed by the differ-
ence in contacts made by wild-type and mutant residues, which
achieved a correlation of q ¼ 0.60 (RMSE of 2.40 kcal/mol), high-
lighting the important role of inter-residue interactions on driving
Ab–antigen affinity and recognition. Pharmacophore modelling was
also an important feature class, achieving a correlation of q ¼ 0.50
(RMSE of 3.12 kcal/mol). Complementary structure-based informa-
tion was also integrated to the method, even with modest perform-
ance, including the change of the RSA upon mutation (q ¼ 0.16
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and RMSE of 10.92 kcal/mol), the change of distance from mutation
site to the antigen interface (q ¼ 0.26 and RMSE of 6.64 kcal/mol).
Other two features incorporated on this new and updated ver-
sion of the method were energy potential terms calculated using
FoldX and sequence-based evolutionary information encoded in
PSSM scoring matrices. These features contributed individually to
a predictive performance of q ¼ 0.26 (RMSE of 6.61 kcal/mol) and
q ¼ 0.42 (RMSE of 3.95 kcal/mol), respectively.
It is interesting to notice that there seems to be little correlation be-
tween the different classes of selected features, as shown in
Supplementary Figure S2, especially to the new evolutionary and energy-
based attributes, indicating they were likely contributing to the predictive
model with non-redundant, novel information. In addition, regardless of
lower performance of evolutionary- and energy-based features, those
have greater importance on the mCSM-AB2 model which indicates
those two features high chance to give synergistic effect with other fea-
tures, not by themselves (Supplementary Figure S3).
By combining the different feature classes to train a regressor al-
gorithm/model, we obtained an improved and optimized model cap-
able of accurately and quantitatively predicting effects of mutations
on Ab–antigen binding affinity across eight different algorithms,
achieving a Pearson’s correlation coefficient of q ¼ 0.73 (RSME of
1.68 kcal/mol) from Extra Tress algorithm (Supplementary Fig. 2A,
Table S3) on 10-fold cross-validation. This model was significantly
different (P0.05 by Diebold–Mariano test) compared with the
null hypothesis using the average of all values as the prediction
(RMSE ¼ 1.80 kcal/mol), the average of just the experimentally
measured changes in binding affinity (RMSE ¼ 2.07 kcal/mol), and
by randomly scrambling the DDG 10 times to keep the same data
distribution (RMSE ¼ 2.56 kcal/mol). The performance of the
method increases to q ¼ 0.84 on 90% of the data and was not sig-
nificantly different when either 5-fold cross-validation or Jackknife
validation were used, providing additional confidence in the model.
Compared with earlier mCSM-AB, we implemented additional
features from both wild-type and mutant structures which demand
more computational cost, but those features improved the perform-
ance on training and two blind tests (Supplementary Table S4). The
reliability of the model structures obtained through FoldX was
assessed by comparing with seven experimental mutant structures
(Supplementary Table S5). The modelled structures used in mCSM-
AB2 showed a low average Ca RMSD of 0.13 Å.
3.2 Comparative performance and blind tests
In order to put mCSM-AB2 prediction results into context, we have
carried out a performance comparison with other available methods
using a non-redundant blind test composed of 754 mutations with
experimentally measured changes in binding affinity. mCSM-AB2
significantly outperformed alternative approaches, achieving a
Pearson’s correlation coefficient of q ¼ 0.64 (P0.0001, as
depicted in Table 1 and Fig. 2B), showing that not only it was able
to accurately predict Ab–antigen binding affinity changes but also
presented a significant improvement in comparison with its previous
version (q ¼ 0.42). This performance was comparable to the cross-
validation performance, increasing our confidence in the method’s
generalization capabilities.
Comparison of mCSM-AB2 performance across the training set
also showed it performed significantly better than other methods
that have been used to guide rational Ab engineering (Table 1).
Interestingly, there were only weak correlations between mCSM-
AB2 and other Ab engineering methods (Supplementary Fig. S4),
including the original method, highlighting its use of complementary
but distinguishing information, and suggesting that a consensus pre-
dictor might be informative.
The experimental datasets were enriched in mutations located at
the antigen interface (>80% within 6 Å as shown in Fig. 2C), which is
not surprising since many experiments have focused on variations in
the CDR loops with alanine scanning (>60% of mutations in the data-
set are to alanine). The distance from a mutation site to the Ab–antigen
interface influenced on the performance of mCSM-AB2. Comparing
performance on mutations less than 6 Å, 6–10 Å and greater than 10 Å
away from the antigen interface, mCSM-AB2 achieved a Pearson’s
correlation of 0.74 (r ¼ 0.004), 0.52 (r ¼ 0.029) and 0.54 (r ¼
0.073), respectively. This deterioration of the performance on muta-
tions located further away from the interface may be due to the limited
number of distal mutations in the training set. As a result of the
distance-based analysis, the mCSM-AB2 web server gives users a confi-
dence level of prediction, high or moderate, depending on the distance
between the mutation and Ab–antigen binding interface.
While mutations to alanine were inherently enriched in the data-
set, the performance of mCSM-AB2 was consistent across mutations
to any residue (Supplementary Table S6). This can be further sup-
ported by the analysis of the experimental blind test results showing
mCSM-AB2 outperforms all other methods across all types of muta-
tions (Supplementary Fig. S5).
An earlier study (Sinha et al., 2002) suggested several experimen-
tal DDGs from the HyHEL-10 Fab and lysozyme complex (PDB:
3HFM), which were measured by indirect methods such as spectro-
scopic inhibition assay (IASP) and spectroscopic method (SP), pre-
sented a large discrepancy with DDG from direct method such as
surface plasmon resonance (SPR). In order to measure the contribu-
tion of each of Ab–antigen complexes on the performance of
mCSM-AB2, we conducted the leave-one-complex-out cross-valid-
ation on the 60 Ab–antigen complexes. Notably, the mutations from
3HFM presented a large portion of outliers in both 10-fold and
leave-one-complex-out cross validations showing 31 and 17 out of
181 worst predicted data points, respectively (Supplementary Table
S7). The overall performance on leave-one-complex-out (Pearson’s
correlation of q ¼ 0.70), however, was comparable with the 10-
fold cross-validation results (Pearson’’s correlation of q ¼ 0.73),
further demonstrating the robustness of the method.
3.3 Performance on homology models
As experimental crystal structures might not always be available, we
also wanted to compare the performance of mCSM-AB2 on predict-
ing effects of mutations on Ab–antigen binding affinity using hom-
ology models. We used a previously proposed homology model
dataset (Sirin et al., 2016) of 87 experimentally measured changes in
binding affinity upon mutation across five homology models of the
corresponding Ab–antigen complex. The mCSM-AB2 predictions
correlated well with the experimental values (q ¼ 0.77, RMSE ¼
1.66), and was significantly more accurate than all other predictive
methods analyzed (Table 1). This highlights the versatility and ro-
bustness of the mCSM-AB2 predictions, and its applicability even in
the absence of an experimental structure of an Ab–antigen complex.
3.4 mCSM-AB2 web server
We have developed a web server to provide the functionalities of
mCSM-AB2 in an intuitive way, increasing reproducibility and




AB-BIND Experimental set Homology model
bASA 0.22a,*** 0.29*** 0.41***
dDFIRE 0.19a,*** 0.31*** 0.53***
DFIRE 0.31a,*** 0.38*** 0.52**
FoldX 0.34a,*** 0.26*** 0.45***
Discovery Studio 0.45a,*** 0.31*** 0.53**
mCSM-PPI 0.35a,*** 0.32*** 0.26***
mCSM-AB 0.56a,*** 0.42*** 0.54*
mCSM-AB2 0.76 0.64 0.77
Note: Pearson’s correlation coefficient of each of the methods were com-
pared with mCSM-AB2 by Fisher’s r-to-z transformation (*P 0.05,
**P 0.001 and ***P 0.0001).
aFrom Sirin et al. (2016).
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Fig. 2. Performance of mCSM-AB2 in predicting Ab–antigen affinity changes upon mutation. mCSM-AB2 achieved a Pearson’s correlation of q ¼ 0.73 (RMSE ¼ 1.68) on 10-
fold cross-validation (A), q ¼ 0.64 (RMSE ¼ 1.85) on a non-redundant experimental dataset for a model trained on the AB-BIND dataset (B). Performance of mCSM-AB2
after excluding the 10% largest errors (red triangles) are shown as black circles. (C) Through 10 times of 10-fold cross-validation runs, mCSM-AB2 achieved a Pearson’s cor-
relation of 0.74 (r ¼ 0.004), 0.52 (r ¼ 0.029) and 0.54 (r ¼ 0.073) on mutations whose distances to their Ab–antigen binding interfaces are less than 6 Å (1442 mutations), be-
tween 6 and 10 Å (269 mutations) and greater than 10 Å (99 mutations), respectively. Fisher’s r-to-z transformation was used to compare Pearson’s correlations from different
size of mutation (* P0.001 and ** P0.0001). (Color version of this figure is available at Bioinformatics online.)
Fig. 3. mCSM-AB2 web server result pages. Single mutation prediction (left) provides predicted DDGAffinity and interaction changes upon mutation via a 3D molecular viewer
for both wild-type and mutant. Alanine scanning (right top) describes mutational effects on interface residues with molecular viewer and bar charts. In saturation mutagenesis
analysis (right bottom), users can check Ab–antigen affinity changes for each of the 19 possible mutations for each interface residues
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facilitating large-scale analyses. The front-end was designed with
Bootstrap framework version 4.1 and the back-end was based on
Python 2.7 via the Flask framework version 1.0.2 on a Linux server
running Apache. It allows users to upload Ab–antigen complexes (in
PDB format) and either analyze specific mutations provided by the
user, or systematically evaluate mutations across the entire Ab–antigen
interface via either alanine scanning or saturation mutagenesis, facilitat-
ing, for instance, the identification of mutations that are more likely to
increase affinity, aiding the rational design of Abs. The results pages
allow easy visualization of the alanine-scanning and saturation-
mutagenesis predictions mapped to the 3D structure as well as
heat-mapped tables (Fig. 3). Users are able to check information such
as distance to binding interface and Chothia annotation calculated by
ANARCI (Dunbar and Deane, 2016) and download all results includ-
ing the predictions as a CSV file, and the provided PDB files with the
predicted changes in binding affinity mapped to the B-factor column.
4 Conclusions
The ability to predict favourable Ab–antigen mutations is a crucial,
but non-trivial, challenge to help guide routine affinity maturation.
While a number of successful computational-guided Ab develop-
ment examples have been published in recent years, computational
tools haven’t had yet transformative effects for Ab engineering due
to limited accuracy of available computational methods.
mCSM-AB2 is a computational approach that leverages both se-
quence and structural information to allow users to accurately assess
the effects of single-point mutations on Ab–antigen binding affinity.
Across all training and blind test evaluations, mCSM-AB2 signifi-
cantly outperformed all currently used Ab mutational analysis
approaches, using both experimental structures and homology mod-
els, highlighting its potential power to help guide Ab development.
This also highlights the power of our graph-based signatures in
terms of predicting mutational effects on Ab–antigen affinities by ef-
ficiently representing structural environment of wild-type and mu-
tant residues, but also show the importance of considering
evolutionary aspects, energetic terms and inter-residue interactions
to better understand molecular recognition.
We believe that mCSM-AB2 will be a powerful tool to not only
streamline Ab development and engineering but also providing bet-
ter insight into the effects of mutations in Ab–antigen interfaces,
including escape mutations. A user-friendly web server implement-
ing mCSM-AB2 functionalities was implemented and is freely
available at http://biosig.unimelb.edu.au/mcsm_ab2, facilitating
large-scale analysis of entire Ab–antigen interfaces.
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a b s t r a c t
Rifampin resistance in leprosy may remain undetected due to the lack of rapid and effective diagnostic
tools. A quick and reliable method is essential to determine the impacts of emerging detrimental muta-
tions in the drug targets. The functional consequences of missense mutations in the b-subunit of RNA
polymerase (RNAP) in Mycobacterium leprae (M. leprae) contribute to phenotypic resistance to rifampin
in leprosy. Here, we report in-silico saturation mutagenesis of all residues in the b-subunit of RNAP to
all other 19 amino acid types (generating 21,394 mutations for 1126 residues) and predict their impacts
on overall thermodynamic stability, on interactions at subunit interfaces, and on b-subunit-RNA and
rifampin affinities (only for the rifampin binding site) using state-of-the-art structure, sequence and nor-
mal mode analysis-based methods. Mutations in the conserved residues that line the active-site cleft
show largely destabilizing effects, resulting in increased relative solvent accessibility and a concomitant
decrease in residue-depth (the extent to which a residue is buried in the protein structure space) of the
mutant residues. The mutations at residue positions S437, G459, H451, P489, K884 and H1035 are iden-
tified as extremely detrimental as they induce highly destabilizing effects on the overall protein stability,
and nucleic acid and rifampin affinities. Destabilizing effects were predicted for all the clinically/exper-
imentally identified rifampin-resistant mutations in M. leprae indicating that this model can be used as a
surveillance tool to monitor emerging detrimental mutations that destabilise RNAP-rifampin interactions
and confer rifampin resistance in leprosy.
Author summary: The emergence of primary and secondary drug resistance to rifampin in leprosy is a
growing concern and poses a threat to the leprosy control and elimination measures globally. In the
absence of an effective in-vitro system to detect and monitor phenotypic resistance to rifampin in leprosy,
diagnosis mainly relies on the presence of mutations in drug resistance determining regions of the rpoB
gene that encodes the b-subunit of RNAP in M. leprae. Few labs in the world perform mouse footpad
propagation of M. leprae in the presence of drugs (rifampin) to determine growth patterns and confirm
resistance, however the duration of these methods lasts from 8 to 12 months making them impractical
for diagnosis. Understanding molecular mechanisms of drug resistance is vital to associating mutations
to clinically detected drug resistance in leprosy. Here we propose an in-silico saturation mutagenesis
approach to comprehensively elucidate the structural implications of any mutations that exist or that
can arise in the b-subunit of RNAP in M. leprae. Most of the predicted mutations may not occur in M.
leprae due to fitness costs but the information thus generated by this approach help decipher the impacts
of mutations across the structure and conversely enable identification of stable regions in the protein that
are least impacted by mutations (mutation coolspots) which can be a potential choice for small molecule
binding and structure guided drug discovery.
 2020 The Authors. Published by Elsevier B.V. on behalf of Research Network of Computational and
Structural Biotechnology. This is an open access article under the CC BY license (http://creativecommons.
org/licenses/by/4.0/).
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1. Introduction
Nonsynonymous mutations in genes that encode drug targets in
mycobacteria can induce structural and consequent functional
changes leading to antimicrobial resistance, the burden of which
is rapidly increasing and is a global health concern. Diagnosis of
~600,000 new cases of rifampin-resistant tuberculosis in 2018 sug-
gest that it poses a risk for the concomitant increase in undiag-
nosed rifampin-resistant leprosy, worldwide [1]. Mycobacterium
leprae (M. leprae), the causative bacilli for leprosy, is phylogeneti-
cally closest to Mycobacterium tuberculosis [2] and developed resis-
tance to rifampin before the introduction of World Health
Organization (WHO) recommended multi-drug therapy (MDT) in
the year 1984. Despite the long duration of chemotherapy with
MDT (six months in paucibacillary to 12 months in multibacillary
disease), rifampin-resistant case numbers are less and represent
only 3-5% of total clinically diagnosed relapsed leprosy cases as
reported by WHO in 2017 [3]. One of the possible reasons for the
low numbers of drug-resistant leprosy cases globally is the lack
of quick, effective and reliable in-vitro diagnostic test for confirm-
ing phenotypic resistance. Current methods rely on identifying
mutations in the rifampin resistance determining region (RRDR)
of the rpoB gene through gene sequencing and/or by testing growth
patterns of M. leprae in response to individual drugs in the MDT in
an in-vivo mouse footpad model; however, the later technique is
both time and labour intensive.
While mutations within the b-subunit of RNAP contribute to
clinical resistance to rifampin, the associated structural changes
can complicate the transcription process in bacteria by modulating
various physiological processes [4], the knowledge of which is
essential for novel drug discovery or alternative therapies to treat
rifampin resistant strains ofM. leprae. In the absence of an artificial
culture system to propagate and study mechanisms of resistance, it
is exceptionally challenging to define an experimental phenotype
for rifampin resistance in leprosy. M. smegmatis as a surrogate host
with cloned M. leprae rpoB gene has proved a dependable model to
study phenotypic effects; however, this technique is limited to bio-
safety level-2 laboratories that have facilities for gene cloning and
sequencing, and cannot be translated to a regular diagnostic set-
ting in leprosy endemic countries [5]. A plausible association
between mutations in drug targets and phenotypic resistance out-
comes could be established if minimum inhibitory concentrations
(MICs) of the drugs are known for the mutant strains. While MICs
can be estimated in cultivable species like M. tuberculosis and M.
smegmatis, obtaining growth information from in vivo propagation
for a slow growing and obligate pathogen likeM. leprae is challeng-
ing and needs time and resources. Alternatively, in-silico methods
that predict structural implications of mutations can be useful in
understanding mechanisms of resistance and help prioritise muta-
tions that require experimental validation in leprosy, owing to the
absence of a tool for quantitative estimation of phenotypic resis-
tance [6].
Mutations contribute to disruption of protein–ligand and
protein-nucleic acid interactions resulting in drug resistance in
mycobacterial diseases [7,8]. Changes in affinity between the drug
target protein and the ligand can result from both orthosteric and
allosteric mechanisms leading to various resistance phenotypes
[4]. The b-subunit of RNAP in M. leprae is encoded by the rpoB gene
(ML1891) whose product is 1178 amino acids in length. The RRDR
is located between the residue positions 410 and 480. Approxi-
mately 40 mutations have been reported in the rpoB gene of
M. leprae that induce clinical resistance to rifampin in leprosy
[9–11]; however, in tuberculosis, nearly 100 mutations have been
reported in the same gene that shares 96% gene sequence identity
with that of M. leprae [12]. As the burden of rifampin resistance is
very high in M. tuberculosis with known and new mutations being
reported from different studies [13–17], it is important to monitor
the emergence of new rifampin-resistant mutations in M. leprae. A
comprehensive understanding of the effect of any mutation on the
structure of RNAP is vital in the context of monitoring emerging
rifampin resistance and its implications on controlling global
leprosy incidence.
In order to decipher the effect of systematic mutations on the
stability of the protein structure, protein sub-unit interfaces,
nucleic acid and ligand interactions, we performed in-silico satura-
tion mutagenesis (mutating every residue to all the other 19 resi-
dues) and predicted the change in stability of the b-subunit and
affinity between b-subunit andrest of the subunits in the complex,
b-subunit-rifampin and b-subunit-RNA interactions. Additionally,
we also assessed the impacts of mutations on the secondary struc-
tures of the polypeptide chains, relative sidechain solvent accessi-
bility, residue-depth and residue-occluded packing density [18].
Residue-level evolutionary conservation scores were determined
and compared with the predicted destabilizing effects. Extremely
detrimental mutations (that destabilize b-subunit of RNAP and
affinity between b-subunit -rest of the subunits in the complex,
b-subunit -rifampin and b-subunit-RNA interactions) were
selected and analysed for changes in their interatomic interactions
that might explain the reasons for the predicted destabilizing
effects. To explore further, the vibrational entropy and enthalpy
changes of the protein in flexible conformations, we employed an
empirical force field-based method – FoldX [19], a course-grained
normal mode analysis (NMA) based elastic network contact model
– ENCoM [20] and a consensus predictor that integrates normal
mode approaches with graph-based distance matrix in the mutat-
ing residue environment– DynaMut [21]. Finally, fragment hot-
spots [22] were mapped on the structures to provide information
on potential druggable sites whose stability is predicted to be least
likely affected by mutations (no mutations in these regions were
identified in leprosy). We termed these sites as ‘‘Mutation cool-
spots” which can be explored for novel/alternative small molecule
binding and structure-guided drug discovery to treat rifampin-
resistant leprosy.
2. Materials & Methods
2.1. Design:
The key stages in the methodology involve comparative protein
3D modelling using known crystal structures of homologues as
templates, quality assessment of the built models, generating
mutation lists from the model and sequential submission of the
lists and the model to stability change prediction servers for
sequence, structure and vibrational entropic terms (Fig. 1A).
2.2. Comparative modelling, quality assessment and model
refinement:
A model for RNAP holoenzyme of M. leprae was built using
Modeller 9.21 [23] with templates from M. tuberculosis (PDB
Id:5UH5 (96% identity, 3.74 Å resolution) containing RNAP, nucleic
acid scaffold with DNA and three nucleotides of RNA complemen-
tary to the template DNA strand, and PDB Id: 5UHC (96% identity,
3.79 Å resolution) containing all the elements similar to 5UH5 and
rifampin) as described earlier by us [4]. The quality of the gener-
ated model was assessed using Molprobity [24] and atomic clashes
were removed by minimizing the energy of the model by 100 steps
using Steepest Decent (step size = 0.02 Å) and by 10 steps
(step size = 0.02 Å) using conjugate gradient methods. Energy
minimizations were performed using UCSF Chimera [25]. The
mutant models were generated using a script from Modeller 9.21
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Fig. 1. [A] Methodology and study design. [B] A lollipop plot with stability predictions for mutations reported in the literature and are known to confer rifampin resistance in
Leprosy.
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(mutate_model.py) and sidechains of the mutants were optimized
using ANDANTE [26], a program that uses v angle conservation cri-
teria to optimize the sidechain rotamers. Multiple models were
generated initially to test the variation in the modelling process.
Structural similarity among the models was tested using root mean
square deviation (RMSD) and TM-Align scores [27]. (Supplemen-
tary Figs. 4–6, and Supplementary Table 3).
2.3. Saturated Mutagenesis:
A systematic list of 21,394 mutations was generated for
residues starting from P28 and ending at E1153 positions in the
b-subunit (the modelled region). This list was programmatically
submitted to a set of servers as stated in Table 1 below:
2.4. Residue conservation:
Conservation scores for each residue in the wild-type model
was estimated using CONSURF – a server that uses evolutionary
patterns of amino acids/nucleic acids from the multiple sequence
alignment and develops a probabilistic framework to calculate
evolutionary rates for each residue in the sequence.
2.5. Effects of mutations on protein stability and interactions:
The effect of mutations on thermodynamic stability of the b-
subunit of RNAP was analyzed using mCSM, SDM and FoldX4. For
SDM, mutant models were generated using ANDANTE. The effect
of mutations on RNA affinity is assessed using mCSM-NA2 on
mutant models with nucleic acid scaffold. The holoenzyme com-
plex of RNAP consists of five subunits and the effects of mutations
on the protein–protein interfaces (between b and all the other
sub-units in RNAP complex) were assessed using mCSM-ppi.
Rifampin binds to the b-subunit of RNAP and we analyzed the
effects of mutations on the protein–ligand affinity using mCSM-
lig. Only residues that are within 10 Å of interatomic distance to
rifampin were analyzed by mCSM-lig.
The stability changes were further compared with predictions
from other sequence- (PROVEAN, I-Mutant 2.0 (Sequence) and
structure-based (MAESTRO, CUPSAT, I-Mutant 2.0 (Structure))
computational tools in order to estimate the reliability of the
predictions.
2.6. Changes in vibrational entropy and normal mode analysis:
In order to determine the effects of the mutations in flexible
conformations of the protein, we used FoldX4, an empirical force
field approach that calculates free energy changes between native
and mutant forms of the protein, and an elastic network contact
model (ENCoM), which is a coarse grain NMA method that consid-
ers the nature of the amino-acids and aids in calculating vibra-
tional entropy changes upon mutations. We also used DynaMut,
a consensus predictor of protein stability based on the vibrational
entropy changes predicted by ENCoM and the stability changes
predicted by graph-based signatures that are used in mCSM
program.
2.7. Conformational changes:
Conformational changes and their impacts on biophysical prop-
erties of the proteins were estimated using SDM. The interatomic
distances between each residue and the interface with other sub-
units in the RNAP holoenzyme, rifampin and nucleic acids in the
structure were measured and included in the analysis. Secondary
Table 1





Function Reference Submission parameters
1 mCSM Predict protein stability changes due to mutations. [28] Model PDB file, mutation and chain id.
2 SDM Predict protein stability changes due to mutations. [18] Model PDB file, mutation and chain id.
3 mCSM-PPI Predict stability of protein–protein interfaces due to
mutations.
[28] Model PDB file, mutation and chain id.
4 mCSM-NA2 Predict stability of protein-nucleic acid interactions
due to mutations
[29] Model PDB file, mutation, chain id and nucleic acid type.
5 mCSM-lig Stability of protein–ligand interactions due to
mutations
[30] Model PDB file, mutation, chain id, three letter code of the
ligand and ligand affinity in wild type structure in nM
concentration.
6 FoldX4 Predict protein stability changes due to mutations. [19] Model PDB file, list of mutations and chain ids.
7 MAESTRO Predict protein stability changes due to mutations. [31] Model PDB file, list of mutations and chain ids.
8 CUPSAT Predict protein stability changes due to mutations. [32] Model PDB file, list of mutations and chain ids.
9 Imutant
2.0-Struc
Predict protein stability changes due to mutations. [33] Model PDB file, list of mutations and chain ids.
10 Imutant
2.0 -Seq
Predict protein stability changes due to mutations
using sequence information.
[33] RNAP sequence file in fasta format, list of mutations and
chain ids.
11 PROVEAN Predict protein stability changes due to mutations
using sequence information.
[34] RNAP sequence file in fasta format, list of mutations and
chain ids.
12 CONSURF To calculate evolutionary conservation score of each
residue in the protein.
[35] Model PDB file
13 ENCoM Conformational Changes in protein due to mutations. [20] Model PDB file, list of mutations and chain ids.
14 DynaMut Conformational Changes in protein due to mutations. [21] Model PDB file, list of mutations and chain ids.
15 Arpeggio Map interatomic interactions between wildtype and
mutant amino acids and the residue environment.
[36] Model PDB file and the residue selection in standard format.
16 Intermezzo Map interatomic interactions between wildtype and
mutant amino acids and the residue environment.
Bernardo Ochoa
Montano & Blundell TL
unpublished
Model PDB file and the residue selection in standard format.
17 ANDANTE Works along with Modeller to generate mutant
models from wildtype model files.




Maps regions on the surface of the protein that has
high propensity for small molecule binding.
[22] Model PDB file.
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structure switches in mutants, changes in relative solvent accessi-
bility, depth of the residue in Å and residue-occluded packing den-
sities were determined for all the mutations.
2.8. Interatomic interactions:
After predicting protein stability changes and changes in RNAP-
rifampin affinities, mutations at two positions vide H451 & P489
that highly destabilize rifampin binding and are experimentally
identified in the rifampin resistant leprosy patients [9,10] (present
in the set of 40 experimentally identified mutations – Supplemen-
tary Table 2), were analyzed for the changes in interatomic interac-
tions of the mutating residues using Arpeggio, a program that
maps the types of interatomic interactions of wildtype and mutant
residues with the residue environment based on atom type, inter-
atomic distance and angle constraints. Additionally, four mutations
at positions S437, G459, K884 & H1035 which are computationally
predicted to highly destabilize RNAP-rifampin interactions were
chosen and subjected to similar analysis. Intermezzo program
(Bernardo Ochoa Montano & Blundell TL unpublished) was also
used for interactive analysis of bonding patterns on Pymol
sessions.
2.9. Fragment hotspot maps:
Fragment hotspot maps aid in locating specific sites on the sur-
face of the protein that are topologically, chemically and entropi-
cally favorable for small molecule (fragment) binding. The atomic
hotspots on the drug target are explored computationally using
donor, acceptor and hydrophobic fragment probes, and introducing
a depth criterion to assist in estimating the small molecule binding
propensity. For ligand-binding proteins, the fragment hotspot
maps aid in understanding the pharmacophore characteristics of
the interacting regions. We mapped the hotspots on the b-
subunit of RNAP and colored the surface with regions that are least
impacted by any mutations (mutation coolspots).
3. Results
In total, 21,394 mutations were generated from 1126 residues
in the b-subunit of RNAP (Supplementary Table 1). The list of
experimentally identified mutations and their effects are sepa-
rately shown in Supplementary Table 2.
3.1. Multivariate analysis of free energy change predictions by various
computational tools for saturated mutations:
Along with the in-house developed mCSM and SDM tools for
prediction of protein stability changes upon saturated mutagenesis
of the b-subunit of RNAP, a comparative analysis was performed
with other sequence (PROVEAN, I-mutant 2.0 – Sequence),
structure- (CUPSAT, I-mutant 2.0-structure, MAESTRO) and NMA-
based tools (FOLDX, ENCOM, DynaMut). Average stability changes
caused by all possible mutations at each residue position in the b-
subunit of RNAP, as predicted by mCSM and SDM, were compared
with other structure-based predictors (Supplementary Fig. 1)
(rifampin-interacting residues are highlighted). Correlation of
overall stability predictions performed by mCSM with each of the
other tools indicated an ‘‘r” value of 0.55 with SDM, 0.61 with
MAESTRO, 0.72 with Imutant 2.0 (Structure) and 0.43 with CUP-
SAT. Correlations between mCSM, SDM and other sequence and
NMA based tools are shown in Supplementary Figs. 2 and 3. The
rationale for performing these correlations is to understand how
mCSM and SDM being structure-based predictors of stability
changes, relate to sequence-based methods and vibrational
entropy changes in normal mode perturbations.
3.2. Experimentally/Clinically identified mutations:
We performed a systematic literature review to list all the
mutations reported in the b-subunit of RNAP in M. leprae. We
noted 40 mutations at 32 unique residue positions. The reference
articles are listed in Supplementary Table 2. As depicted in
Fig. 1B, 77.5% [19] of the experimentally/clinically identified muta-
tions destabilize the b-subunit. Except for A411T and V424G muta-
tions, all the other residues are present in close proximity to
rifampin binding sites (Fig. 2A) and destabilize rifampin interac-
tions (as predicted by mCSM-lig).
3.3. Residue conservation and protein stability:
The stability changes, predicted after saturation mutagenesis of
each residue in the b-subunit, were compared with residue conser-
vation scores. CONSURF scores of less than zero are attributed to
conserved residues and scores of zero and above to variable resi-
dues (score 3 being highly variable). The average change in protein
stability that was predicted by mCSM for mutations at each residue
position ranged from 0.823 to 3.033 kcal/mol and that of SDM
varied from 2.167 to 4.36 kcal/mol. Residues that line the active
center cleft and interact with rifampin and the nucleic acid scaffold
are highly conserved, while surface exposed residues have variable
conservation scores (Fig. 2B). Rifampin-interacting residues
between positions ~400–500 are highly conserved and 87.3% of
the saturated mutations in this region destabilize the protein (Sup-
plementary Table 1). The maximum destabilizing effect of muta-
tions at each of these residues varied between 0.311 to
4.311 kcal/mol (mCSM). The maximum destabilizing mutation
is defined as a mutation that induces a maximum decrease in Gibbs
free energy (stability change) of the b-subunit of RNAP, RNAP-
rifampin and RNAP-subunit interactions among all the 19 possible
mutations at each residue position (when predicted by mCSM,
SDM, mCSM-lig and mCSM-ppi software). The maximum destabi-
lizing effect predicted by mCSM for all possible mutations at each
residue was mapped on the structure to identify regions that are
largely impacted by mutations (Fig. 2C). Conversely, the residues
whose stability is least impacted by all possible mutations are col-
ored in blue to identify ‘‘mutation coolspots” that are potentially
areas of choice for targeting with small molecules in drug discov-
ery (Fig. 2D).
As part of the RNAP holoenzyme complex, the b-subunit inter-
acts with other subunits and has large interfacial regions. The
impact of mutations on the stability of these interfaces was mea-
sured using mCSM-PPI. It was noted that the maximum destabiliz-
ing effect by any mutation at a particular residue in the interface
between b and b0 subunits has an affinity change that ranged from
0.021 to 5.108 kcal/mol (5.108 kcal/mol was noted for muta-
tion W1074R which is not reported experimentally in rifampin
resistant leprosy cases). The interfacial region and the stability
changes are mapped on the structure (Fig. 3A and B).
3.4. Relative sidechain solvent accessibility (RSA), residue-depth,
residue-occluded packing density and protein stability:
The difference in relative solvent accessibility between wild
type and the mutant residues for all the mutations were calculated
using SDM. While analyzing the maximum destabilizing mutations
among all the possible mutations at each residue position, it was
noted that maximum destabilizing mutants at 751 residue posi-
tions (66.79%) showed increase in RSA. The maximum destabilizing
mutants at rest of the 375 positions indicated a decrease in RSA.
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Fig. 2. [A] The b-subunit of RNAP with residues where mutations were reported experimentally from patient samples in various studies (Supplementary Table 2) (highlighted
in red). [B] Each residue in the b-subunit of RNAP that is colored by the conservations scores determined by CONSURF. The residues in green are variable (conservations scores
greater than 1) and are usually surface exposed. The residues in red are conserved with conservation scores less than 1 and usually form the core of the protein. The rifampin
binding site is highly conserved in M. leprae. [C] The maximum destabilizing effect (predicted by mCSM) on the protein stability for any mutation at each residue position, is
mapped on the structure. Red are the regions that are largely destabilized by mutations while the white regions are relatively stable with mutations. [D] The converse of B
where the regions, whose stability is least impacted by mutations, are coloured in blue and we called them ‘‘Mutation CoolSpots”. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 3. [A] The interfacial region of the b-subunit of RNAP highlighted in Maroon. [B]. The maximum destabilizing effect a mutation can induce on the interface stability, is
predicted by mCSM-PPI and mapped on the structure. Red indicates regions that are highly destabilized by mutations (-5.108 Kcal/mol) while the blue indicates stable
regions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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Among the 751 mutants with increase in RSA, 551 were hydropho-
bic and 121 substitutions within 551 were from polar/charged
(wildtype) to hydrophobic residues (mutants). As mutant
hydrophobic residues with increased solvent accessibility often
destabilize the protein [38], the destabilizing effects of these muta-
tions ranged from 1.021 to 4.311 kcal/mol. Additionally, these
substitutions resulted in a decrease in residue-depth [18] (ranging
from 0.01 Å to 1.83 Å), which is concomitant with the increase in
solvent accessibility. These changes in RSA and depth at the
rifampin-binding site are depicted in Fig. 4A and B.
From the maximum destabilizing mutations at all the 1126
positions, mutations at 586 (52.04%) residue positions resulted in
increase in residue-depth that ranged from 0.01 to 2.46 Å. Mutants
were generated using ANDANTE which places the side chains with-
out any steric clashes and the mutant models were subjected to
energy minimization. Hence the change in residue-depth is attrib-
uted to the buriedness of the residue and not just the natural
change from a larger to a smaller amino acid. The decrease in
residue-depth in the remaining 540 (47.95%) residues ranged from
0.1 to 3.02 Å. Similarly, the residue-occluded packing density [18]
increased at 539 residue positions (47.86%). These changes in RSA
and residue-depth are mapped as attributes on to the structure of
the b-subunit of RNAP and it was noted that most of the residues
that line the active center cleft have increase in RSA upon muta-
tions. Decrease in residue-depth was noted in residues at the
rifampin-binding pocket and at the subunit interfaces (Fig. 5A
and B).
3.5. Substitutions to aspartate predominate mutations that destabilize
the b-subunit-RNA affinity in RNAP:
The effects of mutations on b-subunit-RNA affinity was esti-
mated using mCSM-NA2. Substitutions to aspartate residues were
most common among mutations that highly destabilize b-subunit-
RNA interactions in RNAP. The mutant aspartate residues form p-p
interactions with the nucleotides in RNA either by stacking or by
nucleotide-edge T-shaped and amino-edge T-shaped interactions.
Aspartate being an acyclic p-containing amino acid, readily forms
nucleotide (edge) amino (edge) or nucleotide (face) and amino-
acid (edge) interactions [39]. This ability of acyclic amino acids like
arginine, glutamic acid and aspartic acid to form a variety of
charged-p interactions with nucleotides in mutants may impact
the orientation of RNA molecules in the active center cleft of RNAP
leading to loss or gain in function. Approximately, 93% of the highly
destabilizing mutations at RNA-interacting residues are substitu-
tions to aspartate. Mutations to glutamate were also noted in
6.83% and additionally one each of methionine, proline and thre-
onine mutations indicated highly destabilizing effects.
3.6. Substitutions to arginine predominate mutations that destabilize
b-subunit-rifampin affinity:
Systematic mutations in the set of 70 residues that lie 10 Å from
the rifampin binding site reveal that mutations that largely desta-
bilize RNAP-rifampin affinities are primarily arginine and gluta-
mate substitutions (mCSM-lig). In the binding site, R173, R454,
R465 and R613 form hydrogen bonds and a network of other inter-
actions with rifampin that stabilize the molecule in the binding site
[4]. Introduction of additional arginine residues by mutations may
influence the stability and orientation of rifampin in the binding
site. The positively charged guanidinium ion of arginine forms
cation-p interactions with aromatic amino acids as noted in earlier
studies [40,41]. In the predicted mutations S437R and G456R, argi-
nine forms an intricate network of p interactions with surrounding
aromatic amino acids changing the shape of the binding pocket
and leading to a loss in rifampin interactions (rifampin retains only
two polar contacts with Q438 and F439 whereas wildtype has five
hydrogen bonds). The effects of mutations on RNA and rifampin
affinity as predicted by mCSM-NA2 and mCSM-lig were mapped
on to the structure (Fig. 6A and B).
Fig. 4. [A] Change in relative solvent accessibility for maximum destabilizing mutants in the rifampin binding pocket (mCSM). [B]. Change in depth of the highly destabilizing
mutant residue in the rifampin binding pocket (mCSM).
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To determine if mCSM-lig predicted RNAP-rifampin binding
affinities can provide information on the degree of resistance asso-
ciated with each mutation in the rifampin binding site, we
attempted to correlate MIC values of M. tb rpoB mutants with
mCSM-lig predictions for RNAP-rifampin affinity in the structure
ofM. tb (PDB Id: 5UHC). A total of 40 mutations were selected from
two studies [12,42] and mCSM-lig predictions were correlated
with MIC values. It was noted that mCSM-lig predictions were
independent of the MIC values which was also observed in an ear-
lier study [43]. A table with MIC values and corresponding mCSM-
lig predictions was included in Supplementary Material S1
(Table SM1). Additionally, a table with saturated mutations for
all residues within 10 Å of the rifampin and their mCSM-lig predic-
tions were presented in Supplementary Material S1 (Table SM2).
3.7. Detrimental mutations:
Among all the experimentally identified and computational
predicted mutations, we selected those that highly destabilize
(maximum decrease in log affinity fold change among all 19 muta-
tions at each residue position) RNAP-rifampin interactions. Six
residues were chosen based on the following characteristics and
the structural effects of systematic mutations at each residue posi-
tion were analyzed (Table 2) as below:
Fig. 5. [A] The change in relative side chain solvent accessibility with mutations was mapped on to the structure. Blue indicates a decrease in RSA while red indicates an
increase. [B] The changes in depth with highly destabilizing mutations at each residue position was mapped on the structure. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
Fig. 6. [A] Stability changes in b-subunit -RNA and b-subunit- rifampin [B] interactions due to mutations in the binding sites as predicted by mCSM-NA2 and mCSM-lig. The
maximum destabilizing effect a mutation can cause at each residue position in the binding site is depicted on the structure.
278 S.C. Vedithi et al. / Computational and Structural Biotechnology Journal 18 (2020) 271–286
Table 2

















S 437 0.795 0.072 L 1.701 H
H 451 1.214 0.104 Y 1.898 S
G 459 0.713 0.381 V 1.201 W
P 489 1.135 0.507 R 1.771 G
K 884 1.227 0.190 L 2.298 S
H 1035 0.419 0.600 Y 1.421 G
mCSM-ppi (DDG in kcal/mol) S 437 0.254 0.395 H 0.820 R
H 451 0.652 0.050 S 1.451 M
G 459 0.397 0.237 H 1.042 R
P 489 0.738 0.138 W 1.372 R
K 884 0.105 0.160 D 0.685 R
H 1035 0.754 0.115 W 1.726 R
mCSM-NA2 (DDG in kcal/mol) S 437 1.538 4.922 W 3.857 D
H 451 1.300 5.147 W 3.632 D
G 459 2.289 8.556 W 0.221 D
P 489 1.926 8.195 W 0.582 D
K 884 0.221 6.647 W 2.130 D
H 1035 0.847 7.295 W 1.484 D
mCSM-lig (log-affinity change) S 437 0.646 0.484 L 1.062 R
H 451 0.510 0.076 W 0.777 E
G 459 0.981 0.715 A 1.236 R
P 489 0.598 0.254 L 0.917 R
K 884 0.156 0.368 D 0.925 R
H 1035 0.121 0.097 V 0.501 E
SDM (DDG in kcal/mol) S 437 0.087 2.320 V 1.900 P
H 451 0.756 1.290 L 2.800 G
G 459 2.842 1.780 V 3.800 P
P 489 0.432 1.440 Y 1.070 E
K 884 0.108 1.270 V 1.820 P
H 1035 0.200 0.590 V 1.410 P
MAESTRO (DDG in kcal/mol) S 437 0.21 0.14 K 0.24 F
H 451 0.12 0.05 G 0.22 R
G 459 0.23 0.17 S 0.33 W
P 489 0.26 0.22 H 0.31 M
K 884 0.20 0.14 G 0.25 M
H 1035 0.27 0.25 P 0.31 Y
CUPSAT (DDG in kcal/mol) S 437 2.70 7.98 I 1.12 G
H 451 2.01 6.92 W 3.25 K
G 459 2.51 5.00 K 5.53 C
P 489 2.76 0.84 A 5.47 M
K 884 2.99 3.42 I 8.03 H
H 1035 1.07 2.15 C 3.23 Y
Imutant 2.0 Structure (Sign of
prediction)
S 437 4.05 9.00 A 1.00 F
H 451 6.00 8.00 G 3.00 L
G 459 6.63 9.00 N 3.00 I
P 489 7.11 9.00 G 3.00 L
K 884 6.42 9.00 G 2.00 M
H 1035 4.63 8.00 G 2.00 L
PROVEAN (DDG in kcal/mol) S 437 4.79 3.00 A 7.00 W
H 451 8.66 5.73 Y 10.37 C
G 459 8.10 6.00 A 10.00 L
P 489 9.04 7.99 A 10.99 F
K 884 5.97 2.91 R 7.75 C
H 1035 8.98 5.79 Y 10.61 C
Imutant 2.0 Sequence (Sign of
prediction)
S 437 4.47 7.00 F 0.00 H
H 451 3.21 7.00 P 0.00 F
G 459 3.53 7.00 H 0.00 A
P 489 6.89 9.00 G 5.00 L
K 884 3.53 8.00 V 0.00 G
H 1035 2.95 6.00 G 0.00 V
FOldX4 (DDG in kcal/mol) S 437 2.79 1.44 I 12.39 R
H 451 1.78 0.74 L 4.39 W
G 459 9.14 3.96 A 20.76 H
P 489 3.04 2.11 N 4.79 R
K 884 1.06 2.12 Y 9.77 L
H 1035 0.77 1.47 P 5.69 Y
(continued on next page)
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 Mutations that highly destabilize rifampin binding (at wildtype
S437 & G459 positions) as predicted by mCSM-lig.
 Experimentally/clinically identified and validated mutations
that highly destabilize rifampin binding (at wildtype H451 &
P489 positions) [9,10].
 Predicted extremely detrimental mutations for protein stability,
protein–protein and protein-nucleic affinities (at wildtype K884
& H1035 positions).
3.8. Detrimental mutations in the rifampin binding site:
We have noted that any mutation at rifampin-interacting resi-
dues S437, H451, R454, S456, L458, G459, R465, P489, P492 and
N493 destabilize protein ligand affinity (mCSM-lig). Of these we
have chosen wild-type residues H451 and P489, which are exper-
imentally identified mutations, and wild-type residues S437 and
G459, which are computationally predicted (only one mutation
was experimentally identified at residue position S437L (reported
by us earlier [4], and has destabilizing effects on the overall stabil-
ity of the protein and affinity to rifampin).
3.9. S437
Serine at position 437 in the wild-type structure forms main-
chain and sidechain hydrogen bonds with S434, G432 and R173.
The residue has a network of proximal polar interactions and
hence stabilizes the rifampin-binding pocket. It was noted that
any mutation at this position reduces rifampin affinity (mCSM-
lig) and stability of the b-subunit (mCSM) (Supplementary
Table 1) (Fig. 7A). The maximum destabilizing effect was noted
for substitution to histidine (1.701 kcal/mol (mCSM)) and it
forms hydrogen bonds with S434 and Q438, aromatic bonds with
F431, and many ring-ring and p interactions with the surround-
ing residues which might largely effect the shape of the binding
pocket (Fig. 7B). Substitution with leucine causes a minimal
destabilizing effect (0.072 kcal/mol (mCSM)) and stability
effects of all the other amino acid substitutions range from
0.072 to 1.701 kcal/mol (mCSM).
S437 is located at 3.3 Å from the interface of b and b0 subunits.
Arginine substitution destabilized the interface with the predicted
stability change of 0.820 kcal/mol (mCSM-ppi). In the wild-type
structure, S437 is located 11.9 Å from the closest nucleic acid
molecule but is present on the helix that interacts with both
DNA and transcribing RNA in the active center cleft. An aspartate
substitution destabilized the protein-RNA interaction with pre-
dicted affinity change of 3.857 kcal/mol (mCSM-NA2). S437 is
located 4.0 Å from rifampin and forms only proximal interactions
with rifampin. However, this residue forms hydrogen bond
interactions with S434 and R173 that are important for the
attachment of rifampin to the binding pocket. The S437R muta-
tion disrupts the hydrogen bonds with S434 and R173 which
in-turn impact stability of rifampin in the binding pocket
(1.062 kcal/mol (mCSM-lig)).
3.10. G459
Glycine at position 459 forms hydrogen bonds with Q435, L458
and G462, and carbonyl interactions with the P460. G459 is pre-
sent 4.6 Å away from rifampin and is involved in hydrogen bonds
with residues that interact with rifampin (Fig. 7C). A tryptophan
substitution largely destabilizes the binding pocket by the incorpo-
ration of hydrophobic and p interactions with the surrounding
residues. It forms side-chain hydrophobic interactions with L436,
L384 and F430. It also forms a ring–ring interaction with F430,
an atom-ring interaction with L384 and intergroup interactions
with Q178 and Q388. It forms multiple hydrogen bonds with the
surrounding residues, which may impact the orientation of the
binding pocket and destabilize the protein (Fig. 7D).
3.11. Clinically identified mutations that highly destabilize rifampin
binding:
From the 40 mutations that are reported from different
rifampin-resistant leprosy clinical isolates (Supplementary
Table 2), we have chosen two residues where mutations are extre-
mely detrimental to protein stability, protein ligand affinity, pro-
tein nucleic affinity and protein subunit interfaces. These
substitutions at positions H451 and P489 were studied in detail.
3.12. H451:
H451 in the wild-type structure lies 3.7 Å from rifampin and
4.1 Å from the interface. This residue forms cation – p interac-
tions with guanidinium group of R454, which in turn forms polar
interactions with rifampin (Fig. 8A). Additionally, H451 makes
two hydrogen bonds with mainchain amino group of R454 and
oxygen atom of S447. Mutations at this residue site largely
impact the stability and ligand binding. Substitution to serine
induced a change in stability of the protein with a decrease in
Gibbs free energy of 1.898 kcal/mol and a network of p interac-
tions that are present in the native structure, were lost in the
mutant (Fig. 8B).
Methionine substitution destabilizes b – b0 subunit interface
and leads to a change in free energy of 1.451 Kcal/mol. Methion-
ine forms carbonyl interactions with K452 and T450, a hydropho-
















ENCoM (DDSvib in kcal/mol/K) S 437 0.44 0.48 G 1.50 W
H 451 0.34 0.97 G 0.46 W
G 459 0.91 0.29 A 1.55 W
P 489 0.16 0.14 G 0.82 F
K 884 0.18 0.96 G 0.60 W
H 1035 0.19 0.73 G 0.26 W
DynaMut (DDG in kcal/mol) S 437 2.87 6.99 L 2.08 G
H 451 0.74 2.17 Y 3.43 T
G 459 1.93 3.29 N 0.25 S
P 489 0.94 3.26 F 0.72 S
K 884 0.14 3.69 W 1.87 E
H 1035 0.21 2.38 W 2.29 G
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with rifampin. Although histidine or methionine do not directly
interact with the residues of the b0 subunit, the changes in the net-
work of p-interactions coupled with the addition of hydrophobic
bonds among proximal residues in the interface may change their
binding patterns leading to destabilization of the interface.
Substitution with glutamic acid induces a destabilizing effect on
the b-subunit-rifampin interaction. E451 forms weak hydrogen
bond, carbonyl and proximal hydrophobic interactions with the
residue environment but does not form any bonds with rifampin,
unlike the wild-type residue that forms proximal hydrogen bonds
with rifampin.
3.13. P489
Proline at position 489 is present in a loop which is in close
proximity to rifampin and forms hydrophobic interaction with
rifampin and weak hydrogen bond interactions with T488 and
Q490 (Fig. 8C). Mutations at the position 489 were reported in
rifampin-resistant leprosy patients from Thailand [9]. Glycine sub-
stitution destabilizes the protein (1.771 kcal/mol) leading to a
loss of hydrophobic interaction with rifampin. Weak hydrogen
bond and carbonyl interactions, however, were retained in the
mutant model (Fig. 8D). Arginine substitution destabilizes inter-
face and rifampin affinities, with predicted stability changes of
1.372 and 0.917 kcal/mol respectively. FoldX predicted a large
change in stability of 4.79 kcal/mol for difference between mutant
and wild types, which is highly destabilizing. FoldX optimizes the
sidechains and moves the structure to a lowest energy state (usu-
ally represented as a negative value) and hence the difference
between two negative energy values of wild and mutant is consid-
ered destabilizing.
3.14. Extremely detrimental mutations:
Mutations at residues positions K884 and H1035 were consid-
ered to be extremely detrimental. These residues lie in close prox-
imity to the interface, nucleic acids and rifampin. Substitutions at
these sites destabilize protomer, protein–protein interfaces (both
the residues reside at the subunit interface), protein-nucleic acid
and protein–ligand affinities. Both empirical (FoldX) and knowl-
edge based (mCSM and SDM) methods predicted destabilizing
effects.
3.15. K884
K884 is located 3.2 Å from the interface, 3.3 Å from the nucleic
acid and 8.6 Å from rifampin. Lysine forms mainchain hydrogen
bonds with L1033 and proximal hydrophobic interactions with
H1035 and V894. It also forms a cation - p interaction with
H1035 and most importantly a sidechain proximal hydrogen bond
with the sugar phosphate group of guanine (second) nucleotide in
the RNA transcript. This interaction is crucial for maintaining the
RNA interaction with rifampin in order to induce steric clash on
the adjacent nucleotide and halt transcription (Fig. 9A). Serine sub-
stitution at this site results in the loss of this vital interaction. S884
forms weak Van der Waals interactions with D883 and L885 and
Fig. 7. [A] Interactions of S437 with the surrounding residue environment in the wildtype and of H437 in the S437Hmutant [B]. [C] Interactions of G459 with the surrounding
residue environment and [D] W459 in the mutant G459W. The red dotted lines represent hydrogen bonds. Orange dotted lines represent weak hydrogen bond interactions.
Ring-Ring and intergroup interactions are depicted in cyan. Aromatic interactions are represented in sky-blue and carbonyl interactions in pink dotted lines. Green dotted
lines represent hydrophobic interactions. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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hydrogen bonds with L1033 and H1035. Interactions with RNA
backbone are lost in the mutant (Fig. 9B). The mutant is destabi-
lized (2.298 kcal/mol).
Aspartate substitution at this site destabilizes RNA affinity
(2.130 kcal/mol) and the mutant residue forms hydrogen bonds
with L1033 and H1035, and hydrophobic interactions with V894.
3.16. H1035
Histidine at position 1035 is located 3.5 Å from the interface
and RNA, and 8.8 Å away from rifampin. It forms a network of p
interactions with the surrounding residues. The ring-ring p inter-
actions with the fused pyrimidine-imidazole ring of guanine in
the first nucleotide of RNA transcript is vital to the orientation of
RNA transcript in the active center cleft (Fig. 9C). These interac-
tions are lost in substitutions with non-aromatic amino acids. It
was also noted that aspartate substitution largely destabilizes b
subunit -rifampin affinity (Fig. 9D).
3.17. Impact of mutations on flexible conformations:
The stability changes between the wildtype and each mutant in
lowest energy conformation were calculated by FoldX and have a
Pearson’s correlation coefficient (‘‘r” value) of 0.38 with other pre-
dictors mCSM and SDM. Although FoldX does not probe backbone
conformational changes, it optimizes the sidechain rotamers of the
mutant residues to attain a low energy state and calculates the
change in free energy between the states. We further sampled
the fully flexible conformers of the b-subunit and estimated
changes in vibrational entropy DS and protein stability using
ENCoM. A linear combination of vibrational entropy DS by ENCoM
and enthalpy changes by FoldX were used to calculate stability
changes. ENCoM predicted highly destabilizing mutations in the
rifampin binding and RNA interacting sites in the active center cleft
of the holoenzyme. DynaMut predictions correlated with ENCoM
values at an r value of 0.56. The average change in stability pre-
dicted by ENCoM and DynaMut for any mutation at each residue
position in the b subunit was mapped on the model (Fig. 10A
and B).
3.18. Protein stability changes and fragment hotspot maps:
Fragment hotspots were mapped on the structure that is col-
ored by regions predicted to have least protein stability changes
due to any mutations (using mCSM, SDM and FoldX software). As
fragment hotspot maps program identifies small molecule binding
propensity on the surface of the protein, we used only the protein
stability prediction software to identify areas that are stable by any
mutations. The regions of the b subunit that are least impacted by
mutations (mutation coolspots) are overlaid with fragment hotspot
maps. The site B (Fig. 11), which is in close proximity to the RNA
binding region and is a pocket at the b-b0 subunit interface, is least
impacted by mutations and has a hotspot at the contouring score
of 17 with donor, apolar and acceptor regions [22]. Secondly, the
site A, although located away from the catalytic core of the
enzyme, is present in the path of entry/exit point for template
DNA into the holoenzyme complex and a small molecule interac-
tion at this site can potentially impact template DNA interactions
or induce conformational change in the crab-claw-shaped b sub-
unit leading to disruption in the holoenzyme assembly.
Fig. 8. [A] Interactions of P489 with the surrounding residue environment in the wildtype and of G489 in the P489G mutant [B]. [C] Interactions of H451 with the
surrounding residue environment and [D] S451 in the mutant H451S.
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Fig. 10. [A] The maximum destabilizing effects on the protein stability, a mutation can induce at each residue position in the flexible conformations (as predicted by ENCoM
[A] and DynaMut [B]), are mapped on the structure. Regions in red represent highly destabilizing while the blue regions are relatively stable with mutations. (For
interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
Fig. 9. [A] Interactions of K884 with the surrounding residue environment in the wildtype and of S884 in the K884S mutant [B]. [C] Interactions of H1035 with the
surrounding residue environment and [D] D1035 in the mutant H1035D. The blue dotted lines represent cation-p interaction. (For interpretation of the references to colour in
this figure legend, the reader is referred to the web version of this article.)
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4. Discussion
In the absence of a rapid and an effective laboratory-based
diagnostic tool for determining drug resistance in leprosy, identi-
fication of mutations known to confer resistance to individual
drugs in MDT remains an appropriate approach for diagnosing
drug resistance. Associations between mutations in the drug tar-
gets and clinical resistance to individual drugs in MDT are often
validated by mouse-footpad experiments in which, resistant
strains (with known mutations) are propagated in the hind foot-
pads of mice (cross-bred albino) in the presence of drugs under
study [4]. Owing to high percentage identity of the b subunit of
RNAP of M. leprae with that of M. tuberculosis, identical mutations
that are experimentally proven to confer rifampin resistance in
tuberculosis, are considered as likely drug-resistant mutations
in leprosy. The experimentally known mutations in M. leprae
were those identified by DNA sequencing of rpoB gene (derived
from skin tissue DNA of relapsed/drug resistant leprosy patients)
and published in different studies (reference for each mutation is
listed in Supplementary Table 2). Most of these were validated in
either mouse foot-pad experiments or by using surrogate genetic
hosts [5].
Around 40 different rifampin-resistance mutations were noted
in M. leprae from clinical isolates around the world using amplicon
sequencing of RRDR [10]. All of these mutations decrease the sta-
bility of rifampin binding to the b-subunit (Supplementary Table 2)
and the mutant strains exhibited normal grown patterns in the
mouse footpads when administered with rifampin in doses equiv-
alent to WHO regimen of multibacillary MDT [44]. This indicates
that mutations structurally and functionally impact rifampin inter-
actions and influence concomitant resistance.
Thermodynamic stability of the proteins essentially influences
their function and is largely dependent on the sequence. Missense
mutations that lead to amino acid substitutions often impact pro-
tein stability, shifting it towards either a stabilized or a destabi-
lized state [7]. Experimental measurements of stability changes
in proteins are often challenging especially with large and complex
protein machineries like RNAP. However, mutations within each
subunit of the RNAP complex, and primarily the rifampin binding
b-subunit, have clinical implications and influence rifampin-
resistance outcomes in mycobacterial diseases [45]. The perfor-
mance of various structural, sequence and NMA based predictors
for predicting protein stability changes upon mutations vary lar-
gely in terms of their accuracy and bias [46], but offer a quick
and a helpful alternative to understanding the association between
mutations and resistance phenotypes [6].
Given the absence of a rapid and experimentally validated sys-
tem to read the impact of mutations in the b-subunit of RNAP inM.
leprae with clinical rifampin resistance outcomes in leprosy, we
conducted computational saturation mutagenesis to determine
regions on the b-subunit that impact the overall stability,
protein-subunit interfaces, protein-nucleic and protein–ligand
affinities. Being a part of the complex transcriptional machinery
in the mycobacterial cell, the compositional and conformational
stability of the b-subunit is crucial to binding of DNA template
and synthesis of complementary RNA transcript in the active cen-
ter cleft of the holoenzyme [47,48]. As rifampin blocks the growing
RNA transcript through steric occlusion, its binding and orientation
in the binding pocket is vital to its function [47]. Mutations within
the RRDR impact rifampin interactions and overall stability of the
subunit. As noted from Supplementary Table 2, all the experimen-
tally identified rpoB gene mutations from M. leprae indicated a
destabilizing effect on the protein–ligand affinity. Owing to the
robustness of these predictions, we employed an in-silico satura-
tion mutagenesis model to understand the impacts of systematic
mutations at each residue site of the subunit.
The destabilizing mutations are given preference over muta-
tions that are silent or have minimal effects on the stability. This
is to explore and understand the possible structural and functional
implications of emerging detrimental mutations (reported or new)
that can influence rifampin resistance outcomes in leprosy. We
used different structural, sequence and NMA based tools to identify
and compare the predictions. mCSM stability predictions had
better correlations with the other predictors (SDM (r = 0.55),
Fig. 11. Fragment hotspots were mapped on the structure which was coloured with maximum destabilizing effects of systematic mutations at each residue positions. Blue
represents regions which are least impacted by any mutations. Stable and potential small molecule binding sites ‘‘A” and ‘‘B” are depicted on the structure.
284 S.C. Vedithi et al. / Computational and Structural Biotechnology Journal 18 (2020) 271–286
MAESTRO (r = 0.61), Imutant 2.0 Structure (r = 0.72), CUPSAT
(r = 0.43), Imutant 2.0 Sequence (r = 0.62) and DynaMut (r = 0.61)).
Protocols (Computational Saturation Mutagenesis (CoSM)) [49]
that use molecular dynamic equilibration, sidechain flips and
energy minimization to improve side conformations in mutants
enable prediction of stability changes with better accuracy and
correlation with the experimentally deciphered stability changes
(r = 0.9). However, these protocols are computationally intensive
and require high performance computing systems and time. CoSM
had a similar performance to FoldX, which was used in the current
study. Given the large sample size, molecular dynamic equilibra-
tion of sidechain rotamers is beyond the scope of this study.
In conclusion, we have deciphered the predicted effects of all
possible mutations in the b-subunit of RNAP in M. leprae using
computational saturation mutagenesis model, probing structural,
sequence driven and dynamic changes that impact overall stability
of the protein, RNA and rifampin affinities. The predicted impacts
were mapped onto the structures and highly detrimental muta-
tions were further analyzed for their changes in interatomic inter-
actions. Due to the lack of adequate experimental data on stability
changes in b-subunit of RNAP upon mutations, we have limited
information on the accuracy of the predictions, however, all the
prediction tools used in the study are well tested and validated
software which are proven to perform with reasonable accuracy
and minimal bias on various relevant mutational datasets [31].
To date there were no studies describing the phenotypic resis-
tance/susceptibility outcomes in strains with compensatory muta-
tions in RNAP. Further studies on saturation mutagenesis of the
entire RNAP holoenzyme complex may provide comprehensive
information on the effects of co-evolving and compensatory muta-
tions in other subunits on rifampin binding and function.
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Structure guided prediction of 
pyrazinamide resistance mutations 
in pncA
Malancha Karmakar1,2,3, Carlos H. M. Rodrigues  1,2, Kristy Horan4, Justin T. Denholm3 & 
David B. Ascher  1,2,5*
Pyrazinamide plays an important role in tuberculosis treatment; however, its use is complicated by 
side-effects and challenges with reliable drug susceptibility testing. Resistance to pyrazinamide is 
largely driven by mutations in pyrazinamidase (pncA), responsible for drug activation, but genetic 
heterogeneity has hindered development of a molecular diagnostic test. We proposed to use 
information on how variants were likely to affect the 3D structure of pncA to identify variants likely to 
lead to pyrazinamide resistance. We curated 610 pncA mutations with high confidence experimental 
and clinical information on pyrazinamide susceptibility. The molecular consequences of each 
mutation on protein stability, conformation, and interactions were computationally assessed using 
our comprehensive suite of graph-based signature methods, mCSM. The molecular consequences 
of the variants were used to train a classifier with an accuracy of 80%. Our model was tested against 
internationally curated clinical datasets, achieving up to 85% accuracy. Screening of 600 Victorian 
clinical isolates identified a set of previously unreported variants, which our model had a 71% 
agreement with drug susceptibility testing. Here, we have shown the 3D structure of pncA can be used 
to accurately identify pyrazinamide resistance mutations. SUSPECT-PZA is freely available at: http://
biosig.unimelb.edu.au/suspect_pza/.
Tuberculosis (TB), caused by Mycobacterium tuberculosis, is the leading cause of infectious disease death world-
wide. In 2017, 10 million people fell ill, and 1.6 million died, from tuberculosis1. While a range of antibiotics 
are available to treat TB, treatment is prolonged, and the increasing emergence of drug-resistant bacteria is a 
considerable threat to global health. In 2017 alone, an estimated 558,000 people developed multi-drug-resistant 
tuberculosis (MDR-TB), resistant to the two first-line drugs rifampicin and isoniazid1.
Pyrazinamide (PZA) is a first-line drug that exhibits unique sterilizing activity towards both drug-susceptible 
and MDR-TB2. It is responsible for the killing of the persistent tubercle bacilli during the initial intensive phase 
of chemotherapy, allowing treatment to be shortened from 9 months to 6 months for drug susceptible cases3. 
PZA therapy has been linked to improved outcomes for both non-MDR and MDR-TB, and is being considered 
as part of the future regimens in combinations with bedaquiline, delamanid, PA-824 and moxifloxacin, which are 
currently in phase three trials4,5.
Despite the highly important role of PZA in clinical outcomes, resistance has largely been underestimated, 
with up to 20% of non-MDR-TB patients PZA resistant6. Being a central drug in current and future regimens, it 
is important to be able to rapidly and accurately identify resistant isolates and track the emergence and spread of 
drug resistant strains. In vitro drug susceptibility testing (DST) is challenging, expensive and time-consuming as 
PZA is effective against M. tuberculosis only at acidic pH, leading to false resistance rates of up to 70%7–13. This has 
led to the WHO recommending the development of molecular genetics tests.
PZA is a structural analog of nicotinamide and is a pro-drug that needs to be converted into its active form, 
pyrazinoic acid (POA), by the non-essential enzyme pyrazinamidase, encoded by the pncA gene14,15. It has been 
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postulated that the mechanism of action of PZA is through POA, which disrupts the bacterial membrane energet-
ics and inhibits the membrane transport function which is necessary for the survival of the bacterium, at an acidic 
site of infection16. PZA resistance has been linked to mutations in a number of genes, including pncA, rpsA17, 
panD18, clpC119, and the putative efflux pumps Rv0191, Rv3756c, Rv3008, and Rv1667c20, but mutations in pncA 
are the major mechanism for PZA resistance (70–97%)21. While sequencing the pncA gene can be a more reliable 
method to determine resistance than DST, which is prone to missing low-level pyrazinamide resistance caused by 
non-synonymous mutations in pncA22, the development of a genetics based resistance screen is complicated as 
resistant and non-resistant mutations are found across the entire protein.
To solve the problem of a reliable DST for PZA, we previously showed that protein structural information can 
be used in a clinical setting to rapidly, accurately and pre-emptively predict drug resistant mutations in pncA23. 
This showed that mutations that affected protein folding, flexibility, stability and activity were strongly associated 
with resistance. Here we have used a comprehensive combination of structure and sequence-based features to 
develop a predictive tool to characterize novel PncA mutations, which we tested on novel mutations from the 
Victorian Tuberculosis Program, CRyPTIC24 and Miotto et al. dataset25. This highlights the potential of using 
structural information to guide the genetic detection of resistance. We have implemented our model through the 
webserver SUSPECT-PZA (http://biosig.unimelb.edu.au/suspect_pza/), which will enable the rapid structural 
evaluation of the molecular and phenotypic consequences of any pncA nonsynonymous mutation to support 
informed clinical decisions.
Results
We used a structure-guided approach to understand the structural and functional consequences of variants in 
the drug target PncA, and machine learning to build an empirical tool that could identify likely resistant muta-
tions. The workflow used to analyze the mutations and train a Random Forest algorithm is shown in Fig. 1 and it 
comprises three major steps: (1) data curation, which can be subdivided into mutational data set acquisition and 
protein structure curation; (2) feature analysis, which involves the generation and evaluation of features selected 
to develop the predictive model to determine novel drug resistance mutations in PncA; (3) machine learning and 
webserver development, which aims to train, test and validate a supervised machine learning algorithm to accu-
rately predict the susceptibility of the variant followed by a database (SUSPECT-PZA) which has information for 
all possible variants of PncA.
Distribution of the mutations on the structure. We curated a dataset of 1322 nonsynonymous substi-
tutions with high quality experimentally measured PZA susceptibility (71 susceptible mutations from GMTV26, 
12 resistant mutations from GMTV26, 178 resistant mutations from TBdreamDB27, Fig. 2A, 547 resistant and 514 
susceptible mutations from experimental saturation mutagenesis28). After removal of duplicate mutations, we 
were left with a dataset of 610 mutations, which included 305 susceptible and 305 resistant mutations. Mapping 
the complete set of curated 610 nsSNVs (Fig. 1) and just the clinical variants only (Fig. 2B) onto the crystal struc-
ture of PncA revealed that variants were distributed throughout the entire protein structure, complicating resist-
ance inference from sequence analysis. We also observed that the resistance mutations were not solely localized 
at the drug binding site but distributed throughout the protein (Fig. 2C).
Figure 1. Methodology workflow. The methodology can be divided into three steps. In step 1, data is collected 
and curated from various tuberculosis databases and articles with experimental evidence like availability of DST 
results or high-precision laboratory screening study. The curated mutations are shown across both the protein 
sequence and 3D structure, respectively. The protein sequence and structure of PncA is colored by whether 
resistant (red) or susceptible (blue) mutations have been observed at that location. Highlighting the difficulty 
of genomic analysis of pncA, both resistant and susceptible mutations have been observed across many residue 
positions (cyan). In step 2, effects of mutations on protein stability, dynamics, complementary information 
regarding the environment characteristics of the wild-type residue (e.g. relative solvent accessibility, residue 
depth and secondary structure), PZA binding affinity are calculated using different in-silico tools. Step 3, all 
the features are used as evidence to train a supervised machine learning algorithm and after evaluating the 
performance of the predictive model, the consensus predictions are integrated into a server and can be used to 
guide clinical resistance detection.
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PncA is a small protein molecule which constitutes of 186 amino acids. The experimental crystal structure 
of the drug (PZA) bound to the enzyme (PncA) was unavailable. Therefore, PZA was ab initio docked into the 
experimental crystal structure of the holo-wild-type PncA protein (PDB ID: 3PL129). The docked structure 
revealed that PZA formed key interactions within the proteins active site, which includes the catalytic triad (Asp8, 
Lys96, and Cys138), substrate-binding residues (Trp68 and Phe13), and the iron center (Asp49, His51, His57, and 
Fe 21). Analysis of the molecular interactions with Arpeggio30 highlighted a strong network of polar and π- inter-
actions between PZA and PncA (Fig. 2D).
Structural, biophysical and evolutionary consequences of PncA mutations. Looking at the 
SNAP231 and PROVEAN32 scores, which consider evolutionary information to predict functionally important 
nonsynonymous mutations, we observed that resistant mutations were always associated with deleterious scores, 
while susceptible mutations were scored neutral (Table S1; Fig. 3). This suggest that although mutations were 
spread throughout the protein, mutations associated with resistance were having a stronger effect on the structure 
and function of the protein.
The wild-type environment also provided information to differentiate between resistant and susceptible muta-
tions, which included relative solvent accessibility (RSA), residue depth and secondary structure of the wild-type 
residue (Table S1; Fig. 3). This showed that resistant mutations tended to be found at buried residues that were 
less solvent exposed (average RSA of 0.18 for resistant mutations compared to 0.39 for susceptible; average residue 
depth of 1.09 Å for resistant mutations compared to 0.75 Å for susceptible; Table S1). These values were consist-
ent with susceptible mutations being in regions that have milder effects on protein stability and activity than the 
resistance mutations.
The impact of the resistant and susceptible mutations on protein folding, stability and conformation were 
assessed using biophysical tools which relies on graph-based signatures to calculate the change in Gibb’s free 
energy, like mCSM-Stability33, DUET34 and DynaMut35. The effect of the mutations on the binding affinity for 
PZA were assessed using mCSM-Lig36. We observed that resistant mutations led to large decreases in PncA sta-
bility and conformational flexibility, while susceptible mutations were associated with milder changes (Table S1; 
Fig. 3). This is consistent with what we have observed previously for non-essential and drug activating proteins37. 
While resistant mutations, however, tended to be located closer to the PZA binding site (average < 10 Å from the 
PZA; Fig. 3), we did not see a significant difference in the distribution of the effects of resistant and susceptible 
mutations on PZA binding affinity (Table S1, Fig. S2), likely due to the importance of other molecular effects 
leading to resistance.
Machine learning to predict PZA resistance. Building on this structural and sequence-based analysis, 
we tested whether the information generated from these features could be used to train a supervised machine 
learning algorithm capable of accurately predicting resistant mutations in PncA. We grouped our features into 
five distinct categories: stability, dynamics, evolutionary conservation, ligand interactions and backbone geome-
try (structural environment). The performance of predictive models trained on each class of feature was evaluated 
Figure 2. Distribution of clinical resistant and susceptible mutations in PncA. (A) Venn diagram representing 
the distribution of clinical mutations in the different datasets used to build the predictive model. (B) Clinical 
resistant and susceptible mutations mapped on the crystal structure. Amino acid positions where both 
susceptible and resistant mutations were seen are colored in cyan and emphasizes the need for a better and 
improved tool to classify them accurately. (C) Surface view of PncA with the docked PZA (yellow, ball and stick 
representation). Clinical resistant mutations, shown in red, are not just located at the PZA binding site, but are 
spread equally throughout the whole protein. (D) Molecular interactions between PZA (yellow sticks) and the 
surrounding amino acids which are part of the catalytic triad (Asp8) and substrate binding site (Trp68, Phe13). 
Hydrogen bonds are shown as blue dashes, and π-interactions as green dashes.
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separately to explore the contribution of each class to the predictive model (Table S2; Fig. S2). We were able to 
confirm that the individual categories of features did not yield a good metric for a reliable predictive model, but 
in combination using 10-fold cross-validation, models trained using Random Forest algorithm yielded a more 
balanced and accurate performance, highlighting the synergistic effect of these features. The final model correctly 
classified 80.1% and 72.3% of mutations in the training and blind datasets, respectively (Fig. 4; Table 1). The com-
parative performance across iterative non-redundant blind datasets suggested that the model was not overfitted.
Analysis of our model revealed that PncA-resistant mutations were associated with large changes in pro-
tein folding and stability (mCSM-Stability scores < −0.9 Kcal/mol; p < 0.0001, Welch Two Sample t-test) and 
conformational flexibility (DynaMut score < 0.78 Kcal/mol; p < 0.0001, Welch Two Sample t-test) or located in 
close proximity to the catalytic triad and substrate-binding site (<10.8 Å; p < 0.0001, Welch Two Sample t-test). 
Alternatively, susceptible mutations had a relative b-factor value of ≥3.19 (p < 0.0001, Welch Two Sample t-test), 
residue depth of ≥0.9 (p < 0.0001, Welch Two Sample t-test), distance from PZA greater than 11.9 Å and mild 
effects on protein stability (SDM scores ≥ 2.68 Kcal/mol; p < 0.0001, Welch Two Sample t-test).
Validation using Clinical Datasets. We next validated our model using variants reported in the recently 
published CRyPTIC dataset24. 355 pncA nsSNVs associated with PZA resistance were reported, of which 75 were 
not present in our training dataset. Our model correctly classified 79.2% of the mutations across the whole dataset 
Figure 3. PCA analysis of key molecular features distinguishing resistant and susceptible mutations. Features 
used for model building are represented as boxplots for explanatory data analysis. The resistant associated 
mutations (R) are represented as red and the susceptible mutations (S) as blue. (***p < 0.0001, Welch two 
sample t-test).
Figure 4. Evaluation Metric for machine learning. Receiver Operating Characteristic (ROC) curves of PZA 
classifier obtained using the structural and functional consequences of the mutations to accurately identify 
resistant (red) and susceptible (blue) mutations. (AUC = area under the curve).
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(355 mutations), and 72.0% of those non-redundant in amino acid position with the training data (75 mutations). 
The positive predictive value was 94.7% (95% CI [92.5% to 96.2%]).
We also validated our empirical classifier using the dataset reported by Miotto et al.25, which contained 98 
nsSNVs graded by the confidence of their association with phenotypic drug resistance. 44 out of the 98 nsSNVs 
reported in the paper were not present in our training dataset. We accurately predicted the drug susceptibility of 
84.8% of the polymorphism across the whole dataset (98 mutations), with an accuracy of 79.5% for those muta-
tions not included in the training data (44 mutations). The positive predictive value was 95.4% (95% CI [92.1% 
to 97.3%]). We observed mutations such as Q10P (21 cases reported), W68G (16 cases reported) and I133T (17 
cases reported) with 0.98 probability associated with resistant phenotype22 and categorized as high confidence 
for association with resistance, moderate confidence for association with resistance and minimal confidence for 
association with resistance respectively25 were all classified as resistant by our predictive model, highlighting the 
sensitivity of the prediction.
Mutations reported by Miotto et al.25 under the “no association with resistance” category, including I31T, L35R 
and T47A were predicted as resistant, and I6L as susceptible. This is consistent with the available experimental 
data24,28, highlighting the advantage, accuracy and versatility of our approach. A closer look into the different bio-
physical scores for the resistant associated mutations revealed that they had large predicted destabilizing values 
for protein conformational flexibility (I31T, −2.49 Kcal/mol) and stability (I31T, −3.46 Kcal/mol) and one was 
located very close to the catalytic triad (T47A, <6 Å).
Our predictive model was further validated on PZA DST screening at 100 μg/ml of clinical isolates from 
culture collections at Stellenbosch University, South Africa (865 isolates) and the Centers for Disease Control 
and Prevention (CDC), Atlanta, USA (185 isolates)38. They identified 49 isolates with a susceptible phenotype 
containing 8 nsSNVs. All nsSNVs with an MIC < 50 μg/ml were correctly classified by our model as susceptible 
(E37V, D110G, T114M). Whitfield and colleagues suggest that those isolates with an MIC > 50 μg/ml should be 
considered clinically resistant, of which our model classified three as resistant (A170V, V130A and L35R) and two 
as susceptible (V163A and V180I). Overall, our model had a 75% agreement with the DST results and a positive 
predictive value of 100%
Application within a Clinical Setting. In a prospective genomic sequencing and DST analysis of over 600 
Victorian clinical TB isolates, 7 pncA variants were detected in 11 variants phenotypically resistant to PZA, none 
of which were present in our training dataset. Our model correctly classified five out of seven variants as resistant 
(71.4% accuracy). The remaining two mutations, G108V and Q10H, which were susceptible according to the DST 
results were predicted to confer resistance and consistent with other experimental findings24,25,28. Both variants, 
had a SNV frequency of <0.5, which is known to impact upon the reliability of the DST results. This highlights 
the potential clinical power of our model.
Expanding our analysis, four additional pncA mutations (S104R, V128G, Y95R and E15A) were identified 
in Victorian clinical TB isolates lacking DST results. Both S104R and V128G were predicted as resistant by our 
model, consistent with previously reported DST results24–28. The remaining two mutations, Y95R and E15A, have 
not been reported previously. Our model suggests both mutations to confer susceptibility to PZA.
SUSPECT-PZA webserver. We have developed a user-friendly, freely available web server SUSPECT-PZA 
(StrUctural Susceptibility PrEdiCTion on PZA), http://biosig.unimelb.edu.au/suspect_pza/, which is a data-
base for all possible variants of PncA. There are two different input options (Fig. S2): the first one is the “Single 
Mutation” option which allows the users to input one mutation for analysis. The basic format required by the 
server for this input option is that the mutation must be specified as a text string containing the wild-type res-
idue one-letter amino acid code, its corresponding position on the structure and the mutant one-letter amino 
acid code. The second option is the “Mutation List”, which allows the user to upload a list of mutations, in the 
same specified format as above but in a file for batch processing (Fig. S3). Sample submission entries are available 









correctly classified variants 
SUSPECT-PZA (%)




Training dataset (70%) 426 213 159 (74.5) 213 182 (85.5) 83.7 (78.6–87.8) 80.1
Blind test dataset (30%) 184 92 56 (60.8) 92 77 (83.7) 78.9 (69.5–85.9) 72.3
CRyPTIC dataset24 355 325 266 (81.8) 30 15 (50.0) 94.7 (92.5–96.2) 79.2
CRyPTIC novel nsSNVs 75 67 67 (74.6) 8 4 (50.0) 92.6 (86.0–96.2) 72.0
Miotto et al. dataset25 98 92 82 (89.1) 6 2 (33.3) 95.4 (92.1–97.3) 84.8
Miotto novel nsSNVs 44 43 35 (81.4) 1 0 97.2 (96.8–97.6) 79.5
Stellenbosch University 
and CDC, USA nsSNVs38 8 5 3 (60.0) 3 3 (100) 100 75.0
Victorian TB novel 
nsSNVs 7 4 4 (100) 3 1 (33.3) 66. 7 (47.3–81.7) 71.4
Table 1. Evaluation metrics across the train and blind test datasets. Accuracy = (TP + TN)/(TP + TN + FP + FN); 
TP: True positives, TN: True Negatives, FP: False Positives, FN: False Negatives PPV: Positive predictive value, 
predicting PZA resistance (nsSNVs - non-synonymous single nucleotide variant).
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Figure 5 shows a snapshot of the output page for the “Single Mutation” option. The web server displays the 
prediction outcome (Resistant / Susceptible) along with details of the user input data, information on the wildtype 
residue environment and features used for prediction. In addition, there is an interactive 3D viewer, built using 
NGL39, which allows analysis of non-covalent inter-residue interactions for the position specified in the input 
calculated using Arpeggio30 for both wild-type and mutant structures. The results for the “Mutation List” option 
is summarized in a downloadable table. The users can access details of individual mutation as shown in Fig. S4. 
There is a 3D viewer at the bottom of the page in which the residues in the input list is colored according to the 
predicted effect (Fig. S5).
Discussion
PZA was discovered in 1948 in an in vivo screen of nicotinamide derivatives in a structure-activity relationship 
study40 and used as anti-tuberculosis drug in 1952 for the first time. Till the 1970’s PZA was used as a second-line 
drug to treat TB, until they discovered the sterilizing activity and reduction in treatment duration in combination 
with isoniazid and rifampicin. There has been a lot of studies conducted since then and with the continued usage 
of the drug to treat TB, there has been an increased incidence of resistance associated with it. Being an impor-
tant first-line drug, accurate and rapid evaluation of PZA susceptibility is crucial for successful management of 
patients with either susceptible or drug-resistant TB. The existing molecular phenotypic tests are considered 
poorly reliable, expensive, and has a long turnaround time. To account for this situation there is an urgent require-
ment to develop a rapid, reliable and affordable molecular PZA DST. As resistance mutations are spread all over 
the length of the PncA protein, it is quite challenging to develop a new method. In this study, we establish a novel 
computational methodology to better understand the structural and functional consequences of drug resistance 
mutations by exploiting the protein’s 3D structure. Using supervised machine learning algorithm, we developed 
an empirical tool to determine novel drug resistance in PncA followed by a database which has information on 
all possible variants of PncA.
The primary focus of our work is on missense non-synonymous mutations as these typically have more subtle 
molecular effects that can be harder to predict, than in-frame and frameshift indel mutations that have a much 
larger deleterious effect on PncA structure and function and are all classed as high-confidence resistant muta-
tions. The structure-based tools implement the concept of graph-based signatures to predict the effect on single 
point mutations for protein stability. To assess changes in conformational flexibility, graph-based signatures were 
integrated with normal mode analysis to predict the impact on the protein structure. Scores for these features 
which were calculated as change in Gibb’s free energy (ΔΔG) provided important molecular information on 
resistant mutations, signifying larger effects on protein folding and dynamics and minimal effect on PZA bind-
ing affinity. Interpreting the results, we observed, resistance mutations were seen to affect protein activity and 
function through destabilization of the protein structure and conformation. It even helped in correlating earlier 
findings where resistant isolates were not associated with a loss of bacterial fitness41 due to the fact that PncA was 
involved in nicotinamide recycling pathway rather than in its synthesis. These structural insights have been used 
to guide clinical decisions for novel PZA mutations23.
Phenotypic DST which is the current “gold standard”, which encompasses methods like Wayne and Bactec 
MGIT 960, suffers from poor reproducibility. Discrepancies among the results lead to considerable doubt over the 
clinical significance of the method. Next-generation sequencing based diagnostics can be an alternative for inno-
vative tools to reduce false detection of PZA resistance cases and fast and accurate detection of drug resistance by 
molecular DST42. In the past couple of years researchers have used different techniques to come up with a better 
and consistent methodology to detect and determine resistance in PZA. Stoffels et al.41 conducted an elaborate 
study on 14-year complete capture of clinical isolates, where he found frequency of spontaneous acquired resist-
ance to be 10−5 bacilli in vitro. Miotto et al. 2014 work generated the minimum dataset of mutations that should 
be included in any molecular test for PZA, paving the way for predicting PZA resistance using new genome-based 
technologies22. This was followed by Farhat et al. 2016 comprehensive web-based dataset43. Though all these 
approaches were a step up from the existing phenotypic DST, they do not provide information on novel variants. 
The advantage with our database is it provides information on all possible variants for PncA. This data provides 
a basis for use as part of any molecular DST, needed for the valid interpretation of data generated by massive 
sequencing approaches.
Interestingly, comparing performance of SUSPECT-PZA across datasets used to train earlier methods, we 
observed that the weakest performance was across variants classified as susceptible. However, many of these 
mutations have been observed in clinically resistant isolates. Our biophysical analysis and SUSPECT-PZA predic-
tions would be consistent with these mutations potentially being misclassified previously.
We also compared our empirical models output to the “revised DST” of Miotto et al.22, where they accounted 
for enzymatic activity and structural analysis to adjust for possible errors in phenotypic DST. There were 178 
missense mutations listed, of which 162 were labelled resistant (R) and 17 were labelled susceptible (S). Our 
model predicted 88.9% (144/162) of the resistant mutations and 58.8% (10/17) of the susceptible mutations accu-
rately. The positive predictive value was 95.4% (95% CI [92.1% to 97.3%]). The primary divergence from the 
Miotto classifications was in predicting susceptible mutations. This is likely due to discrepancies in phenotypic 
and molecular DST results from different laboratory setups16. For example, mutations reported as susceptible in 
the “revised DST” like L159V, F81S, A102V, T135S, T168I and A46V were unanimously reported as resistant in 
other studies24,26–28. Our predictive tool also predicts them to be resistant and hence, proves to be more reliable, 
reproducible, free to use and a fast alternative to the existing gold standard methods.
This study highlights the power of using computational prediction of the structural consequences of variants 
in PncA to identify likely pyrazinamide resistance mutations, a critically important first-line drug in the treat-
ment of tuberculosis. This approach, however, is not limited to pncA and has been developed for application to 
other antimicrobial agents like bedaquiline44, a last line resort to treat multi-drug and extremely drug resistant 
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TB. A major advantage of our tool is that it was built using a very well-balanced dataset. In case of mutations 
reported as both susceptible and resistant in the same or different datasets, we looked for frequency of occurrence 
and clinical information. We have extensively evaluated the method through both cross-validation and inde-
pendent non-redundant blind tests, which provide a measure of a methods applicability and robustness. Across 
all test sets the method performed equally well, providing strong confidence in the approach. As with all machine 
Figure 5. SUSPECT-PZA webserver Single point mutation prediction result page. The predicted outcome 
of the submitted mutation is displayed along with complimentary information on features used to aid in the 
development of the tool. The interactive 3D viewer allows user to further analyze non-covalent interactions for 
both wild type and mutant residues on the protein. A variety of controllers are provided to customize molecule 
representation.
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learning approaches, the availability of more phenotypic and clinical data will enable the development and vali-
dation of stronger approaches. This will be an iterative approach moving forward. The other aspect to improving 
our predictive model is through the inclusion of new features or parameters. We have shown previously that this 
approach can even capture strain dependent variations in resistant patterns23. While we did not have the data 
available to build into our current model, we next aim to integrate lineage specific information, which will enable 
more refined and personalized predictions. This comprehensive web server can be used in clinical settings as an 
improved diagnostic tool to help realize the power of whole genome sequencing diagnostic approaches.
Methods
Data set. A list of 610 nonsynonymous single-nucleotide mutations (nsSNVs) of pncA was obtained from the 
GMTV (Genome-wide Mycobacterium tuberculosis Variation) Database Project26, Tuberculosis Drug Resistance 
Mutation Database27, and saturation mutagenesis28. The clinical validation datasets used in the paper were from 
CRyPTIC24 and Miotto et al.25.
Modelling the biophysical consequences of missense mutations. We have developed a compre-
hensive in silico mutational analysis platform that uses graph-based signatures to represent the 3D structure of a 
protein and quantitatively predict the molecular consequences of point mutations on protein structure, function 
and interactions30,33–36,45. This has been used to characterize and preemptively identify likely resistance mutations 
in drug targets23,37,46–54. Using these tools, we assessed the molecular consequences of each mutation on the struc-
ture of PncA and drug activation.
The experimental crystal structure of holo-wild-type PncA (PDB ID: 3PL1)29 was minimized in Prime, and 
PZA docked into the active site using Glide (Schrödinger Suite). The effects of mutations on PncA folding and sta-
bility were assessed using SDM55, mCSM-Stability33 and DUET34, and their effects on protein flexibility and con-
formational was predicted using normal mode analysis by DynaMut35. The effect of the changes on the binding 
affinity of PZA towards PncA were predicted using mCSM-Lig36,56. These approaches are novel machine-learning 
algorithms. We also included structural information of the wild-type residue, including relative solvent accessi-
bility, residue depth, secondary structure and dihedral angles of the PncA chain ϕ (phi) and ψ (psi). Additionally, 
SNAP231 and PROVEAN32 were used to provide additional evolutionary information. Moreover, the scores calcu-
lated for the various structural and sequence-based features are independent of pH and temperature.
Machine learning. Here we used the Random Forest binary classifier using the Weka toolkit57 to train our 
predictive models. Random Forest is an ensemble-learning robust classification algorithm, in which multiple 
decision trees are included over a random subset of features and decide the output via majority voting. The model 
was trained using 10-fold cross-validation and performance evaluated by area under the Receiver Operating 
Characteristic (AUROC) curve, precision and accuracy. Further validation of the models was performed using 
a blind-test set of 184 mutations, which were non-redundant at the position-level with mutations in the training 
set. Analysis of the final model revealed a set of structural features that distinguished between susceptible and 
resistant pncA point mutations.
Webserver development. The server front-end was built using materialize CSS framework version 1.0.0, 
while the backend was built in Python via the Flask framework (version 0.12.2). It is hosted on a Linux server 
running Apache.
Sequencing and DST of clinical isolates. Genomic DNA was extracted according to the mechanical cell 
disruption and ethanol precipitation method outlined in Votintseva 201558 with slight modifications. Briefly, no 
pre-treatment was used and approximately 3 × 1 µL loops of culture were dispersed in 700 µL TE buffer (Sigma 
Aldrich) as the starting material. The precipitated DNA pellet was only washed once and resuspended into 50 µL EB 
Buffer (Qiagen) at 55 °C for 10 minutes with regular vortexing. Finally, samples were centrifuged 3 min at 13,000 rpm 
and 45 µL of DNA extract was transferred into a clean tube for downstream processing. Each extract was interrogated 
for Mycobacterium tuberculosis viability by inoculating 15 µL of DNA extract into MGIT tube (Becton Dickinson, 
UK) and incubated in the Bactec MGIT 960 system (Becton Dickinson, UK). Unique dual indexed libraries were 
prepared using the Nextera XT DNA sample preparation kit (Illumina). Libraries were sequenced on the Illumina 
NextSeq. 500 with 150-cycle paired end chemistry as described by the manufacturer’s protocols.
Sequences were aligned to H37Rv (NC_0009623.3) and small nucleotide variations (SNV) mutations in pncA 
were identified using LoFreq (http://csb5.github.io/lofreq/). SNVs with a frequency > 0.6 were used to compare the 
genotype of isolates to the phenotype observed using standard laboratory methods for PZA susceptibility testing.
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Wandré N. P. Veloso, Joicymara S. Xavier, Malancha Karmakar,
Yoochan Myung, João P. V. Linhares, Carlos H. M. Rodrigues, Michael Silk,
and David B. Ascher
Abstract
High-throughput computational techniques have become invaluable tools to help increase the overall
success, process efficiency, and associated costs of drug development. By designing ligands tailored to
specific protein structures in a disease of interest, an understanding of molecular interactions and ways to
optimize them can be achieved prior to chemical synthesis. This understanding can help direct crucial
chemical and biological experiments by maximizing available resources on higher quality leads. Moreover,
predicting molecular binding affinity within specific biological contexts, as well as ligand pharmacokinetics
and toxicities, can aid in filtering out redundant leads early on within the process. We describe a set of
computational tools which can aid in drug discovery at different stages, from hit identification (EasyVS) to
lead optimization and candidate selection (CSM-lig, mCSM-lig, Arpeggio, pkCSM). Incorporating these
tools along the drug development process can help ensure that candidate leads are chemically and biologi-
cally feasible to become successful and tractable drugs.
Key words Graph-based signatures, mCSM, Mutation, Protein-ligand, Interatomic interactions,
Docking, Drug development
1 Introduction
Structure-guided drug development uses knowledge of the three-
dimensional structure of the biological target to more efficiently
guide the design of small molecule binders. While it has become an
integral strategy for both lead generation and optimization, the
application of computational tools to take advantage of the explo-
sion in structural information has often required specialist knowl-
edge and resources and in some cases has been limited to
commercial software.
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Using the concept of graph-based signatures, we have devel-
oped a robust, user-friendly, and freely accessible platform to ana-
lyze protein structures and interactions [1–12] and guide disease
characterization [13–28] and drug development [29–32]. These
include methods to perform virtual screening (EasyVS), score
protein-small molecule docking solutions (CSM-lig [3]), look at
all the molecular interactions being made (Arpeggio [7]), identify
mutations that are likely to affect compound binding (mCSM-lig
[5]), and characterize the pharmacokinetic and toxicity properties
of the proposed molecules (pkCSM [33, 34]). These have been
successfully employed in a number of drug development projects
[30–32, 35–37] and together comprise a powerful platform that
allows users to enhance their structure-guided drug development
efforts (Fig. 1). Here we discuss how this platform can be leveraged
to guide drug development.
2 Materials
Here we present four structure-based tools to help guide drug
development. For each method, users are required to provide:
1. Wild-type protein structure in PDB format: For all methods,
a wild-type structure in the Protein Data Bank [38] format
must be provided to perform the analysis. This can be an
experimentally solved structure previously deposited into the
Protein Data Bank (www.rcsb.org or http://www.ebi.ac.uk/
pdbe/) or a model, for instance, obtained by comparative
homology modeling. We have previously shown that homol-
ogy models built using templates down to 25% sequence iden-
tity do not significantly affect the accuracy of the methods
[9, 10]. For Arpeggio, CSM-lig, and mCSM-lig, the protein
structure file needs to include the ligand of interest, either
already present in the experimental structure or computation-
ally docked into the binding site. PDB structures are required
to have a valid chain identifier (see Note 1), a single conforma-
tion (multiple occupancies need to be filtered out; seeNote 2),
and a single model, in case of NMR structures (see Note 3).
2. Three-letter code of the ligand of interest: When a structure
of a protein-ligand complex is provided to the predictive web
servers (CSM-lig and mCSM-lig), users will be asked to pro-
vide a three-letter code that identifies the residue ID for that
ligand within the PDB file, according to the PDB format
standards. In addition to the three-letter code, CSM-lig also
requires the canonical SMILES of the compound of interest for
additional property calculations. Several tools are available to
aid users to convert between small molecule formats. These
include stand-alone packages such as OpenBabel [39] and
Avogadro [40].
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Fig. 1 A structure-based computational platform to guide drug development. To complement and support
traditional experimental approaches, including high-throughput screening (HTS) and fragment-based drug
discovery, this in silico platform supports hit identification via virtual screening, methods to better understand






1. Virtual screening is a powerful, high-throughput technique for
computationally screening large libraries of small molecules
(often in the order of millions) in order to identify those
ligands which are most likely to bind to a drug target protein.
When compared to traditional screening methods, this leads to
significantly higher hit rates that can proceed to lead optimiza-
tion [41, 42]. It can, however, be computationally intensive
and usually requires specialist knowledge. EasyVS provides an
easy-to-use web interface at http://biosig.unimelb.edu.au/
easyvs/, allowing users to rapidly set up and analyze their
virtual screening results.
2. Users can upload the structure of the protein target of interest
as either a PDB file or by providing the PDB ID of a previously
solved experimental structure. Any ligands, ions, or water
molecules already bound to the provided structure will be
disregarded.
3. On the following step, the provided PDB file or identifier will
be processed, and pockets will be automatically detected using
Ghecom [43] (Fig. 2a-1). Users can either select one of the
identified pockets to determine the docking grid (the three-
dimensional space where the ligands will be docked into) or
provide specific grid coordinates and size (Fig. 2a-2).
4. Users then need to select the ligand library they want to screen,
which includes libraries of purchasable compounds, natural
products, or FDA-approved drugs (Fig. 2b). These can be
further filtered based upon their molecular properties (e.g.,
Lipinski’s rule of five [44] or the rule of three) or grouped by
similarity.
5. The selected molecules will then be docked into the selected
docking grid (Fig. 2c-1), and the top 20 poses per ligand can be
downloaded. The server also provides an interactive visualiza-
tion tool to compare ligand docking poses (Fig. 2c-2). The
example on this figure shows the docking poses for ligands
docked to the Ribosome-Inactivating Protein Ricin A (PDB
ID: 1BR5). While poses are sorted by predicted affinity (kcal/
mol) using autodock’s scoring function, users can evaluate






1. Following virtual screening or docking, the affinity of the top
docked ligand poses can be quantified using CSM-lig. This is a
machine learning-based tool which acts as a scoring function
and enables the numerical affinity comparison between poses.
It is implemented via an easy-to-use web interface at http://
biosig.unimelb.edu.au/csm_lig, which is compatible with
most operating systems and browsers.
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Fig. 2 Automated docking with EasyVS. After choosing a target of interest, EasyVS will automatically identify
pockets (a-1) and allow user to further customize the docking protocol (a-2). A range of ligand libraries can be
selected for docking (b), including FDA-approved drugs, purchasable compounds, and natural products, which
can be further filtered based on physicochemical properties. Docking results are shown in tabular format (c-1),
depicting ligands, their properties, and docking scores. An interactive viewer allows users to inspect the best
poses for each ligand (c-2)
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2. By selecting the “Predict” tab, users are presented with two job
options, “Single Structure” and “Multiple Structures.”
3. For “Single Structure” prediction, provide (Fig. 3a-1) the
protein-small molecule complex you would like to evaluate
the pose of in PDB format (Fig. 3a-2), the three-letter code
for the small molecule (as in the provided PDB file) and
(Fig. 3a-3) and the SMILES string of the small molecule.
4. Alternatively, for “Multiple Structures,” provide two files. The
first file (Fig. 3a-4) is a compressed zip file with all protein-small
molecule PDB files you would like to evaluate. These could be,
for instance, different poses or conformations for a given
protein-ligand complex or multiple different complexes. The
second (Fig. 3a-5) is a tab-separated file with the following
information for each uploaded complex in the .zip file:
(a) structure file name (file in PDB format), (b) three-letter
code for the small molecule (as in the structure file), and
(c) canonical SMILES for the small molecule.
5. The output prediction page for the “Single Structure” jobs
depicted in Fig. 1b presents (Fig. 3b-1) the predicted affinity
(as log10(affinity) in molar, meaning a compound with an
affinity predicted as 1 nM would have a predicted value of 9).
The example presented in the figure and the web server shows
the affinity prediction for the ligand Zanamivir bound to
human sialidase-2 (PDB ID: 2F0Z). For this complex,
CSM-lig generates a score of 12.6, denoting very high affinity
(larger numbers denote higher affinity). A depiction figure of
the small molecule is shown, together with calculated proper-
ties, including molecular weight (in Da) and partition coeffi-
cient (log P), among others (Fig. 3b-2). An interactive
visualization of the protein-small molecule complex is also
exhibited (Fig. 3b-3). The interatomic non-covalent interac-
tions between protein and small molecule are also calculated
and are available as a downloadable Pymol [45] session
(Fig. 3b-4). Pharmacokinetics and toxicity predictions by
pkCSM for the provided small molecule are also available by
clicking on the red button at the bottom-left corner of the
results page.
6. The output for “Multiple Structures” jobs are shown in tabular
format (Fig. 3c-1), depicting predicted affinity values, SMILES
identifying the molecules and their calculated molecular prop-
erties. These results are available as a tabular file and can be
downloaded (Fig. 3c-2).
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Fig. 3 CSM-lig submission and results web interface. The submission page (a) allows users to provide either
single or multiple protein-ligand complexes for evaluation. The results page for single complex/pose
assessment (b) provides the calculated affinity, ligand properties and depiction, as well as an interactive
visualization of the complex. For multiple poses, CSM-lig provides the predicted affinities in a downloadable
tabular format, together with ligand properties (c)






1. Once a structure of the target protein with the candidate
molecule is available, either through experimental determina-
tion or docking or other alternative approach (for instance,
those combining blind docking with molecular dynamics like
the Wrap ‘n’ Shake method [46]), Arpeggio enables the visual-
ization of intermolecular interactions occurring between the
lead and its target. During lead optimization, Arpeggio can
therefore be used to understand the mechanism of binding
and guide medicinal chemistry efforts.
2. Arpeggio is freely available as a user-friendly web interface and
is compatible with multiple operating systems and browsers.
Open up the prediction server, http://biosig.unimelb.edu.au/
arpeggioweb/, on a web browser of your preference.
3. Provide the complexed protein structure of interest by either
uploading it as a PDB file or providing the PDB ID of the
experimentally solved structure in complex with the ligand of
interest (Fig. 4a-1).
4. Select the ligand or ligands of interest under the “Heteroatom”
selection heading to calculate all molecular interactions being
made by that ligand (Fig. 4b-1; see Note 4).
5. The results page will show an interactive image of all the
molecular interactions made by the ligand(s) selected
(Fig. 5a) and a table with a count of the total number of specific
molecular interactions being made, including hydrophobic
interactions, hydrogen bonds, pi-interactions, and ionic inter-
actions (Fig. 4c).
6. A Pymol session file (PSE file) containing the submitted PDB
file and all of the calculated interactions can be downloaded and
opened in Pymol to enable visualization of the interaction
network in 3D and to facilitate high-quality image generation
for manuscripts (Fig. 5b).
3.4 Predicting
the Effects
of Mutations on Small
Molecule Affinity
with mCSM-lig
1. During lead optimization, it is important to consider how
genetic diversity might affect the binding of candidate mole-
cules and, in particular, if resistance is likely to arise. mCSM-lig
uses graph-based signatures to calculate the change upon
mutation in small molecule binding affinity. In order to run a
prediction, open up the mCSM-lig server at http://biosig.
unimelb.edu.au/mcsm_lig/ on a web browser of your prefer-
ence (the web server is compatible with the most common
operating systems and browsers).
2. Users are required to provide the protein structure in complex
with the ligand of interest by either uploading a PDB file or
supplying a valid four-letter code PDB accession code of a
deposited experimental structure (Fig. 6a-1). Users also need
to provide the mutation information, the mutation chain, the
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Fig. 4 Arpeggio submission and results web interface. (a) The submission page allows users to either provide
their own PDB file or an accession code of a deposited experimental structure of the protein of interest. By
selecting the molecule of interest (b), all molecular interactions will be calculated and displayed (c)
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three-letter code of the ligand of interest in the PDB file, and
the approximate binding affinity (in nM) (Fig. 6a-2). If the
binding affinity is not available, this can be approximated using
CSM-lig. The mCSM-lig values do not vary significantly across
most biologically relevant binding affinities.
3. After processing, the results page is shown (Fig. 6b-1), which
includes information about the mutation and the predicted
effects on the ligand binding affinity. An interactive molecular
visualization is shown, allowing users to inspect the wild-type
residue environment (Fig. 6b-2).
4. Predicted effects are outputted as the log fold change in bind-
ing affinity, in which negative values denote destabilizing muta-
tions and positive values, stabilizing ones. The example shown
in Fig. 6 and the web server depicts the prediction for a muta-
tion on the HIV-1 protease bound to an inhibitor. Mutation
from Aspartic Acid to Asparagine on residue position 30 is
predicted to considerably reduce protein-ligand affinity. While
users should interpret the values in the context of the protein
system being studied, for competitive binding inhibitors, it is
often important to consider the relative effect of a mutation on
not only inhibitor binding but also the competitive ligand. This
Fig. 5 Molecular interaction visualization using Arpeggio. The molecular interactions calculated by Arpeggio
can be visualized either online (a) or by downloading the PSE file for visualization in Pymol (b)
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can be done by submitting a structure of the protein containing
the ligand. Resistance mutations are more likely to affect, or
have a larger effect, on inhibitor binding affinity than the
natural ligand. This has been used to successfully preemptively
guide detection of likely resistance variants [29–31, 47–53].
Fig. 6 mCSM-lig submission and results web interface. To predict the effects of a mutation on protein-ligand
affinity, users need to provide a protein-ligand structure of interest (a-1) as well as mutation and ligand
information (a-2). Once the calculations have finished, the results page will show the predicted change in
ligand binding affinity (b-1) as well as an interactive visualization of the mutated residue within its molecular
environment (b-2)
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4 Notes
1. The chain ID for the provided PDB file is a mandatory field for
CSM-Lig and mCSM-Lig, and blank characters are not
allowed. It is possible that homology modeling tools might
not automatically add a chain ID. If this is the case, the user will
need to modify the PDB file prior to submission to the servers.
There are several tools available to perform this task.
2. Another source of error comes from multiple occupancies,
common in high-resolution experimental X-ray crystal struc-
tures. Multiple occupancies should first be filtered out, with the
highest occupancy conformation normally selected.
3. NMR experimental structures often contain multiple models.
It is an important practice to filter NMR structures, selecting a
single model. The predictive tool will show a warning message
in case multiple models are identified.
4. Arpeggio will sometimes fail if the PDB file contains an element
with upper and lower case letters (e.g., Fe as opposed to FE).
These can be altered using a text editor.
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